
<html lang="en"     class="pb-page"  data-request-id="62fbde2e-8578-475d-ab14-c555d3dfdd18"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";issue:issue:10.1021/jmcmar.2020.63.issue-23;requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;article:article:10.1021/acs.jmedchem.0c01163;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Discovery of AZD9833, a Potent and Orally Bioavailable Selective Estrogen Receptor Degrader and Antagonist" /></meta><meta name="dc.Creator" content="James S.  Scott" /></meta><meta name="dc.Creator" content="Thomas A.  Moss" /></meta><meta name="dc.Creator" content="Amber  Balazs" /></meta><meta name="dc.Creator" content="Bernard  Barlaam" /></meta><meta name="dc.Creator" content="Jason  Breed" /></meta><meta name="dc.Creator" content="Rodrigo J.  Carbajo" /></meta><meta name="dc.Creator" content="Elisabetta  Chiarparin" /></meta><meta name="dc.Creator" content="Paul R. J.  Davey" /></meta><meta name="dc.Creator" content="Oona  Delpuech" /></meta><meta name="dc.Creator" content="Stephen  Fawell" /></meta><meta name="dc.Creator" content="David I.  Fisher" /></meta><meta name="dc.Creator" content="Sladjana  Gagrica" /></meta><meta name="dc.Creator" content="Eric T.  Gangl" /></meta><meta name="dc.Creator" content="Tyler  Grebe" /></meta><meta name="dc.Creator" content="Ryan D.  Greenwood" /></meta><meta name="dc.Creator" content="Sudhir  Hande" /></meta><meta name="dc.Creator" content="Holia  Hatoum-Mokdad" /></meta><meta name="dc.Creator" content="Kara  Herlihy" /></meta><meta name="dc.Creator" content="Samantha  Hughes" /></meta><meta name="dc.Creator" content="Thomas A.  Hunt" /></meta><meta name="dc.Creator" content="Hoan  Huynh" /></meta><meta name="dc.Creator" content="Sophie L. M.  Janbon" /></meta><meta name="dc.Creator" content="Tony  Johnson" /></meta><meta name="dc.Creator" content="Stefan  Kavanagh" /></meta><meta name="dc.Creator" content="Teresa  Klinowska" /></meta><meta name="dc.Creator" content="Mandy  Lawson" /></meta><meta name="dc.Creator" content="Andrew S.  Lister" /></meta><meta name="dc.Creator" content="Stacey  Marden" /></meta><meta name="dc.Creator" content="Dermot F.  McGinnity" /></meta><meta name="dc.Creator" content="Christopher J.  Morrow" /></meta><meta name="dc.Creator" content="J. Willem M.  Nissink" /></meta><meta name="dc.Creator" content="Daniel H.  O’Donovan" /></meta><meta name="dc.Creator" content="Bo  Peng" /></meta><meta name="dc.Creator" content="Radoslaw  Polanski" /></meta><meta name="dc.Creator" content="Darren S.  Stead" /></meta><meta name="dc.Creator" content="Stephen  Stokes" /></meta><meta name="dc.Creator" content="Kumar  Thakur" /></meta><meta name="dc.Creator" content="Scott R.  Throner" /></meta><meta name="dc.Creator" content="Michael J.  Tucker" /></meta><meta name="dc.Creator" content="Jeffrey  Varnes" /></meta><meta name="dc.Creator" content="Haixia  Wang" /></meta><meta name="dc.Creator" content="David M.  Wilson" /></meta><meta name="dc.Creator" content="Dedong  Wu" /></meta><meta name="dc.Creator" content="Ye  Wu" /></meta><meta name="dc.Creator" content="Bin  Yang" /></meta><meta name="dc.Creator" content="Wenzhan  Yang" /></meta><meta name="dc.Description" content="Herein we report the optimization of a series of tricyclic indazoles as selective estrogen receptor degraders (SERD) and antagonists for the treatment of ER+ breast cancer. Structure based design t..." /></meta><meta name="Description" content="Herein we report the optimization of a series of tricyclic indazoles as selective estrogen receptor degraders (SERD) and antagonists for the treatment of ER+ breast cancer. Structure based design t..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="September 10, 2020" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.0c01163" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c01163" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.0c01163" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c01163" /></link>
        
    
    

<title>Discovery of AZD9833, a Potent and Orally Bioavailable Selective Estrogen Receptor Degrader and Antagonist | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.0c01163" /></meta><meta property="og:title" content="Discovery of AZD9833, a Potent and Orally Bioavailable Selective Estrogen Receptor Degrader and Antagonist" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01163/20201203/images/large/jm0c01163_0029.jpeg" /></meta><meta property="og:description" content="Herein we report the optimization of a series of tricyclic indazoles as selective estrogen receptor degraders (SERD) and antagonists for the treatment of ER+ breast cancer. Structure based design together with systematic investigation of each region of the molecular architecture led to the identification of N-[1-(3-fluoropropyl)azetidin-3-yl]-6-[(6S,8R)-8-methyl-7-(2,2,2-trifluoroethyl)-6,7,8,9-tetrahydro-3H-pyrazolo[4,3-f]isoquinolin-6-yl]pyridin-3-amine (28). This compound was demonstrated to be a highly potent SERD that showed a pharmacological profile comparable to fulvestrant in its ability to degrade ERα in both MCF-7 and CAMA-1 cell lines. A stringent control of lipophilicity ensured that 28 had favorable physicochemical and preclinical pharmacokinetic properties for oral administration. This, combined with demonstration of potent in vivo activity in mouse xenograft models, resulted in progression of this compound, also known as AZD9833, into clinical trials." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.0c01163"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01163">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.0c01163&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.0c01163&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.0c01163&amp;href=/doi/10.1021/acs.jmedchem.0c01163" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2020</span><span class="cit-fg-volume">, 63</span><span class="cit-fg-issue">, 23</span><span class="cit-fg-pageRange">, 14530-14559</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/63/23" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.0c00978" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Drug Annotation</span><a href="/doi/10.1021/acs.jmedchem.0c01947" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery of AZD9833, a Potent and Orally Bioavailable Selective Estrogen Receptor Degrader and Antagonist</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">James S. Scott</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">James S. Scott</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom</div></div><span class="conrtib-corresp"><strong>*</strong>E-mail: <a href="/cdn-cgi/l/email-protection#f19b909c9894df82929e8585b190828583908b949f949290df929e9c"><span class="__cf_email__" data-cfemail="573d363a3e327924343823231736242325362d32393234367934383a">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=James+S.++Scott">James S. Scott</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-2263-7024" title="Orcid link">http://orcid.org/0000-0002-2263-7024</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Thomas A. Moss</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Thomas A. Moss</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom</div></div><span class="conrtib-corresp"><strong>*</strong>E-mail: <a href="/cdn-cgi/l/email-protection#493d212624283a6724263a3a09283a3d3b28332c272c2a28672a2624"><span class="__cf_email__" data-cfemail="5e2a3631333f2d7033312d2d1e3f2d2a2c3f243b303b3d3f703d3133">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Thomas+A.++Moss">Thomas A. Moss</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Amber Balazs</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Amber Balazs</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology R&D, AstraZeneca, R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Amber++Balazs">Amber Balazs</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Bernard Barlaam</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Bernard Barlaam</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Bernard++Barlaam">Bernard Barlaam</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-0904-7556" title="Orcid link">http://orcid.org/0000-0002-0904-7556</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jason Breed</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jason Breed</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Discovery Sciences R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jason++Breed">Jason Breed</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Rodrigo J. Carbajo</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Rodrigo J. Carbajo</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Rodrigo+J.++Carbajo">Rodrigo J. Carbajo</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Elisabetta Chiarparin</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Elisabetta Chiarparin</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Elisabetta++Chiarparin">Elisabetta Chiarparin</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-2998-1346" title="Orcid link">http://orcid.org/0000-0002-2998-1346</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Paul R. J. Davey</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Paul R. J. Davey</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Paul+R.+J.++Davey">Paul R. J. Davey</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Oona Delpuech</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Oona Delpuech</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Oona++Delpuech">Oona Delpuech</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Stephen Fawell</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Stephen Fawell</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology R&D, AstraZeneca, R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Stephen++Fawell">Stephen Fawell</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">David I. Fisher</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">David I. Fisher</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Discovery Sciences R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=David+I.++Fisher">David I. Fisher</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Sladjana Gagrica</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Sladjana Gagrica</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Sladjana++Gagrica">Sladjana Gagrica</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Eric T. Gangl</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Eric T. Gangl</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology R&D, AstraZeneca, R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Eric+T.++Gangl">Eric T. Gangl</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Tyler Grebe</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Tyler Grebe</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology R&D, AstraZeneca, R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Tyler++Grebe">Tyler Grebe</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Ryan D. Greenwood</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ryan D. Greenwood</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ryan+D.++Greenwood">Ryan D. Greenwood</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Sudhir Hande</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Sudhir Hande</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology R&D, AstraZeneca, R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Sudhir++Hande">Sudhir Hande</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Holia Hatoum-Mokdad</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Holia Hatoum-Mokdad</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology R&D, AstraZeneca, R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Holia++Hatoum-Mokdad">Holia Hatoum-Mokdad</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Kara Herlihy</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Kara Herlihy</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Discovery Sciences R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Kara++Herlihy">Kara Herlihy</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Samantha Hughes</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Samantha Hughes</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Samantha++Hughes">Samantha Hughes</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Thomas A. Hunt</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Thomas A. Hunt</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Thomas+A.++Hunt">Thomas A. Hunt</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Hoan Huynh</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Hoan Huynh</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology R&D, AstraZeneca, R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Hoan++Huynh">Hoan Huynh</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Sophie L. M. Janbon</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Sophie L. M. Janbon</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Early Chemical Development, Pharmaceutical Sciences, R&D, Macclesfield, United Kingdom</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Sophie+L.+M.++Janbon">Sophie L. M. Janbon</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-7908-8292" title="Orcid link">http://orcid.org/0000-0001-7908-8292</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Tony Johnson</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Tony Johnson</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Tony++Johnson">Tony Johnson</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Stefan Kavanagh</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Stefan Kavanagh</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology Safety, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Cambridge, United Kingdom</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Stefan++Kavanagh">Stefan Kavanagh</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Teresa Klinowska</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Teresa Klinowska</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Teresa++Klinowska">Teresa Klinowska</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Mandy Lawson</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Mandy Lawson</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Mandy++Lawson">Mandy Lawson</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Andrew S. Lister</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Andrew S. Lister</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Andrew+S.++Lister">Andrew S. Lister</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Stacey Marden</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Stacey Marden</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Advanced Drug Delivery, Pharmaceutical Sciences, R&D, Boston, Massachusetts, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Stacey++Marden">Stacey Marden</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Dermot F. McGinnity</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Dermot F. McGinnity</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Dermot+F.++McGinnity">Dermot F. McGinnity</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Christopher J. Morrow</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Christopher J. Morrow</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Christopher+J.++Morrow">Christopher J. Morrow</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">J. Willem M. Nissink</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">J. Willem M. Nissink</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=J.+Willem+M.++Nissink">J. Willem M. Nissink</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-2572-9140" title="Orcid link">http://orcid.org/0000-0003-2572-9140</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Daniel H. O’Donovan</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Daniel H. O’Donovan</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Daniel+H.++O%E2%80%99Donovan">Daniel H. O’Donovan</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-8400-2198" title="Orcid link">http://orcid.org/0000-0002-8400-2198</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Bo Peng</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Bo Peng</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology R&D, AstraZeneca, R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Bo++Peng">Bo Peng</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Radoslaw Polanski</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Radoslaw Polanski</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Discovery Sciences R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Radoslaw++Polanski">Radoslaw Polanski</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Darren S. Stead</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Darren S. Stead</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Darren+S.++Stead">Darren S. Stead</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Stephen Stokes</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Stephen Stokes</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Stephen++Stokes">Stephen Stokes</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Kumar Thakur</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Kumar Thakur</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology R&D, AstraZeneca, R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Kumar++Thakur">Kumar Thakur</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Scott R. Throner</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Scott R. Throner</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology R&D, AstraZeneca, R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Scott+R.++Throner">Scott R. Throner</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Michael J. Tucker</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Michael J. Tucker</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Michael+J.++Tucker">Michael J. Tucker</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jeffrey Varnes</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jeffrey Varnes</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology R&D, AstraZeneca, R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jeffrey++Varnes">Jeffrey Varnes</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Haixia Wang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Haixia Wang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology R&D, AstraZeneca, R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Haixia++Wang">Haixia Wang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">David M. Wilson</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">David M. Wilson</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=David+M.++Wilson">David M. Wilson</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Dedong Wu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Dedong Wu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Advanced Drug Delivery, Pharmaceutical Sciences, R&D, Boston, Massachusetts, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Dedong++Wu">Dedong Wu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Ye Wu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ye Wu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology R&D, AstraZeneca, R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ye++Wu">Ye Wu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Bin Yang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Bin Yang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology R&D, AstraZeneca, R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Bin++Yang">Bin Yang</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-1499-5569" title="Orcid link">http://orcid.org/0000-0002-1499-5569</a></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Wenzhan Yang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Wenzhan Yang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Advanced Drug Delivery, Pharmaceutical Sciences, R&D, Boston, Massachusetts, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Wenzhan++Yang">Wenzhan Yang</a></span></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c01163&amp;href=/doi/10.1021%2Facs.jmedchem.0c01163" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2020</span></span><span class="cit-volume">, 63</span><span class="cit-issue">, 23</span><span class="cit-pageRange">, 14530–14559</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">September 10, 2020</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>7 July 2020</li><li><span class="item_label"><b>Published</b> online</span>10 September 2020</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 10 December 2020</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.0c01163" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01163</a></div><div class="article_header-article-copyright"><strong>Copyright © 2020 <span class="NLM_copyright-holder">American Chemical Society</span></strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D14530%26pageCount%3D30%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DJames%2BS.%2BScott%252C%2BThomas%2BA.%2BMoss%252C%2BAmber%2BBalazs%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D63%26issueNum%3D23%26contentID%3Dacs.jmedchem.0c01163%26title%3DDiscovery%2Bof%2BAZD9833%252C%2Ba%2BPotent%2Band%2BOrally%2BBioavailable%2BSelective%2BEstrogen%2BReceptor%2BDegrader%2Band%2BAntagonist%26numPages%3D30%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D14559%26publicationDate%3DDecember%2B2020">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.0c01163"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">3919</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">5</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.0c01163" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery of AZD9833, a Potent and Orally Bioavailable Selective Estrogen Receptor Degrader and Antagonist&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;James&quot;,&quot;last_name&quot;:&quot;S. Scott&quot;},{&quot;first_name&quot;:&quot;Thomas&quot;,&quot;last_name&quot;:&quot;A. Moss&quot;},{&quot;first_name&quot;:&quot;Amber&quot;,&quot;last_name&quot;:&quot;Balazs&quot;},{&quot;first_name&quot;:&quot;Bernard&quot;,&quot;last_name&quot;:&quot;Barlaam&quot;},{&quot;first_name&quot;:&quot;Jason&quot;,&quot;last_name&quot;:&quot;Breed&quot;},{&quot;first_name&quot;:&quot;Rodrigo&quot;,&quot;last_name&quot;:&quot;J. Carbajo&quot;},{&quot;first_name&quot;:&quot;Elisabetta&quot;,&quot;last_name&quot;:&quot;Chiarparin&quot;},{&quot;first_name&quot;:&quot;Paul&quot;,&quot;last_name&quot;:&quot;R. J. Davey&quot;},{&quot;first_name&quot;:&quot;Oona&quot;,&quot;last_name&quot;:&quot;Delpuech&quot;},{&quot;first_name&quot;:&quot;Stephen&quot;,&quot;last_name&quot;:&quot;Fawell&quot;},{&quot;first_name&quot;:&quot;David&quot;,&quot;last_name&quot;:&quot;I. Fisher&quot;},{&quot;first_name&quot;:&quot;Sladjana&quot;,&quot;last_name&quot;:&quot;Gagrica&quot;},{&quot;first_name&quot;:&quot;Eric&quot;,&quot;last_name&quot;:&quot;T. Gangl&quot;},{&quot;first_name&quot;:&quot;Tyler&quot;,&quot;last_name&quot;:&quot;Grebe&quot;},{&quot;first_name&quot;:&quot;Ryan&quot;,&quot;last_name&quot;:&quot;D. Greenwood&quot;},{&quot;first_name&quot;:&quot;Sudhir&quot;,&quot;last_name&quot;:&quot;Hande&quot;},{&quot;first_name&quot;:&quot;Holia&quot;,&quot;last_name&quot;:&quot;Hatoum-Mokdad&quot;},{&quot;first_name&quot;:&quot;Kara&quot;,&quot;last_name&quot;:&quot;Herlihy&quot;},{&quot;first_name&quot;:&quot;Samantha&quot;,&quot;last_name&quot;:&quot;Hughes&quot;},{&quot;first_name&quot;:&quot;Thomas&quot;,&quot;last_name&quot;:&quot;A. Hunt&quot;},{&quot;first_name&quot;:&quot;Hoan&quot;,&quot;last_name&quot;:&quot;Huynh&quot;},{&quot;first_name&quot;:&quot;Sophie&quot;,&quot;last_name&quot;:&quot;L. M. Janbon&quot;},{&quot;first_name&quot;:&quot;Tony&quot;,&quot;last_name&quot;:&quot;Johnson&quot;},{&quot;first_name&quot;:&quot;Stefan&quot;,&quot;last_name&quot;:&quot;Kavanagh&quot;},{&quot;first_name&quot;:&quot;Teresa&quot;,&quot;last_name&quot;:&quot;Klinowska&quot;},{&quot;first_name&quot;:&quot;Mandy&quot;,&quot;last_name&quot;:&quot;Lawson&quot;},{&quot;first_name&quot;:&quot;Andrew&quot;,&quot;last_name&quot;:&quot;S. Lister&quot;},{&quot;first_name&quot;:&quot;Stacey&quot;,&quot;last_name&quot;:&quot;Marden&quot;},{&quot;first_name&quot;:&quot;Dermot&quot;,&quot;last_name&quot;:&quot;F. McGinnity&quot;},{&quot;first_name&quot;:&quot;Christopher&quot;,&quot;last_name&quot;:&quot;J. Morrow&quot;},{&quot;first_name&quot;:&quot;J.&quot;,&quot;last_name&quot;:&quot;Willem M. Nissink&quot;},{&quot;first_name&quot;:&quot;Daniel&quot;,&quot;last_name&quot;:&quot;H. O’Donovan&quot;},{&quot;first_name&quot;:&quot;Bo&quot;,&quot;last_name&quot;:&quot;Peng&quot;},{&quot;first_name&quot;:&quot;Radoslaw&quot;,&quot;last_name&quot;:&quot;Polanski&quot;},{&quot;first_name&quot;:&quot;Darren&quot;,&quot;last_name&quot;:&quot;S. Stead&quot;},{&quot;first_name&quot;:&quot;Stephen&quot;,&quot;last_name&quot;:&quot;Stokes&quot;},{&quot;first_name&quot;:&quot;Kumar&quot;,&quot;last_name&quot;:&quot;Thakur&quot;},{&quot;first_name&quot;:&quot;Scott&quot;,&quot;last_name&quot;:&quot;R. Throner&quot;},{&quot;first_name&quot;:&quot;Michael&quot;,&quot;last_name&quot;:&quot;J. Tucker&quot;},{&quot;first_name&quot;:&quot;Jeffrey&quot;,&quot;last_name&quot;:&quot;Varnes&quot;},{&quot;first_name&quot;:&quot;Haixia&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;David&quot;,&quot;last_name&quot;:&quot;M. Wilson&quot;},{&quot;first_name&quot;:&quot;Dedong&quot;,&quot;last_name&quot;:&quot;Wu&quot;},{&quot;first_name&quot;:&quot;Ye&quot;,&quot;last_name&quot;:&quot;Wu&quot;},{&quot;first_name&quot;:&quot;Bin&quot;,&quot;last_name&quot;:&quot;Yang&quot;},{&quot;first_name&quot;:&quot;Wenzhan&quot;,&quot;last_name&quot;:&quot;Yang&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2020&quot;,&quot;month&quot;:&quot;09&quot;,&quot;day&quot;:&quot;10&quot;,&quot;issue&quot;:&quot;23&quot;,&quot;volume&quot;:&quot;63&quot;,&quot;pages&quot;:&quot;14530-14559&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.0c01163&quot;},&quot;abstract&quot;:&quot;Herein we report the optimization of a series of tricyclic indazoles as selective estrogen receptor degraders (SERD) and antagonists for the treatment of ER+ breast cancer. Structure based design together with systematic investigation of each region of the molecular architecture led to the identification of N-[1-(3-fluoropropyl)azetidin-3-yl]-6-[(6S,8R)-8-methyl-7-(2,2,2-trifluoroethyl)-6,7,8,9-tetrahydro-3H-pyrazolo[4,3-f]isoquinolin-6-yl]pyridin-3-amine (28). This compound was demonstrated to be a highly potent SERD that showed a pharmacological profile comparable to fulvestrant in its ability to degrade ERα in both MCF-7 and CAMA-1 cell lines. A stringent control of lipophilicity ensured that 28 had favorable physicochemical and preclinical pharmacokinetic properties for oral administration. This, combined with demonstration of potent in vivo activity in mouse xenograft models, resulted in progression of this compound, also known as AZD9833, into clinical trials.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01163&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01163" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01163&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01163" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01163&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01163" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c01163&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01163&amp;href=/doi/10.1021/acs.jmedchem.0c01163" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.0c01163" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.0c01163" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (7 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01163&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.0c01163%26sid%3Dliteratum%253Aachs%26pmid%3D32910656%26genre%3Darticle%26aulast%3DScott%26date%3D2020%26atitle%3DDiscovery%2Bof%2BAZD9833%252C%2Ba%2BPotent%2Band%2BOrally%2BBioavailable%2BSelective%2BEstrogen%2BReceptor%2BDegrader%2Band%2BAntagonist%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D63%26issue%3D23%26spage%3D14530%26epage%3D14559%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291300" title="Palladium">Palladium</a>,</li><li><a href="/action/doSearch?ConceptID=291781" title="Degradation">Degradation</a>,</li><li><a href="/action/doSearch?ConceptID=291240" title="Cyclization">Cyclization</a>,</li><li><a href="/action/doSearch?ConceptID=291880" title="Crystal structure">Crystal structure</a>,</li><li><a href="/action/doSearch?ConceptID=292349" title="Alkyls">Alkyls</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/63/23" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/jmcmar.2020.63.issue-23/20201210/jmcmar.2020.63.issue-23.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01163/20201203/images/medium/jm0c01163_0029.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01163/20201203/images/large/jm0c01163_0029.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01163&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Herein we report the optimization of a series of tricyclic indazoles as selective estrogen receptor degraders (SERD) and antagonists for the treatment of ER<sup>+</sup> breast cancer. Structure based design together with systematic investigation of each region of the molecular architecture led to the identification of <i>N</i>-[1-(3-fluoropropyl)azetidin-3-yl]-6-[(6<i>S</i>,8<i>R</i>)-8-methyl-7-(2,2,2-trifluoroethyl)-6,7,8,9-tetrahydro-3<i>H</i>-pyrazolo[4,3-<i>f</i>]isoquinolin-6-yl]pyridin-3-amine (<b>28</b>). This compound was demonstrated to be a highly potent SERD that showed a pharmacological profile comparable to fulvestrant in its ability to degrade ERα in both MCF-7 and CAMA-1 cell lines. A stringent control of lipophilicity ensured that <b>28</b> had favorable physicochemical and preclinical pharmacokinetic properties for oral administration. This, combined with demonstration of potent in vivo activity in mouse xenograft models, resulted in progression of this compound, also known as AZD9833, into clinical trials.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_16204" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_16204" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Breast cancer is the most prevalent cancer in women, accounting for 24% of all cancer incidence and 15% of all cancer related deaths in women, according to the Global Cancer Statistics 2018 analysis.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Of these, ∼70% of patients express the hormone receptors (HR) estrogen receptor α (ERα) and/or ERα’s downstream target, progesterone receptor (PR), without the expression of human epidermal growth factor receptor 2 (HER2). These are classed as HR+, HER2-.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> Antihormonal therapies targeting ERα, either indirectly with aromatase inhibitors which reduce the levels of estradiol, or directly with the selective estrogen receptor modulator tamoxifen, have been the mainstay of treatment for HR+, HER2- breast cancer patients for the last 40+ years.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> However, there remains a significant unmet clinical need, with ∼10–40% of patients receiving adjuvant antihormonal treatment developing advanced breast cancer within 20 years<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> and a 25% 5-year survival rate for patients with advanced disease.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a></div><div class="NLM_p">While antihormonal therapies remain effective in the advanced setting, resistance emerges. Resistance mechanisms include ligand independent activation of ERα through point mutations of ERα,<a onclick="showRef(event, 'ref6 ref7'); return false;" href="javascript:void(0);" class="ref ref6 ref7">(6,7)</a> activation of signaling pathways that can activate ERα in the absence of estradiol,<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> or changes in expression of ERα cofactors that convert ERα modulators into agonists.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> However, in all these scenarios the cell maintains a reliance on ERα, and effectively targeting ERα remains a valid therapeutic strategy. Selective ERα degraders (SERDs), which both degrade and antagonize ERα, are one approach to continue to target ERα.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a></div><div class="NLM_p">To date, the only clinically approved SERD is fulvestrant (Faslodex), which can degrade and completely antagonize ERα in all settings tested<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> and has proven to be superior to the aromatase inhibitor anastrozole in clinical trials.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> However, fulvestrant is administered clinically via monthly intramuscular injection, which limits the maximum administrable dose to 500 mg.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> Therefore, there has been much interest in developing orally bioavailable SERDs to further enhance the benefit to patients brought through this class of ERα targeting agents. A number of potential oral SERD candidates have been advanced into clinical trials with selected examples shown in <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>. These have been grouped into two families according to the charge class of the side chain projecting from the aryl group. The first group is comprised of acrylic acids with examples including GDC-0810<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> (<b>1a</b>) from Aragon/Seragon/Genentech, AZD9496<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> (<b>1b</b>) from AstraZeneca, LSZ102<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> (<b>1c</b>) from Novartis and G1T48<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> (<b>1d</b>) from the University of Illinois at Chicago/G1 therapeutics. The second group includes basic degraders as exemplified by RAD1901<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> (<b>2a</b>) from Radius and GDC-0927<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> (<b>2b</b>) from Aragon/Seragon/Genentech. SAR439859<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> (<b>2c</b>) from Sanofi also contains a basic side chain attached to the aryl group but notably contains an acidic group in the core, making this an example of a zwitterionic SERD.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01163/20201203/images/medium/jm0c01163_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01163/20201203/images/large/jm0c01163_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Selected examples of oral SERDs.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01163/20201203/images/large/jm0c01163_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01163&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Acrylic acid containing oral SERDs, exemplified by <b>1a</b> and <b>1b</b>, were only able to degrade ERα in certain cell lines and had the potential to agonize ER in uterine models and some breast cancer cell lines.<a onclick="showRef(event, 'ref21 ref22'); return false;" href="javascript:void(0);" class="ref ref21 ref22">(21,22)</a> This divergence in chemotype from fulvestrant could theoretically lead to cofactor changes converting the drugs to ER agonists in the clinic, in a manner similar to tamoxifen. Some SERDs containing a basic group, such as <b>2b</b>, have been able to address this issue, degrading ERα to the same extent as fulvestrant in all cell lines tested and giving no sign of ER agonism in breast cell lines.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a></div><div class="NLM_p">As part of our ongoing research efforts at AstraZeneca, we have previously reported a series of tricyclic indazole acid SERDs<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> (<b>3</b> as an exemplar), themselves derived from a series of tetrahydroisoquinoline (THIQ) phenols (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>).<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> We had also described the discovery of a novel tricyclic indole core and the optimization to the clinical candidate <b>1b</b>.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> In subsequent work on this core, we also investigated switching between the charge classes with the replacement of the acrylic acid with a basic group (<b>4</b> as an exemplar).<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> Interestingly, this compound has also arisen independently from the research efforts of other groups.<a onclick="showRef(event, 'cit19c ref26'); return false;" href="javascript:void(0);" class="ref cit19c ref26">(19c,26)</a></div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01163/20201203/images/medium/jm0c01163_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01163/20201203/images/large/jm0c01163_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Medchem strategy for basic series of tricyclic indazole SERDs.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01163/20201203/images/large/jm0c01163_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01163&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">During the course of our research efforts, we became aware that <b>1b</b>, while an excellent degrader in certain ER<sup>+</sup> cell lines (e.g., MCF-7 which showed 87% protein degradation vs fulvestrant by Western blot) did not degrade to the same extent in other cell lines (e.g., CAMA-1 proving to be a particularly challenging line with only 28% degradation vs fulvestrant). Indazole acid <b>3</b> showed a profile similar to <b>1b</b> with better degradation being observed in MCF-7 (84%) than CAMA-1 (56%). In contrast, basic compound <b>4</b> showed a more balanced degradation profile between the cell lines with MCF-7 (77%) and CAMA-1 (69%).</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_10255" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_10255" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">In this paper, we describe our efforts to amalgamate both strands of work to realize a basic series of tricyclic indazole SERDs with good degradation in both MCF-7 and CAMA-1 cell lines. Our design strategy was predicated on maximizing cellular potency (pIC<sub>50</sub> > 9.5) while controlling lipophilicity (logD<sub>7.4</sub> < 3) so as to minimize general risks associated with basic lipophilic compounds (e.g., hERG, phospholipidosis, off-target pharmacology) and maximize our chances of identifying a candidate with favorable druglike properties (e.g., good solubility, high permeability, high metabolic stability) as summarized in <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>.</div><div class="NLM_p">Our first example of a basic indazole, compound <b>5</b>, showed pharmacology very similar to previously reported indole <b>4</b> (pIC<sub>50</sub> 9.9 (<i>D</i><sub>max</sub> 95%) for <b>5</b> vs pIC<sub>50</sub> 10.1 (<i>D</i><sub>max</sub> 96%) for <b>4</b>). The lipophilicity of <b>5</b> was high (logD<sub>7.4</sub> 4.4) but measurable, whereas for <b>4</b> this was out of the range of our standard assay. The hypothesis that the indazole was intrinsically more polar than the indole core was supported by lower plasma protein binding (0.79% fraction unbound for <b>5</b> vs 0.23% for <b>4</b>). The higher aqueous solubility (33 μM for <b>5</b> vs <3 μM for <b>4</b>) also provided encouragement to embark on an optimization campaign, and we therefore developed chemical routes toward these motifs (<b>5</b>–<b>40</b>) as shown in <a class="ref internalNav" href="#sch1" aria-label="Schemes 1">Schemes 1</a>–<a class="ref internalNav" href="#sch10" aria-label="10">10</a>.</div><figure id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01163/20201203/images/medium/jm0c01163_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01163/20201203/images/large/jm0c01163_0013.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Routes to Anilines Bearing a Diversity of <i>N</i>-Alkyl Substituents<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01163/20201203/images/large/jm0c01163_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01163&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) <i>n</i>-BuLi, THF, −78 to 0 °C, 1 h, then 4 N HCl/dioxane, RT, 1 h, 60%; (b) alkyl triflate, DIPEA, 1,4-dioxane, 90 °C, 63–74% or isobutyrylaldehyde, Na(OAc)<sub>3</sub>BH, THF, 0 °C, 56%; (c) benzophenone imine, Pd<sub>2</sub>dba<sub>3</sub>, Rac-BINAP, NaO<sup><i>t</i></sup>Bu, toluene, 90 °C, then 1 N aq. HCl, 71–85%; (d) <i>n</i>-BuLi, THF, −78 to 0 °C, 1 h, then 4 N HCl/dioxane, RT, 4 h; (e) NH<sub>2</sub>OH, NH<sub>2</sub>OH·HCl, EtOH, reflux. 84% over two steps; (f) alkyl triflate, DIPEA, 1,4-dioxane, 90 °C, 44–100% or 1-fluorocyclopropane-1-carboxylic acid, HATU, Et<sub>3</sub>N, DMF, RT, 61%, then BH<sub>3</sub>·THF, THF, 65 °C, 82%.</p></p></figure><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5"> Synthetic Chemistry</h3><div class="NLM_p">Drawing on our previous experience,<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> we initially chose to construct the tricyclic scaffold from a Pictet–Spengler cyclization on an aniline substrate, followed by late-stage formation of the indazole ring. This approach required us to synthesize a range of anilines bearing a diversity of <i>N</i>-alkyl substituents (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>). To this end, we adopted two complementary approaches. In the first, treatment of 2,6-dibromotoluene <b>41a</b> with <i>n</i>-BuLi in THF at −78 °C, followed by addition of cyclic sulfamidate <b>42</b> gave the aliphatic amine <b>43</b> after Boc deprotection. <i>N</i>-Alkylation could be achieved by heating this amine with the requisite alkyl triflate and DIPEA in 1,4-dioxane to give compounds <b>44</b>. Buchwald amination with benzophenone imine, followed by hydrolysis with aqueous acid, afforded the anilines <b>45</b>. In order to facilitate later-stage variation of the alkyl chain, we also adopted an approach that introduced the aniline at an earlier stage and circumvented repeated Buchwald aminations. 3-Bromo-2-methyl aniline was first protected as the dimethyl pyrrole. With the protected aniline <b>41b</b> in hand, an analogous approach was adopted where the alkyl chain was introduced via ring opening of the cyclic sulfamidate to give <b>46</b>. Following Boc deprotection and removal of the pyrrole protecting group with hydroxylamine, the diamine <b>47</b> could be selectively alkylated on the aliphatic nitrogen by heating with the alkyl triflate as per the approach described above. In a slight variation of the method, the fluoro-cyclopropyl analogue was accessed by amide formation on the diamine with HATU and subsequent reduction of the amide by heating with borane solution in THF to afford the required amine <b>45c</b>.</div><div class="NLM_p">The anilines <b>45</b> were then subjected to a Pictet–Spengler cyclization with the requisite 4-bromo aldehydes to furnish the cyclized products <b>48</b> as the desired <i>trans</i> isomers.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> The cyclization was found to proceed more smoothly with a small amount of water present in the AcOH; it was hypothesized that the water helps to hydrolyze the imine formed from condensation of the aniline with the aldehyde, allowing cyclization to occur. Indazole formation could then be achieved by treatment with NaNO<sub>2</sub> in a mixture of propionic acid and water under cooling.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> The indazoles were then protected with THP to give <b>49</b>, which allowed installation of the azetidine moiety by a palladium-catalyzed ether formation facilitated by the RockPhos third generation Pd-precatalyst.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> Finally, removal of the THP protecting group under acidic conditions afforded the tricyclic indazoles <b>5</b>–<b>13</b>, <b>29</b>, and <b>30</b> (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>).</div><figure id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01163/20201203/images/medium/jm0c01163_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01163/20201203/images/large/jm0c01163_0014.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Pictet–Spengler Approach to <i>O</i>-Linked Tricyclic Indazoles<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01163/20201203/images/large/jm0c01163_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01163&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) aldehyde, AcOH (1% H<sub>2</sub>O), 90 °C, then aq. HCl or NH<sub>2</sub>OH, 44–100%; (b) NaNO<sub>2</sub>, propionic acid, H<sub>2</sub>O, −20 °C, 17–75%; (c) 3,4-dihydro-2<i>H</i>-pyran, PTSA hydrate, DCM, reflux, 53–99%; (d) 2-[3-(fluoromethyl)azetidin-1-yl]ethanol, RockPhos third generation Pd precatalyst, Cs<sub>2</sub>CO<sub>3</sub>, toluene, 90 °C, 42–78%; (e) 4 N HCl dioxane, RT, 37–78%.</p></p></figure><div class="NLM_p">Starting from the THP protected tricyclic indazoles bearing a 4-bromo aryl substituent <b>49g</b>, the acyclic amine was introduced by Pd-catalyzed ether formation with the <i>N</i>-Boc protected ethanolamine (step a). Removal of both the Boc and THP protecting groups (step b) gave the desired acyclic ether <b>14</b>. The oxy-linked azetidine was found to be a challenging substrate to install by Pd-catalyzed coupling. Instead, the bromo intermediate <b>49g</b> was first converted to the phenol <b>51</b> via the pinacol boronate <b>50</b> (steps d, e). Mitsonobu reaction with the <i>N</i>-Boc protected hydroxy-azetidine was then used to install the ether linkage (step f), and then deprotection of both the Boc and THP protecting groups followed by <i>N</i>-alkylation (steps h, i) furnished the oxy-linked azetidine <b>15</b> (<a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>). To introduce the acyclic amino linker on the pyridyl substrate a Buchwald amination on intermediate <b>49h’</b> (intermediate before THP protection in the synthesis of <b>49h</b>), catalyzed by BrettPhos 3rd generation precatalyst,<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> installed the unprotected acyclic diamine selectively on the primary amine. In this instance, it was possible to perform the coupling reaction directly on the unprotected tricyclic indazole (R = H) to give <b>17</b>. Amino-azetidines were also accessed via Buchwald amination. For the methoxyphenyl substrate <b>49g</b>, formation of the <i>N</i>-Boc protected amino-azetidine occurred in excellent yield (91%); then, simultaneous deprotection of both the Boc and THP groups with HCl followed by <i>N</i>-alkylation with 3-fluoroiodopropane furnished the <i>N</i>-alkylated azetidine <b>16</b>. For the pyridyl substrate <b>49h</b>, the amination was carried out using an amino-azetidine with the fluoropropyl chain already preinstalled to give <b>18</b> after deprotection of the THP group.</div><figure id="sch3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01163/20201203/images/medium/jm0c01163_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01163/20201203/images/large/jm0c01163_0015.jpeg" id="gr15" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Variation of the <i>O</i>- and <i>N</i>-Linked Basic Substituent<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01163/20201203/images/large/jm0c01163_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01163&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) <i>tert</i>-butyl (3-fluoropropyl)(2-hydroxyethyl)carbamate, RockPhos third generation Pd precatalyst, Cs<sub>2</sub>CO<sub>3</sub>, toluene, 90 °C, 92% (from <b>49g</b>); (b) HCl/dioxane, RT, 29%; (c) <i>N</i><sup>1</sup>-(3-fluoropropyl)ethane-1,2-diamine. 2HCl, BrettPhos third generation Pd precatalyst, NaO<sup>t</sup>Bu, dioxane, 50 °C, 18% (from <b>49h′</b>); (d) (B(Pin))<sub>2</sub>, Pd(dppf)Cl<sub>2</sub>, KOAc, dioxane, 80 °C, 46%; (e) Aq. H<sub>2</sub>O<sub>2</sub>, 1 M NaOH, THF, 5 °C, 63%; (f) <i>tert</i>-butyl 3-hydroxyazetidine-1-carboxylate, DEAD, PPh<sub>3</sub>, toluene, 110 °C, 75% (from <b>51</b>); (g) <i>tert</i>-butyl 3-aminoazetidine-1-carboxylate, BrettPhos third generation Pd precatalyst, Cs<sub>2</sub>CO<sub>3</sub>, dioxane, MW, 100 °C, 91% (from <b>49g</b>); (h) HCl/dioxane, RT, 36–87%; (i) 1-fluoro-3-iodopropane, DIPEA, NMP, RT, 18–39%; (j) 1-(3-fluoropropyl)azetidin-3-amine, BrettPhos third generation Pd precatalyst, NaO<sup>t</sup>Bu, dioxane, 90 °C, then DCM, TFA, RT, 10% (from <b>49h</b>).</p></p></figure><div class="NLM_p">With this methodology in hand, we next investigated variation of the <i>N</i>-alkyl group on the piperidine ring. As we established during our previous investigations, the alkyl group could be varied according to <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>; following formation of the <i>N</i>-alkyl diamines <b>45</b>, Pictet–Spengler cyclization to <b>48</b> followed by indazole formation furnished the tricyclic ring (Method A), which could be THP protected to give <b>49</b>. The amino-azetidine could then be installed by Buchwald amination to give compounds <b>19</b>–<b>28</b> (<a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>).</div><figure id="sch4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01163/20201203/images/medium/jm0c01163_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01163/20201203/images/large/jm0c01163_0016.jpeg" id="gr16" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Pictet–Spengler Approach to <i>N</i>-Linked Tricyclic Indazoles (Method A)<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01163/20201203/images/large/jm0c01163_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01163&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) aldehyde, AcOH (1% H<sub>2</sub>O), 90 °C, then aq. HCl or NH<sub>2</sub>OH, 16–68%; (b) NaNO<sub>2</sub>, propionic acid, H<sub>2</sub>O, −20 °C, 34–75%; (c) 3,4-dihydro-2<i>H</i>-pyran, PTSA hydrate, DCM; (d) if R<sup>3</sup> = CH<sub>2</sub>OSiPh<sub>2</sub>tBu, 1 M TBAF, THF, RT, 71%; (e) 1-(3-fluoropropyl)azetidin-3-amine or <i>tert</i>-butyl 3-aminoazetidine-1-carboxylate, BrettPhos third generation Pd precatalyst, NaO<sup>t</sup>Bu or Cs<sub>2</sub>CO<sub>3</sub>, dioxane, 27–88%; (f) HCl/dioxane, RT, 40–92%; (f) (when <i>tert</i>-butyl 3-aminoazetidine-1-carboxylate used in step (e)) 1-fluoro-3-iodopropane, DIPEA, NMP, RT, 29–51%.</p></p></figure><div class="NLM_p">As our interest in compound <b>28</b> grew, we sought an improved route that would circumvent the indazole formation step, as we envisaged that this could be challenging to carry out on multigram scale. To this end, we found that when a combination of a 2-pyridyl aldehyde and a polyfluorinated <i>N</i>-alkyl side chain were employed, Pictet–Spengler cyclization was possible on the preformed indazole (Method B). The indazole starting material was accessed by lithiation of 4-bromo indazole <b>52</b> and subsequent reaction with the cyclic sulfamidate <b>42</b>. Boc deprotection and selective alkylation of the aliphatic amine with the alkyl triflate afforded the <i>N</i>-trifluoroethyl alkylated indazole <b>53</b>. Pictet–Spengler cyclization in a toluene/TFA mixture then afforded the <i>trans</i> tricyclic indazole <b>54</b>. Finally, the amino-azetidine was added in the usual manner through Buchwald amination. Pleasingly, we found that the Buchwald amination could proceed without the need to protect the indazole provided that an excess of base was used, circumventing the need for a protection/deprotection sequence. Through these improvements, the route toward <b>28</b> was reduced from nine synthetic steps to only four steps and provided <b>28</b> in an overall yield of 30% (<a class="ref internalNav" href="#sch5" aria-label="Scheme 5">Scheme 5</a>).</div><figure id="sch5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01163/20201203/images/medium/jm0c01163_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01163/20201203/images/large/jm0c01163_0017.jpeg" id="gr17" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Pictet–Spengler Approach on Preformed Indazole to Access <b>28</b> (Method B)<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01163/20201203/images/large/jm0c01163_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01163&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) <i>n</i>-BuLi, <i>tert</i>-butyl (<i>R</i>)-4-methyl-1,2,3-oxathiazolidine-3-carboxylate 2,2-dioxide, THF, −78 °C, 57% then HCl/dioxane, DCM, RT, 57%. Isolated as 2HCl salt; (b) 2,2,2-trifluoroethyl trifluoromethanesulfonate, K<sub>2</sub>CO<sub>3</sub>, DCM, reflux, 93%; (c) 5-bromopicolinaldehyde, toluene, TFA, 80 °C, 75%; (d) 1-(3-fluoropropyl)azetidin-3-amine, BrettPhos third generation Pd precatalyst, NaO<sup>t</sup>Bu, dioxane, 55 °C, 74%.</p></p></figure><div class="NLM_p">We next sought to access 1-methyl substituted quaternary tricyclic indazoles. Pictet–Spengler cyclizations with ketones are typically more challenging and often require specialized conditions when compared to aldehydes.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> After initial unsuccessful attempts to close the ring in this way, an alternative approach was developed. We envisaged that the quaternary center could be formed by addition of suitable nucleophilic species to the iminium ion of the precyclized system. Thus, the THP protected tricyclic indazole <b>49j</b> was treated with cerium(IV) ammonium nitrate in acetonitrile/water to form the iminium ion, which could then be reacted with methylmagnesium bromide to form the quaternary center of <b>55</b> as a 3:2 mixture of diastereoisomers in low yield.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> Removal of the THP protecting group and subsequent Buchwald amination and separation of the isomers afforded the desired product <b>31</b> (<a class="ref internalNav" href="#sch6" aria-label="Scheme 6">Scheme 6</a>).</div><figure id="sch6" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01163/20201203/images/medium/jm0c01163_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01163/20201203/images/large/jm0c01163_0018.jpeg" id="gr18" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Oxidation/Grignard Approach to the Quaternary Substituted core <b>31</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01163/20201203/images/large/jm0c01163_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01163&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) cerium(IV) ammonium nitrate, MeCN/H<sub>2</sub>O, RT, then MeMgBr, THF, −78 °C, 14%, 3:2 mixture of diastereoisomers; (b) HCl/dioxane, MeOH, RT, 28%, 3:2 mixture of diastereoisomers; (c) 1-(3-fluoropropyl)azetidin-3-amine, BrettPhos third generation Pd precatalyst, NaO<sup>t</sup>Bu, dioxane, 65 °C, SFC separation, 12%.</p></p></figure><div class="NLM_p">Introduction of <i>geminal</i>-dimethyl substitution into the saturated ring could be achieved from the THP-protected 4-bromo-indazole <b>56</b> according to our previously reported procedure.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> Lithium-halogen exchange with <i>n</i>-BuLi followed by quenching with dimethyloxirane and BF<sub>3</sub>·Et<sub>2</sub>O afforded the tertiary alcohol <b>57</b>. The Ritter reaction with chloroacetonitrile gave <b>58</b>, which following cleavage of the amide with thiourea furnished the <i>gem</i>-dimethyl amine <b>59</b>. The saturated ring was then constructed with a Pictet–Spengler cyclization using 2-pyridyl-4-bromobenzaldehyde on the unalkylated amine to give <b>60</b>. THP protection of the racemic indazole gave <b>61</b>; then, alkylation with the difluoroethyl triflate and DIPEA afforded <b>62</b>. Subsequent Buchwald amination reaction installed the amino-azetidine and deprotection of the THP group and chiral separation of the enantiomers afforded enantiopure <b>32</b> (<a class="ref internalNav" href="#sch7" aria-label="Scheme 7">Scheme 7</a>). In the case of 2-trifluoroethyl triflate, alkylation of the sterically congested cyclic amine proved to be challenging. Thus, in a related approach, the more accessible gem-dimethyl amine could instead be alkylated, and the resulting product taken through the same reaction sequence.</div><figure id="sch7" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01163/20201203/images/medium/jm0c01163_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01163/20201203/images/large/jm0c01163_0019.jpeg" id="gr19" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 7. Pictet–Spengler Route to <i>gem</i>-Dimethyl Substituted Tricyclic Indazole <b>32</b> and <b>33</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01163/20201203/images/large/jm0c01163_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01163&amp;id=sch7"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) <i>n</i>-BuLi, 2,2-dimethyloxirane, BF<sub>3</sub>·Et<sub>2</sub>O, THF, −78 °C, 1 h, 62%; (b) 2-chloroacetonitrile, AcOH, H<sub>2</sub>SO<sub>4</sub>, RT, 48 h, 59%; (c) thiourea, EtOH, AcOH, reflux, 16 h, 83%; (d) 5-bromopicolinaldehyde, toluene, TFA, 150 °C, MW, 72%; (e) 3,4-dihydro-2<i>H</i>-pyran, PTSA hydrate, DCM, 50 °C, 95%; (f) 2,2-difluoroethyl trifluoromethanesulfonate (0.4 M in DCM), DIPEA, dioxane, 60 °C, 81%; (g) 1-(3-fluoropropyl)azetidin-3-amine, BrettPhos third generation Pd precatalyst, NaO<sup>t</sup>Bu, dioxane, 60 °C, then DCM, TFA, RT, 68%; (h) SFC chromatography; (i) 2,2,2-trifluoroethyl trifluoromethanesulfonate (0.32 M in chloroform), DIPEA, dioxane, 65 °C, 53%; (j) 5-bromopicolinaldehyde, toluene, TFA, 100 °C, 25%; (k) 1-(3-fluoropropyl)azetidin-3-amine, BrettPhos third generation Pd precatalyst, NaO<sup>t</sup>Bu, dioxane, 80 °C, 30%.</p></p></figure><div class="NLM_p">In order to access the analogous indole core, it was necessary to develop a new route drawing on our experience from the indazole series (<a class="ref internalNav" href="#sch8" aria-label="Scheme 8">Scheme 8</a>). 1-Bromo-2-methyl-3-nitrobenzene <b>65</b> was treated with potassium hydroxide and formaldehyde to afford the homologated hydroxy compound <b>66</b>. Following nitro reduction, the free aniline <b>67</b> was protected as a 2,5-dimethylpyrrole and the hydroxy group with a 4-methoxybenzyl to give fully protected bromide <b>68</b>. We then employed our previously established methodology to install the alkyl-amino unit via lithium-halogen exchange and ring opening of the cyclic sulfamidate. Following removal of both the <i>N</i>-Boc and pyrrole protecting groups, the diamine <b>69</b> was alkylated through formation of the trifluoroacetamide and subsequent reduction with borane solution in THF. Alkyl diamine <b>70</b> successfully underwent Lewis-acid mediated Pictet-Spengler cyclization to afford the cyclic intermediate <b>71</b>, following removal of the PMB protecting group with HCl in dioxane. Indole formation was then achieved through iridium catalyzed cyclization of the amino-alcohol<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> to give <b>72</b>. Finally, the amino-azetidine moiety was installed through Buchwald amination to give <b>34</b>.</div><figure id="sch8" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01163/20201203/images/medium/jm0c01163_0020.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01163/20201203/images/large/jm0c01163_0020.jpeg" id="gr20" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 8. Pictet–Spengler Route to Tricyclic Indole <b>34</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01163/20201203/images/large/jm0c01163_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01163&amp;id=sch8"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) paraformaldehyde, KOH, DMA, RT, 72%; (b) ammonium formate, Zn, MeOH, RT, 96%; (c) hexane-2,5-dione, PTSA hydrate, toluene, 100 °C, 98%; (d) PMBCl, NaH, NaI, DMF, RT, 80%; (e) <i>n</i>-BuLi, <i>tert</i>-butyl (4<i>R</i>)-4-methyl-1,2-oxathiolane-3-carboxylate 2,2-dioxide, THF, −78 °C, 61%; (f) HCl/dioxane, MeOH, RT, 57%; (g) Aq. NH<sub>2</sub>OH, NH<sub>2</sub>OH.HCl, EtOH, 50 °C, 36%; (h) ethyl 2,2,2-trifluoroacetate, DIPEA, MeOH, RT, quant. (i) BH<sub>3</sub>.THF, THF, 65 °C, 77%; (j) 5-bromopicolinaldehyde, Yb(III)Tf, MeCN/H<sub>2</sub>O, 70 °C, 77%; (k) HCl/dioxane, MeOH, RT, 79%; (l) pentamethylcyclopentadienyl iridium dichloride, K<sub>2</sub>CO<sub>3</sub>, toluene, 100 °C, 80%; (m) 1-(3-fluoropropyl)azetidin-3-amine, BrettPhos third generation Pd precatalyst, NaO<sup>t</sup>Bu, dioxane, 50 °C, 62%.</p></p></figure><div class="NLM_p">Variation of the azetidine moiety was achieved by making use of the common tricyclic indazole intermediate <b>54</b>, the synthesis of which is described in <a class="ref internalNav" href="#sch5" aria-label="Scheme 5">Scheme 5</a>. Buchwald amination proceeded smoothly with the quaternary methyl azetidine to give <b>73</b>, after which the Boc group could be removed under acidic conditions and the azetidine alkylated in the usual manner to give <b>36</b>. The aniline of <b>28</b> could also be homologated under reductive amination conditions using paraformaldehyde and NaCNBH<sub>3</sub> to afford the <i>N</i>-Me compound <b>37</b> (<a class="ref internalNav" href="#sch9" aria-label="Scheme 9">Scheme 9</a>).</div><figure id="sch9" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01163/20201203/images/medium/jm0c01163_0021.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01163/20201203/images/large/jm0c01163_0021.jpeg" id="gr21" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 9. Variation of the Azetidine Substituent<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01163/20201203/images/large/jm0c01163_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01163&amp;id=sch9"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) amine, BrettPhos third generation Pd precatalyst, NaO<sup><i>t</i></sup>Bu, dioxane, 57%; (b) TFA, DCM, RT, then 1-fluoro-3-iodopropane, DIPEA, DMF, RT, 75%; (c) paraformaldehyde, NaCNBH<sub>3</sub>, AcOH, <sup><i>i</i></sup>PrOH, 70 °C, 72%.</p></p></figure><div class="NLM_p">Finally, we wished to reinvestigate the amine component. Using the same tricyclic bromide <b>54</b>, Buchwald amination proceeded with the CbZ protected acyclic diamine to give <b>74</b>, after which the protecting group could be removed by hydrogenation to give <b>35</b>. Buchwald amination was successful with Boc protected (<i>S</i>)-amino-pyrrolidine on unprotected indazole <b>54</b> to give <b>75</b> but with the Pd-catalyzed ether formation with (<i>S</i>)-hydroxy-pyrrolidine this required THP-protected indazole <b>49k</b> to give <b>76</b>. Boc deprotection and subsequent reaction with 3-fluoro iodopropane afforded the <i>N</i>-alkylated products <b>38</b> and <b>40</b>. Finally, in the case of amino-pyrrolidine <b>39</b>, reductive amination on the aniline <b>38</b> with formaldehyde and NaCNBH<sub>3</sub> afforded the <i>N</i>-methylated product.<named-content content-type="anchor" rid="sch10" type="simple"></named-content></div><figure id="sch10" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Scheme 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01163/20201203/images/medium/jm0c01163_0022.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01163/20201203/images/large/jm0c01163_0022.jpeg" id="gr22" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 10. Variation of the <i>N</i>-Linked Basic Substituent<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01163/20201203/images/large/jm0c01163_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01163&amp;id=sch10"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) benzyl (2-aminoethyl)(3-fluoropropyl)carbamate, BrettPhos third generation Pd precatalyst, NaO<sup><i>t</i></sup>Bu, dioxane, RT, 58% (from <b>54</b>); (b) Pd/C, H<sub>2</sub>, EtOH, RT, 80%; (c) (X = NH): <i>tert</i>-butyl (<i>S</i>)-3-aminopyrrolidine-1-carboxylate, BrettPhos third generation Pd precatalyst, NaO<sup>t</sup>Bu, dioxane, 80 °C, 81% (from <b>54</b>); (d) (X = O): <i>tert</i>-butyl (<i>S</i>)-3-hydroxypyrrolidine-1-carboxylate, RockPhos third generation Pd precatalyst, Cs<sub>2</sub>CO<sub>3</sub>, toluene, 90 °C, 70% (from <b>49k</b>); (e) DCM, TFA, or HCl/dioxane, MeOH, RT, then 1-fluoro-3-iodopropane, DIPEA, DMF, RT, 14–69%; (f) paraformaldehyde, NaCNBH<sub>3</sub>, AcOH, MeOH, 50 °C, 19%.</p></p></figure></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> Initial Optimization: Control of Lipophilicity and Pharmacology</h3><div class="NLM_p">Our initial optimization began with a matrix of indazoles altering the aryl ring substitution and varying the alkyl chain (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). Compounds were evaluated in an ER binding assay and cellular degradation assay in MCF7 cells as described previously.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> The SAR in our program was primarily driven by the cellular assay but ER degradation in MCF-7 and CAMA-1 cells was also determined by Western blot for key compounds. On the basis of previously reported SAR with the indazole acids, we were pleased to find that, with the 2-F<sup>i</sup>Bu side chain (R<sup>1</sup> = A), the switch from the 2,6-difluorophenyl (Core W) to the 2-methoxyphenyl (Core Y) maintained potency (cf. <b>5</b> vs <b>6</b>). Importantly, this was associated with a reduction in lipophilicity (ΔlogD<sub>7.4</sub> −0.8) and a corresponding increase in fraction unbound and reduction in rat hepatocyte clearance. In the case of the <sup>i</sup>Bu side chain (R<sup>1</sup> = B), deletion of the fluorine substituents (Core X) allowed lipophilicity reduction (cf. <b>7</b> vs <b>8</b>), and addition of the 2-methoxyphenyl (Core Y) provided our first compound <b>9</b> with logD<sub>7.4</sub> < 3. Importantly, investigation of heteroaryl rings revealed that a 2-pyridyl (Core Z) <b>10</b> was tolerated in terms of potency. An additional strategy to lower the lipophilicity involved modifying the alkyl substituent with the formal linkage of the two methyl groups of the 2-F<sup>i</sup>Bu side chain to form a cyclopropyl ring (R<sup>1</sup> = C). Comparison of the matched pair <b>11</b> with <b>6</b> (core Y) revealed significant lipophilicity lowering (ΔlogD<sub>7.4</sub> −0.8) with no effect on potency. Compound <b>12</b> with this alkyl side chain also displayed good potency at low lipophilicity (logD<sub>7.4</sub> 2.6). Further investigation highlighted the fluorooxetane (R<sup>1</sup> = D) as a group that could also be used to access highly potent, low lipophilicity compounds such as <b>13</b>.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Data for Aryl Ring and Alkyl Chain Variation</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01163/20201203/images/medium/jm0c01163_0023.gif" alt="" id="GRAPHIC-d7e1858-autogenerated" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">cpd</th><th class="colsep0 rowsep0" align="center">core</th><th class="colsep0 rowsep0" align="center">R<sup>1</sup></th><th class="colsep0 rowsep0" align="center">ER bind pIC<sub>50</sub><a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">ER DR pIC<sub>50</sub> (<i>D</i><sub>max</sub> (%))<a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">log D<sub>7.4</sub> (LLE)<a class="ref internalNav" href="#t1fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center">human % free<a class="ref internalNav" href="#t1fn4" aria-label="d">d</a></th><th class="colsep0 rowsep0" align="center">rat/human hepatocyte CL<sub>int</sub> (μL/min/10<sup>6</sup> cells)<a class="ref internalNav" href="#t1fn5" aria-label="e">e</a></th><th class="colsep0 rowsep0" align="center">% deg vs Fv MCF-7/CAMA-1<a class="ref internalNav" href="#t1fn6" aria-label="f">f</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5</b></td><td class="colsep0 rowsep0" align="left">W</td><td class="colsep0 rowsep0" align="left">A</td><td class="colsep0 rowsep0" align="left">9.0</td><td class="colsep0 rowsep0" align="left">9.9 (95)</td><td class="colsep0 rowsep0" align="left">4.4 (5.5)</td><td class="colsep0 rowsep0" align="left">0.8</td><td class="colsep0 rowsep0" align="left">88/8</td><td class="colsep0 rowsep0" align="left">84/66</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6</b></td><td class="colsep0 rowsep0" align="left">Y</td><td class="colsep0 rowsep0" align="left">A</td><td class="colsep0 rowsep0" align="left">8.5</td><td class="colsep0 rowsep0" align="left">9.8 (95)</td><td class="colsep0 rowsep0" align="left">3.6 (6.2)</td><td class="colsep0 rowsep0" align="left">6.5</td><td class="colsep0 rowsep0" align="left">28/12</td><td class="colsep0 rowsep0" align="left">69/74</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7</b></td><td class="colsep0 rowsep0" align="left">W</td><td class="colsep0 rowsep0" align="left">B</td><td class="colsep0 rowsep0" align="left">9.1<a class="ref internalNav" href="#t1fn7" aria-label="g">g</a></td><td class="colsep0 rowsep0" align="left">9.7 (99)</td><td class="colsep0 rowsep0" align="left">4.6 (5.1)</td><td class="colsep0 rowsep0" align="left">0.4</td><td class="colsep0 rowsep0" align="left">74/9</td><td class="colsep0 rowsep0" align="left">–/–</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8</b></td><td class="colsep0 rowsep0" align="left">X</td><td class="colsep0 rowsep0" align="left">B</td><td class="colsep0 rowsep0" align="left">8.7<a class="ref internalNav" href="#t1fn7" aria-label="g">g</a></td><td class="colsep0 rowsep0" align="left">9.8 (99)</td><td class="colsep0 rowsep0" align="left">3.4 (6.4)</td><td class="colsep0 rowsep0" align="left">11</td><td class="colsep0 rowsep0" align="left">66/8</td><td class="colsep0 rowsep0" align="left">–/–</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>9</b></td><td class="colsep0 rowsep0" align="left">Y</td><td class="colsep0 rowsep0" align="left">B</td><td class="colsep0 rowsep0" align="left">8.1</td><td class="colsep0 rowsep0" align="left">9.3 (98)</td><td class="colsep0 rowsep0" align="left">2.4 (6.9)</td><td class="colsep0 rowsep0" align="left">52</td><td class="colsep0 rowsep0" align="left">9/3</td><td class="colsep0 rowsep0" align="left">94/74</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10</b></td><td class="colsep0 rowsep0" align="left">Z</td><td class="colsep0 rowsep0" align="left">B</td><td class="colsep0 rowsep0" align="left">8.0<a class="ref internalNav" href="#t1fn7" aria-label="g">g</a></td><td class="colsep0 rowsep0" align="left">9.4 (99)</td><td class="colsep0 rowsep0" align="left">3.2 (6.2)</td><td class="colsep0 rowsep0" align="left">19</td><td class="colsep0 rowsep0" align="left">41/8</td><td class="colsep0 rowsep0" align="left">–/–</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11</b></td><td class="colsep0 rowsep0" align="left">Y</td><td class="colsep0 rowsep0" align="left">C</td><td class="colsep0 rowsep0" align="left">8.0<a class="ref internalNav" href="#t1fn7" aria-label="g">g</a></td><td class="colsep0 rowsep0" align="left">9.9 (96)<a class="ref internalNav" href="#t1fn8" aria-label="h">h</a></td><td class="colsep0 rowsep0" align="left">2.8 (7.1)</td><td class="colsep0 rowsep0" align="left">21</td><td class="colsep0 rowsep0" align="left">20/7</td><td class="colsep0 rowsep0" align="left">79/88</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12</b></td><td class="colsep0 rowsep0" align="left">Z</td><td class="colsep0 rowsep0" align="left">C</td><td class="colsep0 rowsep0" align="left">8.9</td><td class="colsep0 rowsep0" align="left">9.4 (98)<a class="ref internalNav" href="#t1fn7" aria-label="g">g</a></td><td class="colsep0 rowsep0" align="left">2.6 (6.8)</td><td class="colsep0 rowsep0" align="left">34</td><td class="colsep0 rowsep0" align="left">38/8</td><td class="colsep0 rowsep0" align="left">75/87</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>13</b></td><td class="colsep0 rowsep0" align="left">Y</td><td class="colsep0 rowsep0" align="left">D</td><td class="colsep0 rowsep0" align="left">8.4<a class="ref internalNav" href="#t1fn7" aria-label="g">g</a></td><td class="colsep0 rowsep0" align="left">9.6 (95)</td><td class="colsep0 rowsep0" align="left">2.7 (6.9)</td><td class="colsep0 rowsep0" align="left">25</td><td class="colsep0 rowsep0" align="left">42/–</td><td class="colsep0 rowsep0" align="left">79/75</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">ER binding based on <i>n</i> ≥ 2 with SEM within 0.2 units, unless otherwise stated.</p></div><div class="footnote" id="t1fn2"><sup><sup>b</sup></sup><p class="last">ER degradation based on <i>n</i> ≥ 2 with SEM within 0.2 units, unless otherwise stated and degradation (%<i>D</i><sub>max</sub>) relative to fulvestrant.</p></div><div class="footnote" id="t1fn3"><sup><sup>c</sup></sup><p class="last">LogD<sub>7.4</sub> determined by shake flask method with a buffer/octanol volume ratio of 100:1 (LLE = ER DR pIC<sub>50</sub> – logD<sub>7.4</sub>).</p></div><div class="footnote" id="t1fn4"><sup><sup>d</sup></sup><p class="last">Determined from DMSO stock solution by equilibrium dialysis in 10% human plasma supplied by Quintiles.</p></div><div class="footnote" id="t1fn5"><sup><sup>e</sup></sup><p class="last">Rate of metabolism (μL/min/10<sup>6</sup> cells) determined from DMSO stock solution in isolated hepatocytes diluted to 1 × 10<sup>6</sup> cells/mL.</p></div><div class="footnote" id="t1fn6"><sup><sup>f</sup></sup><p class="last">% degradation of ER relative to fulvestrant (Fv) in MCF-7 and CAMA-1 cells as determined by Western blot at 0.1 μM.</p></div><div class="footnote" id="t1fn7"><sup><sup>g</sup></sup><p class="last"><i>n</i> = 1.</p></div><div class="footnote" id="t1fn8"><sup><sup>h</sup></sup><p class="last">SEM = 0.23.</p></div></div></div><div class="NLM_p">With compounds in the desired lipophilicity space, we turned our attention to optimization of the basic group fixing the alkyl chain as the 2-F<sup>c</sup>Pr substituent (R<sup>1</sup> = C from <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). The SAR was found to be particularly steep in this region with most changes resulting in poorer potency or degradation efficiency. One aspect that did prove productive however was shifting the connectivity of the azetidine ring. Acyclic base <b>14</b> (core S) represents a ring opening of the azetidine and resulted in a significant reduction in the extent of degradation (cf. <b>14</b> vs <b>11</b><i>D</i><sub>max</sub> 82% vs 96%). Reconstruction of an azetidine ring proximal to the aryl ring (core T) restored the degradation efficiency (cf. <b>15</b> vs <b>11</b><i>D</i><sub>max</sub> 97% vs 96%) albeit with increased lipophilicity. Switching the linkage from an ether to an amine (<b>16</b>) maintained potency and degradation efficiency while lowering lipophilicity and giving a compound with low clearance in both rat and human hepatocytes.</div><div class="NLM_p last">Similar SAR was observed with the pyridyl ring; the acyclic base <b>17</b> (Core U) with an amine linker had a slightly lower degradation efficiency (<i>D</i><sub>max</sub> 93%) with cyclization to form an azetidine <b>18</b> (Core V) restoring this (<i>D</i><sub>max</sub> 96%) and giving a compound in our target zone of lipophilicity. Importantly, the degradation measured by Western blot in both MCF-7 and CAMA-1 lines was generally higher for this arrangement of the azetidine than the motif described in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>.</div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> Structure and Conformation of Early Leads</h3><div class="NLM_p">Both compounds <b>14</b> and <b>16</b> (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>) show comparable binding potency and high cellular pIC<sub>50</sub>, but significant enhancement in maximum degradation (<i>D</i><sub>max</sub>) was observed for <b>16</b> (96% vs 82%). We investigated the conformation of the <i>para</i>-linked base as well as the behavior of the <i>ortho</i>-methoxy substituted ring by NMR. Solution conformational analysis of <b>16</b> by NMR shows that the para-linked basic group is able to rotate; however, unlike the fully flexible linear chain of <b>14</b>, the base is more restricted in the space it can access, as a result of the lower number of rotatable bonds (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>a). The NMR analysis highlighted that the aryl ring of <b>16</b> is rotationally restricted by the presence of the methoxy group which is oriented below the plane of the molecular core. The orientation of this group corresponds to the one seen in the protein–ligand crystal structure, where the methoxy group fills a small pocket toward the back of the binding site (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>a,b). The same orientation of the methoxy group was observed previously for tricyclic indazoles carrying an acrylic acid group rather than a basic one, with the group filling the same pocket.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> The <i>N</i>-alkyl side chain is conformationally rigid with the hydrogens in the α-position and the fluorine pointing away from the phenyl ring, again corresponding closely to the binding mode observed in the protein–ligand crystal structure (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>a,c).</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Data for Basic Group Variation in the Methoxyphenyl and Pyridine Series<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01163/20201203/images/medium/jm0c01163_0024.gif" alt="" id="GRAPHIC-d7e2363-autogenerated" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">cpd</th><th class="colsep0 rowsep0" align="center">core</th><th class="colsep0 rowsep0" align="center">L</th><th class="colsep0 rowsep0" align="center">ER bind pIC<sub>50</sub></th><th class="colsep0 rowsep0" align="center">ER DR pIC<sub>50</sub> (<i>D</i><sub>max</sub> (%))</th><th class="colsep0 rowsep0" align="center">log D<sub>7.4</sub> (LLE)</th><th class="colsep0 rowsep0" align="center" char=".">human % free</th><th class="colsep0 rowsep0" align="center">rat/human hepatocyte CL<sub>int</sub> (μL/min/10<sup>6</sup> cells)</th><th class="colsep0 rowsep0" align="center">% deg vs Fv MCF-7/CAMA-1</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>14</b></td><td class="colsep0 rowsep0" align="left">S</td><td class="colsep0 rowsep0" align="left">O</td><td class="colsep0 rowsep0" align="left">8.1<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">9.5 (82)<a class="ref internalNav" href="#t2fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">2.4 (7.1)</td><td class="colsep0 rowsep0" align="char" char=".">18</td><td class="colsep0 rowsep0" align="left">9/–</td><td class="colsep0 rowsep0" align="left">–/–</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>15</b></td><td class="colsep0 rowsep0" align="left">T</td><td class="colsep0 rowsep0" align="left">O</td><td class="colsep0 rowsep0" align="left">8.1</td><td class="colsep0 rowsep0" align="left">9.4 (97)<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">3.5 (5.9)</td><td class="colsep0 rowsep0" align="char" char=".">11</td><td class="colsep0 rowsep0" align="left">16/–</td><td class="colsep0 rowsep0" align="left">90/90</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>16</b></td><td class="colsep0 rowsep0" align="left">T</td><td class="colsep0 rowsep0" align="left">NH</td><td class="colsep0 rowsep0" align="left">8.1</td><td class="colsep0 rowsep0" align="left">9.5 (96)</td><td class="colsep0 rowsep0" align="left">2.4 (7.1)</td><td class="colsep0 rowsep0" align="char" char=".">34</td><td class="colsep0 rowsep0" align="left">7/2</td><td class="colsep0 rowsep0" align="left">89/84</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>17</b></td><td class="colsep0 rowsep0" align="left">U</td><td class="colsep0 rowsep0" align="left">NH</td><td class="colsep0 rowsep0" align="left">8.0<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">9.0 (93)</td><td class="colsep0 rowsep0" align="left">2.0 (7.0)</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="left">22/–</td><td class="colsep0 rowsep0" align="left">–/–</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>18</b></td><td class="colsep0 rowsep0" align="left">V</td><td class="colsep0 rowsep0" align="left">NH</td><td class="colsep0 rowsep0" align="left">8.2</td><td class="colsep0 rowsep0" align="left">9.2 (96)</td><td class="colsep0 rowsep0" align="left">2.5 (6.7)</td><td class="colsep0 rowsep0" align="char" char=".">26</td><td class="colsep0 rowsep0" align="left">24/5</td><td class="colsep0 rowsep0" align="left">90/102</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">Legend as <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>.</p></div><div class="footnote" id="t2fn2"><sup><sup>b</sup></sup><p class="last"><i>n</i> = 1.</p></div><div class="footnote" id="t2fn3"><sup><sup>c</sup></sup><p class="last">SEM = 0.29.</p></div></div></div><figure id="fig3" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01163/20201203/images/medium/jm0c01163_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01163/20201203/images/large/jm0c01163_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. (a) Solution conformation of <b>16</b>. Flexibility is illustrated with thin-wire depictions of the basic group which is capable of adopting different conformations in solution; (b) X-ray crystallography of <b>16</b> (cyan, pdb: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6zoq">6zoq</a>) bound to the ERα ligand binding domain construct with aligned structure of tamoxifen (white, pdb: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5aav">5aav</a>) for reference; (c) aligned protein–ligand crystal structures of <b>16</b> and <b>18</b> (magenta, pdb: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6zos">6zos</a>). The loop connecting helices 11 and 12 is tagged in b and c, as well as key residues.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01163/20201203/images/large/jm0c01163_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01163&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The binding of the [5.6.6] indazole core of the molecule is in line with the binding mode seen previously.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> The tricyclic core is bound in a deep pocket that is mostly lined with hydrophobic residues. The nitrogens of the tricyclic indazole interact with a conserved water and form short hydrogen-bonding contacts with Glu353, which itself forms a water-mediated salt bridge to Arg394. Unlike the previously reported tricyclic [6.5.6] indole core of <b>1b</b>, the tricyclic indazole lacks the indole NH hydrogen bond donor on the central ring that interacts with the backbone carbonyl of Leu346.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> However, the distance of the carbonyl oxygen from the protein backbone to the central ring of the tricyclic indazole is short (3.6 Å), and this is not an unfavorable contact.</div><div class="NLM_p">A closer analysis of the protein–ligand complexes of <b>16</b> and <b>18</b>, which have <i>ortho</i>-methoxy phenyl and pyridyl ring substituents, shows a close alignment of the core binding modes, and similar placements of the basic group (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>c). The orientation of the pyridyl group in <b>18</b> cannot be discerned in the crystal structure and was observed to be freely rotatable in solution by NMR. The protein construct used in these structures has a L536S mutation in the loop connecting helix 11 (H11) and helix 12 (H12) that biases its conformation and that of the connected H12 toward the antagonist orientation.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> The fluorinated terminal group of the basic azetidine is positioned close to H12. In the case of compound <b>16</b>, the base forms a strong hydrogen-bonding contact to the backbone carbonyl of Val533 (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>c, distance 2.9 Å), which resides in the flexible loop connecting helices 11 and 12. The structure of <b>18</b> suggests that the base is oriented toward the acidic side chain of Asp351, forming again a strong contact (distance 2.8 Å). The proximity of the basic group to H12 and its ability to stabilize the conformation of a flexible loop by forming close hydrogen-bonded contacts may suggest that this plays a role in the process that ultimately leads to recognition of ERα by the cellular degradation machinery.</div><div class="NLM_p">In addition to the solution and protein–ligand structures, a small molecule crystal structure of <b>16</b> was also obtained to allow unambiguous confirmation of the chemical structure and stereochemistry. Single crystal analysis of <b>16</b> revealed a sesqui-<i>tert</i>-butyl methyl ether (TBME) solvate form that crystallized in a nonsymmetric monoclinic <i>C</i>2 space group (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>). The <i>ortho</i>-methoxy phenyl group showed a orientation similar to that observed in the solution and protein–ligand structures. The terminal fluoropropyl chain was orientated as a low energy <i>anti</i>-conformer with a staggered conformation, which is in line with the solution conformation measured by NMR. The <i>N</i>-alkyl group in the piperidine ring is found in a pseudo equatorial position, while the methyl group reflects a pseudo axial position. Intermolecular hydrogen bonding was observed in the crystal lattice between the indazole NH (N22) and the N atom of the azetidine ring (N27) and also between the anilinic NH (N7) and the indazole N atom (N23) constructing a two-dimensional network in the crystal lattice.</div><figure id="fig4" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01163/20201203/images/medium/jm0c01163_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01163/20201203/images/large/jm0c01163_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. (a) Molecular conformation of <b>16</b> from single crystal structure; (b) crystal packing of <b>16</b> in the unit cell (the TBME molecules are shown as ball and stick models).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01163/20201203/images/large/jm0c01163_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01163&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> Physicochemical and DMPK Profiling of <b>16</b></h3><div class="NLM_p">The favorable potency and human in vitro clearance characteristics of <b>16</b> prompted us to profile this further as an exemplar of the series (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>). In terms of its physicochemical properties, <b>16</b> was highly soluble in aqueous media (>900 μM) but had modest intrinsic cellular permeability (<i>P</i><sub>app</sub> 1.8 × 10<sup>–6</sup> cm/s) with significant potential for being a substrate for active transport (efflux ratio = 28) as measured in a Caco-2 assay. Compound <b>16</b> showed high fraction unbound levels in plasma protein binding assays across species (>10% free drug) and was dibasic with both the azetidine and piperidine (measured p<i>K</i><sub>a</sub><sub>(BH+)</sub> 8.7 and 7.8 respectively) having the potential to protonate at physiological pH. Profiling against a high throughput human liver microsome panel of five cytochrome P450 enzymes showed a clean profile against three isoforms (CYP1A2, CYP2C19, CYP2C9) but activity against CYP2D6 (IC<sub>50</sub> 1.2 μM) and CYP3A4 (IC<sub>50</sub> 11 μM). Additionally, the compound was shown to have the potential to interact with the hERG ion channel (IC<sub>50</sub> 9.1 μM), which became a focus of subsequent optimization efforts.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Physicochemical and in Vitro DMPK Data for <b>16</b></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">intrinsic Caco2 <i>P</i><sub>app</sub> (efflux ratio)<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">Sol (μM)<a class="ref internalNav" href="#t3fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">mu/rat/dog % free</th><th class="colsep0 rowsep0" align="center">p<i>K</i><sub>a(BH+)</sub><a class="ref internalNav" href="#t3fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center" char=".">CYP 2D6 (μM)<a class="ref internalNav" href="#t3fn4" aria-label="d">d</a></th><th class="colsep0 rowsep0" align="center" char=".">CYP 3A4 (μM)<a class="ref internalNav" href="#t3fn4" aria-label="d">d</a></th><th class="colsep0 rowsep0" align="center" char=".">hERG (μM)<a class="ref internalNav" href="#t3fn5" aria-label="e">e</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">1.8 (28)</td><td class="colsep0 rowsep0" align="left">>900</td><td class="colsep0 rowsep0" align="left">39/51/22</td><td class="colsep0 rowsep0" align="left">8.7/7.8</td><td class="colsep0 rowsep0" align="char" char=".">1.2</td><td class="colsep0 rowsep0" align="char" char=".">11</td><td class="colsep0 rowsep0" align="char" char=".">9.1</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">Compounds were incubated at 10 μM in cultured Caco-2 cells. Intrinsic permeability was measured in units of × 10<sup>–6</sup> cm/s in the apical direction in the presence of transport inhibitors quinidine (50 μM), sulfasalazine (20 μM), and benzbromarone (30 μM) with an apical/basolateral pH of 6.5:7.4, respectively. Efflux ratio is reported as the ratio of basolateral (B to A) to apical (A to B) transport in the absence of any inhibitors and an apical/basolateral pH of 7.4:7.4.</p></div><div class="footnote" id="t3fn2"><sup><sup>b</sup></sup><p class="last">Solubility of compounds in aqueous phosphate buffer at pH 7.4 after 24 h at 25 °C from DMSO stock solution.</p></div><div class="footnote" id="t3fn3"><sup><sup>c</sup></sup><p class="last">p<i>K</i><sub>a</sub> measured using UV absorption (Sirius) in 0.1 M potassium chloride at 20 °C.</p></div><div class="footnote" id="t3fn4"><sup><sup>d</sup></sup><p class="last">Inhibition of cytochrome P450 enzymes IC<sub>50</sub>.</p></div><div class="footnote" id="t3fn5"><sup><sup>e</sup></sup><p class="last">Inhibition of the hERG tail current was measured using a plate-based planar patch clamp system (Syncropatch).</p></div></div></div><div class="NLM_p">We also obtained in vivo rat pharmacokinetic data (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>). In rats, <b>16</b> was found to have very high clearance (125 mL/min/kg) and exhibited poor bioavailability (3%), likely due to first pass clearance by the liver. The volume of distribution was assessed at 71 L/kg and resulted in a long half-life of 11 h. This was consistent with the dibasic nature of the compound as discussed above. While a large volume of distribution would aid in achieving a desirable long half-life in human, it would potentially carry risks of toxicity under chronic administration scenarios (e.g., phospholipidosis). Accordingly, our strategy became to reduce the volume of distribution by attenuating the dibasicity while maintaining the low human in vitro clearance characteristics.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Summary of Pharmacokinetic Parameters of <b>16</b> after IV and PO Dosing in Rat<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">species</th><th class="colsep0 rowsep0" align="center">Clint (μL/min/10<sup>6</sup> cells)</th><th class="colsep0 rowsep0" align="center">dose<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a> IV/PO (mg/kg)</th><th class="colsep0 rowsep0" align="center">CL (mL/min/kg)</th><th class="colsep0 rowsep0" align="center">Vd<sub>ss</sub> (L/kg)</th><th class="colsep0 rowsep0" align="center"><i>t</i><sub>1/2</sub> (h)</th><th class="colsep0 rowsep0" align="center">% <i>F</i></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">rat</td><td class="colsep0 rowsep0" align="left">7</td><td class="colsep0 rowsep0" align="left">0.5/1</td><td class="colsep0 rowsep0" align="left">125</td><td class="colsep0 rowsep0" align="left">71</td><td class="colsep0 rowsep0" align="left">11</td><td class="colsep0 rowsep0" align="left">3</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup><sup>a</sup></sup><p class="last">Compound was dosed in rat intravenously at 0.5 and orally at 1 mg/kg. The formulation was 5% DMSO/95% hydroxylpropyl β-cyclodextrin (30% w/v) at a volume of 1 mL/kg and 4 mL/kg, IV and PO respectively.</p></div></div></div></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> Final Optimization: Identification of a Candidate</h3><div class="NLM_p">We aimed to reduce the volume of distribution by lowering the basicity of the piperidine ring nitrogen through aliphatic fluorination of the side chain in both the methoxyphenyl (Core Q) and pyridyl (Core R) series (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>). Formal opening of the cyclopropyl ring gave the 2-F<sup>i</sup>Bu side chain (A) present in <b>1b</b> with similar levels of potency for <b>19</b> and <b>20</b> but increased lipophilicity as expected. Using the 2,2-difluoropropyl side chain (B) allowed us to maintain potency while reducing the p<i>K</i><sub>a</sub> of the piperidine in <b>21</b> and <b>22</b>. For <b>21</b>, the lipophilicity was undesirably high, and to ameliorate this we introduced a hydroxy group on the terminal methyl (C). This decreased potency (ΔpIC<sub>50</sub> −0.7 and −0.2) while dramatically lowering the lipophilicity (ΔlogD<sub>7.4</sub> −1.2 and −0.9) for matched pairs <b>23</b> versus <b>21</b> and <b>24</b> versus <b>22</b> respectively. Deletion of the hydroxymethyl substituent gave the 2,2-difluoroethyl side chain (D), which gave highly potent compounds <b>25</b> and <b>26</b> with the pyridyl (Core R) having lower lipophilicity than the methoxyphenyl (Core Q). Addition of a third fluorine atom to the ethyl side chain (E) resulted in a modest rise in lipophilicity and exquisitely potent compounds <b>27</b> and <b>28</b>. Pyridyl compounds <b>26</b> and <b>28</b> matched both our potency and lipophilicity criteria and with low turnover in human hepatocytes.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Data for Alkyl Group Variation in the 3-Fluoropropyl Azetidine Base Series<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01163/20201203/images/medium/jm0c01163_0025.gif" alt="" id="GRAPHIC-d7e3017-autogenerated" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">cpd</th><th class="colsep0 rowsep0" align="center">core</th><th class="colsep0 rowsep0" align="center">R<sup>1</sup></th><th class="colsep0 rowsep0" align="center">ER bind pIC<sub>50</sub></th><th class="colsep0 rowsep0" align="center">ER DR pIC<sub>50</sub> (<i>D</i><sub>max</sub> (%))</th><th class="colsep0 rowsep0" align="center">log D<sub>7.4</sub> (LLE)</th><th class="colsep0 rowsep0" align="center">human % free</th><th class="colsep0 rowsep0" align="center">rat/human hepatocyte CL<sub>int</sub> (μL/min/10<sup>6</sup> cells)</th><th class="colsep0 rowsep0" align="center">% deg vs Fv MCF-7/CAMA-1</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>19</b></td><td class="colsep0 rowsep0" align="left">Q</td><td class="colsep0 rowsep0" align="left">A</td><td class="colsep0 rowsep0" align="left">8.2</td><td class="colsep0 rowsep0" align="left">9.7 (96)</td><td class="colsep0 rowsep0" align="left">3.2 (6.5)</td><td class="colsep0 rowsep0" align="left">14</td><td class="colsep0 rowsep0" align="left">8/–</td><td class="colsep0 rowsep0" align="left">86/89</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>20</b></td><td class="colsep0 rowsep0" align="left">R</td><td class="colsep0 rowsep0" align="left">A</td><td class="colsep0 rowsep0" align="left">8.5<a class="ref internalNav" href="#t5fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">9.5 (96)</td><td class="colsep0 rowsep0" align="left">3.2 (6.3)</td><td class="colsep0 rowsep0" align="left">10</td><td class="colsep0 rowsep0" align="left">26/–</td><td class="colsep0 rowsep0" align="left">–/–</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>21</b></td><td class="colsep0 rowsep0" align="left">Q</td><td class="colsep0 rowsep0" align="left">B</td><td class="colsep0 rowsep0" align="left">8.6</td><td class="colsep0 rowsep0" align="left">10.4 (98)</td><td class="colsep0 rowsep0" align="left">3.7 (7.1)</td><td class="colsep0 rowsep0" align="left">4.3</td><td class="colsep0 rowsep0" align="left">15/5</td><td class="colsep0 rowsep0" align="left">80/101</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>22</b></td><td class="colsep0 rowsep0" align="left">R</td><td class="colsep0 rowsep0" align="left">B</td><td class="colsep0 rowsep0" align="left">8.4<a class="ref internalNav" href="#t5fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">9.5 (98)</td><td class="colsep0 rowsep0" align="left">2.9 (6.6)</td><td class="colsep0 rowsep0" align="left">24</td><td class="colsep0 rowsep0" align="left">49/–</td><td class="colsep0 rowsep0" align="left">102/100</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>23</b></td><td class="colsep0 rowsep0" align="left">Q</td><td class="colsep0 rowsep0" align="left">C</td><td class="colsep0 rowsep0" align="left">8.3<a class="ref internalNav" href="#t5fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">9.7 (98)</td><td class="colsep0 rowsep0" align="left">2.5 (7.2)</td><td class="colsep0 rowsep0" align="left">23</td><td class="colsep0 rowsep0" align="left">20/–</td><td class="colsep0 rowsep0" align="left">–/–</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>24</b></td><td class="colsep0 rowsep0" align="left">R</td><td class="colsep0 rowsep0" align="left">C</td><td class="colsep0 rowsep0" align="left">8.2</td><td class="colsep0 rowsep0" align="left">9.3 (99)</td><td class="colsep0 rowsep0" align="left">2.0 (7.3)</td><td class="colsep0 rowsep0" align="left">64</td><td class="colsep0 rowsep0" align="left">16/–</td><td class="colsep0 rowsep0" align="left">104/105</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>25</b></td><td class="colsep0 rowsep0" align="left">Q</td><td class="colsep0 rowsep0" align="left">D</td><td class="colsep0 rowsep0" align="left">8.7</td><td class="colsep0 rowsep0" align="left">10.0 (99)</td><td class="colsep0 rowsep0" align="left">3.2 (6.8)</td><td class="colsep0 rowsep0" align="left">12</td><td class="colsep0 rowsep0" align="left">14/6</td><td class="colsep0 rowsep0" align="left">99/100</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>26</b></td><td class="colsep0 rowsep0" align="left">R</td><td class="colsep0 rowsep0" align="left">D</td><td class="colsep0 rowsep0" align="left">8.4</td><td class="colsep0 rowsep0" align="left">9.5 (99)</td><td class="colsep0 rowsep0" align="left">2.4 (7.1)</td><td class="colsep0 rowsep0" align="left">40</td><td class="colsep0 rowsep0" align="left">22/5</td><td class="colsep0 rowsep0" align="left">95/98</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>27</b></td><td class="colsep0 rowsep0" align="left">Q</td><td class="colsep0 rowsep0" align="left">E</td><td class="colsep0 rowsep0" align="left">8.3<a class="ref internalNav" href="#t5fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">10.2 (98)</td><td class="colsep0 rowsep0" align="left">3.6 (6.6)</td><td class="colsep0 rowsep0" align="left">6.0</td><td class="colsep0 rowsep0" align="left">12/5</td><td class="colsep0 rowsep0" align="left">95/110</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>28</b></td><td class="colsep0 rowsep0" align="left">R</td><td class="colsep0 rowsep0" align="left">E</td><td class="colsep0 rowsep0" align="left">8.6</td><td class="colsep0 rowsep0" align="left">9.8 (99)</td><td class="colsep0 rowsep0" align="left">2.9 (6.9)</td><td class="colsep0 rowsep0" align="left">23</td><td class="colsep0 rowsep0" align="left">23/6</td><td class="colsep0 rowsep0" align="left">94/98</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup><sup>a</sup></sup><p class="last">Legend as <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>.</p></div><div class="footnote" id="t5fn2"><sup><sup>b</sup></sup><p class="last"><i>n</i> = 1.</p></div></div></div><div class="NLM_p">With <b>26</b> and <b>28</b> looking particularly promising, the corresponding compounds with the original basic group <b>29</b> and <b>30</b> were made for comparison (<a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>). These proved to have very similar potency, lipophilicity, and properties (cf. <b>26</b> vs <b>29</b> and <b>28</b> vs <b>30</b>). Further profiling however revealed important differences in their pharmacology in terms of the ability of the compounds to degrade ER across different cell lines. Each of the four compounds (<b>26</b>, <b>28</b>–<b>30</b>) were effective in degrading ER in the MCF-7 cell line, but compounds <b>29</b> and <b>30</b> were notably less effective in the CAMA-1 cell line.</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Data for O-Linked Azetidine Compounds<a class="ref internalNav" href="#t6fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01163/20201203/images/medium/jm0c01163_0026.gif" alt="" id="GRAPHIC-d7e3400-autogenerated" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">cpd</th><th class="colsep0 rowsep0" align="center">core</th><th class="colsep0 rowsep0" align="center">R<sup>1</sup></th><th class="colsep0 rowsep0" align="center">ER bind pIC<sub>50</sub></th><th class="colsep0 rowsep0" align="center">ER DR pIC<sub>50</sub> (<i>D</i><sub>max</sub> (%))</th><th class="colsep0 rowsep0" align="center">log D<sub>7.4</sub> (LLE)</th><th class="colsep0 rowsep0" align="center" char=".">human % free</th><th class="colsep0 rowsep0" align="center">rat/human hepatocyte CL<sub>int</sub> (μL/min/10<sup>6</sup> cells)</th><th class="colsep0 rowsep0" align="center">% deg vs Fv MCF-7/CAMA-1</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>29</b></td><td class="colsep0 rowsep0" align="left">P</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">8.6<a class="ref internalNav" href="#t6fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">9.3 (98)</td><td class="colsep0 rowsep0" align="left">2.4 (6.9)</td><td class="colsep0 rowsep0" align="char" char=".">49</td><td class="colsep0 rowsep0" align="left">36/5</td><td class="colsep0 rowsep0" align="left">97/88</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>30</b></td><td class="colsep0 rowsep0" align="left">P</td><td class="colsep0 rowsep0" align="left">F</td><td class="colsep0 rowsep0" align="left">8.9<a class="ref internalNav" href="#t6fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">9.4 (96)</td><td class="colsep0 rowsep0" align="left">3.0 (6.4)</td><td class="colsep0 rowsep0" align="char" char=".">22</td><td class="colsep0 rowsep0" align="left">45/3</td><td class="colsep0 rowsep0" align="left">91/80</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup><sup>a</sup></sup><p class="last">Legend as <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>.</p></div><div class="footnote" id="t6fn2"><sup><sup>b</sup></sup><p class="last">SEM = 0.34.</p></div><div class="footnote" id="t6fn3"><sup><sup>c</sup></sup><p class="last">SEM = 0.21.</p></div></div></div><div class="NLM_p">This finding was mirrored across the larger data set as shown in <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> Compounds with the two-carbon link to the azetidine (A = NH/O) could sometimes achieve >90% degradation in the MCF-7 cell line, but the majority showed less degradation in the CAMA-1 cell line. In contrast, when the azetidine was directly connected to the linker atom (A = NH/O), degradation was more consistent between both cell lines and in most cases >90% relative to fulvestrant.</div><figure id="fig5" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01163/20201203/images/medium/jm0c01163_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01163/20201203/images/large/jm0c01163_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Plot of %ER degradation relative to fulvestrant in CAMA-1 and MCF-7 cell lines as measured by Western blot (A = NH/O linkage to indazole scaffold) and trellised by azetidine connectivity.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01163/20201203/images/large/jm0c01163_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01163&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">We subsequently fixed the 3-fluoropropyl azetidine base and looked to reinvestigate the effect of core modifications relative to lead compounds <b>26</b> and <b>28</b> (<a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a></a>). Addition of a 1-Me substituent (<b>31</b>, core M) had previously been shown to be tolerated on the indazole scaffold,<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> but in this instance the effect was to lower potency, increase lipophilicity, and increase rat hepatocyte clearance relative to matched pair <b>26</b>. Similarly, 3,3-dimethyl substitution (core N) was detrimental to potency, increased lipophilicity, and, in contrast to previous examples in the indazole scaffold,<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> dramatically increased turnover in rat hepatocytes (cf. <b>32</b> vs <b>26</b> and <b>33</b> vs <b>28</b> respectively). Surprisingly, in contrast to previous matched pairs in the acrylic acid series,<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> the indole analogue (core O) had potency comparable to the indazole (cf. <b>34</b> vs <b>28</b>). The indole was slightly more lipophilic (ΔlogD<sub>7.4</sub> + 0.3) and with lower clearance (both rat and human hepatocytes) was of considerable interest. However, a suboptimal hERG activity (IC<sub>50</sub> 13 μM) ultimately precluded progression of this compound.</div><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. Core Variations in the 3-Fluoropropyl Azetidine Base Series<a class="ref internalNav" href="#t7fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01163/20201203/images/medium/jm0c01163_0027.gif" alt="" id="GRAPHIC-d7e3606-autogenerated" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col /></col><col /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">cpd</th><th class="colsep0 rowsep0" align="center">core</th><th class="colsep0 rowsep0" align="center">R<sup>1</sup></th><th class="colsep0 rowsep0" align="center" char=".">ER bind pIC<sub>50</sub></th><th class="colsep0 rowsep0" align="center">ER DR pIC<sub>50</sub> (<i>D</i><sub>max</sub> (%))</th><th class="colsep0 rowsep0" align="center">logD<sub>7.4</sub> (LLE)</th><th class="colsep0 rowsep0" align="center">human % free</th><th class="colsep0 rowsep0" align="center">rat/human hepatocyte CL<sub>int</sub> (μL/min/10<sup>6</sup> cells)</th><th class="colsep0 rowsep0" align="center">% deg vs Fv MCF-7/CAMA-1</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>31</b></td><td class="colsep0 rowsep0" align="left">M</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="char" char=".">8.0<a class="ref internalNav" href="#t7fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">9.0 (96)</td><td class="colsep0 rowsep0" align="left">3.2 (5.8)</td><td class="colsep0 rowsep0" align="left">10</td><td class="colsep0 rowsep0">114/–</td><td class="colsep0 rowsep0">–/–</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>32</b></td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="char" char=".">8.5<a class="ref internalNav" href="#t7fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">9.1 (98)</td><td class="colsep0 rowsep0" align="left">3.0 (6.1)</td><td class="colsep0 rowsep0" align="left">22</td><td class="colsep0 rowsep0">270/–</td><td class="colsep0 rowsep0">–/–</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>33</b></td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="left">F</td><td class="colsep0 rowsep0" align="char" char=".">8.5</td><td class="colsep0 rowsep0" align="left">9.3 (95)</td><td class="colsep0 rowsep0" align="left">3.3 (6.0)</td><td class="colsep0 rowsep0" align="left">14</td><td class="colsep0 rowsep0">296/–</td><td class="colsep0 rowsep0">–/–</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>34</b></td><td class="colsep0 rowsep0" align="left">O</td><td class="colsep0 rowsep0" align="left">F</td><td class="colsep0 rowsep0" align="char" char=".">8.5</td><td class="colsep0 rowsep0" align="left">9.8 (98)</td><td class="colsep0 rowsep0" align="left">3.2 (6.6)</td><td class="colsep0 rowsep0" align="left">7.3</td><td class="colsep0 rowsep0">10/3</td><td class="colsep0 rowsep0">98/85</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t7fn1"><div class="footnote" id="t7fn1"><sup><sup>a</sup></sup><p class="last">Legend as <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>.</p></div><div class="footnote" id="t7fn2"><sup><sup>b</sup></sup><p class="last"><i>n</i> = 1.</p></div></div></div><div class="NLM_p">The SAR of the basic group was also re-examined with the alkyl chain fixed as trifluoromethyl (<a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">Table <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">8</a></a>). Ring opening of the azetidine to the acyclic chain (core I) resulted in lower potency and reduced extent of degradation (cf. <b>35</b> vs <b>28</b>). Methyl substitution on the azetidine (core J) was even more detrimental to potency and gave a compound with a partial degrader phenotype (cf. <b>36</b> vs <b>28</b>). Methylation of the linking nitrogen (<b>37</b>, core K) gave a compound with comparable pharmacology; however, the slightly increased lipophilicity (ΔlogD<sub>7.4</sub> + 0.3) resulted in an undesirable level of hERG activity (IC<sub>50</sub> 7.7 μM). Ring expansion to the pyrrolidine (<b>38</b>, core L) with an NH linkage gave a very similar profile (cf. <b>38</b> vs <b>28</b>), but extended evaluation revealed less favorable characteristics including undesirable levels of hERG activity (IC<sub>50</sub> 13 μM). Methylation of the linking nitrogen adversely impacted potency and degradation efficiency (cf. <b>39</b> vs <b>38</b>), and switching to an ether linkage resulted in less potency for more lipophilicity (cf. <b>40</b> vs <b>38</b>). Following extensive profiling, <b>28</b> was viewed as having the most favorable balance of properties from this series.</div><div class="NLM_table-wrap" id="tbl8"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 8. Data for Basic Group Variation<a class="ref internalNav" href="#t8fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01163/20201203/images/medium/jm0c01163_0028.gif" alt="" id="GRAPHIC-d7e3844-autogenerated" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">cpd</th><th class="colsep0 rowsep0" align="center">core</th><th class="colsep0 rowsep0" align="center">L</th><th class="colsep0 rowsep0" align="center">ER bind pIC<sub>50</sub></th><th class="colsep0 rowsep0" align="center">ER DR pIC<sub>50</sub> (<i>D</i><sub>max</sub> (%))</th><th class="colsep0 rowsep0" align="center">logD<sub>7.4</sub> (LLE)</th><th class="colsep0 rowsep0" align="center">human % free</th><th class="colsep0 rowsep0" align="center">rat/human hepatocyte CL<sub>int</sub> (μL/min/10<sup>6</sup> cells)</th><th class="colsep0 rowsep0" align="center">% deg vs Fv MCF-7/CAMA-1</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>35</b></td><td class="colsep0 rowsep0" align="left">I</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">8.3<a class="ref internalNav" href="#t8fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">9.2 (94)</td><td class="colsep0 rowsep0" align="left">2.7 (6.5)</td><td class="colsep0 rowsep0" align="left">16</td><td class="colsep0 rowsep0" align="left">22/–</td><td class="colsep0 rowsep0" align="left">–/–</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>36</b></td><td class="colsep0 rowsep0" align="left">J</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">8.1<a class="ref internalNav" href="#t8fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">8.5 (82)</td><td class="colsep0 rowsep0" align="left">3.2 (5.3)</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">35/–</td><td class="colsep0 rowsep0" align="left">–/–</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>37</b></td><td class="colsep0 rowsep0" align="left">K</td><td class="colsep0 rowsep0" align="left">NMe</td><td class="colsep0 rowsep0" align="left">8.7<a class="ref internalNav" href="#t8fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">9.7 (98)</td><td class="colsep0 rowsep0" align="left">3.2 (6.4)</td><td class="colsep0 rowsep0" align="left">15</td><td class="colsep0 rowsep0" align="left">20/–</td><td class="colsep0 rowsep0" align="left">85/82</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>38</b></td><td class="colsep0 rowsep0" align="left">L</td><td class="colsep0 rowsep0" align="left">NH</td><td class="colsep0 rowsep0" align="left">8.6</td><td class="colsep0 rowsep0" align="left">9.9 (99)</td><td class="colsep0 rowsep0" align="left">3.0 (6.9)</td><td class="colsep0 rowsep0" align="left">18</td><td class="colsep0 rowsep0" align="left">22/5</td><td class="colsep0 rowsep0" align="left">95/104</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>39</b></td><td class="colsep0 rowsep0" align="left">L</td><td class="colsep0 rowsep0" align="left">NMe</td><td class="colsep0 rowsep0" align="left">7.4<a class="ref internalNav" href="#t8fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">9.1 (87)<a class="ref internalNav" href="#t8fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">3.5 (5.6)</td><td class="colsep0 rowsep0" align="left">5.7</td><td class="colsep0 rowsep0" align="left">34/-</td><td class="colsep0 rowsep0" align="left">–/–</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>40</b></td><td class="colsep0 rowsep0" align="left">L</td><td class="colsep0 rowsep0" align="left">O</td><td class="colsep0 rowsep0" align="left">8.7<a class="ref internalNav" href="#t8fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">9.4 (98)</td><td class="colsep0 rowsep0" align="left">3.2 (6.2)</td><td class="colsep0 rowsep0" align="left">15</td><td class="colsep0 rowsep0" align="left">44/-</td><td class="colsep0 rowsep0" align="left">–/–</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t8fn1"><div class="footnote" id="t8fn1"><sup><sup>a</sup></sup><p class="last">Legend as <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>.</p></div><div class="footnote" id="t8fn2"><sup><sup>b</sup></sup><p class="last"><i>n</i> = 1.</p></div><div class="footnote" id="t8fn3"><sup><sup>c</sup></sup><p class="last">SEM = 0.32.</p></div></div></div></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> Structure and Conformation of <b>28</b></h3><div class="NLM_p"><a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>a shows the results of a conformational analysis by NMR of <b>28</b> in solution. As seen for compounds <b>16</b> and <b>18</b> (<i>vide supra</i>), the <i>para</i>-linked base has a degree of flexibility. The pyridyl ring was observed to rotate freely between two preferred orientations. The <i>N</i>-trifluoroethyl substituent showed a single fixed conformation, with the hydrogens on the carbon alpha to the nitrogen pointing away from the pyridyl ring. The core conformation observed by NMR corresponds closely to that observed in the crystal protein–ligand structure (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>a,b).</div><figure id="fig6" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01163/20201203/images/medium/jm0c01163_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01163/20201203/images/large/jm0c01163_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. (a) Conformational analysis by NMR of <b>28</b>. Flexibility is illustrated with thin-wire depictions of the basic group, which is capable of adopting different conformations in solution; (b) X-ray crystallography of <b>28</b> (green, pdb: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6zor">6zor</a>) bound to the ERα ligand binding domain construct; (c) alignment of the binding mode of <b>28</b> with that of <b>1b</b> (yellow, pdb: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5acc">5acc</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01163/20201203/images/large/jm0c01163_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01163&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The binding mode of <b>28</b> is similar to that seen before for <b>16</b> and <b>18</b>, albeit with a slightly different orientation of the <i>para</i>-linked basic group. The tricyclic core of the molecule is again closely enveloped by hydrophilic residues that make up most of the pocket, forming contacts similar to those highlighted before, namely, short hydrogen-bonding contacts to the hydrophilic residues Glu353 and Arg394, and the conserved water in between these. Comparison of <b>28</b> to <b>1b</b><a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> shows close alignment of the [5.6.6] ring system of <b>28</b> with the [6.5.6] core of the tricyclic indole of <b>1b</b> (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>c). The acrylic acid group of <b>1b</b> and the basic group of <b>28</b> reside in the same area, again in proximity to both Val533 and Asp351 (cf. <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>).</div><div class="NLM_p">Single crystal structure analysis of <b>28</b> showed an anhydrous form which crystallized in a monoclinic <i>P</i>2(1) space group and was selected for development as “form A” (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>). In the crystal structure, an intermolecular hydrogen bond was formed between the indazole NH (N2) and the N atom (N6) in the four-membered azetidine ring. Furthermore, the secondary amine NH (N5) interacted with the terminal fluoro atom (F4) in the fluoropropyl chain in the neighboring molecule, resulting in a gauche conformer in a staggered conformation for the terminal fluoropropyl chain. It was observed that the piperidine nitrogen, with the trifluorethyl group in an axial position, was sterically congested and did not participate in the hydrogen bonding network, residing in a largely hydrophobic environment created by the aromatic groups of neighboring molecules. It is noteworthy that the piperidine ring of <b>28</b> flips to orient the methyl substituent (C10) pseudo equatorial and the <i>N</i>-alkyl (N3) substituent pseudo axial, which differs from that observed with the single crystal X-ray of <b>16</b>. In contrast to <b>16</b>, the NMR derived solution conformation of <b>28</b> showed a population of the six-membered ring with the methyl in the equatorial position, in rapid conformational exchange (nanosecond time scale) with the conformation having the methyl in the axial position (see <a class="ref internalNav" href="#notes1" aria-label="Supporting Information">Supporting Information</a>).</div><figure id="fig7" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01163/20201203/images/medium/jm0c01163_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01163/20201203/images/large/jm0c01163_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. (a) Molecular conformation of <b>28</b> from single crystal structure; (b) crystal packing of <b>28</b> in the unit cell.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01163/20201203/images/large/jm0c01163_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01163&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> Physicochemical, DMPK, and Safety Profiling of <b>28</b></h3><div class="NLM_p">Compound <b>28</b> was profiled in terms of its physicochemical properties and was found to be highly soluble in aqueous media (833 μM) as well as having good intrinsic cellular permeability (<i>P</i><sub>app</sub> 13 × 10<sup>–6</sup> cm/s) as measured in a Caco-2 assay. In line with the low lipophilicity, <b>28</b> showed consistently high fraction unbound levels in plasma protein binding assays across species (>10% free drug). The compound has two formal basic centers in the azetidine (p<i>K</i><sub>a(BH+)</sub> 8.4) and the pyridine (p<i>K</i><sub>a(BH+)</sub> 4.8); however, the potential for diprotonation is much lower than for compound <b>16</b>. In terms of drug–drug interaction liability, <b>28</b> was assessed against a high throughput human liver microsome panel of five cytochrome P450 enzymes and showed no activity (IC<sub>50</sub> values >30 μM) against three isoforms (CYP1A2, CYP2C19, CYP2C9) and modest activity against CYP2D6 (IC<sub>50</sub> 4.3 μM) and CYP3A4 (IC<sub>50</sub> 2.2 μM). Using both static and dynamic drug–drug interaction prediction approaches, we assessed low probability of drug–drug interaction potential against sensitive substrates of CYP 2D6 and 3A4/5. The compound was also profiled against the hERG ion channel and was found to have only weak activity (IC<sub>50</sub> 22 μM), again leading to a low risk assessment for potential QT prolongation (<a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a></a>).<named-content content-type="anchor" rid="tbl10" type="simple"></named-content><named-content content-type="anchor" rid="tbl11" type="simple"></named-content></div><div class="NLM_table-wrap" id="tbl9"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 9. Physicochemical and in Vitro DMPK Data for <b>28</b><a class="ref internalNav" href="#t9fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">intrinsic Caco2 <i>P</i><sub>app</sub> (efflux ratio)</th><th class="colsep0 rowsep0" align="center">Sol (μM)</th><th class="colsep0 rowsep0" align="center">mu/rat/dog % free</th><th class="colsep0 rowsep0" align="center">p<i>K</i><sub>a(BH+)</sub></th><th class="colsep0 rowsep0" align="center">CYP 2D6 (μM)</th><th class="colsep0 rowsep0" align="center">CYP 3A4 (μM)</th><th class="colsep0 rowsep0" align="center">hERG (μM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">13 (4)</td><td class="colsep0 rowsep0" align="left">833</td><td class="colsep0 rowsep0" align="left">23/26/15</td><td class="colsep0 rowsep0" align="left">8.4/4.8</td><td class="colsep0 rowsep0" align="left">4.3</td><td class="colsep0 rowsep0" align="left">2.2</td><td class="colsep0 rowsep0" align="left">22</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t9fn1"><div class="footnote" id="t9fn1"><sup><sup>a</sup></sup><p class="last">Legend as <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>.</p></div></div></div><div class="NLM_p">The chemical stability of <b>28</b> in solution was also investigated using our NMR based approach described previously.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> No evidence of any degradation in deuterated buffer (pH 4 and 7.4) was observed over an 8 day study. Further solution profiling under forcing conditions (in buffers at pH 1, 7.4 and 10, stored light protected at temperatures 22, 50, and 60 °C) showed slight degradation after 5 days at ambient room temperature under acidic and basic conditions, and only minimal change at neutral pH.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> In terms of chemical stability in the solid state, compound <b>28</b> was identified as having a potential autoxidation risk associated with the doubly benzylic proton between the indole and pyridine rings. This was supported by the low bond dissociated energy (BDE) estimated using quantum mechanical calculations.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> The BDE of the neutral form was calculated at 71 kcal/mol and with the piperidine N protonated, at 78 kcal/mol. Early batches of <b>28</b> were amorphous and exhibited poor thermal and light stability, a potential risk in terms of development as a drug product. Extensive crystallization efforts led to the discovery of crystalline solids, which showed superior stability compared to the amorphous form, and one in particular was selected for further development. To determine the stability risk, compound <b>28</b> was subjected to elevated light and thermal/humidity conditions by placing the amorphous compound and the “selected” crystalline counterpart in controlled stability environments. Light-exposed samples of the amorphous sample showed evidence of autoxidation products as the result of light-induced ionization of the benzylic proton. The elevated temperature and humidity samples (e.g., 60 °C/75% relative humidity (RH)) of the amorphous compound tended to deliquesce, which produced degradation data that made prediction of long-term storage at room temperature challenging. However, discovery of crystalline solids mitigated both the autoxidation risk and the high temperature/humidity risks as shown in <a class="ref showTableEvent internalNav" data-ID="tbl10" href="#tbl10">Table <a class="ref showTableEvent internalNav" data-ID="tbl10" href="#tbl10">10</a></a>. In addition, the selected form for development showed a solubility of about 1.5 mg/mL in fasted state simulated intestinal fluid (FaSSIF v2, pH6.5) and >10 mg/mL in simulated gastric fluid (SGF). In pH 7.4 phosphate buffer, this form showed a solubility of approximately 0.4 mg/mL.</div><div class="NLM_table-wrap" id="tbl10"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 10. Comparison of Stability of Amorphous and the Selected Crystalline Form of <b>28</b></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">condition</th><th class="colsep0 rowsep0" align="center">duration</th><th class="colsep0 rowsep0" align="center" char=".">amorphous<a class="ref internalNav" href="#t10fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char=".">selected form<a class="ref internalNav" href="#t10fn1" aria-label="a">a</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">control</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char=".">99.6</td><td class="colsep0 rowsep0" align="char" char=".">99.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">40 °C/75% RH</td><td class="colsep0 rowsep0" align="left">3 months</td><td class="colsep0 rowsep0" align="char" char=".">90.5</td><td class="colsep0 rowsep0" align="char" char=".">99.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">60 °C/75% RH</td><td class="colsep0 rowsep0" align="left">1 week</td><td class="colsep0 rowsep0" align="char" char=".">82.4</td><td class="colsep0 rowsep0" align="char" char=".">99.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">60 °C ambient dry</td><td class="colsep0 rowsep0" align="left">2 weeks</td><td class="colsep0 rowsep0" align="char" char=".">98.4</td><td class="colsep0 rowsep0" align="char" char=".">99.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">light exposure</td><td class="colsep0 rowsep0" align="left">per ICH Q1B<a class="ref internalNav" href="#t10fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="char" char=".">78.9</td><td class="colsep0 rowsep0" align="char" char=".">98.9</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t10fn1"><div class="footnote" id="t10fn1"><sup><sup>a</sup></sup><p class="last">Results reported as parent chromatographic area %.</p></div><div class="footnote" id="t10fn2"><sup><sup>b</sup></sup><p class="last">1.2 mil lux·h white light and 200 W·h/m<sup>2</sup> UV light.</p></div></div></div><div class="NLM_p">The in vitro hepatocyte and in vivo pharmacokinetic (noncompartmental) properties of <b>28</b> were investigated in mouse and rat, and the values are reported in <a class="ref showTableEvent internalNav" data-ID="tbl11" href="#tbl11">Table <a class="ref showTableEvent internalNav" data-ID="tbl11" href="#tbl11">11</a></a><named-content content-type="anchor" rid="fig8" type="simple"></named-content>. <i>In vitro</i> clearance was moderate to high in mouse (18 μL/min/10<sup>6</sup> cells) and rat (23 μL/min/10<sup>6</sup> cells). <i>In vivo</i> clearance was generally high at 59 mL/min/kg in mouse and 73 mL/min/kg in rat representing approximately 66% and 106% of liver blood flow respectively in mouse and rat. Scaling of in vitro clearance with free fraction and blood/plasma ratio yielded an <i>in vitro/in vivo</i> correlation within 2-fold for mouse and rat (data not shown). Volume of distribution was high in all species tested and was consistent with the high free fraction and basic properties of the compound. Bioavailability of <b>28</b> was modest in mice (16%) and in rats (19%). Given the good physical chemical properties (i.e., high solubility) and good permeability characteristics, we attributed the low % <i>F</i> to high first pass gut/hepatic extraction. More specifically, we assessed compound <b>28</b> to have high fraction absorbed (<i>F</i><sub>abs</sub>) with concomitantly high first pass extraction. Compound <b>28</b> was observed to have low to moderate clearance in human hepatocytes (5.6 μL/min/10<sup>6</sup> cells). When factoring in the high unbound fraction in vitro (fu<sub>inc</sub> 0.3), compound <b>28</b> yields a desirable low unbound intrinsic clearance that predicts clearance at ∼50% hepatic blood flow in human. These properties of high fraction absorbed and moderate human clearance thus predict good bioavailability in human (i.e., > 40% <i>F</i>). These properties were deemed suitable to pursue in vivo pharmacodynamics studies in mice.</div><div class="NLM_table-wrap" id="tbl11"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 11. Summary of Pharmacokinetic Parameters of <b>28</b> after IV and PO Dosing in Mouse and Rat<a class="ref internalNav" href="#t11fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="left" /></col><col align="char" char="." /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">species</th><th class="colsep0 rowsep0" align="center" char=".">Clint (μL/min/10<sup>6</sup> cells)</th><th class="colsep0 rowsep0" align="center">dose<a class="ref internalNav" href="#t11fn1" aria-label="a">a</a> IV/PO (mg/kg)</th><th class="colsep0 rowsep0" align="center" char=".">CL (mL/min/kg)</th><th class="colsep0 rowsep0" align="center">Vd<sub>ss</sub> (L/kg)</th><th class="colsep0 rowsep0" align="center" char="."><i>t</i><sub>1/2</sub> (h)</th><th class="colsep0 rowsep0" align="center" char=".">% <i>F</i></th><th class="colsep0 rowsep0" align="center">% fraction absorbed</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">mouse</td><td class="colsep0 rowsep0" align="char" char=".">18</td><td class="colsep0 rowsep0" align="left">2/5</td><td class="colsep0 rowsep0" align="char" char=".">59</td><td class="colsep0 rowsep0" align="left">9.2</td><td class="colsep0 rowsep0" align="char" char=".">5.1</td><td class="colsep0 rowsep0" align="char" char=".">16</td><td class="colsep0 rowsep0" align="left">50</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">rat</td><td class="colsep0 rowsep0" align="char" char=".">23</td><td class="colsep0 rowsep0" align="left">0.5/1</td><td class="colsep0 rowsep0" align="char" char=".">73</td><td class="colsep0 rowsep0" align="left">13</td><td class="colsep0 rowsep0" align="char" char=".">3.0</td><td class="colsep0 rowsep0" align="char" char=".">19</td><td class="colsep0 rowsep0" align="left">>95</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t11fn1"><div class="footnote" id="t11fn1"><sup><sup>a</sup></sup><p class="last">Compounds were dosed in rat intravenously at 0.5 and orally at 1 mg/kg and mouse at 2/5 mg/kg IV/PO. The formulation by both routes was 5% DMSO/95% hydroxylpropyl β-cyclodextrin (30% w/v) at a volume of 1 mL/kg and 4 mL/kg, IV and PO respectively.</p></div></div></div><div class="NLM_p last"><b>28</b> was tested in a panel of <i>in vitro</i> safety assays and demonstrated excellent selectivity against a diverse range of off-target or secondary pharmacology assays using radioligand binding, enzyme activity, cellular functional, and phenotypic assays covering known key target systems relevant to clinical toxicity. Predicted safety margins of over 250 fold were achieved in all of the in-house functional and phenotypic safety assays conducted when comparing the IC<sub>50</sub> of those assays where activity was detected with the predicted efficacious human free <i>C</i><sub>max</sub>. The secondary pharmacology profile (consisting of 195 diverse enzyme, membrane transporter, G-protein-coupled receptor (GPCR), kinase, nuclear hormone receptor, and ion channel targets, generated externally at CEREP, France) was also very selective, with only one target (histamine H3, antagonist) demonstrating activity (IC<sub>50</sub> = 0.33 μM) within a 30 fold margin of the predicted <i>C</i><sub>max</sub>. Antagonists and inverse agonists of the H3 receptor have been evaluated clinically with no substantial adverse liabilities.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> Furthermore, H3 receptors are located on presynaptic histaminergic neurons in the CNS, with a limited role in the periphery, and antagonists such as Pitolisan, ABT-288, and MK-0249 require a high level of receptor occupancy to drive CNS mediated adverse events such as nocturnal insomnia and wakefulness.<a onclick="showRef(event, 'ref38 ref39'); return false;" href="javascript:void(0);" class="ref ref38 ref39">(38,39)</a> Clinically, CNS exposures of <b>28</b> were predicted to be lower than that achieved in the periphery, due in part to the weak Caco2-efflux characteristics observed with <b>28</b>. Consequently, the histamine H3 activity was considered a low risk due to very low predicted histamine H3 occupancy in the CNS.<named-content content-type="anchor" rid="fig9" type="simple"></named-content><named-content content-type="anchor" rid="fig10" type="simple"></named-content></div></div><div id="sec2_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> In Vitro Pharmacology of <b>28</b></h3><div class="NLM_p">Compound <b>28</b> was extensively profiled in order to characterize its pharmacological profile. As shown in <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>a, a concentration-dependent decrease in ERα expression (black curve, pIC<sub>50</sub> 9.8) was observed, with no evidence of ERα agonism as measured in the progesterone receptor (PR) assay (blue curve, pIC<sub>50</sub> < 6.5), a downstream marker for ERα transcriptional activation. Additionally, as shown in <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>b, no change in ERα down-regulation potency was observed in the presence of protein synthesis inhibitor cycloheximide (blue curve, pIC<sub>50</sub> 9.9), while an expected decrease in potency was observed when treated with tamoxifen (red curve, pIC<sub>50</sub> 8.2) due to competition at the ERα ligand binding site. The ability of <b>28</b> to cause agonism of ERα was further assessed by determining the effect on mRNA expression of the ERα target genes PGR, TFF1, and GREB1. While the natural ligand and agonist of ER, estradiol, caused an increase in the expression of all three genes, <b>28</b>, like fulvestrant, did not increase the expression of any of the genes and, in the case of TFF1 and GREB1, <b>28</b> significantly reduced their expression. These observations are consistent with an SERD mode of action for compound <b>28</b>.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a></div><figure id="fig8" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01163/20201203/images/medium/jm0c01163_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01163/20201203/images/large/jm0c01163_0008.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. (a) Treatment of MCF-7 cells with compound <b>28</b> showed a concentration-dependent decrease in ERα expression (black) and no increase in PR expression (blue) consistent with no ERα agonism; (b) ERα protein expression curve (black) and decrease in potency in the presence of 0.25 μM tamoxifen (red) due to competition at the ERα ligand binding site and no effect with cycloheximide (blue); (c) MCF7 cells were treated with DMSO, 1 nM estradiol (E2), or 100 nM 4-OH tamoxifen, fulvestrant, or <b>28</b> for 24 h. Expression of the ERα regulated genes PGR, TFF1, and GREB1 was assessed. Data points represent individual biological repeats, with lines representing mean ± SEM *<i>P</i> < 0.05, **<i>P</i> < 0.01, ***<i>P</i> < 0.001 compared to DMSO control according to a paired student’s <i>t</i> test.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01163/20201203/images/large/jm0c01163_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01163&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The antagonist profile of <b>28</b> was also characterized in both ERα wild-type (WT) and Y537S ERα-expressing mutant MCF-7 cells. As shown in <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>, using an immunofluorescence assay, compound <b>28</b> potently and completely inhibited estradiol-induced PR expression in MCF-7 (WT) cells (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>a) and blocked constitutive PR expression in MCF-7 (Y537S) cells (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>b) consistent with the desired ERα degrader-antagonist profile.</div><figure id="fig9" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01163/20201203/images/medium/jm0c01163_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01163/20201203/images/large/jm0c01163_0009.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Concentration-dependent antagonism of wild-type and Y537S mutant ERα by <b>28</b>. (a) Parental MCF7 cells grown in the presence of 0.1 nM estradiol and (b) MCF7 cells engineered to express a Y537S mutant version of ERα were exposed to <b>28</b> for 24 h. Expression of PR was assessed by immunofluorescence. Data are normalized to DMSO treated cells (0) and 100 nM fulvestrant treated cells (100). Data represent the mean ± SEM from four to five independent experiments.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01163/20201203/images/large/jm0c01163_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01163&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The ability of <b>28</b> to effect degradation of ERα was also investigated by Western blot analysis. MCF-7 or CAMA-1 cells were incubated with either fulvestrant or <b>28</b> for 48 h at a range of concentrations with total protein extracted and the effects on ERα protein expression determined by immunoblotting. As shown in <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>, <b>28</b> was a potent degrader of ERα with a profile very similar to fulvestrant in both MCF-7 and CAMA-1 cells.</div><figure id="fig10" data-index="20" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01163/20201203/images/medium/jm0c01163_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01163/20201203/images/large/jm0c01163_0010.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Concentration-dependent degradation of ERα by fulvestrant and <b>28</b> by Western blot analysis in both MCF-7 (WT) and CAMA-1 cell lines.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01163/20201203/images/large/jm0c01163_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01163&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The antiproliferative activity of compound <b>28</b> was also investigated. As shown in <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>, a concentration-dependent decrease in estradiol-driven cell growth of the wild-type MCF-7 cell line was observed with <b>28</b> (<a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>a), with a potency slightly decreased in the mutant MCF-7 (Y537S) cell line (<a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>b).</div><figure id="fig11" data-index="21" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01163/20201203/images/medium/jm0c01163_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01163/20201203/images/large/jm0c01163_0011.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Concentration-dependent inhibition of proliferation of wild-type and Y537S mutant ERα by <b>28</b>. (a) Parental MCF7 cells grown in the presence of 0.1 nM estradiol and (b) MCF7 cells engineered to express a Y537S mutant version of ERα were exposed to <b>28</b> for 4 or 6 days, respectively. Total cell number was calculated by using saponin permeabilization and a Sytox green fluorescent end point. Data are expressed as mean % growth ± SEM from at least four independent experiments where zero growth represents the initial seeding density on the day of dosing, and 100% growth represents the vehicle control at the end of incubation.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01163/20201203/images/large/jm0c01163_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01163&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> In Vivo Pharmacology of <b>28</b></h3><div class="NLM_p">To determine the activity of <b>28</b> in vivo, the effect of different doses of <b>28</b> on the growth of and expression of PR in MCF-7 xenografts was assessed (<a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>). This was compared to the effect of 5 mg of fulvestrant 3 times a week. Treatment with <b>28</b> caused a dose-dependent decrease in tumor volume with no tolerance issues. Specifically, a dose of 2 mg/kg caused 73% (<i>p</i> = 0.0012) tumor growth inhibition, while doses of 10 mg/kg and 50 mg/kg caused 15% and 53% tumor regressions respectively (<a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>a). Treatment with 10 mg/kg and 50 mg/kg of <b>28</b> also caused a statistically significant reduction in the expression in PR, with levels being reduced to 8.9% and 6.3% of vehicle control respectively (<a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>b). Both 10 mg/kg and 50 mg/kg <b>28</b> gave greater antitumor and pharmacodynamic effects than 5 mg of fulvestrant dosed 3 times a week.</div><figure id="fig12" data-index="22" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01163/20201203/images/medium/jm0c01163_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01163/20201203/images/large/jm0c01163_0012.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. <b>28</b> caused antitumor and pharmacodynamic effects on MCF-7 xenografts. MCF-7 cells were injected into male SCID mice supplemented with an estradiol pellet. Once tumors had reached ∼300 mm<sup>3</sup>, they were randomized into groups and treated with vehicle control or doses of <b>28</b>, ranging from 0.5 mg/kg to 50 mg/kg daily, or 5 mg of fulvestrant three times a week for 21 days. (a) Tumor volumes were measured twice a week. Tumor volume is plotted as the geometric mean of the group relative to the day 0 geomean ±95% confidence intervals. To determine statistical significance between groups a one-tailed unpaired <i>t</i> test with Welch’s correction was carried out. **<i>p</i> < 0.01, ***<i>p</i> < 0.001. (b) 24 h after the last dose, tumors were collected, and the level of PR expression in each tumor determined by Western blotting and normalized to expression of vinculin. Data represent individual tumor samples relative to the mean of the vehicle control group. Lines represent the geomean of each group ±95% confidence interval. To determine statistical significance for each group compared to vehicle control a Kruskal–Wallis test followed by Dunn’s posthoc correction was carried out. NS not significant, **<i>p</i> < 0.01, ***<i>p</i> < 0.001.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01163/20201203/images/large/jm0c01163_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01163&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i34">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_81747" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_81747" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">In conclusion, we have described the optimization of a series of tricyclic indazoles as selective estrogen receptor degraders (SERD) and antagonists for the treatment of ER<sup>+</sup> breast cancer. Structure based design together with systematic investigation of each region of the molecular architecture led to the identification of <i>N</i>-[1-(3-fluoropropyl)azetidin-3-yl]-6-[(6<i>S</i>,8<i>R</i>)-8-methyl-7-(2,2,2-trifluoroethyl)-6,7,8,9-tetrahydro-3<i>H</i>-pyrazolo[4,3-<i>f</i>]isoquinolin-6-yl]pyridin-3-amine (<b>28</b>). This compound was demonstrated to be a highly potent SERD that showed a pharmacological profile comparable to fulvestrant in its ability to degrade ERα in both MCF-7 and CAMA-1 cell lines. A stringent control of lipophilicity ensured that <b>28</b> had favorable physicochemical and preclinical pharmacokinetic properties for oral administration, and this, combined with demonstration of potent in vivo activity in mouse xenograft models, resulted in progression of this compound (also known as AZD9833) into clinical trials. This compound is currently in Ph2b studies for treating ER<sup>+</sup> breast cancer patients and further details of its pharmacology, human pharmacokinetics, and clinical efficacy will be reported in due course.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i35">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_45506" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_45506" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36"> General Procedures</h3><div class="NLM_p">All solvents and chemicals used were reagent grade. Anhydrous solvents THF, DCM, and DMF were purchased from Aldrich. Solutions were dried over anhydrous magnesium sulfate or sodium sulfate, and solvent was removed by rotary evaporation under reduced pressure. Microwave reactions were run in a Biotage “Initiator Robot 60” (100–120/220–240 V, 50–60 Hz, 100 VA). Flash column chromatography was carried out using prepacked silica cartridges (from 4 g up to 330 g) from Grace, Redisep, or Silicycle and eluted using an Isco Companion system. The purity of compounds submitted for screening was >95% as determined by UV analysis of liquid chromatography–mass spectroscopy (LCMS) chromatograms at 254 nM and substantiated using the total absorption chromatogram (TAC). Further support for the purity statement was provided using the MS total ion current (TIC) trace in ESI positive and negative ion modes, HRMS and NMR analysis. NMR spectra were recorded on Bruker Avance Neo 500 MHz or Bruker Avance DPX400 and were determined in CDCl<sub>3</sub>, DMSO-<i>d</i><sub>6</sub>, or MeOH-<i>d</i><sub>4</sub>. Chemical shifts are reported as δ in ppm relative to TMS (0.00 ppm) or solvent peaks as the internal reference. Splitting patterns are indicated as follows: s, singlet; d, doublet; t, triplet; m, multiplet; br, broad peak. Analytical LCMS was carried out using a suitable system, such as a Waters 2790/95 LC system with a 2996 PDA and a 2000 amu ZQ single quadrupole mass spectrometer, or a UPLC system utilizing a Waters Aquity Binary pump with sample manager, Aquity PDA and SQD Mass spectrometer. Accurate mass and MSMS fragmentation data were obtained using a Thermo Scientific hybrid LTQ-FT mass spectrometer with an Agilent 1100 Quaternary pump with PDA and Autosampler; 5 μL of sample dissolved in 50:50 acetonitrile/water 0.1% formic acid was injected onto a Thermo Scientific Hypersil Gold 50 × 2.1 mm 5 μm particle LC Column and eluted with a gradient of 5–100% B over 17 min with 3 min re-equilibration time at 5% B. The flow rate was 0.5 mL/min with A being 0.1% formic acid in water and B 0.1% formic acid in acetonitrile. The MS and MSMS spectra were obtained in ESI positive mode in both the ion trap and ion cyclotron resonance (ICR) cell using helium as the collision gas at a normalized collision energy of 35 eV. The ICR cell was run at resolution settings of 25 000 in MS mode and 12 500 in MSMS mode.</div><div class="NLM_p">All IC<sub>50</sub> data are quoted as geometric mean values, and statistical analysis is available in the <a class="ref internalNav" href="#notes1" aria-label="Supporting Information">Supporting Information</a>.</div><div class="NLM_p">All experimental activities involving animals were carried out in accordance with AstraZeneca animal welfare protocols, which are consistent with The American Chemical Society Publications rules and ethical guidelines.</div><div id="sec4_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> (6<i>S</i>,8<i>R</i>)-6-(2,6-Difluoro-4-(2-(3-(fluoromethyl)azetidin-1-yl)ethoxy)phenyl)-7-(2-fluoro-2-methylpropyl)-8-methyl-6,7,8,9-tetrahydro-3<i>H</i>-pyrazolo[4,3-<i>f</i>]isoquinoline (<b>5</b>)</h4><div class="NLM_p last">HCl in dioxane (4 N; 0.42 mL) was added to a solution of (6<i>S</i>,8<i>R</i>)-6-(2,6-difluoro-4-(2-(3-(fluoromethyl)azetidin-1-yl)ethoxy)phenyl)-7-(2-fluoro-2-methylpropyl)-8-methyl-3-(tetrahydro-2<i>H</i>-pyran-2-yl)-6,7,8,9-tetrahydro-3<i>H</i>-pyrazolo[4,3-<i>f</i>]isoquinoline (120 mg, 0.20 mmol) in MeOH (0.51 mL), and the reaction was stirred at room temperature for 30 min. The solvents were evaporated, and the resulting residue was dissolved in DCM and washed with saturated aqueous NaHCO<sub>3</sub>. The aqueous layer was extracted with DCM, and the combined organic layers were dried over sodium sulfate, filtered, and concentrated to dryness. The resulting residue was purified by flash silica chromatography, elution gradient 0–20% MeOH in DCM. Product fractions were concentrated under reduced pressure and lyophilized to afford (6<i>S</i>,8<i>R</i>)-6-(2,6-difluoro-4-(2-(3-(fluoromethyl)azetidin-1-yl)ethoxy)phenyl)-7-(2-fluoro-2-methylpropyl)-8-methyl-6,7,8,9-tetrahydro-3<i>H</i>-pyrazolo[4,3-<i>f</i>]isoquinoline (80 mg, 78%) as a beige solid. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>, 27 °C) 0.98 (d, <i>J</i> = 6.5 Hz, 3H), 1.11 (d, <i>J</i> = 22.1 Hz, 3H), 1.16 (d, <i>J</i> = 21.6 Hz, 3H), 2.27 (dd, <i>J</i> = 27.7, 14.9 Hz, 1H), 2.69 (m, 1H), 2.75 (m, 2H), 2.90 (m, 2H), 3.04 (m, 2H), 3.26 (dd, <i>J</i> = 16.4, 5.0 Hz, 1H), 3.35 (m, 2H), 3.62 (m, 1H), 3.93 (t, <i>J</i> = 5.4 Hz, 2H), 4.50 (dd, <i>J</i> = 47.6, 6.1 Hz, 2H), 5.13 (s, 1H), 6.61 (d, <i>J</i> = 11.2 Hz, 2H), 6.65 (d, <i>J</i> = 8.7 Hz, 1H), 7.20 (d, <i>J</i> = 8.6 Hz, 1H), 8.06 (s, 1H), 12.96 (s, 1H); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>, 27 °C) 11.1, 24.1 (d, <i>J</i> = 24.6 Hz), 25.2 (d, <i>J</i> = 24.5 Hz), 30.6 (d, <i>J</i> = 19.8 Hz), 31.9, 49.1 (d, <i>J</i> = 3.9 Hz), 53.9, 56.0 (d, <i>J</i> = 7.8 Hz, 2C), 56.7, 56.9 (d, <i>J</i> = 22.0 Hz), 66.9, 84.4 (d, <i>J</i> = 163.8 Hz), 97.0 (d, <i>J</i> = 166.3 Hz), 98.6 (d, <i>J</i> = 26.4 Hz, 2C), 107.7, 112.2 (t, <i>J</i> = 15.6 Hz), 122.6, 125.2, 125.7, 126.9, 131.8, 138.4, 159.0 (t, <i>J</i> = 14.4 Hz), 161.8 (d, <i>J</i> = 246.0 Hz), 161.9 (d, <i>J</i> = 247.2 Hz); <sup>19</sup>F NMR (376 MHz, DMSO-<i>d</i><sub>6</sub>, 27 °C) −220.1 (1F), −137.0 (1F), −111.5 (2F); <i>m</i>/<i>z</i> (ES+), [M + H]<sup>+</sup> = 505, HRMS (ESI) (MH<sup>+</sup>); calcd, 505.2590; found, 505.2589.</div></div><div id="sec4_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> (6<i>S</i>,8<i>R</i>)-7-(2-Fluoro-2-methylpropyl)-6-(4-(2-(3-(fluoromethyl)azetidin-1-yl)ethoxy)-2-methoxyphenyl)-8-methyl-6,7,8,9-tetrahydro-3<i>H</i>-pyrazolo[4,3-<i>f</i>]isoquinoline (<b>6</b>)</h4><div class="NLM_p last">To a solution of (6<i>S</i>,8<i>R</i>)-7-(2-fluoro-2-methylpropyl)-6-(4-(2-(3-(fluoromethyl)azetidin-1-yl)ethoxy)-2-methoxyphenyl)-8-methyl-2-(tetrahydro-2<i>H</i>-pyran-2-yl)-6,7,8,9-tetrahydro-2<i>H</i>-pyrazolo[4,3-<i>f</i>]isoquinoline and (6<i>S</i>,8<i>R</i>)-7-(2-fluoro-2-methylpropyl)-6-(4-(2-(3-(fluoromethyl)azetidin-1-yl)ethoxy)-2-methoxyphenyl)-8-methyl-3-(tetrahydro-2<i>H</i>-pyran-2-yl)-6,7,8,9-tetrahydro-3<i>H</i>-pyrazolo[4,3-<i>f</i>]isoquinoline (1.08 g, 1.85 mmol) in dichloromethane (6 mL) was slowly added HCl/dioxane (4.0 M; 4.63 mL, 18.5 mmol). The sticky suspension was stirred vigorously for 30 min. The reaction mixture was evaporated to a solid, coevaporated with toluene, and dissolved in DMSO. The crude product was purified by preparative HPLC using decreasingly polar mixtures of water (containing 1% NH<sub>3</sub>) and MeCN as eluents. Fractions containing the desired compound were evaporated to dryness to afford (6<i>S</i>,8<i>R</i>)-7-(2-fluoro-2-methylpropyl)-6-(4-(2-(3-(fluoromethyl)azetidin-1-yl)ethoxy)-2-methoxyphenyl)-8-methyl-6,7,8,9-tetrahydro-3<i>H</i>-pyrazolo[4,3-<i>f</i>]isoquinoline (0.460 g, 50%) as an off-white foam. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>, 27 °C) 0.97 (d, <i>J</i> = 6.5 Hz, 3H), 1.19 (d, <i>J</i> = 21.5 Hz, 3H), 1.22 (d, <i>J</i> = 21.5 Hz, 3H), 2.27 (dd, <i>J</i> = 25.9, 14.7 Hz, 1H), 2.69 (m, 2H), 2.75 (m, 2H), 2.83 (dd, <i>J</i> = 16.7, 6.1 Hz, 1H), 2.99 (t, <i>J</i> = 6.5 Hz, 2H), 3.18 (dd, <i>J</i> = 16.7, 4.9 Hz, 1H), 3.30 (m, 2H), 3.58 (m, 1H), 3.84 (s, 3H), 3.86 (t, <i>J</i> = 6.4 Hz, 2H), 4.49 (dd, <i>J</i> = 47.6, 6.2 Hz, 2H), 5.25 (s, 1H), 6.29 (dd, <i>J</i> = 8.5, 2.4 Hz, 1H), 6.54 (d, <i>J</i> = 2.4 Hz, 1H), 6.62 (d, <i>J</i> = 8.6 Hz, 1H), 6.66 (d, <i>J</i> = 8.5 Hz, 1H), 7.16 (d, <i>J</i> = 8.6 Hz, 1H), 8.03 (s, 1H), 12.92 (s, 1H); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>, 27 °C) 13.5, 24.8 (d, <i>J</i> = 24.4 Hz), 25.5 (d, <i>J</i> = 24.8 Hz), 30.7 (d, <i>J</i> = 19.9 Hz), 30.9, 46.9, 55.4, 55.8, 56.1 (2C), 56.7, 57.4, 66.2, 84.6 (d, <i>J</i> = 163.6 Hz), 97.2 (d, <i>J</i> = 165.5 Hz), 98.2, 105.1, 107.7, 122.5, 124.9, 125.9, 127.0, 128.6, 131.7 (2C), 138.3, 158.3, 158.4; <sup>19</sup>F NMR (376 MHz, DMSO-<i>d</i><sub>6</sub>, 27 °C) −219.7 (1F), −134.8 (1F); <i>m</i>/<i>z</i> (ES+), [M + H]<sup>+</sup> = 499, HRMS (ESI) (MH<sup>+</sup>); calcd, 499.2885; found, 499.2867.</div></div><div id="sec4_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> (6<i>S</i>,8<i>R</i>)-6-(2,6-Difluoro-4-(2-(3-(fluoromethyl)azetidin-1-yl)ethoxy)phenyl)-7-isobutyl-8-methyl-6,7,8,9-tetrahydro-3<i>H</i>-pyrazolo[4,3-<i>f</i>]isoquinoline (<b>7</b>)</h4><div class="NLM_p last">HCl in dioxane (4.0 M, 0.17 mL, 0.69 mmol) was added to a solution of (6<i>S</i>,8<i>R</i>)-6-(2,6-difluoro-4-(2-(3-(fluoromethyl)azetidin-1-yl)ethoxy)phenyl)-7-isobutyl-8-methyl-3-(tetrahydro-2<i>H</i>-pyran-2-yl)-6,7,8,9-tetrahydro-3<i>H</i>-pyrazolo[4,3-<i>f</i>]isoquinoline (79 mg, 0.14 mmol) in MeOH (2 mL), and the reaction was stirred for 30 min. After evaporation, the crude material was purified by preparative HPLC using decreasingly polar mixtures of water (containing 1% NH<sub>3</sub>) and MeCN as eluents. Fractions containing the desired compound were evaporated to dryness to afford (6<i>S</i>,8<i>R</i>)-6-(2,6-difluoro-4-(2-(3-(fluoromethyl)azetidin-1-yl)ethoxy)phenyl)-7-isobutyl-8-methyl-6,7,8,9-tetrahydro-3<i>H</i>-pyrazolo[4,3-<i>f</i>]isoquinoline (31 mg, 46%) as a white solid. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>, 27 °C) 0.64 (d, <i>J</i> = 6.6 Hz, 3H), 0.78 (d, <i>J</i> = 6.6 Hz, 3H), 0.94 (d, <i>J</i> = 6.4 Hz, 3H), 1.63 (ddd, <i>J</i> = 12.5, 8.3, 6.1 Hz, 1H), 1.96 (dd, <i>J</i> = 12.8, 8.7 Hz, 1H), 2.41 (dd, <i>J</i> = 12.8, 5.9 Hz, 1H), 2.71 (m, 3H), 2.91 (dd, <i>J</i> = 16.0, 3.8 Hz, 1H), 3.00 (t, <i>J</i> = 6.7 Hz, 2H), 3.22 (dd, <i>J</i> = 16.1, 5.0 Hz, 1H), 3.32 (m, 2H), 3.44 (m, 1H), 3.92 (t, <i>J</i> = 5.5 Hz, 2H), 4.49 (dd, <i>J</i> = 47.6, 6.2 Hz, 2H), 5.03 (s, 1H), 6.60 (d, <i>J</i> = 11.6 Hz, 2H), 6.67 (d, <i>J</i> = 8.6 Hz, 1H), 7.19 (d, <i>J</i> = 8.6 Hz, 1H), 8.05 (d, <i>J</i> = 1.3 Hz, 1H), 12.94 (s, 1H); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>, 27 °C) 11.0, 20.1, 20.7, 25.8, 30.6, 32.2, 47.7, 53.9, 56.0 (2C), 57.5, 67.0, 84.5 (d, <i>J</i> = 163.5 Hz), 98.6 (2C), 107.6, 112.6 (t, <i>J</i> = 15.5 Hz), 122.6, 125.3, 125.7, 127.0, 131.8, 138.4, 158.9 (t, <i>J</i> = 14.7 Hz), 161.8 (d, <i>J</i> = 247.0 Hz, 2C); <sup>19</sup>F NMR (376 MHz, DMSO-<i>d</i><sub>6</sub>, 27 °C) −219.9 (1F), −111.9 (2F); <i>m</i>/<i>z</i> (ES+), [M + H]<sup>+</sup> = 487, HRMS (ESI) (MH<sup>+</sup>); calcd, 487.2685; found, 487.2682.</div></div><div id="sec4_1_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> (6<i>R</i>,8<i>R</i>)-6-(4-(2-(3-(Fluoromethyl)azetidin-1-yl)ethoxy)phenyl)-7-isobutyl-8-methyl-6,7,8,9-tetrahydro-3<i>H</i>-pyrazolo[4,3-<i>f</i>]isoquinoline (<b>8</b>)</h4><div class="NLM_p last">A solution of (6<i>R</i>,8<i>R</i>)-6-(4-bromophenyl)-7-isobutyl-8-methyl-3-(tetrahydro-2<i>H</i>-pyran-2-yl)-6,7,8,9-tetrahydro-3<i>H</i>-pyrazolo[4,3-<i>f</i>]isoquinoline (130 mg, 0.27 mmol) and 2-(3-(fluoromethyl)azetidin-1-yl)ethan-1-ol (71.8 mg, 0.54 mmol) in toluene (2.25 mL) was degassed and backfilled with nitrogen (×3). Cesium carbonate (219 mg, 0.67 mmol) and RockPhos third generation Pd precatalyst (11.3 mg, 0.01 mmol) were added successively. The suspension was heated to 90 °C for 90 min. After cooling, the reaction was diluted with EtOAc (50 mL) and washed with water (50 mL). The aqueous phase was extracted with EtOAc (3 × 30 mL), and then the combined organics were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and evaporated. The residue was purified by flash silica chromatography, 0–10% MeOH in DCM. Fractions containing the desired product were evaporated to afford (6<i>R</i>,8<i>R</i>)-6-(4-(2-(3-(fluoromethyl)azetidin-1-yl)ethoxy)phenyl)-7-isobutyl-8-methyl-6,7,8,9-tetrahydro-3<i>H</i>-pyrazolo[4,3-<i>f</i>]isoquinoline (56 mg, 46%) as a beige solid. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>, 27 °C) 0.74 (d, <i>J</i> = 6.6 Hz, 3H), 0.87 (d, <i>J</i> = 6.5 Hz, 3H), 0.97 (d, <i>J</i> = 6.6 Hz, 3H), 1.76 (h, <i>J</i> = 6.7 Hz, 1H), 2.04 (dd, <i>J</i> = 12.8, 7.1 Hz, 1H), 2.29 (dd, <i>J</i> = 12.8, 7.4 Hz, 1H), 2.73 (m, 3H), 2.81 (dd, <i>J</i> = 16.7, 6.9 Hz, 1H), 3.04 (m, 2H), 3.07 (m, 1H), 3.32 (m, 3H), 3.87 (t, <i>J</i> = 5.6 Hz, 2H), 4.50 (dd, <i>J</i> = 47.6, 6.1 Hz, 2H), 4.72 (s, 1H), 6.78 (m, 3H), 7.06 (m, 2H), 7.21 (d, <i>J</i> = 8.6 Hz, 1H), 8.04 (d, <i>J</i> = 1.3 Hz, 1H), 12.95 (s, 1H); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>, 27 °C) 14.4, 20.5, 20.8, 26.1, 30.5, 30.6 (d, <i>J</i> = 20.0 Hz), 45.8, 55.3, 56.0 (d, <i>J</i> = 7.7 Hz, 2C), 57.1, 63.7, 65.9, 84.5 (d, <i>J</i> = 163.7 Hz), 107.4, 113.6 (2C), 122.6, 126.3, 127.5, 127.6, 130.1 (2C), 131.8, 137.3, 138.4, 157.1; <sup>19</sup>F NMR (376 MHz, DMSO-<i>d</i><sub>6</sub>, 27 °C) −219.9 (1F); <i>m</i>/<i>z</i> (ES+), [M + H]<sup>+</sup> = 451, HRMS (ESI) (MH<sup>+</sup>); calcd, 451.2873; found, 451.2864.</div></div><div id="sec4_1_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> (6<i>S</i>,8<i>R</i>)-6-(4-(2-(3-(Fluoromethyl)azetidin-1-yl)ethoxy)-2-methoxyphenyl)-7-isobutyl-8-methyl-6,7,8,9-tetrahydro-3<i>H</i>-pyrazolo[4,3-<i>f</i>]isoquinoline (<b>9</b>)</h4><div class="NLM_p last">(6<i>S</i>,8<i>R</i>)-6-(4-(2-(3-(Fluoromethyl)azetidin-1-yl)ethoxy)-2-methoxyphenyl)-7-isobutyl-8-methyl-3-(tetrahydro-2<i>H</i>-pyran-2-yl)-6,7,8,9-tetrahydro-3<i>H</i>-pyrazolo[4,3-<i>f</i>]isoquinoline (120 mg, 0.21 mmol) was dissolved in MeOH (2 mL) and treated slowly with HCl in dioxane (4 M; 0.53 mL, 2.1 mmol) at room temperature. The reaction was stirred for 30 min under these conditions and then concentrated under reduced pressure. The resulting residue was purified by preparative HPLC (Waters Xbridge Phenyl column, 5 μm silica, 19 mm diameter, 100 mm length, 20 mL/min), eluting with 50–80% acetonitrile in water containing 0.2% NH<sub>4</sub>OH (pH 10) over 6 min. Product fractions were concentrated under reduced pressure to afford (6<i>S</i>,8<i>R</i>)-6-(4-(2-(3-(fluoromethyl)azetidin-1-yl)ethoxy)-2-methoxyphenyl)-7-isobutyl-8-methyl-6,7,8,9-tetrahydro-3<i>H</i>-pyrazolo[4,3-<i>f</i>]isoquinoline (38 mg, 37%) as a light yellow solid. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>, 27 °C) 0.72 (d, <i>J</i> = 6.4 Hz, 3H), 0.83 (d, <i>J</i> = 6.4 Hz, 3H), 0.96 (d, <i>J</i> = 6.5 Hz, 3H), 1.85 (p, <i>J</i> = 6.7 Hz, 1H), 1.98 (dd, <i>J</i> = 12.6, 7.0 Hz, 1H), 2.26 (m, 1H), 2.68 (m, 3H), 2.80 (dd, <i>J</i> = 16.7, 6.6 Hz, 1H), 2.99 (dd, <i>J</i> = 7.2, 5.8 Hz, 2H), 3.11 (dd, <i>J</i> = 16.6, 4.7 Hz, 1H), 3.30 (m, 2H), 3.39 (m, 1H), 3.85 (s, 3H), 3.87 (m, 2H), 4.50 (dd, <i>J</i> = 47.6, 6.2 Hz, 2H), 5.15 (s, 1H), 6.28 (dd, <i>J</i> = 8.5, 2.4 Hz, 1H), 6.54 (d, <i>J</i> = 2.3 Hz, 1H), 6.65 (m, 2H), 7.16 (d, <i>J</i> = 8.6 Hz, 1H), 8.02 (s, 1H), 12.89 (s, 1H); <i>m</i>/<i>z</i> (ES+), [M + H]<sup>+</sup> = 481</div></div><div id="sec4_1_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> (6<i>S</i>,8<i>R</i>)-6-(5-(2-(3-(Fluoromethyl)azetidin-1-yl)ethoxy)pyridin-2-yl)-7-isobutyl-8-methyl-6,7,8,9-tetrahydro-3<i>H</i>-pyrazolo[4,3-<i>f</i>]isoquinoline (<b>10</b>)</h4><div class="NLM_p last">A solution of (6<i>S</i>,8<i>R</i>)-6-(5-bromopyridin-2-yl)-7-isobutyl-8-methyl-3-(tetrahydro-2<i>H</i>-pyran-2-yl)-6,7,8,9-tetrahydro-3<i>H</i>-pyrazolo[4,3-<i>f</i>]isoquinoline (42 mg, 0.09 mmol) and 2-(3-(fluoromethyl)azetidin-1-yl)ethan-1-ol (23.1 mg, 0.17 mmol) in toluene (1.5 mL) was degassed by nitrogen bubbling. Cesium carbonate (70.8 mg, 0.22 mmol) and RockPhos third generation Pd precatalyst (3.64 mg, 4.34 μmol) were added successively, and the reaction was heated at 90 °C for 4 h. Water was added, and reaction was extracted with ethyl acetate (×3). The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and evaporated. The residue was dissolved in MeOH (2.0 mL), and HCl in dioxane (4.0 M 0.105 mL, 0.42 mmol) was added. The reaction was stirred at room temperature for 30 min, and then the volatiles were evaporated. The crude material was purified by reverse phase chromatography, followed by further purification by silica gel chromatography, 0–20% MeOH in DCM to afford (6<i>S</i>,8<i>R</i>)-6-(5-(2-(3-(fluoromethyl)azetidin-1-yl)ethoxy)pyridin-2-yl)-7-isobutyl-8-methyl-6,7,8,9-tetrahydro-3<i>H</i>-pyrazolo[4,3-<i>f</i>]isoquinoline (17.1 mg, 45%) as a white solid. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>, 27 °C) 0.73 (d, <i>J</i> = 6.5 Hz, 3H), 0.81 (d, <i>J</i> = 6.5 Hz, 3H), 0.97 (d, <i>J</i> = 6.5 Hz, 3H), 1.72 (m, 1H), 1.96 (dd, <i>J</i> = 12.8, 8.3 Hz, 1H), 2.37 (m, 1H), 2.71 (m, 3H), 2.88 (dd, <i>J</i> = 16.5, 5.2 Hz, 1H), 3.00 (m, 2H), 3.20 (dd, <i>J</i> = 16.4, 4.9 Hz, 1H), 3.31 (m, 2H), 3.46 (p, <i>J</i> = 5.8 Hz, 1H), 3.95 (td, <i>J</i> = 5.8, 1.8 Hz, 2H), 4.48 (m, 2H), 4.78 (s, 1H), 6.76 (d, <i>J</i> = 8.6 Hz, 1H), 7.17 (d, <i>J</i> = 8.7 Hz, 2H), 7.25 (dd, <i>J</i> = 8.7, 2.9 Hz, 1H), 8.04 (s, 1H), 8.13 (d, <i>J</i> = 2.9 Hz, 1H), 12.93 (s, 1H); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>, 27 °C) 12.7, 20.3, 20.8, 25.7, 30.7 (d, <i>J</i> = 19.8 Hz), 31.7, 46.4, 56.0 (d, <i>J</i> = 7.7 Hz, 2C), 56.6, 57.2, 65.5, 66.6, 84.6 (d, <i>J</i> = 163.8 Hz), 107.4, 122.0, 122.6, 123.5, 125.4, 126.8, 127.6, 131.8, 134.9, 138.4, 153.4, 156.8; <sup>19</sup>F NMR (376 MHz, DMSO-<i>d</i><sub>6</sub>, 27 °C) −219.9 (1F); <i>m</i>/<i>z</i> (ES+), [M + H]<sup>+</sup> = 452, HRMS (ESI) (MH<sup>+</sup>); calcd, 452.2826; found, 452.2828.</div></div><div id="sec4_1_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> (6<i>S</i>,8<i>R</i>)-7-((1-Fluorocyclopropyl)methyl)-6-(4-(2-(3-(fluoromethyl)azetidin-1-yl)ethoxy)-2-methoxyphenyl)-8-methyl-6,7,8,9-tetrahydro-3<i>H</i>-pyrazolo[4,3-<i>f</i>]isoquinoline (<b>11</b>)</h4><div class="NLM_p last">HCl in dioxane (4 M; 0.5 mL, 2 mmol) was added to a solution of (6<i>S</i>,8<i>R</i>)-7-((1-fluorocyclopropyl)methyl)-6-(4-(2-(3-(fluoromethyl)azetidin-1-yl)ethoxy)-2-methoxyphenyl)-8-methyl-3-(tetrahydro-2<i>H</i>-pyran-2-yl)-6,7,8,9-tetrahydro-3<i>H</i>-pyrazolo[4,3-<i>f</i>]isoquinoline (0.052 g, 0.09 mmol) and (6<i>S</i>,8<i>R</i>)-7-((1-fluorocyclopropyl)methyl)-6-(4-(2-(3-(fluoromethyl)azetidin-1-yl)ethoxy)-2-methoxyphenyl)-8-methyl-2-(tetrahydro-2<i>H</i>-pyran-2-yl)-6,7,8,9-tetrahydro-2<i>H</i>-pyrazolo[4,3-<i>f</i>]isoquinoline (0.065 g, 0.11 mmol) in MeOH (1 mL). The resulting solution was stirred at room temperature for 2 h and then concentrated under reduced pressure. The resulting residue was purified directly by reverse phase HPLC (Waters XBridge Phenyl column, 19 mm diameter, 100 mm length, 5 μm silica), elution gradient 50–80% MeCN in water containing 0.2% ammonium hydroxide (pH 10) as a modifier, to give (6<i>S</i>,8<i>R</i>)-7-((1-fluorocyclopropyl)methyl)-6-(4-(2-(3-(fluoromethyl)azetidin-1-yl)ethoxy)-2-methoxyphenyl)-8-methyl-6,7,8,9-tetrahydro-3<i>H</i>-pyrazolo[4,3-<i>f</i>]isoquinoline (0.037 g, 37%) as a white solid. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>, 27 °C) 0.48 (m, 1H), 0.56 (m, 1H), 0.90 (m, 2H), 0.99 (d, <i>J</i> = 6.5 Hz, 3H), 2.56 (m, 1H), 2.69 (m, 2H), 2.71 (m, 1H), 2.88 (m, 1H), 2.96 (m, 1H), 2.99 (m, 2H), 3.25 (dd, <i>J</i> = 16.3, 5.2 Hz, 1H), 3.31 (m, 3H), 3.70 (q, <i>J</i> = 5.6 Hz, 1H), 3.86 (s, 3H), 3.87 (m, 1H), 4.50 (dd, <i>J</i> = 47.6, 6.3 Hz, 2H), 5.24 (s, 1H), 6.32 (dd, <i>J</i> = 8.5, 2.4 Hz, 1H), 6.55 (d, <i>J</i> = 2.4 Hz, 1H), 6.63 (d, <i>J</i> = 8.7 Hz, 1H), 6.78 (d, <i>J</i> = 8.5 Hz, 1H), 7.15 (d, <i>J</i> = 8.6 Hz, 1H), 8.03 (d, <i>J</i> = 1.2 Hz, 1H), 12.91 (s, 1H); <i>m</i>/<i>z</i> (ES+), [M + H]<sup>+</sup> = 497.</div></div><div id="sec4_1_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> (6<i>S</i>,8<i>R</i>)-7-((1-Fluorocyclopropyl)methyl)-6-(5-(2-(3-(fluoromethyl)azetidin-1-yl)ethoxy)pyridin-2-yl)-8-methyl-6,7,8,9-tetrahydro-3<i>H</i>-pyrazolo[4,3-<i>f</i>]isoquinoline (<b>12</b>)</h4><div class="NLM_p last">(6<i>S</i>,8<i>R</i>)-7-((1-Fluorocyclopropyl)methyl)-6-(5-(2-(3-(fluoromethyl)azetidin-1-yl)ethoxy)pyridin-2-yl)-8-methyl-3-(tetrahydro-2<i>H</i>-pyran-2-yl)-6,7,8,9-tetrahydro-3<i>H</i>-pyrazolo[4,3-<i>f</i>]isoquinoline (69 mg, 0.12 mmol) was dissolved in MeOH (1.13 mL) and cooled to 0 °C. The solution was then treated slowly with HCl in dioxane (4 M; 0.16 mL, 0.62 mmol), and the reaction was stirred at room temperature for 30 min. The reaction mixture was then concentrated under reduced pressure, and the resulting residue was purified by preparative HPLC (Waters Xbridge C18 column, 5 μm silica, 19 mm diameter, 150 mm length, 20 mL/min), eluting with 40–70% acetonitrile in water containing 0.2% NH<sub>4</sub>OH (pH 10) over 5 min. Product fractions were combined and concentrated under reduced pressure to afford (6<i>S</i>,8<i>R</i>)-7-((1-fluorocyclopropyl)methyl)-6-(5-(2-(3-(fluoromethyl)azetidin-1-yl)ethoxy)pyridin-2-yl)-8-methyl-6,7,8,9-tetrahydro-3<i>H</i>-pyrazolo[4,3-<i>f</i>]isoquinoline (27 mg, 45%) as a light yellow solid. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>, 27 °C) 0.47 (m, 1H), 0.66 (m, 1H), 0.92 (m, 2H), 1.02 (d, <i>J</i> = 6.5 Hz, 3H), 2.64 (m, 1H), 2.71 (t, <i>J</i> = 5.2 Hz, 2H), 2.72 (m, 1H), 2.90 (dd, <i>J</i> = 16.6, 5.4 Hz, 1H), 2.99 (dd, <i>J</i> = 7.4, 6.0 Hz, 2H), 3.02 (m, 1H), 3.19 (m, 1H), 3.30 (m, 2H), 3.68 (q, <i>J</i> = 5.7 Hz, 1H), 3.95 (t, <i>J</i> = 5.6 Hz, 2H), 4.49 (dd, <i>J</i> = 47.6, 6.2 Hz, 2H), 4.92 (s, 1H), 6.78 (d, <i>J</i> = 8.7 Hz, 1H), 7.20 (m, 2H), 7.26 (dd, <i>J</i> = 8.7, 2.8 Hz, 1H), 8.05 (s, 1H), 8.13 (d, <i>J</i> = 2.8 Hz, 1H), 12.91 (s, 1H); <i>m</i>/<i>z</i> (ES+), [M + H]<sup>+</sup> = 468.</div></div><div id="sec4_1_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45"> (6<i>S</i>,8<i>R</i>)-6-(4-(2-(3-(Fluoromethyl)azetidin-1-yl)ethoxy)-2-methoxyphenyl)-7-((3-fluorooxetan-3-yl)methyl)-8-methyl-6,7,8,9-tetrahydro-3<i>H</i>-pyrazolo[4,3-<i>f</i>]isoquinoline (<b>13</b>)</h4><div class="NLM_p last">A solution of (6<i>S</i>,8<i>R</i>)-6-(4-bromo-2-methoxyphenyl)-7-((3-fluorooxetan-3-yl)methyl)-8-methyl-3-(tetrahydro-2<i>H</i>-pyran-2-yl)-6,7,8,9-tetrahydro-3<i>H</i>-pyrazolo[4,3-<i>f</i>]isoquinoline (233 mg, 0.43 mmol) and 2-(3-(fluoromethyl)azetidin-1-yl)ethan-1-ol (114 mg, 0.86 mmol) in toluene (3 mL) was degassed by nitrogen bubbling. Cesium carbonate (349 mg, 1.07 mmol) and RockPhos third generation Pd precatalyst (17.9 mg, 0.02 mmol) were added successively. The reaction was heated at 90 °C for 2 h. Water was added, and the reaction was extracted with EtOAc (×3). The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and evaporated. H<sub>2</sub>SO<sub>4</sub> (1 N in MeOH; 2 mL) was added, and the reaction was stirred at room temperature overnight. The methanol was evaporated, and then the residue was diluted with water, basified with saturated NaHCO<sub>3</sub>, and extracted with EtOAc (×2). The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and evaporated. The crude residue was purified by flash silica chromatography 0–40% MeOH in DCM to afford (6<i>S</i>,8<i>R</i>)-6-(4-(2-(3-(fluoromethyl)azetidin-1-yl)ethoxy)-2-methoxyphenyl)-7-((3-fluorooxetan-3-yl)methyl)-8-methyl-6,7,8,9-tetrahydro-3<i>H</i>-pyrazolo[4,3-<i>f</i>]isoquinoline (59.0 mg, 40%) as an off-white solid. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>, 27 °C) 1.02 (d, <i>J</i> = 6.5 Hz, 3H), 2.70 (m, 1H), 2.78 (m, 2H), 2.82 (dd, <i>J</i> = 16.9, 7.2 Hz, 1H), 3.06 (m, 3H), 3.12 (m, 1H), 3.29 (m, 2H), 3.37 (m, 1H), 3.41 (m, 1H), 3.85 (s, 3H), 3.88 (m, 2H), 4.36 (dd, <i>J</i> = 20.4, 7.6 Hz, 1H), 4.47 (m, 2H), 4.55 (m, 3H), 5.30 (s, 1H), 6.30 (dd, <i>J</i> = 8.5, 2.4 Hz, 1H), 6.56 (m, 2H), 6.65 (d, <i>J</i> = 8.6 Hz, 1H), 7.19 (d, <i>J</i> = 8.6 Hz, 1H), 8.04 (s, 1H), 12.95 (s, 1H); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>, 27 °C) 14.8, 30.1, 30.6 (d, <i>J</i> = 19.7 Hz), 46.8, 50.4 (d, <i>J</i> = 21.9 Hz), 55.5, 56.0 (d, <i>J</i> = 7.8 Hz, 2C), 57.1, 57.4, 66.0, 78.7 (d, <i>J</i> = 24.2 Hz, 2C), 84.5 (d, <i>J</i> = 163.6 Hz), 96.3 (d, <i>J</i> = 207.5 Hz), 98.5, 105.0, 107.9, 122.4, 124.7, 126.2, 127.1, 127.5, 131.4, 131.7, 138.4, 158.3, 158.5; <sup>19</sup>F NMR (376 MHz, DMSO-<i>d</i><sub>6</sub>, 27 °C) −219.9 (1F), −146.3 (1F); <i>m</i>/<i>z</i> (ES+), [M + H]<sup>+</sup> = 513, HRMS (ESI) (MH<sup>+</sup>); calcd, 513.2677; found, 513.2678.</div></div><div id="sec4_1_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> 3-Fluoro-<i>N</i>-(2-(4-((6<i>S</i>,8<i>R</i>)-7-((1-fluorocyclopropyl)methyl)-8-methyl-6,7,8,9-tetrahydro-3<i>H</i>-pyrazolo[4,3-<i>f</i>]isoquinolin-6-yl)-3-methoxyphenoxy)ethyl)propan-1-amine (<b>14</b>)</h4><div class="NLM_p last">4 M HCl in dioxane (1.72 mL, 6.88 mmol) was added to a solution of <i>tert</i>-butyl (2-(4-((6<i>S</i>,8<i>R</i>)-7-((1-fluorocyclopropyl)methyl)-8-methyl-3-(tetrahydro-2<i>H</i>-pyran-2-yl)-6,7,8,9-tetrahydro-3<i>H</i>-pyrazolo[4,3-<i>f</i>]isoquinolin-6-yl)-3-methoxyphenoxy)ethyl)(3-fluoropropyl)carbamate (0.46 g, 0.69 mmol) in MeOH (3.0 mL). The mixture was stirred at room temperature for 2 h, and then the volatiles were evaporated. The crude product was purified by preparative HPLC, using decreasingly polar mixtures of water (containing 0.1% NH<sub>3</sub>) and MeCN as eluents. Fractions containing the desired compound were evaporated to dryness to afford 3-fluoro-<i>N</i>-(2-(4-((6<i>S</i>,8<i>R</i>)-7-((1-fluorocyclopropyl)methyl)-8-methyl-6,7,8,9-tetrahydro-3<i>H</i>-pyrazolo[4,3-<i>f</i>]isoquinolin-6-yl)-3-methoxyphenoxy)ethyl)propan-1-amine (0.095 g, 29%) as a colorless solid. [α]<sup>26</sup><sub>D</sub> −177 (c 1.9, MeOH); <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>, 27 °C) 0.52 (m, 2H), 0.90 (m, 2H), 0.99 (d, <i>J</i> = 6.6, 3H), 1.78 (m, 2H), 2.58 (dd, <i>J</i> = 20.1, 14.5 Hz, 1H), 2.65 (t, <i>J</i> = 6.9 Hz, 2H), 2.83 (t, <i>J</i> = 5.7 Hz, 2H), 2.88 (m, 1H), 2.94 (m, 1H), 3.25 (dd, <i>J</i> = 16.5, 5.1 Hz, 1H), 3.69 (m, 1H), 3.87 (s, 3H), 3.96 (m, 2H), 4.49 (dtd, <i>J</i> = 47.5, 6.1, 1.5 Hz, 2H), 5.25 (s, 1H), 6.35 (dt, <i>J</i> = 8.5, 1.9 Hz, 1H), 6.59 (t, <i>J</i> = 1.8 Hz, 1H), 6.64 (d, <i>J</i> = 8.6 Hz, 1H), 6.79 (dd, <i>J</i> = 8.5, 1.1 Hz, 1H), 7.15 (d, <i>J</i> = 8.6 Hz, 1H), 8.03 (s, 1H), 12.91 (s, 1H); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>, 27 °C) 8.9 (d, <i>J</i> = 11.5 Hz), 10.2 (d, <i>J</i> = 12.1 Hz), 12.3, 30.4 (d, <i>J</i> = 19.2 Hz), 31.5, 45.1 (d, <i>J</i> = 5.6 Hz), 46.9, 48.2, 51.9 (d, <i>J</i> = 20.8 Hz), 55.3, 55.6, 67.4, 78.2 (d, <i>J</i> = 216.5 Hz), 82.3 (d, <i>J</i> = 160.8 Hz), 98.4, 105.6, 107.7, 122.5, 125.1, 125.3, 126.7, 128.7, 130.9, 131.7, 138.3, 158.2, 158.5; <sup>19</sup>F NMR (376 MHz, DMSO-<i>d</i><sub>6</sub>, 27 °C) −218.1 (1F), −179.8 (1F); <i>m</i>/<i>z</i> (ES+), [M + H]<sup>+</sup> = 485, HRMS (ESI) (MH<sup>+</sup>); calcd, 485.2728; found, 485.2733.</div></div><div id="sec4_1_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i47" class="anchor-spacer"></div><h4 class="article-section__title" id="_i47"> (6<i>S</i>,8<i>R</i>)-7-((1-Ffluorocyclopropyl)methyl)-6-(4-((1-(3-fluoropropyl)azetidin-3-yl)oxy)-2-methoxyphenyl)-8-methyl-6,7,8,9-tetrahydro-3<i>H</i>-pyrazolo[4,3-<i>f</i>]isoquinoline (<b>15</b>)</h4><div class="NLM_p last">1-Fluoro-3-iodopropane (5.79 μL, 0.05 mmol) was added to a solution of (6<i>S</i>,8<i>R</i>)-6-(4-(azetidin-3-yloxy)-2-methoxyphenyl)-7-((1-fluorocyclopropyl)methyl)-8-methyl-6,7,8,9-tetrahydro-3<i>H</i>-pyrazolo[4,3-<i>f</i>]isoquinoline trifluoroacetic acid salt (0.030 g, 0.050 mmol) and DIPEA (0.029 mL, 0.16 mmol) in NMP (0.52 mL) at room temperature. After 3 h, the reaction was diluted with EtOAc (40 mL) and washed with saturated aqueous sodium chloride (3 × 20 mL). The organic layer was dried over MgSO<sub>4</sub>, filtered, and concentrated under reduced pressure. The resulting residue was purified by flash silica chromatography, elution gradient 15–30% (MeOH in DCM containing 1% ammonium hydroxide) in DCM to afford (6<i>S</i>,8<i>R</i>)-7-((1-fluorocyclopropyl)methyl)-6-(4-((1-(3-fluoropropyl)azetidin-3-yl)oxy)-2-methoxyphenyl)-8-methyl-6,7,8,9-tetrahydro-3<i>H</i>-pyrazolo[4,3-<i>f</i>]isoquinoline (5 mg, 18%) as a white solid. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>, 27 °C) 0.52 (m, 2H), 0.89 (m, 2H), 0.99 (d, <i>J</i> = 6.5 Hz, 3H), 1.65 (m, 2H), 2.59 (dd, <i>J</i> = 14.6, 20.1 Hz, 1H), 2.87 (m, 1H), 2.90 (m, 2H), 2.94 (m, 1H), 3.23 (dd, <i>J</i> = 16.5, 5.0 Hz, 1H), 3.31 (m, 2H), 3.67 (m, 1H), 3.72 (m, 2H), 3.86 (s, 3H), 4.44 (dt, <i>J</i> = 47.4, 6.1 Hz, 2H), 4.74 (p, <i>J</i> = 5.8 Hz, 1H), 5.25 (s, 1H), 6.22 (dd, <i>J</i> = 8.5, 2.4 Hz, 1H), 6.49 (d, <i>J</i> = 2.4 Hz, 1H), 6.64 (d, <i>J</i> = 8.7 Hz, 1H), 6.76 (d, <i>J</i> = 8.5 Hz, 1H), 7.16 (d, <i>J</i> = 8.6 Hz, 1H), 8.03 (d, <i>J</i> = 1.0 Hz, 1H), 12.90 (s, 1H); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>, 27 °C) 9.0 (d, <i>J</i> = 11.7 Hz), 10.1 (d, <i>J</i> = 12.1 Hz), 12.7, 28.2 (d, <i>J</i> = 19.5 Hz), 31.3, 46.8, 51.9 (d, <i>J</i> = 21.0 Hz), 54.8 (d, <i>J</i> = 5.6 Hz), 55.6, 60.8 (2C), 66.0, 78.1 (d, <i>J</i> = 216.5 Hz), 82.0 (d, <i>J</i> = 161.3 Hz), 98.4, 105.5, 107.8, 122.5, 125.5, 125.6, 126.7, 128.5, 131.1, 131.6, 138.3, 156.6, 158.3; <sup>19</sup>F NMR (376 MHz, DMSO-<i>d</i><sub>6</sub>, 27 °C) −218.1 (1F), −179.9 (1F); <i>m</i>/<i>z</i> (ES+), [M + H]<sup>+</sup> = 497, HRMS (ESI) (MH<sup>+</sup>); calcd, 497.2728; found, 497.2737.</div></div><div id="sec4_1_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i48" class="anchor-spacer"></div><h4 class="article-section__title" id="_i48"> <i>N</i>-(4-((6<i>S</i>,8<i>R</i>)-7-((1-Fluorocyclopropyl)methyl)-8-methyl-6,7,8,9-tetrahydro-3<i>H</i>-pyrazolo[4,3-<i>f</i>]isoquinolin-6-yl)-3-methoxyphenyl)-1-(3-fluoropropyl)azetidin-3-amine (<b>16</b>)</h4><div class="NLM_p last">1-Fluoro-3-iodopropane (40.9 μL, 0.39 mmol) was added to a solution of <i>N</i>-(4-((6<i>S</i>,8<i>R</i>)-7-((1-fluorocyclopropyl)methyl)-8-methyl-6,7,8,9-tetrahydro-3<i>H</i>-pyrazolo[4,3-<i>f</i>]isoquinolin-6-yl)-3-methoxyphenyl)azetidin-3-amine (169 mg, 0.39 mmol) and DIPEA (203 μL, 1.16 mmol) in NMP (1.7 mL) at room temperature. After 18 h, the reaction was concentrated under reduced pressure. The resulting residue was purified by reverse phase flash chromatography (C18), eluting with decreasingly polar mixtures of water (containing 0.2% ammonium hydroxide) and MeCN as eluents. Product fractions were combined and lyophilized to afford <i>N</i>-(4-((6<i>S</i>,8<i>R</i>)-7-((1-fluorocyclopropyl)methyl)-8-methyl-6,7,8,9-tetrahydro-3<i>H</i>-pyrazolo[4,3-<i>f</i>]isoquinolin-6-yl)-3-methoxyphenyl)-1-(3-fluoropropyl)azetidin-3-amine (75 mg, 39%) as a clear residue. [α]<sup>26</sup><sub>D</sub> −195 (c 1.9, MeOH); <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>, 27 °C) 0.49 (m, 1H), 0.57 (m, 1H), 0.86 (m, 1H), 0.91 (m, 1H), 0.99 (d, <i>J</i> = 6.5 Hz, 3H), 1.64 (dp, <i>J</i> = 25.7, 6.5 Hz, 2H), 2.45 (t, <i>J</i> = 7.0 Hz, 2H), 2.60 (dd, <i>J</i> = 19.9, 14.5 Hz, 1H), 2.71 (q, <i>J</i> = 6.6 Hz, 2H), 2.85 (dd, <i>J</i> = 16.4, 5.0 Hz, 1H), 2.92 (dd, <i>J</i> = 19.7, 14.6 Hz, 1H), 3.21 (dd, <i>J</i> = 16.4, 5.0 Hz, 1H), 3.62 (q, <i>J</i> = 6.4 Hz, 2H), 3.68 (m, 1H), 3.80 (s, 3H), 3.92 (h, <i>J</i> = 6.6 Hz, 1H), 4.44 (dt, <i>J</i> = 47.5, 6.1 Hz, 2H), 5.17 (s, 1H), 5.92 (dd, <i>J</i> = 8.4, 2.2 Hz, 1H), 5.96 (d, <i>J</i> = 6.9 Hz, 1H), 6.16 (d, <i>J</i> = 2.1 Hz, 1H), 6.56 (d, <i>J</i> = 8.3 Hz, 1H), 6.65 (d, <i>J</i> = 8.7 Hz, 1H), 7.14 (d, <i>J</i> = 8.6 Hz, 1H), 8.01 (s, 1H), 12.89 (s, 1H); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>, 27 °C) 8.9 (d, <i>J</i> = 11.6 Hz), 10.1 (d, <i>J</i> = 12.0 Hz), 12.6, 28.3 (d, <i>J</i> = 19.5 Hz), 31.5, 43.3, 46.8, 51.7 (d, <i>J</i> = 21.1 Hz), 54.8 (d, <i>J</i> = 5.6 Hz), 55.2, 55.5, 61.6 (2C), 78.3 (d, <i>J</i> = 216.2 Hz), 82.0 (d, <i>J</i> = 161.2 Hz), 95.2, 104.3, 107.5, 120.4, 122.5, 125.3, 127.0, 129.2, 130.9, 131.6, 138.2, 147.6, 158.2; <sup>19</sup>F NMR (376 MHz, DMSO-<i>d</i><sub>6</sub>, 27 °C) −218.1 (1F), −179.7 (1F); <i>m</i>/<i>z</i> (ES+), [M + H]<sup>+</sup> = 496, HRMS (ESI) (MH<sup>+</sup>); calcd, 496.2888; found, 496.2912.</div></div><div id="sec4_1_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i49" class="anchor-spacer"></div><h4 class="article-section__title" id="_i49"> <i>N</i>1-(6-((6<i>S</i>,8<i>R</i>)-7-((1-Fluorocyclopropyl)methyl)-8-methyl-6,7,8,9-tetrahydro-3<i>H</i>-pyrazolo[4,3-<i>f</i>]isoquinolin-6-yl)pyridin-3-yl)-<i>N</i>2-(3-fluoropropyl)ethane-1,2-diamine (<b>17</b>)</h4><div class="NLM_p last">To a flask containing (6<i>S</i>,8<i>R</i>)-6-(5-bromopyridin-2-yl)-7-((1-fluorocyclopropyl)methyl)-8-methyl-6,7,8,9-tetrahydro-3<i>H</i>-pyrazolo[4,3-<i>f</i>]isoquinoline (0.20 g, 0.48 mmol), <i>N</i><sup>1</sup>-(3-fluoropropyl)ethane-1,2-diamine·2HCl (0.112 g, 0.58 mmol), BrettPhos third generation Pd precatalyst (0.022 g, 0.02 mmol) and sodium <i>tert</i>-butoxide (0.278 g, 2.89 mmol) was added 1,4-dioxane (2.5 mL). The reaction was evacuated and backfilled with N<sub>2</sub> (×2). The reaction was stirred at 50 °C for 4 h and then was allowed to cool to room temperature and filtered. The filtrate was evaporated, and the residue was purified by silica gel chromatography, 0–20% MeOH in DCM to afford the product as a mixture of isomers. The mixture was further purified by SFC to afford <i>N</i><sup>1</sup>-(6-((6<i>S</i>,8<i>R</i>)-7-((1-fluorocyclopropyl)methyl)-8-methyl-6,7,8,9-tetrahydro-3<i>H</i>-pyrazolo[4,3-<i>f</i>]isoquinolin-6-yl)pyridin-3-yl)-<i>N</i><sup>2</sup>-(3-fluoropropyl)ethane-1,2-diamine (0.040 g, 18%) as a light tan solid. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>, 27 °C) 0.47 (m, 1H), 0.67 (m, 1H), 0.90 (m, 2H), 1.01 (d, <i>J</i> = 6.5 Hz, 3H), 1.76 (m, 2H), 2.61 (t, <i>J</i> = 6.9 Hz, 2H), 2.65 (m, 1H), 2.69 (t, <i>J</i> = 6.3 Hz, 2H), 2.88 (dd, <i>J</i> = 16.5, 5.2 Hz, 1H), 2.99 (dd, <i>J</i> = 19.4, 14.6 Hz, 1H), 3.07 (q, <i>J</i> = 6.1 Hz, 2H), 3.21 (dd, <i>J</i> = 16.5, 5.1 Hz, 1H), 3.69 (m, 1H), 4.49 (dt, <i>J</i> = 47.5, 6.0 Hz, 2H), 4.80 (s, 1H), 5.64 (t, <i>J</i> = 5.6 Hz, 1H), 6.78 (d, <i>J</i> = 8.7 Hz, 1H), 6.85 (dd, <i>J</i> = 8.6, 2.8 Hz, 1H), 6.94 (d, <i>J</i> = 8.5 Hz, 1H), 7.17 (d, <i>J</i> = 8.6 Hz, 1H), 7.83 (d, <i>J</i> = 2.8 Hz, 1H), 8.04 (s, 1H), 12.93 (s, 1H); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>, 27 °C) 8.7 (d, <i>J</i> = 11.4 Hz), 10.1 (d, <i>J</i> = 11.9 Hz), 12.9, 30.4 (d, <i>J</i> = 19.2 Hz), 31.5, 42.5, 44.9 (d, <i>J</i> = 5.7 Hz), 47.0, 48.1, 51.6 (d, <i>J</i> = 21.2 Hz), 65.4, 78.3 (d, <i>J</i> = 216.1 Hz), 82.3 (d, <i>J</i> = 160.9 Hz), 107.4, 119.0, 122.6, 123.1, 125.2, 126.9, 127.7, 131.8, 132.6, 138.4, 143.6, 151.1; <sup>19</sup>F NMR (376 MHz, DMSO-<i>d</i><sub>6</sub>, 27 °C) −218.1 (1F), −180.4 (1F); <i>m</i>/<i>z</i> (ES+), [M + H]<sup>+</sup> = 455, HRMS (ESI) (MH<sup>+</sup>); calcd, 455.27293; found, 455.27466.</div></div><div id="sec4_1_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i50" class="anchor-spacer"></div><h4 class="article-section__title" id="_i50"> 6-((6<i>S</i>,8<i>R</i>)-7-((1-fFluorocyclopropyl)methyl)-8-methyl-6,7,8,9-tetrahydro-3<i>H</i>-pyrazolo[4,3-<i>f</i>]isoquinolin-6-yl)-<i>N</i>-(1-(3-fluoropropyl)azetidin-3-yl)pyridin-3-amine (<b>18</b>)</h4><div class="NLM_p last">[(2-Dicyclohexylphosphino-3,6-dimethoxy-2′,4′,6′-triisopropyl-1,1′-biphenyl)-2-(2′-amino-1,1′ -biphenyl)]palladium(II) methanesulfonate (BrettPhos Pd G3) (12.11 mg, 0.01 mmol) and sodium <i>tert</i>-butoxide (85 mg, 0.89 mmol) were added to a degassed solution of (6<i>S</i>,8<i>R</i>)-6-(5-bromopyridin-2-yl)-7-((1-fluorocyclopropyl)methyl)-8-methyl-3-(tetrahydro-2<i>H</i>-pyran-2-yl)-6,7,8,9-tetrahydro-3<i>H</i>-pyrazolo[4,3-<i>f</i>]isoquinoline (177 mg, 0.35 mmol) and 1-(3-fluoropropyl)azetidin-3-amine (94 mg, 0.71 mmol) in 1,4-dioxane (2835 μL), and the reaction was heated to 90 °C for 5 h. After cooling, the reaction was diluted with DCM and washed with water. The organic phase was evaporated, then dissolved in DCM (2 mL), before TFA (1 mL) was added. The mixture was stirred at room temperature for 1 h and then was diluted with DCM and washed with saturated NaHCO<sub>3</sub> solution. The layers were separated, and the aqueous phase was extracted with DCM. The combined organics were dried and evaporated to give the crude product. The crude product was purified by preparative LCMS (Waters SunFire column, 5 μ silica, 19 mm diameter, 100 mm length), using decreasingly polar mixtures of water (containing 1% NH<sub>3</sub>) and MeCN as eluents. Fractions containing the desired compounds were evaporated to dryness to give 6-((6<i>S</i>,8<i>R</i>)-7-((1-fluorocyclopropyl)methyl)-8-methyl-6,7,8,9-tetrahydro-3<i>H</i>-pyrazolo[4,3-<i>f</i>]isoquinolin-6-yl)-<i>N</i>-(1-(3-fluoropropyl)azetidin-3-yl)pyridin-3-amine (17.0 mg, 10%) as a beige solid. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>, 27 °C) 0.47 (m, 1H), 0.67 (m, 1H), 0.90 (m, 2H), 1.00 (d, <i>J</i> = 6.5 Hz, 3H), 1.65 (dp, <i>J</i> = 25.7, 6.5 Hz, 2H), 2.48 (t, <i>J</i> = 11.2 Hz, 2H), 2.65 (dd, <i>J</i> = 18.8, 14.6 Hz, 1H), 2.75 (q, <i>J</i> = 6.3 Hz, 2H), 2.87 (dd, <i>J</i> = 16.5, 5.5 Hz, 1H), 2.99 (dd, <i>J</i> = 19.4, 14.6 Hz, 1H), 3.20 (d, <i>J</i> = 5.0 Hz, 1H), 3.64 (m, 2H), 3.67 (m, 1H), 3.93 (h, <i>J</i> = 6.6 Hz, 1H), 4.44 (dt, <i>J</i> = 47.4, 6.0 Hz, 2H), 4.81 (s, 1H), 6.17 (d, <i>J</i> = 7.0 Hz, 1H), 6.77 (d, <i>J</i> = 8.5 Hz, 1H), 6.80 (m, 1H), 6.95 (d, <i>J</i> = 8.5 Hz, 1H), 7.17 (d, <i>J</i> = 8.6 Hz, 1H), 7.75 (d, <i>J</i> = 2.7 Hz, 1H), 8.03 (s, 1H), 12.92 (s, 1H); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>, 27 °C) 8.7 (d, <i>J</i> = 11.6 Hz), 10.1 (d, <i>J</i> = 11.9 Hz), 13.2, 28.2 (d, <i>J</i> = 19.5 Hz), 31.3, 43.0, 46.9, 51.5 (d, <i>J</i> = 20.8 Hz), 54.8 (d, <i>J</i> = 5.7 Hz, 2C), 61.3 (d, <i>J</i> = 2.2 Hz), 65.4, 78.3 (d, <i>J</i> = 216.1 Hz), 82.0 (d, <i>J</i> = 161.3 Hz), 107.4, 119.4, 122.6, 123.2, 125.3, 126.9, 127.5, 131.8, 132.6, 138.4, 142.2, 151.7; <sup>19</sup>F NMR (376 MHz, DMSO-<i>d</i><sub>6</sub>, 27 °C) −218.2 (1F), −180.5 (1F); <i>m</i>/<i>z</i> (ES+), [M + H]<sup>+</sup> = 467, HRMS (ESI) (MH<sup>+</sup>); calcd, 467.2735; found, 467.2735.</div></div><div id="sec4_1_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i51" class="anchor-spacer"></div><h4 class="article-section__title" id="_i51"> <i>N</i>-(4-((6<i>S</i>,8<i>R</i>)-7-(2-Fluoro-2-methylpropyl)-8-methyl-6,7,8,9-tetrahydro-3H-pyrazolo[4,3-<i>f</i>]isoquinolin-6-yl)-3-methoxyphenyl)-1-(3-fluoropropyl)azetidin-3-amine (<b>19</b>)</h4><div class="NLM_p last">1-(3-Fluoropropyl)azetidin-3-amine (59.2 mg, 0.45 mmol) was added in 1,4-dioxane (1.8 mL) to a vial containing (6<i>S</i>,8<i>R</i>)-6-(4-bromo-2-methoxyphenyl)-7-(2-fluoro-2-methylpropyl)-8-methyl-6,7,8,9-tetrahydro-3<i>H</i>-pyrazolo[4,3-<i>f</i>]isoquinoline (100 mg, 0.22 mmol), sodium <i>tert</i>-butoxide (64.6 mg, 0.67 mmol), and BrettPhos third generation Pd precatalyst (15.2 mg, 0.02 mmol). The vial was degassed with bubbling nitrogen and then was heated to 90 °C for 3 h. A further portion of sodium <i>tert</i>-butoxide (64.6 mg, 0.67 mmol) and BrettPhos third generation Pd precatalyst (15.21 mg, 0.02 mmol) were added, and reaction was heated at 90 °C for a further 16 h. After cooling, the reaction was filtered through Celite and washed with EtOAc (20 mL). The filtrate was washed with water (2 × 15 mL) and brine (15 mL), dried over MgSO<sub>4</sub>, filtered, and evaporated. The residue was purified by flash silica chromatography, 0–8% 1 M NH<sub>3</sub>-MeOH in DCM to afford <i>N</i>-(4-((6<i>S</i>,8<i>R</i>)-7-(2-fluoro-2-methylpropyl)-8-methyl-6,7,8,9-tetrahydro-3<i>H</i>-pyrazolo[4,3-<i>f</i>]isoquinolin-6-yl)-3-methoxyphenyl)-1-(3-fluoropropyl)azetidin-3-amine (37.0 mg, 33%) as a straw-colored foam. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>, 27 °C) 0.97 (d, <i>J</i> = 6.5 Hz, 3H), 1.21 (d, <i>J</i> = 21.5 Hz, 3H), 1.23 (d, <i>J</i> = 21.6 Hz, 3H), 1.64 (dp, <i>J</i> = 25.7, 6.5 Hz, 2H), 2.29 (dd, <i>J</i> = 25.5, 14.6 Hz, 1H), 2.45 (t, <i>J</i> = 6.9 Hz, 2H), 2.71 (m, 3H), 2.79 (dd, <i>J</i> = 17.1, 6.8 Hz, 1H), 3.13 (dd, <i>J</i> = 16.6, 4.9 Hz, 1H), 3.60 (m, 1H), 3.62 (m, 2H), 3.78 (s, 3H), 3.91 (h, <i>J</i> = 6.7 Hz, 1H), 4.44 (dt, <i>J</i> = 47.4, 6.1 Hz, 2H), 5.18 (s, 1H), 5.89 (dd, <i>J</i> = 8.3, 2.1 Hz, 1H), 5.96 (d, <i>J</i> = 6.9 Hz, 1H), 6.15 (d, <i>J</i> = 2.2 Hz, 1H), 6.44 (d, <i>J</i> = 8.3 Hz, 1H), 6.63 (d, <i>J</i> = 8.6 Hz, 1H), 7.15 (d, <i>J</i> = 8.6 Hz, 1H), 8.01 (s, 1H), 12.90 (s, 1H); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>, 27 °C) 13.9, 24.8 (d, <i>J</i> = 24.3 Hz), 25.5 (d, <i>J</i> = 24.6 Hz), 28.3 (d, <i>J</i> = 19.5 Hz), 30.8, 43.3, 46.7, 54.8 (d, <i>J</i> = 5.7 Hz), 54.9, 55.6 (d, <i>J</i> = 22.1 Hz), 57.0, 61.6 (2C), 82.0 (d, <i>J</i> = 161.2 Hz), 95.3, 97.3 (d, <i>J</i> = 165.3 Hz), 103.8, 107.5, 120.2, 122.4, 125.9, 127.3, 129.0, 131.6, 131.7, 138.3, 147.6, 158.2; <sup>19</sup>F NMR (376 MHz, DMSO-<i>d</i><sub>6</sub>, 27 °C) −218.1 (1F), −134.6 (1F); <i>m</i>/<i>z</i> (ES+), [M + H]<sup>+</sup> = 498, HRMS (ESI) (MH<sup>+</sup>); calcd, 498.3044; found, 498.3040.</div></div><div id="sec4_1_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i52" class="anchor-spacer"></div><h4 class="article-section__title" id="_i52"> 6-((6<i>S</i>,8<i>R</i>)-7-(2-Fluoro-2-methylpropyl)-8-methyl-6,7,8,9-tetrahydro-3<i>H</i>-pyrazolo[4,3-<i>f</i>]isoquinolin-6-yl)-<i>N</i>-(1-(3-fluoropropyl)azetidin-3-yl)pyridin-3-amine (<b>20</b>)</h4><div class="NLM_p last">1-Fluoro-3-iodopropane (59.6 mg, 0.32 mmol) was added to a solution of <i>N</i>-(azetidin-3-yl)-6-((6<i>S</i>,8<i>R</i>)-7-(2-fluoro-2-methylpropyl)-8-methyl-6,7,8,9-tetrahydro-3<i>H</i>-pyrazolo[4,3-<i>f</i>]isoquinolin-6-yl)pyridin-3-amine (108 mg, 0.26 mmol) and DIPEA (0.139 mL, 0.79 mmol) in DMF (3 mL), and the reaction was stirred at room temperature for 5 h. The reaction was diluted with DCM and washed with saturated NH<sub>4</sub>Cl solution. The aqueous was extracted with DCM, and then the combined organics were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and evaporated. The residue was purified by preparative HPLC, using decreasingly polar mixtures of water (containing 0.1% NH<sub>3</sub>) and MeCN as eluents. Fractions containing the desired compound were evaporated to dryness to afford 6-((6<i>S</i>,8<i>R</i>)-7-(2-fluoro-2-methylpropyl)-8-methyl-6,7,8,9-tetrahydro-3<i>H</i>-pyrazolo[4,3-<i>f</i>]isoquinolin-6-yl)-<i>N</i>-(1-(3-fluoropropyl)azetidin-3-yl)pyridin-3-amine (53 mg, 43%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>, 27 °C) 1.01 (d, <i>J</i> = 6.6 Hz, 3H), 1.23 (d, <i>J</i> = 21.6 Hz, 3H), 1.28 (d, <i>J</i> = 21.7 Hz, 3H), 1.69 (dp, <i>J</i> = 25.8, 6.5 Hz, 2H), 2.36 (m, 1H), 2.63 (m, 2H), 2.78 (dd, <i>J</i> = 11.2, 3.6 Hz, 1H), 2.82 (m, 1H), 2.94 (m, 2H), 3.04 (dd, <i>J</i> = 16.8, 4.6 Hz, 1H), 3.51 (m, 1H), 3.77 (m, 2H), 4.00 (p, <i>J</i> = 6.6 Hz, 1H), 4.46 (dt, <i>J</i> = 47.3, 6.0 Hz, 2H), 4.88 (s, 1H), 6.21 (d, <i>J</i> = 6.9 Hz, 1H), 6.79 (d, <i>J</i> = 8.6 Hz, 1H), 6.83 (dd, <i>J</i> = 8.6, 2.9 Hz, 1H), 7.03 (d, <i>J</i> = 8.5 Hz, 1H), 7.19 (d, <i>J</i> = 8.6 Hz, 1H), 7.74 (d, <i>J</i> = 2.8 Hz, 1H), 8.03 (s, 1H), 12.93 (s, 1H); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>, 27 °C) 15.3, 24.9 (d, <i>J</i> = 24.2 Hz), 25.2 (d, <i>J</i> = 24.6 Hz), 27.7 (d, <i>J</i> = 18.4 Hz), 30.0, 42.8, 46.7, 54.3, 54.9 (d, <i>J</i> = 20.9 Hz), 61.1 (2C), 66.7, 81.9 (d, <i>J</i> = 161.4 Hz), 97.3 (d, <i>J</i> = 165.7 Hz), 107.2, 119.2, 122.5, 123.5, 126.3, 127.1, 127.7, 131.6, 131.7, 132.8, 141.8, 151.7; <sup>19</sup>F NMR (376 MHz, DMSO-<i>d</i><sub>6</sub>, 27 °C) −218.3 (1F), −136.7 (1F); <i>m</i>/<i>z</i> (ES+), [M + H]<sup>+</sup> = 469, HRMS (ESI) (MH<sup>+</sup>); calcd, 469.2891; found, 469.2887.</div></div><div id="sec4_1_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i53" class="anchor-spacer"></div><h4 class="article-section__title" id="_i53"> <i>N</i>-(4-((6<i>S</i>,8<i>R</i>)-7-(2,2-Difluoropropyl)-8-methyl-6,7,8,9-tetrahydro-3<i>H</i>-pyrazolo[4,3-<i>f</i>]isoquinolin-6-yl)-3-methoxyphenyl)-1-(3-fluoropropyl)azetidin-3-amine (<b>21</b>)</h4><div class="NLM_p last">DMF (2 mL) and DIPEA (0.074 mL, 0.42 mmol) were added sequentially to a flask charged with <i>N</i>-(4-((6<i>S</i>,8<i>R</i>)-7-(2,2-difluoropropyl)-8-methyl-6,7,8,9-tetrahydro-3<i>H</i>-pyrazolo[4,3-<i>f</i>]isoquinolin-6-yl)-3-methoxyphenyl)azetidin-3-amine (75 mg, 0.17 mmol). 1-Fluoro-3-iodopropane (31.9 mg, 0.17 mmol) in DMF (0.1 mL) was then added, and stirring was continued for 2 h. The reaction was stopped and diluted with saturated aqueous sodium chloride, and the compound was extracted in EtOAC (×3). The combined extracts were washed with water and dried over sodium sulfate, filtered, and concentrated under reduced pressure to afford a film. This material was purified by flash silica chromatography, eluting with 2–10% (methanol containing 1% ammonium hydroxide) in DCM to afford <i>N</i>-(4-((6<i>S</i>,8<i>R</i>)-7-(2,2-difluoropropyl)-8-methyl-6,7,8,9-tetrahydro-3<i>H</i>-pyrazolo[4,3-<i>f</i>]isoquinolin-6-yl)-3-methoxyphenyl)-1-(3-fluoropropyl)azetidin-3-amine (43 mg, 51%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>, 27 °C) 1.01 (d, <i>J</i> = 6.6 Hz, 3H), 1.53 (t, <i>J</i> = 19.2 Hz, 3H), 1.64 (dp, <i>J</i> = 25.7, 6.6 Hz, 2H), 2.45 (t, <i>J</i> = 7.0 Hz, 2H), 2.52 (m, 1H), 2.71 (m, 2H), 2.80 (dd, <i>J</i> = 16.9, 7.2 Hz, 1H), 2.93 (m, 1H), 3.11 (dd, <i>J</i> = 16.9, 4.8 Hz, 1H), 3.46 (td, <i>J</i> = 6.9, 4.9 Hz, 1H), 3.62 (q, <i>J</i> = 5.8 Hz, 2H), 3.79 (s, 3H), 3.92 (h, <i>J</i> = 6.6 Hz, 1H), 4.44 (dt, <i>J</i> = 47.4, 6.1 Hz, 2H), 5.22 (s, 1H), 5.90 (dd, <i>J</i> = 8.3, 2.2 Hz, 1H), 6.01 (d, <i>J</i> = 6.9 Hz, 1H), 6.17 (d, <i>J</i> = 2.2 Hz, 1H), 6.36 (d, <i>J</i> = 8.3 Hz, 1H), 6.65 (d, <i>J</i> = 8.5 Hz, 1H), 7.18 (d, <i>J</i> = 8.6 Hz, 1H), 8.03 (s, 1H), 12.93 (m, 1H); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>, 27 °C) 14.9, 21.1 (t, <i>J</i> = 25.9 Hz), 28.3 (d, <i>J</i> = 19.4 Hz), 30.2, 43.3, 46.6, 52.1 (t, <i>J</i> = 29.3 Hz), 54.8 (d, <i>J</i> = 5.6 Hz), 54.9, 57.4, 61.5 (2C), 82.0 (d, <i>J</i> = 161.3 Hz), 95.3, 103.6, 107.7, 119.4, 122.3, 125.8 (t, <i>J</i> = 238.0 Hz), 126.1, 127.3, 128.0, 131.6, 131.8, 138.3, 147.8, 158.2; <sup>19</sup>F NMR (376 MHz, DMSO-<i>d</i><sub>6</sub>, 27 °C) −218.1 (1F), −88.4 (2F); <i>m</i>/<i>z</i> (ES+), [M + H]<sup>+</sup> = 502, HRMS (ESI) (MH<sup>+</sup>); calcd, 502.2794; found, 502.2776.</div></div><div id="sec4_1_18" class="NLM_sec NLM_sec_level_3"><div id="ac_i54" class="anchor-spacer"></div><h4 class="article-section__title" id="_i54"> 6-((6<i>S</i>,8<i>R</i>)-7-(2,2-Difluoropropyl)-8-methyl-6,7,8,9-tetrahydro-3<i>H</i>-pyrazolo[4,3-<i>f</i>]isoquinolin-6-yl)-<i>N</i>-(1-(3-fluoropropyl)azetidin-3-yl)pyridin-3-amine (<b>22</b>)</h4><div class="NLM_p last">1-Fluoro-3-iodopropane (135 mg, 0.72 mmol) was added to a solution of <i>N</i>-(azetidin-3-yl)-6-((6<i>S</i>,8<i>R</i>)-7-(2,2-difluoropropyl)-8-methyl-6,7,8,9-tetrahydro-3<i>H</i>-pyrazolo[4,3-<i>f</i>]isoquinolin-6-yl)pyridin-3-amine (247 mg, 0.6 mmol) and DIPEA (0.42 mL, 2.40 mmol) in DMF (7.0 mL). The reaction was stirred at room temperature for 3 h then treated with a further portion DIPEA (0.100 mL, 0.572 mmol) and 1-fluoro-3-iodopropane (135 mg, 0.72 mmol) and stirred at room temperature overnight. The residue was purified by prep HPLC using decreasingly polar mixtures of water (containing 0.1% NH<sub>3</sub>) and MeCN as eluents. Fractions containing the desired compound were evaporated to dryness to afford 6-((6<i>S</i>,8<i>R</i>)-7-(2,2-difluoropropyl)-8-methyl-6,7,8,9-tetrahydro-3<i>H</i>-pyrazolo[4,3-<i>f</i>]isoquinolin-6-yl)-<i>N</i>-(1-(3-fluoropropyl)azetidin-3-yl)pyridin-3-amine (55 mg, 19%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>, 27 °C) 1.07 (d, <i>J</i> = 6.6 Hz, 3H), 1.58 (d, <i>J</i> = 19.1 Hz, 3H), 1.90 (m, 2H), 2.64 (m, 1H), 2.86 (m, 1H), 3.11 (m, 1H), 3.14 (m, 1H), 3.32 (m, 2H), 3.47 (m 1H), 3.88 (m, 2H), 4.34 (m 1H), 4.58 (m, 2H), 4.54 (m, 2H), 4.99 (s, 1H), 6.80 (dd, <i>J</i> = 8.7, 2.7 Hz, 1H), 7.08 (m, 2H), 7.24 (d, <i>J</i> = 8.6 Hz, 1H), 7.83 (m, 1H), 8.08 (s, 1H), 9.74 (s, 1H), 13.00 (s, 1H); <sup>19</sup>F NMR (376 MHz, DMSO-<i>d</i><sub>6</sub>, 27 °C) −219.2 (1F), −90.6 (2F).</div></div><div id="sec4_1_19" class="NLM_sec NLM_sec_level_3"><div id="ac_i55" class="anchor-spacer"></div><h4 class="article-section__title" id="_i55"> 2,2-Difluoro-3-((6<i>S</i>,8<i>R</i>)-6-(4-((1-(3-fluoropropyl)azetidin-3-yl)amino)-2-methoxyphenyl)-8-methyl-3,6,8,9-tetrahydro-7<i>H</i>-pyrazolo[4,3-<i>f</i>]isoquinolin-7-yl)propan-1-ol (<b>23</b>)</h4><div class="NLM_p last">1-(3-Fluoropropyl)azetidin-3-amine (58.5 mg, 0.44 mmol), (6<i>S</i>,8<i>R</i>)-6-(4-bromo-2-methoxyphenyl)-7-(3-((<i>tert</i>-butyldiphenylsilyl)oxy)-2,2-difluoropropyl)-8-methyl-6,7,8,9-tetrahydro-3<i>H</i>-pyrazolo[4,3-<i>f</i>]isoquinoline (156 mg, 0.22 mmol) and sodium <i>tert</i>-butoxide (128 mg, 1.33 mmol) were suspended in 1,4-dioxane (0.460 mL). The mixture was degassed, and Brettphos third generation Pd precatalyst (20.07 mg, 0.02 mmol) was added. The reaction was heated to 80 °C for 1 h. After cooling, the reaction mixture was diluted with EtOAc (15 mL) and washed with water (15 mL). The organic layer was evaporated then TBAF solution (1 M in THF, 2 mL, 2.00 mmol) was added, and the reaction was stirred at room temperature for 30 min. The reaction mixture was diluted with EtOAc (10 mL) and washed with water (10 mL). The organic phase was dried over MgSO<sub>4</sub>, filtered, and evaporated. The residue was purified by preparative HPLC using decreasingly polar mixtures of water (containing 1% NH<sub>3</sub>) and MeCN as eluents. Fractions containing the desired compound were evaporated to dryness to afford 2,2-difluoro-3-((6<i>S</i>,8<i>R</i>)-6-(4-((1-(3-fluoropropyl)azetidin-3-yl)amino)-2-methoxyphenyl)-8-methyl-3,6,8,9-tetrahydro-7<i>H</i>-pyrazolo[4,3-<i>f</i>]isoquinolin-7-yl)propan-1-ol (46.0 mg, 40%) as a gum. [α]<sup>26</sup><sub>D</sub> −243 (c 1.9, MeOH); <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>, 27 °C) 1.01 (d, <i>J</i> = 6.6 Hz, 3H), 1.63 (m, 2H), 2.44 (t, <i>J</i> = 6.9 Hz, 2H), 2.57 (m, 1H), 2.70 (m, 2H), 2.78 (dd, <i>J</i> = 17.1, 7.9 Hz, 1H), 2.98 (m, 1H), 3.05 (dd, <i>J</i> = 17.2, 4.9 Hz, 1H), 3.45 (m, 1H), 3.55 (m, 1H), 3.60 (m, 2H), 3.73 (m, 1H), 3.78 (s, 3H), 3.91 (h, <i>J</i> = 6.6 Hz, 1H), 4.44 (dt, <i>J</i> = 47.4, 6.1 Hz, 2H), 5.11 (t, <i>J</i> = 6.2 Hz, 1H), 5.23 (s, 1H), 5.87 (dd, <i>J</i> = 8.4, 2.1 Hz, 1H), 6.00 (d, <i>J</i> = 6.9 Hz, 1H), 6.16 (d, <i>J</i> = 2.2 Hz, 1H), 6.29 (d, <i>J</i> = 8.3 Hz, 1H), 6.65 (d, <i>J</i> = 8.7 Hz, 1H), 7.18 (d, <i>J</i> = 8.6 Hz, 1H), 8.03 (s, 1H), 12.94 (s, 1H); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>, 27 °C) 15.6, 28.3 (d, <i>J</i> = 19.4 Hz), 29.8, 46.3, 48.8 (t, <i>J</i> = 28.4 Hz), 54.8 (d, <i>J</i> = 5.7 Hz), 54.9, 57.9, 60.6 (t, <i>J</i> = 27.0 Hz), 61.5 (2C), 82.0 (d, <i>J</i> = 161.2 Hz), 95.4, 103.4, 107.7, 119.3, 122.3, 123.9, 126.4, 127.3, 127.7, 131.6, 131.8, 138.4, 147.8, 158.2; <sup>19</sup>F NMR (376 MHz, DMSO-<i>d</i><sub>6</sub>, 27 °C) −218.1 (1F), −107.3 (2F); <i>m</i>/<i>z</i> (ES+), [M + H]<sup>+</sup> = 518, HRMS (ESI) (MH<sup>+</sup>); calcd, 518.2743; found, 518.2738.</div></div><div id="sec4_1_20" class="NLM_sec NLM_sec_level_3"><div id="ac_i56" class="anchor-spacer"></div><h4 class="article-section__title" id="_i56"> 2,2-Difluoro-3-((6<i>S</i>,8<i>R</i>)-6-(5-((1-(3-fluoropropyl)azetidin-3-yl)amino)pyridin-2-yl)-8-methyl-3,6,8,9-tetrahydro-7<i>H</i>-pyrazolo[4,3-<i>f</i>]isoquinolin-7-yl)propan-1-ol (<b>24</b>)</h4><div class="NLM_p last">HCl (2.0 M, 0.5 mL) was added to 2,2-difluoro-3-((6<i>S</i>,8<i>R</i>)-6-(5-((1-(3-fluoropropyl)azetidin-3-yl)amino)pyridin-2-yl)-8-methyl-3-(tetrahydro-2<i>H</i>-pyran-2-yl)-3,6,8,9-tetrahydro-7H-pyrazolo[4,3-<i>f</i>]isoquinolin-7-yl)propan-1-ol (0.132 g, 0.23 mmol), and the solution was stirred at room temperature for 3 h. The reaction mixture was purified by ion exchange chromatography, using an SCX column. The desired product was eluted from the column using 1 M NH<sub>3</sub>/MeOH to afford 2,2-difluoro-3-((6<i>S</i>,8<i>R</i>)-6-(5-((1-(3-fluoropropyl)azetidin-3-yl)amino)pyridin-2-yl)-8-methyl-3,6,8,9-tetrahydro-7<i>H</i>-pyrazolo[4,3-<i>f</i>]isoquinolin-7-yl)propan-1-ol (0.084 g, 75%) as a white solid. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>, 27 °C) 1.05 (d, <i>J</i> = 6.7 Hz, 3H), 1.66 (dp, <i>J</i> = 25.8, 6.5 Hz, 2H), 2.52 (m, 2H), 2.66 (q, <i>J</i> = 14.6 Hz, 1H), 2.85 (m, 3H), 3.00 (dd, <i>J</i> = 17.1, 4.6 Hz, 1H), 3.14 (q, <i>J</i> = 14.1 Hz, 1H), 3.43 (m, 1H), 3.68 (m, 4H), 3.96 (m, 1H), 4.45 (dt, <i>J</i> = 47.4, 6.0 Hz, 2H), 4.95 (s, 1H), 5.44 (t, <i>J</i> = 6.3 Hz, 1H), 6.23 (d, <i>J</i> = 6.9 Hz, 1H), 6.81 (m, 2H), 6.92 (d, <i>J</i> = 8.5 Hz, 1H), 7.22 (d, <i>J</i> = 8.6 Hz, 1H), 7.76 (d, <i>J</i> = 2.8 Hz, 1H), 8.04 (s, 1H), 12.96 (s, 1H); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>, 27 °C) 13.9, 28.0 (d, <i>J</i> = 19.4 Hz), 29.5, 42.9, 46.6, 48.6 (t, <i>J</i> = 29.1 Hz), 54.6, 60.8 (t, <i>J</i> = 29.0 Hz), 61.2 (2C), 67.0, 82.0 (d, <i>J</i> = 161.3 Hz), 107.5, 118.8, 122.4, 123.6, 124.8 (t, <i>J</i> = 243.0 Hz), 126.3, 126.6, 127.7, 131.7, 133.3, 138.5, 142.1, 150.6; <sup>19</sup>F NMR (376 MHz, DMSO-<i>d</i><sub>6</sub>, 27 °C) −218.2 (1F), −108.2 (2F); <i>m</i>/<i>z</i> (ES+), [M + H]<sup>+</sup> = 489, HRMS (ESI) (MH<sup>+</sup>); calcd, 489.2590; found, 489.2581.</div></div><div id="sec4_1_21" class="NLM_sec NLM_sec_level_3"><div id="ac_i57" class="anchor-spacer"></div><h4 class="article-section__title" id="_i57"> <i>N</i>-(4-((6<i>S</i>,8<i>R</i>)-7-(2,2-Difluoroethyl)-8-methyl-6,7,8,9-tetrahydro-3<i>H</i>-pyrazolo[4,3-<i>f</i>]isoquinolin-6-yl)-3-methoxyphenyl)-1-(3-fluoropropyl)azetidin-3-amine (<b>25</b>)</h4><div class="NLM_p last">HCl in dioxane (4 M; 1.23 mL, 5.2 mmol) was added dropwise to a stirred solution of <i>tert</i>-butyl 3-(4-((6<i>S</i>,8<i>R</i>)-7-(2,2-difluoroethyl)-8-methyl-2-(tetrahydro-2<i>H</i>-pyran-2-yl)-6,7,8,9-tetrahydro-2<i>H</i>-pyrazolo[4,3-<i>f</i>]isoquinolin-6-yl)-3-methoxyphenylamino)azetidine-1-carboxylate (316 mg, 0.52 mmol) in MeOH (5 mL). The mixture was stirred at room temperature for 18 h. The reaction was concentrated under reduced pressure, and the resulting residue was dissolved in MeOH. Excess tetraalkylammonium carbonate macroporous resin (Aldrich; 18–50 mesh; 2.5–3.5 mmol/g N loading) was added, and the mixture was stirred at room temperature for 5 min. The mixture was filtered, and the filtrate was dried over sodium sulfate, filtered, and concentrated under reduced pressure to afford crude <i>N</i>-(4-((6<i>S</i>,8<i>R</i>)-7-(2,2-difluoroethyl)-8-methyl-6,7,8,9-tetrahydro-3<i>H</i>-pyrazolo[4,3-<i>f</i>]isoquinolin-6-yl)-3-methoxyphenyl)azetidin-3-amine as a gum (220 mg). To this was added 1-fluoro-3-iodopropane (106 mg, 0.57 mmol) and DIPEA (0.270 mL, 1.54 mmol) in DMF (5 mL), and the reaction mixture was stirred at room temperature for 18 h. The reaction was diluted with DCM and washed with saturated aqueous ammonium chloride. The aqueous layer was extracted with DCM, and the combined organic layers were dried over sodium sulfate, filtered, and concentrated under reduced pressure. The resulting residue was purified by preparative HPLC (Xbridge C18 column, 19 mm × 150 mm; 5 μm; flow rate: 20 mL/min), eluting with 40–80% acetonitrile in water containing 0.2% ammonium hydroxide. Product fractions were concentrated under reduced pressure, and the resulting residue was purified by preparative SFC (2-ethylpyridine column, 19 mm × 150 mm, 5 μm; flow rate: 75 mL/min; column temperature: 40 °C; outlet pressure: 100 bar), eluting with 15% methanol containing 0.2% ammonium hydroxide in carbon dioxide, to afford <i>N</i>-(4-((6<i>S</i>,8<i>R</i>)-7-(2,2-difluoroethyl)-8-methyl-6,7,8,9-tetrahydro-3<i>H</i>-pyrazolo[4,3-<i>f</i>]isoquinolin-6-yl)-3-methoxyphenyl)-1-(3-fluoropropyl)azetidin-3-amine (82 mg, 33% over two steps) as a white solid. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>, 27 °C) 1.03 (d, <i>J</i> = 6.6 Hz, 3H), 1.64 (dp, <i>J</i> = 25.6, 6.5 Hz, 2H), 2.45 (t, <i>J</i> = 6.9 Hz, 2H), 2.60 (m, 1H), 2.71 (q, <i>J</i> = 6.4 Hz, 2H), 2.77 (dd, <i>J</i> = 16.9, 7.6 Hz, 1H), 2.95 (tdd, <i>J</i> = 14.9, 11.9, 5.7 Hz, 1H), 3.09 (dd, <i>J</i> = 16.9, 4.6 Hz, 1H), 3.38 (td, <i>J</i> = 7.1, 4.9 Hz, 1H), 3.62 (q, <i>J</i> = 5.6 Hz, 2H), 3.81 (s, 3H), 3.92 (h, <i>J</i> = 6.7 Hz, 1H), 4.44 (dt, <i>J</i> = 47.4, 6.1 Hz, 2H), 5.21 (s, 1H), 5.90 (m, 2H), 6.01 (d, <i>J</i> = 7.0 Hz, 1H), 6.19 (d, <i>J</i> = 2.1 Hz, 1H), 6.34 (d, <i>J</i> = 8.2 Hz, 1H), 6.67 (d, <i>J</i> = 8.6 Hz, 1H), 7.19 (d, <i>J</i> = 8.6 Hz, 1H), 8.03 (s, 1H), 12.94 (s, 1H); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>, 27 °C) 15.6, 28.3 (d, <i>J</i> = 19.5 Hz), 30.2, 43.3, 46.9, 50.8 (dd, <i>J</i> = 26.7, 24.2 Hz), 54.8 (d, <i>J</i> = 5.7 Hz), 55.2, 57.3, 61.5 (2C), 82.0 (d, <i>J</i> = 161.2 Hz), 95.5, 103.6, 107.8, 116.7 (t, <i>J</i> = 239.5 Hz), 119.4, 122.3, 126.3, 127.3, 127.4, 131.1, 131.7, 138.4, 147.9, 158.2; <sup>19</sup>F NMR (376 MHz, DMSO-<i>d</i><sub>6</sub>, 27 °C) −218.1 (1F), −119.2 (2F); <i>m</i>/<i>z</i> (ES+), [M + H]<sup>+</sup> = 488, HRMS (ESI) (MH<sup>+</sup>); calcd, 488.2637; found, 488.2626.</div></div><div id="sec4_1_22" class="NLM_sec NLM_sec_level_3"><div id="ac_i58" class="anchor-spacer"></div><h4 class="article-section__title" id="_i58"> 6-((6<i>S</i>,8<i>R</i>)-7-(2,2-Difluoroethyl)-8-methyl-6,7,8,9-tetrahydro-3<i>H</i>-pyrazolo[4,3-<i>f</i>]isoquinolin-6-yl)-<i>N</i>-(1-(3-fluoropropyl)azetidin-3-yl)pyridin-3-amine (<b>26</b>)</h4><div class="NLM_p last">HCl in dioxane (4 N; 0.86 mL, 3.4 mmol) was added dropwise to a solution of <i>tert</i>-butyl 3-((6-((6<i>S</i>,8<i>R</i>)-7-(2,2-difluoroethyl)-8-methyl-3-(tetrahydro-2<i>H</i>-pyran-2-yl)-6,7,8,9-tetrahydro-3<i>H</i>-pyrazolo[4,3-<i>f</i>]isoquinolin-6-yl)pyridin-3-yl)amino)azetidine-1-carboxylate (0.20 g, 0.34 mmol) in MeOH (2.5 mL), and the reaction was stirred at room temperature for 2 h. The reaction was concentrated under reduced pressure to afford <i>N</i>-(azetidin-3-yl)-6-((6<i>S</i>,8<i>R</i>)-7-(2,2-difluoroethyl)-8-methyl-6,7,8,9-tetrahydro-3<i>H</i>-pyrazolo[4,3-<i>f</i>]isoquinolin-6-yl)pyridin-3-amine hydrochloride (200 mg) as a solid (<i>m/z:</i> (ES+), [M + H]<sup>+</sup> 399). DMF (0.5 mL) and 1-fluoro-3-iodopropane (0.036 mL, 0.34 mmol) were added sequentially at ambient temperature. Then excess diisopropylethylamine (1.2 mL, 6.80 mmol) was added dropwise. The reaction was stirred at room temperature for 18 h and then concentrated under reduced pressure. The resulting residue was purified by reverse phase flash C18 chromatography, elution gradient 20–75% acetonitrile in water (containing 0.2% NH<sub>4</sub>OH), to afford 6-((6<i>S</i>,8<i>R</i>)-7-(2,2-difluoroethyl)-8-methyl-6,7,8,9-tetrahydro-3<i>H</i>-pyrazolo[4,3-<i>f</i>]isoquinolin-6-yl)-<i>N</i>-(1-(3-fluoropropyl)azetidin-3-yl)pyridin-3-amine (45 mg, 29%) as a solid. [α]<sup>26</sup><sub>D</sub> −213 (c 2.1, MeOH); <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>, 27 °C) 1.05 (d, <i>J</i> = 6.5 Hz, 3H), 1.64 (m, 2H), 2.46 (t, <i>J</i> = 7.0 Hz, 2H), 2.65 (m, 1H), 2.74 (td, <i>J</i> = 6.8, 4.7 Hz, 2H), 2.84 (dd, <i>J</i> = 16.8, 6.5 Hz, 1H), 3.02 (m, 1H), 3.15 (dd, <i>J</i> = 16.7, 4.8 Hz, 1H), 3.48 (td, <i>J</i> = 6.6, 4.9 Hz, 1H), 3.63 (tdd, <i>J</i> = 6.8, 4.5, 1.9 Hz, 2H), 3.93 (h, <i>J</i> = 6.5 Hz, 1H), 4.45 (dt, <i>J</i> = 47.5, 6.1 Hz, 2H), 4.87 (s, 1H), 5.83 (tt, <i>J</i> = 56.4, 4.4 Hz, 1H), 6.22 (d, <i>J</i> = 7.0 Hz, 1H), 6.75 (d, <i>J</i> = 8.7 Hz, 1H), 6.81 (dd, <i>J</i> = 8.5, 2.8 Hz, 1H), 6.96 (d, <i>J</i> = 8.5 Hz, 1H), 7.19 (d, <i>J</i> = 8.6 Hz, 1H), 7.76 (d, <i>J</i> = 2.7 Hz, 1H), 8.04 (s, 1H), 12.95 (s, 1H); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>, 27 °C) 14.7, 28.2 (d, <i>J</i> = 19.5 Hz), 31.0, 43.0, 47.8, 51.0 (t, <i>J</i> = 24.9 Hz), 54.8 (d, <i>J</i> = 5.7 Hz), 61.3 (2C), 66.0, 82.0 (d, <i>J</i> = 161.3 Hz), 107.5, 116.6 (t, <i>J</i> = 239.6 Hz), 119.2, 122.5, 123.6, 125.6, 127.0, 127.0, 131.8, 132.9, 138.5, 142.3, 150.7; <sup>19</sup>F NMR (376 MHz, DMSO-<i>d</i><sub>6</sub>, 27 °C) −218.1 (1F), −119.4 (2F); <i>m</i>/<i>z</i> (ES+), [M + H]<sup>+</sup> = 459, HRMS (ESI) (MH<sup>+</sup>); calcd, 459.2484; found, 459.2473.</div></div><div id="sec4_1_23" class="NLM_sec NLM_sec_level_3"><div id="ac_i59" class="anchor-spacer"></div><h4 class="article-section__title" id="_i59"> 1-(3-Fluoropropyl)-<i>N</i>-(3-methoxy-4-((6<i>S</i>,8<i>R</i>)-8-methyl-7-(2,2,2-trifluoroethyl)-6,7,8,9-tetrahydro-3<i>H</i>-pyrazolo[4,3-<i>f</i>]isoquinolin-6-yl)phenyl)azetidin-3-amine (<b>27</b>)</h4><div class="NLM_p last">BrettPhos third generation precatalyst (10 mg, 0.01 mmol) and sodium <i>tert</i>-butoxide (0.127 g, 1.32 mmol) were added in one portion to a degassed solution of 1-(3-fluoropropyl)azetidin-3-amine (0.033 g, 0.25 mmol) and (6<i>S</i>,8<i>R</i>)-6-(4-bromo-2-methoxyphenyl)-8-methyl-7-(2,2,2-trifluoroethyl)-6,7,8,9-tetrahydro-3<i>H</i>-pyrazolo[4,3-<i>f</i>]isoquinoline (0.10 g, 0.22 mmol) in 1,4-dioxane (1.10 mL). The orange mixture was then immersed in an oil bath that had been preheated to 50 °C. After 5 min, the reaction was cooled to room temperature. In a separate flask, sodium <i>tert</i>-butoxide (1.81 g, 18.8 mmol) and BrettPhos third generation precatalyst (0.17 g, 0.19 mmol) were added in one portion to a degassed solution of (6<i>S</i>,8<i>R</i>)-6-(4-bromo-2-methoxyphenyl)-8-methyl-7-(2,2,2-trifluoroethyl)-6,7,8,9-tetrahydro-3<i>H</i>-pyrazolo[4,3-<i>f</i>]isoquinoline (1.71 g, 3.76 mmol) and 1-(3-fluoropropyl)azetidin-3-amine (0.597 g, 4.52 mmol) in 1,4-dioxane (18.8 mL). The light orange mixture was immersed in an oil bath that had been preheated to 50 °C. After 5 min, the reaction was cooled to room temperature. Once cooled, both reactions were combined, diluted with ethyl acetate, and washed sequentially with water (×2) and saturated aqueous sodium chloride. The organic layer was dried over sodium sulfate, filtered, and concentrated under reduced pressure. The resulting orange oil was purified by flash silica chromatography, elution gradient 0–10% methanol in DCM, to afford 1-(3-fluoropropyl)-<i>N</i>-(3-methoxy-4-((6<i>S</i>,8<i>R</i>)-8-methyl-7-(2,2,2-trifluoroethyl)-6,7,8,9-tetrahydro-3<i>H</i>-pyrazolo[4,3-<i>f</i>]isoquinolin-6-yl)phenyl)azetidin-3-amine (1.84 g, 92%) as a solid and an ∼84:16 trans:cis mixture based on UV HPLC profile. This material was resolved using preparative SFC (column: Chiralpak AD, 21.2 × 250 mm, 5 μm; 75 mL/min), eluting with 20% (methanol containing 0.2% NH<sub>4</sub>OH) in CO<sub>2</sub>, to afford 1-(3-fluoropropyl)-<i>N</i>-(3-methoxy-4-((6<i>S</i>,8<i>R</i>)-8-methyl-7-(2,2,2-trifluoroethyl)-6,7,8,9-tetrahydro-3<i>H</i>-pyrazolo[4,3-<i>f</i>]isoquinolin-6-yl)phenyl)azetidin-3-amine (1.01 g) as a light orange solid and a second eluting peak. This material was further purified by flash silica chromatography, elution gradient 0–30% methanol in ethyl acetate, to afford 1-(3-fluoropropyl)-<i>N</i>-(3-methoxy-4-((6<i>S</i>,8<i>R</i>)-8-methyl-7-(2,2,2-trifluoroethyl)-6,7,8,9-tetrahydro-3<i>H</i>-pyrazolo[4,3-<i>f</i>]isoquinolin-6-yl)phenyl)azetidin-3-amine (0.954 g) as a white solid. This material was purified a final time by preparative HPLC (column: Xbridge C18, 30 × 100 mm, 5 μm, 40 mL/min), eluting with 40 to 70% acetonotrile in (water containing 0.2% NH<sub>4</sub>OH). Product fractions were combined and washed with ethyl acetate (×3), and the combined organic layers were washed with saturated aqueous sodium chloride, dried over sodium sulfate, filtered, and concentrated under reduced pressure to afford 1-(3-fluoropropyl)-<i>N</i>-(3-methoxy-4-((6<i>S</i>,8<i>R</i>)-8-methyl-7-(2,2,2-trifluoroethyl)-6,7,8,9-tetrahydro-3<i>H</i>-pyrazolo[4,3-<i>f</i>]isoquinolin-6-yl)phenyl)azetidin-3-amine (551 mg, 27%) as an off-white foam solid. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>, 27 °C) 1.05 (d, <i>J</i> = 6.5 Hz, 3H), 1.64 (dp, <i>J</i> = 25.6, 6.5 Hz, 2H), 2.45 (t, <i>J</i> = 6.9 Hz, 2H), 2.71 (td, <i>J</i> = 6.6, 4.4 Hz, 2H), 2.82 (dd, <i>J</i> = 17.2, 7.7 Hz, 1H), 2.88 (m, 1H), 3.10 (dd, <i>J</i> = 17.1, 4.7 Hz, 1H), 3.36 (m, 1H), 3.45 (td, <i>J</i> = 7.2, 5.0 Hz, 1H), 3.62 (q, <i>J</i> = 5.6 Hz, 2H), 3.78 (s, 3H), 3.92 (h, <i>J</i> = 6.6 Hz, 1H), 4.44 (dt, <i>J</i> = 47.5, 6.1 Hz, 2H), 5.29 (s, 1H), 5.89 (dd, <i>J</i> = 8.4, 2.2 Hz, 1H), 6.02 (d, <i>J</i> = 6.9 Hz, 1H), 6.17 (d, <i>J</i> = 2.2 Hz, 1H), 6.34 (d, <i>J</i> = 8.3 Hz, 1H), 6.66 (d, <i>J</i> = 8.7 Hz, 1H), 7.19 (d, <i>J</i> = 8.6 Hz, 1H), 8.03 (s, 1H), 12.95 (s, 1H); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>, 27 °C) 15.8, 28.2 (d, <i>J</i> = 19.5 Hz), 30.3, 43.3, 46.8, 48.8 (q, <i>J</i> = 30.8 Hz), 54.8 (d, <i>J</i> = 5.7 Hz), 55.2, 58.0, 61.5 (2C), 82.0 (d, <i>J</i> = 161.2 Hz), 95.5, 103.6, 107.8, 118.8, 122.2, 126.1, 126.2 (d, <i>J</i> = 278.8 Hz), 127.2, 127.7, 131.6, 131.7, 138.4, 148.0, 158.3; <sup>19</sup>F NMR (376 MHz, DMSO-<i>d</i><sub>6</sub>, 27 °C) −218.1 (1F), −69.0 (3F); <i>m</i>/<i>z</i> (ES+), [M + H]<sup>+</sup> = 506, HRMS (ESI) (MH<sup>+</sup>); calcd, 506.2543; found, 506.2531.</div></div><div id="sec4_1_24" class="NLM_sec NLM_sec_level_3"><div id="ac_i60" class="anchor-spacer"></div><h4 class="article-section__title" id="_i60"> <i>N</i>-[1-(3-Fluoropropyl)azetidin-3-yl]-6-[(6<i>S</i>,8<i>R</i>)-8-methyl-7-(2,2,2-trifluoroethyl)-3,6,8,9-tetrahydropyrazolo[4,3-<i>f</i>]isoquinolin-6-yl]pyridin-3-amine (<b>28</b>)</h4><div class="NLM_p last">1-(3-Fluoropropyl)azetidin-3-amine (6.31 g, 37.98 mmol) was added to a solution of (6<i>S</i>,8<i>R</i>)-6-(5-bromopyridin-2-yl)-8-methyl-7-(2,2,2-trifluoroethyl)-6,7,8,9-tetrahydro-3<i>H</i>-pyrazolo[4,3-<i>f</i>]isoquinoline (15.47 g, 34.92 mmol) in 1,4-dioxane (175 mL). The resulting solution was degassed under a vacuum for 5 min and then backfilled with nitrogen (×2). Sodium <i>tert</i>-butoxide (13.43 g, 139.7 mmol) was added, followed by BrettPhos third generation precatalyst (0.95 g, 1.05 mmol). The resulting mixture was heated at 55 °C for 18 h. The mixture was poured into EtOAc and water. Saturated brine was added, and the layers were separated. The organic layer was washed with saturated aqueous sodium chloride (×3), and the combined aqueous layers were extracted with EtOAc. The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure. The resulting residue was purified by flash silica chromatography, elution gradient 0–50% methanol in ethyl acetate. Fractions containing the desired product were combined, concentrated under reduced pressure, and then repurified by flash silica chromatography, elution gradient 0–40% EtOAc in hexanes, to afford a red-orange solid. This solid was dissolved in 10% MeOH in DCM, filtered, and washing the filter cake with DCM. The combined filtrates were concentrated under reduced pressure to give <i>N</i>-(1-(3-fluoropropyl)azetidin-3-yl)-6-((6<i>S</i>,8<i>R</i>)-8-methyl-7-(2,2,2-trifluoroethyl)-6,7,8,9-tetrahydro-3<i>H</i>-pyrazolo[4,3-<i>f</i>]isoquinolin-6-yl)pyridin-3-amine (15.28 g, 92%) as a light orange foam solid. Trace amounts of cis isomer were separated by preparative SFC ((<i>S</i>,<i>S</i>) Whelk-O1 column, 30 mm diameter, 250 mm length), eluting with 30% (0.2% NH<sub>4</sub>OH in MeOH) in CO<sub>2</sub>, 100 bar mobile phase at a flow rate of 20 mL/min at 40 °C). The fractions containing the trans isomer were concentrated under reduced pressure. The resulting residue was further purified by flash silica chromatography, elution gradient 0–30% MeOH in EtOAc. Fractions containing the desired product were concentrated under reduced pressure, then concentrated from MeCN (×2) to give <i>N</i>-(1-(3-fluoropropyl)azetidin-3-yl)-6-((6<i>S</i>,8<i>R</i>)-8-methyl-7-(2,2,2-trifluoroethyl)-6,7,8,9-tetrahydro-3<i>H</i>-pyrazolo[4,3-<i>f</i>]isoquinolin-6-yl)pyridin-3-amine (10.76 g, 74%) as a pale yellow foam/solid. [α]<sup>26</sup><sub>D</sub> −147 (c 2.3, MeOH); <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>, 27 °C) 1.08 (d, <i>J</i> = 6.6 Hz, 3H), 1.64 (dp, <i>J</i> = 25.0, 6.3 Hz, 2H), 2.45 (t, <i>J</i> = 6.9 Hz, 2H), 2.73 (t, <i>J</i> = 6.8 Hz, 2H), 2.84 (dd, <i>J</i> = 17.1, 8.2 Hz, 1H), 2.96 (dt, <i>J</i> = 19.6, 9.8 Hz, 1H), 3.07 (dd, <i>J</i> = 17.2, 4.6 Hz, 1H), 3.49 (m, 1H), 3.50–3.58 (m, 1H), 3.58–3.66 (m, 2H), 3.92 (h, <i>J</i> = 6.5 Hz, 1H), 4.44 (dtd, <i>J</i> = 47.4, 6.1, 1.3 Hz, 2H), 4.93 (s, 1H), 6.23 (d, <i>J</i> = 6.9 Hz, 1H), 6.80 (d, <i>J</i> = 8.6 Hz, 1H), 6.83 (dt, <i>J</i> = 8.8, 2.0 Hz, 1H), 6.97 (d, <i>J</i> = 8.5 Hz, 1H), 7.22 (d, <i>J</i> = 8.6 Hz, 1H), 7.73 (d, <i>J</i> = 2.8 Hz, 1H), 8.05 (d, <i>J</i> = 1.3 Hz, 1H), 12.97 (s, 1H); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>, 27 °C) 16.2, 28.2 (d, <i>J</i> = 19.4 Hz), 30.1, 43.0, 47.3, 48.7 (q, <i>J</i> = 30.1 Hz), 54.8 (d, <i>J</i> = 5.6 Hz), 61.3 (2C), 67.1, 82.0 (d, <i>J</i> = 161.3 Hz), 107.5, 119.0, 122.4, 123.7, 126.1, 126.2 (q, <i>J</i> = 278.5 Hz), 126.4, 127.5, 131.7, 132.9, 138.5, 142.3, 150.0; <sup>19</sup>F NMR (376 MHz, DMSO-<i>d</i><sub>6</sub>, 27 °C) −218.1 (1F), −69.7 (3F); <i>m</i>/<i>z</i> (ES+), [M + H]<sup>+</sup> = 477, HRMS (ESI) (MH<sup>+</sup>); calcd, 477.2408; found, 477.2390.</div></div><div id="sec4_1_25" class="NLM_sec NLM_sec_level_3"><div id="ac_i61" class="anchor-spacer"></div><h4 class="article-section__title" id="_i61"> (6<i>S</i>,8<i>R</i>)-7-(2,2-Difluoroethyl)-6-(5-(2-(3-(fluoromethyl)azetidin-1-yl)ethoxy)pyridin-2-yl)-8-methyl-6,7,8,9-tetrahydro-3<i>H</i>-pyrazolo[4,3-<i>f</i>]isoquinoline (<b>29</b>)</h4><div class="NLM_p last">A solution of (6<i>S</i>,8<i>R</i>)-6-(5-bromopyridin-2-yl)-7-(2,2-difluoroethyl)-8-methyl-3-(tetrahydro-2<i>H</i>-pyran-2-yl)-6,7,8,9-tetrahydro-3<i>H</i>-pyrazolo[4,3-<i>f</i>]isoquinoline (120 mg, 0.24 mmol) in toluene (5 mL) was dried azeotropically under reduced pressure and then redissolved in toluene (5 mL) containing 2-(3-(fluoromethyl)azetidin-1-yl)ethan-1-ol (65 mg, 0.49 mmol). The solution was degassed by infusion with a stream of nitrogen for 5 min. Cesium carbonate (199 mg, 0.61 mmol) and RockPhos third generation precatalyst (10 mg, 0.01 mmol) were added sequentially, and the reaction mixture was heated at 90 °C for 2 h. The reaction mixture was then diluted with water and extracted with ethyl acetate. The organic layer was dried over sodium sulfate, filtered, and concentrated under reduced pressure. HCl in dioxane (4 M; 0.20 mL, 0.78 mmol) was added to a solution of the resulting residue in MeOH (2 mL), and this new solution was stirred for 5 h at room temperature. The reaction was concentrated under reduced pressure, and the new residue was purified by reversed phase HPLC (Teledyne ISCO C18 Redi<i>Sep</i> Rf Gold 40 g column), eluting with 0 to 80% acetonitrile in water containing 0.1% ammonium hydroxide (pH 10). Product fractions were concentrated under reduced pressure to afford (6<i>S</i>,8<i>R</i>)-7-(2,2-difluoroethyl)-6-(5-(2-(3-(fluoromethyl)azetidin-1-yl)ethoxy)pyridin-2-yl)-8-methyl-6,7,8,9-tetrahydro-3<i>H</i>-pyrazolo[4,3-<i>f</i>]isoquinoline (46 mg, 64%) as a light yellow solid. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>, 27 °C) 1.06 (d, <i>J</i> = 6.6 Hz, 3H), 2.63 (m, 1H), 2.70 (m, 1H), 2.71 (t, <i>J</i> = 5.5 Hz, 2H), 2.87 (dd, <i>J</i> = 16.8, 6.7 Hz, 1H), 3.00 (m, 2H), 3.07 (m, 1H), 3.16 (dd, <i>J</i> = 16.8, 4.8 Hz, 1H), 3.31 (m, 2H), 3.48 (td, <i>J</i> = 6.7, 4.9 Hz, 1H), 3.96 (t, <i>J</i> = 5.5 Hz, 2H), 4.49 (dd, <i>J</i> = 47.6, 6.2 Hz, 2H), 4.99 (s, 1H), 5.90 (tt, <i>J</i> = 56.3, 4.3 Hz, 1H), 6.77 (d, <i>J</i> = 8.7 Hz, 1H), 7.21 (m, 2H), 7.29 (dd, <i>J</i> = 8.7, 3.0 Hz, 1H), 8.06 (s, 1H), 8.14 (d, <i>J</i> = 3.0 Hz, 1H), 12.97 (s, 1H); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>, 27 °C) 14.8, 30.7 (d, <i>J</i> = 19.9 Hz), 30.8, 47.8, 50.9 (t, <i>J</i> = 24.8 Hz), 56.0 (d, <i>J</i> = 7.6 Hz, 2C), 57.2, 66.0, 66.7, 84.6 (d, <i>J</i> = 163.7 Hz), 107.6, 116.5 (t, <i>J</i> = 239.5 Hz), 122.0, 122.5, 124.0, 125.8, 126.4, 127.0, 131.8, 135.4, 138.5, 153.6, 155.2; <sup>19</sup>F NMR (376 MHz, DMSO-<i>d</i><sub>6</sub>, 27 °C) −219.8 (1F), −119.6 (2F); <i>m</i>/<i>z</i> (ES+), [M + H]<sup>+</sup> = 460, HRMS (ESI) (MH<sup>+</sup>); calcd, 460.2324; found, 460.2303.</div></div><div id="sec4_1_26" class="NLM_sec NLM_sec_level_3"><div id="ac_i62" class="anchor-spacer"></div><h4 class="article-section__title" id="_i62"> (6<i>S</i>,8<i>R</i>)-6-(5-(2-(3-(Fluoromethyl)azetidin-1-yl)ethoxy)pyridin-2-yl)-8-methyl-7-(2,2,2-trifluoroethyl)-6,7,8,9-tetrahydro-3<i>H</i>-pyrazolo[4,3-<i>f</i>]isoquinoline (<b>30</b>)</h4><div class="NLM_p last">4 M HCl-dioxane (7.39 mL, 29.6 mmol) was added to a stirred solution of (6<i>S</i>,8<i>R</i>)-6-(5-(2-(3-(fluoromethyl)azetidin-1-yl)ethoxy)pyridin-2-yl)-8-methyl-2-(tetrahydro-2<i>H</i>-pyran-2-yl)-7-(2,2,2-trifluoroethyl)-6,7,8,9-tetrahydro-3<i>H</i>-pyrazolo[4,3-<i>f</i>]isoquinoline with (6<i>S</i>,8<i>R</i>)-6-(5-(2-(3-(fluoromethyl)azetidin-1-yl)ethoxy)pyridin-2-yl)-8-methyl-3-(tetrahydro-2<i>H</i>-pyran-2-yl)-7-(2,2,2-trifluoroethyl)-6,7,8,9-tetrahydro-3<i>H</i>-pyrazolo[4,3-<i>f</i>]isoquinoline (1.66 g, 2.96 mmol) in methanol (5 mL), and the reaction mixture was stirred at room temperature for 16 h. The mixture was concentrated under reduced pressure, and the residue was dissolved in EtOAc (50 mL) and saturated NaHCO<sub>3</sub> solution (50 mL). The layers were separated, and the aqueous layer was extracted with EtOAc (3 × 50 mL). The combined organic layers were dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and concentrated under reduced pressure to give the crude product as a light brown oil. The crude product was purified by flash silica chromatography, elution gradient 0–10% 1 M NH<sub>3</sub>/MeOH in DCM, and then by chiral by SFC (Phenomonex Lux C1, 30 × 250 mm, 5 μm) eluting with 30% MeOH + 0.1% NH<sub>3</sub>/70% supercritical CO<sub>2</sub> to afford (6<i>S</i>,8<i>R</i>)-6-(5-(2-(3-(fluoromethyl)azetidin-1-yl)ethoxy)pyridin-2-yl)-8-methyl-7-(2,2,2-trifluoroethyl)-6,7,8,9-tetrahydro-3<i>H</i>-pyrazolo[4,3-<i>f</i>]isoquinoline (0.989 g, 70%) as a pale yellow foam. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>, 27 °C) 1.09 (d, <i>J</i> = 6.6 Hz, 3H), 2.71 (t, <i>J</i> = 5.6 Hz, 2H), 2.71 (m, 1H), 2.87 (dd, <i>J</i> = 17.1, 8.1 Hz, 1H), 2.99 (m, 3H), 3.09 (dd, <i>J</i> = 17.1, 4.6 Hz, 1H), 3.31 (m, 2H), 3.45 (m, 1H), 3.56 (dq, <i>J</i> = 15.8, 9.8 Hz, 1H), 3.95 (t, <i>J</i> = 5.5 Hz, 2H), 4.49 (dd, <i>J</i> = 47.6, 6.2 Hz, 2H), 5.05 (s, 1H), 6.82 (d, <i>J</i> = 8.6 Hz, 1H), 7.22 (m, 2H), 7.31 (dd, <i>J</i> = 8.7, 3.0 Hz, 1H), 8.06 (s, 1H), 8.11 (d, <i>J</i> = 2.9 Hz, 1H), 12.99 (s, 1H); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>, 27 °C) 16.1, 30.0, 30.7 (d, <i>J</i> = 19.9 Hz), 47.5, 48.8 (q, <i>J</i> = 30.3 Hz), 56.0 (d, <i>J</i> = 7.7 Hz, 2C), 57.2, 66.7, 67.0, 84.6 (d, <i>J</i> = 163.6 Hz), 107.6, 121.9, 122.4, 124.0, 125.8, 126.2 (q, <i>J</i> = 278.5 Hz), 126.3, 127.5, 131.8, 135.4, 138.6, 153.6, 154.6; <sup>19</sup>F NMR (376 MHz, DMSO-<i>d</i><sub>6</sub>, 27 °C) −219.6 (1F), −69.8 (3F); <i>m</i>/<i>z</i> (ES+), [M + H]<sup>+</sup> = 478, HRMS (ESI) (MH<sup>+</sup>); calcd, 478.2230; found, 478.2250.</div></div><div id="sec4_1_27" class="NLM_sec NLM_sec_level_3"><div id="ac_i63" class="anchor-spacer"></div><h4 class="article-section__title" id="_i63"> 6-((6<i>S</i>,8<i>R</i>)-7-(2,2-Difluoroethyl)-6,8-dimethyl-6,7,8,9-tetrahydro-3<i>H</i>-pyrazolo[4,3-<i>f</i>]isoquinolin-6-yl)-<i>N</i>-(1-(3-fluoropropyl)azetidin-3-yl)pyridin-3-amine (<b>31</b>)</h4><div class="NLM_p last">Sodium <i>tert</i>-butoxide (60.2 mg, 0.63 mmol) and BrettPhos third generation Pd precatalyst (4.73 mg, 5.22 μmol) were added to a degassed solution of (6<i>S</i>,8<i>R</i>)-6-(5-bromopyridin-2-yl)-7-(2,2-difluoroethyl)-6,8-dimethyl-6,7,8,9-tetrahydro-3<i>H</i>-pyrazolo[4,3-<i>f</i>]isoquinoline (44 mg, 0.10 mmol) and 1-(3-fluoropropyl)azetidin-3-amine (15.9 mg, 0.12 mmol) in 1,4-dioxane (1.04 mL). The reaction was warmed to 65 °C and stirred for 4 h. After cooling, the reaction was diluted with EtOAc (10 mL) and water (10 mL), and the layers were separated. The aqueous was extracted with EtOAc (10 mL), and then the combined organics were dried over MgSO<sub>4</sub>, filtered, and evaporated. The residue was purified by preparative HPLC using decreasingly polar mixtures of water (containing 1% NH<sub>3</sub>) and MeCN as eluents. Fractions containing the desired compound were evaporated to dryness to afford the product (16 mg, 32%) as a mixture of diastereoisomers. This mixture was further purified using the SFC to afford 6-((6<i>S</i>,8<i>R</i>)-7-(2,2-difluoroethyl)-6,8-dimethyl-6,7,8,9-tetrahydro-3<i>H</i>-pyrazolo[4,3-<i>f</i>]isoquinolin-6-yl)-<i>N</i>-(1-(3-fluoropropyl)azetidin-3-yl)pyridin-3-amine (6 mg, 12%) as a solid. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>, 27 °C) 1.20 (d, <i>J</i> = 6.6 Hz, 3H), 1.74 (m, 2H), 1.87 (s, 3H), 2.59 (t, <i>J</i> = 7.2 Hz, 2H), 2.83 (ddd, <i>J</i> = 15.4, 9.1, 3.4 Hz, 1H), 2.89 (dd, <i>J</i> = 9.8, 4.8 Hz, 2H), 3.00 (m, 2H), 3.32 (dd, <i>J</i> = 16.3, 5.4 Hz, 1H), 3.59 (q, <i>J</i> = 5.9 Hz, 1H), 3.72 (m, 2H), 3.93 (d, <i>J</i> = 7.2 Hz, 1H), 4.07 (p, <i>J</i> = 6.3 Hz, 1H), 4.48 (dt, <i>J</i> = 47.2, 5.9 Hz, 2H), 5.43 (m, 1H), 6.68 (dd, <i>J</i> = 8.7, 2.9 Hz, 1H), 7.01 (d, <i>J</i> = 8.6 Hz, 1H), 7.08 (d, <i>J</i> = 8.6 Hz, 1H), 7.20 (d, <i>J</i> = 8.8 Hz, 1H), 7.83 (d, <i>J</i> = 2.8 Hz, 1H), 8.06 (s, 1H), 10.02 (s, 1H); <sup>19</sup>F NMR (376 MHz, DMSO-<i>d</i><sub>6</sub>, 27 °C) −218.1 (1F), −118.5 (2F); <i>m</i>/<i>z</i> (ES+), [M + H]<sup>+</sup> = 473, HRMS (ESI) (MH<sup>+</sup>); calcd, 473.2641; found, 473.2653.</div></div><div id="sec4_1_28" class="NLM_sec NLM_sec_level_3"><div id="ac_i64" class="anchor-spacer"></div><h4 class="article-section__title" id="_i64"> (<i>S</i>)-6-(7-(2,2-Difluoroethyl)-8,8-dimethyl-6,7,8,9-tetrahydro-3<i>H</i>-pyrazolo[4,3-<i>f</i>]isoquinolin-6-yl)-<i>N</i>-(1-(3-fluoropropyl)azetidin-3-yl)pyridin-3-amine (<b>32</b>)</h4><div class="NLM_p last">BrettPhos third generation Pd precatalyst (42.5 mg, 0.04 mmol) was added to a degassed solution of 6-(5-bromopyridin-2-yl)-7-(2,2-difluoroethyl)-8,8-dimethyl-3-(tetrahydro-2<i>H</i>-pyran-2-yl)-6,7,8,9-tetrahydro-3<i>H</i>-pyrazolo[4,3-<i>f</i>]isoquinoline <b>62</b> (450 mg, 0.89 mmol), 1-(3-fluoropropyl)azetidin-3-amine (129 mg, 0.98 mmol), and sodium <i>tert</i>-butoxide (171 mg, 1.78 mmol) in 1,4-dioxane (5 mL). The reaction was heated to 60 °C for 4 h. After cooling, the reaction was diluted with DCM and water. The layers were separated, and the aqueous layer was extracted with DCM. The combined organics were evaporated, and then the residue was dissolved in DCM (3 mL) and TFA (1.5 mL) was added. The reaction was stirred at room temperature for 2 h, and then the reaction was diluted with DCM and washed with saturated NaHCO<sub>3</sub> solution. The layers were separated and the aqueous was extracted with DCM. The combined organics were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and evaporated. The residue was purified by flash silica chromatography, 0–10% MeOH in DCM. Pure fractions were evaporated to dryness to afford 6-(7-(2,2-difluoroethyl)-8,8-dimethyl-6,7,8,9-tetrahydro-3<i>H</i>-pyrazolo[4,3-<i>f</i>]isoquinolin-6-yl)-<i>N</i>-(1-(3-fluoropropyl)azetidin-3-yl)pyridin-3-amine (286 mg, 68%) as a beige solid. The racemic mixture was purified by chiral SFC (Phenomonex Lux C1, 30 × 250 mm, 5 μm) eluting with 40% MeOH + 0.1% NH<sub>3</sub>/60% supercritical CO<sub>2</sub> to afford (<i>S</i>)-6-(7-(2,2-difluoroethyl)-8,8-dimethyl-6,7,8,9-tetrahydro-3<i>H</i>-pyrazolo[4,3-<i>f</i>]isoquinolin-6-yl)-<i>N</i>-(1-(3-fluoropropyl)azetidin-3-yl)pyridin-3-amine as a colorless solid. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>, 27 °C) 0.97 (s, 3H), 1.34 (s, 3H), 1.66 (dp, <i>J</i> = 25.7, 6.5 Hz, 2H), 2.77 (m, 1H), 2.79 (m, 2H), 2.96 (d, <i>J</i> = 16.2 Hz, 1H), 3.12 (d, <i>J</i> = 16.1 Hz, 1H), 3.28 (m, 3H), 3.66 (q, <i>J</i> = 7.0 Hz, 2H), 3.96 (h, <i>J</i> = 6.5 Hz, 1H), 4.45 (dt, <i>J</i> = 47.4, 6.0 Hz, 2H), 4.75 (s, 1H), 4.82 (tdd, <i>J</i> = 57.4, 6.0, 3.1 Hz, 1H), 6.27 (d, <i>J</i> = 6.9 Hz, 1H), 6.59 (d, <i>J</i> = 8.7 Hz, 1H), 6.81 (dd, <i>J</i> = 8.6, 2.8 Hz, 1H), 6.87 (d, <i>J</i> = 8.5 Hz, 1H), 7.15 (d, <i>J</i> = 8.7 Hz, 1H), 7.79 (d, <i>J</i> = 2.7 Hz, 1H), 8.05 (s, 1H), 12.95 (s, 1H); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>, 27 °C) 17.5, 28.1 (d, <i>J</i> = 19.6 Hz), 29.7, 41.0, 43.0, 51.6 (dd, <i>J</i> = 27.7, 24.8 Hz), 53.1, 54.7, 61.2 (d, <i>J</i> = 1.9 Hz, 2C), 69.1, 82.0 (d, <i>J</i> = 161.3 Hz), 107.7, 116.5 (t, <i>J</i> = 241.6 Hz), 119.7, 122.1, 124.3, 124.9, 125.7, 128.6, 131.8, 132.3, 138.4, 142.5, 152.1; <sup>19</sup>F NMR (376 MHz, DMSO-<i>d</i><sub>6</sub>, 27 °C) −218.2 (1F), −119.1 (2F); <i>m</i>/<i>z</i> (ES+), [M + H]<sup>+</sup> = 473, HRMS (ESI) (MH<sup>+</sup>); calcd, 473.2641; found, 473.2653.</div></div><div id="sec4_1_29" class="NLM_sec NLM_sec_level_3"><div id="ac_i65" class="anchor-spacer"></div><h4 class="article-section__title" id="_i65"> (<i>S</i>)-6-(8,8-Dimethyl-7-(2,2,2-trifluoroethyl)-6,7,8,9-tetrahydro-3<i>H</i>-pyrazolo[4,3-<i>f</i>]isoquinolin-6-yl)-<i>N</i>-(1-(3-fluoropropyl)azetidin-3-yl)pyridin-3-amine (<b>33</b>)</h4><div class="NLM_p last">1-(3-Fluoropropyl)azetidin-3-amine (0.085 g, 0.64 mmol), 6-(5-bromopyridin-2-yl)-8,8-dimethyl-7-(2,2,2-trifluoroethyl)-6,7,8,9-tetrahydro-3<i>H</i>-pyrazolo[4,3-<i>f</i>]isoquinoline <b>64</b> (0.141 g, 0.32 mmol) and sodium <i>tert</i>-butoxide (0.185 g, 1.93 mmol) were suspended in 1,4-dioxane (2 mL). The mixture was degassed, and Brettphos third generation Pd precatalyst (0.029 g, 0.03 mmol) was added. The reaction was heated to 80 °C for 1.5 h. The reaction was diluted with DCM (20 mL) and washed with water (20 mL). The organic layer was evaporated, and then the residue was purified by flash silica chromatography, 0–20% MeOH in DCM to afford 6-(8,8-dimethyl-7-(2,2,2-trifluoroethyl)-6,7,8,9-tetrahydro-3<i>H</i>-pyrazolo[4,3-<i>f</i>]isoquinolin-6-yl)-<i>N</i>-(1-(3-fluoropropyl)azetidin-3-yl)pyridin-3-amine (0.047 g, 30%) as a cream solid. The racemic mixture was purified by chiral SFC (Phenomonex Lux C1, 30 × 250 mm, 5 μm) eluting with 20% MeOH + 0.1% NH<sub>3</sub>/80% supercritical CO<sub>2</sub> to afford (<i>S</i>)-6-(8,8-dimethyl-7-(2,2,2-trifluoroethyl)-6,7,8,9-tetrahydro-3<i>H</i>-pyrazolo[4,3-<i>f</i>]isoquinolin-6-yl)-<i>N</i>-(1-(3-fluoropropyl)azetidin-3-yl)pyridin-3-amine (15 mg, 10%). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>, 27 °C) 1.06 (s, 3H), 1.41 (s, 3H), 1.76 (m, 2H), 2.61 (t, <i>J</i> = 7.2 Hz, 2H), 2.92 (m, 2H) 2.93 (d, <i>J</i> = 15.6 Hz, 1H), 3.25 (m, 1H), 3.30 (d, <i>J</i> = 16.1 Hz, 1H), 3.45 (m, 1H), 3.71 (dt, <i>J</i> = 7.5, 5.9 Hz, 2H), 4.09 (m, 1H), 4.48 (dt, <i>J</i> = 47.2, 5.9 Hz, 2H), 4.98 (m, 1H), 6.72 (dd, <i>J</i> = 8.6, 2.8 Hz, 1H), 6.77 (d, <i>J</i> = 8.8 Hz, 1H), 6.98 (dd, <i>J</i> = 8.6, 0.7 Hz, 1H), 7.11 (dt, <i>J</i> = 8.6, 1.0 Hz, 1H), 7.83 (dd, <i>J</i> = 2.9, 0.7 Hz, 1H), 8.04 (d, <i>J</i> = 1.1 Hz, 1H), 10.72 (s, 1H); <sup>19</sup>F NMR (376 MHz, DMSO-<i>d</i><sub>6</sub>, 27 °C) −218.3 (1F), −67.3 (3F); <i>m</i>/<i>z</i> (ES+), [M + H]<sup>+</sup> = 491, HRMS (ESI) (MH<sup>+</sup>); calcd, 491.2546; found, 491.2566.</div></div><div id="sec4_1_30" class="NLM_sec NLM_sec_level_3"><div id="ac_i66" class="anchor-spacer"></div><h4 class="article-section__title" id="_i66"> <i>N</i>-(1-(3-Fluoropropyl)azetidin-3-yl)-6-((6<i>S</i>,8<i>R</i>)-8-methyl-7-(2,2,2-trifluoroethyl)-6,7,8,9-tetrahydro-3<i>H</i>-pyrrolo[3,2-<i>f</i>]isoquinolin-6-yl)pyridin-3-amine (<b>34</b>)</h4><div class="NLM_p last">1-(3-Fluoropropyl)azetidin-3-amine (13 mg, 0.080 mmol) was added to a red-orange solution of (6<i>S</i>,8<i>R</i>)-6-(5-bromopyridin-2-yl)-8-methyl-7-(2,2,2-trifluoroethyl)-6,7,8,9-tetrahydro-3<i>H</i>-pyrrolo[3,2-<i>f</i>]isoquinoline <b>72</b> (30 mg, 0.070 mmol) in 1,4-dioxane (0.35 mL). Nitrogen was bubbled through the solution for 5 min then solid sodium <i>tert</i>-butoxide (27 mg, 0.28 mmol) was added followed by BrettPhos third Generation Precatalyst (3.2 mg, 3.5 μmol), and the reaction was heated at 50 °C for 1.5 h. In a separate flask, 1-(3-fluoropropyl)azetidin-3-amine (72 mg, 0.43 mmol) was added to a red-orange solution of (6<i>S</i>,8<i>R</i>)-6-(5-bromopyridin-2-yl)-8-methyl-7-(2,2,2-trifluoroethyl)-6,7,8,9-tetrahydro-3<i>H</i>-pyrrolo[3,2-<i>f</i>]isoquinoline <b>72</b> (167 mg, 0.39 mmol) in 1,4-dioxane (2 mL). Nitrogen was bubbled through the solution for 5 min. Solid sodium <i>tert</i>-butoxide (151 mg, 1.57 mmol) was added followed by BrettPhos third generation precatalyst (18 mg, 0.020 mmol), and reaction was heated at 50 °C for 2.5 h. The contents of both reactions were combined and concentrated under reduced pressure. The resulting residue was purified by flash silica chromatography, elution gradient 0–40% methanol in DCM, to afford an amber foam solid (216 mg). This material was further purified by preparative SFC (Column: (<i>S</i>,<i>S</i>) Whelk-O1, length: 250 mm, diameter: 30 mm, 5 μm; flow rate: 120 mL/min), eluting with 30% (0.2% NH<sub>4</sub>OH in methanol) in CO<sub>2</sub>, as a yellow solid (175 mg). This solid was repurified by flash silica chromatography, elution gradient 0–40% methanol in DCM. Product fractions were concentrated under reduced pressure to afford the title compound (116 mg, 62%) as a pale yellow foam. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>, 27 °C) 1.08 (d, <i>J</i> = 6.6 Hz, 3H), 1.89 (m, 2H), 2.78 (dd, <i>J</i> = 16.7, 7.8 Hz, 1H), 2.95 (m, 1H), 3.02 (dd, <i>J</i> = 16.6, 4.8 Hz, 1H), 3.31 (m 2H), 3.47 (m, 1H), 3.54 (m, 1H), 3.86 (m, 1H), 4.05 (m, 1H), 4.32 (m, 1H), 4.35 (m, 1H), 4.52 (dt, <i>J</i> = 47, 5.6 Hz, 2H), 4.54 (m, 1H), 4.96 (s, 1H), 6.42 (m, 1H), 6.54 (d, <i>J</i> = 8.4 Hz, 1H), 6.92 (m, 1H), 7.02 (d, <i>J</i> = 8.5 Hz, 1H), 7.10 (d, <i>J</i> = 8.4 Hz, 1H), 7.30 (m, 1H), 7.80 (m, 1H), 10.02 (s, 1H), 11.03 (s, 1H); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>, 27 °C) 15.9, 25.3 (d, <i>J</i> = 20.6 Hz), 30.5, 41.5, 47.8, 48.7, 52.2, 59.3, 60.9, 67.1, 81.1 (d, <i>J</i> = 162.0 H z), 99.1 109.2, 120.4, 122.0, 124.1, 124.7, 125.0, 126.3 (d, <i>J</i> = 278.1 Hz), 126.6, 132.7, 133.9, 138.9, 141.2, 152.5; <sup>19</sup>F NMR (376 MHz, DMSO-<i>d</i><sub>6</sub>, 27 °C) −219.1 (1F), −69.6 (3F); <i>m</i>/<i>z</i> (ES+), [M + H]<sup>+</sup> = 476, HRMS (ESI) (MH<sup>+</sup>); calcd, 476.2437; found, 476.2443.</div></div><div id="sec4_1_31" class="NLM_sec NLM_sec_level_3"><div id="ac_i67" class="anchor-spacer"></div><h4 class="article-section__title" id="_i67"> <i>N</i>1-(3-Fluoropropyl)-<i>N</i>2-(6-((6<i>S</i>,8<i>R</i>)-8-methyl-7-(2,2,2-trifluoroethyl)-6,7,8,9-tetrahydro-3<i>H</i>-pyrazolo[4,3-<i>f</i>]isoquinolin-6-yl)pyridin-3-yl)ethane-1,2-diamine (<b>35</b>)</h4><div class="NLM_p last">Benzyl (3-fluoropropyl)(2-((6-((6<i>S</i>,8<i>R</i>)-8-methyl-7-(2,2,2-trifluoroethyl)-6,7,8,9-tetrahydro-3<i>H</i>-pyrazolo[4,3-<i>f</i>]isoquinolin-6-yl)pyridin-3-yl)amino)ethyl)carbamate <b>74</b> (119 mg, 0.20 mmol) in EtOH (2 mL) was subject to hydrogenation at atmospheric pressure in the presence of 10% Pd/C (12 mg, 0.01 mmol) at room temperature. After 2 h additional 10% Pd/C (12 mg, 0.01 mmol) was added, and the reaction was recharged with hydrogen. The reaction was stirred at room temperature for a further 1 h. The mixture was diluted with DCM and filtered through Celite. The solids were washed with DCM. The filtrate was evaporated, and then the residue was purified by flash silica chromatography, 1–10% 1 M NH<sub>3</sub>/MeOH in DCM. Product fractions were concentrated under reduced pressure to afford a pale yellow foam. The resulting residue was further purified by preparative SFC (Whelk-O 1 (S,S) column, 5 μm, 4.6 mm diameter, 100 mm length), 40 °C column temperature, 100 bar outlet pressure, 20 mL/min flow rate), eluting with 25% MeOH containing 0.2% NH<sub>4</sub>OH in CO<sub>2</sub>, to afford <i>N</i><sup>1</sup>-(3-fluoropropyl)-<i>N</i><sup>2</sup>-(6-((6<i>S</i>,8<i>R</i>)-8-methyl-7-(2,2,2-trifluoroethyl)-6,7,8,9-tetrahydro-3<i>H</i>-pyrazolo[4,3-<i>f</i>]isoquinolin-6-yl)pyridin-3-yl)ethane-1,2-diamine (74.0 mg, 80%) as a pale yellow dry film. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>, 27 °C) 1.09 (d, <i>J</i> = 6.6 Hz, 3H), 1.77 (m, 2H), 2.60 (t, <i>J</i> = 6.9 Hz, 2H), 2.68 (t, <i>J</i> = 6.3 Hz, 2H), 2.85 (dd, <i>J</i> = 17.0, 7.9 Hz, 1H), 2.98 (m, 1H), 3.06 (m, 2H), 3.11 (dd, <i>J</i> = 16.1, 4.6 Hz, 1H), 3.50 (m, 2H), 4.49 (dt, <i>J</i> = 47.5, 6.0 Hz, 2H), 4.93 (s, 1H), 5.69 (t, <i>J</i> = 5.6 Hz, 1H), 6.79 (d, <i>J</i> = 8.6 Hz, 1H), 6.88 (dd, <i>J</i> = 8.6, 2.8 Hz, 1H), 6.95 (d, <i>J</i> = 8.6 Hz, 1H), 7.21 (dd, <i>J</i> = 8.6, 1.0 Hz, 1H), 7.81 (d, <i>J</i> = 2.8 Hz, 1H), 8.05 (s, 1H), 12.97 (s, 1H); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>, 27 °C) 15.9, 30.3, 30.4 (d, <i>J</i> = 19.2 Hz), 42.5, 44.9 (d, <i>J</i> = 5.7 Hz), 47.4, 48.1, 48.7 (q, <i>J</i> = 30.7 Hz), 66.9, 82.3 (d, <i>J</i> = 160.8 Hz), 107.5, 118.6, 122.4, 123.7, 126.0, 126.2 (q, <i>J</i> = 278.2 Hz), 126.6, 127.4, 131.7, 132.9, 138.5, 143.7, 149.4; <sup>19</sup>F NMR (376 MHz, DMSO-<i>d</i><sub>6</sub>, 27 °C) −218.1 (1F), −69.7 (3F); <i>m</i>/<i>z</i> (ES+), [M + H]<sup>+</sup> = 464, HRMS (ESI) (MNa<sup>+</sup>); calcd, 487.2209; found, 487.2234.</div></div><div id="sec4_1_32" class="NLM_sec NLM_sec_level_3"><div id="ac_i68" class="anchor-spacer"></div><h4 class="article-section__title" id="_i68"> <i>N</i>-(1-(3-Fluoropropyl)-3-methylazetidin-3-yl)-6-((6<i>S</i>,8<i>R</i>)-8-methyl-7-(2,2,2-trifluoroethyl)-6,7,8,9-tetrahydro-3<i>H</i>-pyrazolo[4,3-<i>f</i>]isoquinolin-6-yl)pyridin-3-amine (<b>36</b>)</h4><div class="NLM_p last">TFA (1.2 mL) was added to a solution of <i>tert</i>-butyl 3-methyl-3-((6-((6<i>S</i>,8<i>R</i>)-8-methyl-7-(2,2,2-trifluoroethyl)-6,7,8,9-tetrahydro-3<i>H</i>-pyrazolo[4,3-<i>f</i>]isoquinolin-6-yl)pyridin-3-yl)amino)azetidine-1-carboxylate <b>73</b> (250 mg, 0.47 mmol) in DCM (2.4 mL), and the reaction was stirred at room temperature for 30 min. The residue was passed through an SCX-2 column, eluting with MeOH, and then 1 N NH<sub>3</sub>/MeOH to elute the product. The filtrate was evaporated under a vacuum, and then the residue was dissolved in DMF (2.5 mL). DIPEA (204 μL, 1.18 mmol) was added followed by 1-fluoro-3-iodopropane (106 mg, 0.57 mmol). The reaction was stirred at room temperature for 4 h, and then was diluted with EtOAc and washed with brine. The aqueous phase was extracted with EtOAc, and then the combined organics were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and evaporated. The residue was purified by flash silica chromatography, 0–20% MeOH in EtOAc. Pure fractions were evaporated to dryness to afford the product (156 mg) as a beige solid, in a 10:1 mixture of diasteroisomers. The mixture was further purified by chiral SFC to afford <i>N</i>-(1-(3-fluoropropyl)-3-methylazetidin-3-yl)-6-((6<i>S</i>,8<i>R</i>)-8-methyl-7-(2,2,2-trifluoroethyl)-6,7,8,9-tetrahydro-3<i>H</i>-pyrazolo[4,3-<i>f</i>]isoquinolin-6-yl)pyridin-3-amine (86 mg, 75%) as a coloress solid. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>, 27 °C) 1.09 (d, <i>J</i> = 6.6 Hz, 3H), 1.45 (s, 3H), 1.65 (m, 2H), 2.51 (m, 2H), 2.84 (dd, <i>J</i> = 17.1, 8.4 Hz, 1H), 2.98 (m, 1H), 3.03 (m, 2H), 3.06 (dd, <i>J</i> = 17.1, 4.6, 1H), 3.34 (m, 2H), 3.48 (m, 1H), 3.53 (m, 1H), 4.44 (dt, <i>J</i> = 47.4, 6.0 Hz, 2H), 4.93 (s, 1H), 6.16 (s, 1H), 6.70 (dd, <i>J</i> = 8.5, 2.9 Hz, 1H), 6.82 (d, <i>J</i> = 8.6 Hz, 1H), 6.97 (d, <i>J</i> = 8.5 Hz, 1H), 7.23 (d, <i>J</i> = 8.5 Hz, 1H), 7.63 (d, <i>J</i> = 2.8 Hz, 1H), 8.05 (s, 1H), 12.96 (s, 1H); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>, 27 °C) 16.4, 23.3, 28.1 (d, <i>J</i> = 17.2 Hz), 30.0, 47.1, 48.6 (q, <i>J</i> = 29.8 Hz), 49.3, 54.5, 65.4 (2C), 67.2, 82.0 (d, <i>J</i> = 161.3 Hz), 107.5, 119.5, 122.4, 123.6, 126.2, 126.3 (q, <i>J</i> = 278.6 Hz), 126.3, 127.6, 131.7, 133.5, 138.5, 141.0, 149.4; <sup>19</sup>F NMR (376 MHz, DMSO-<i>d</i><sub>6</sub>, 27 °C) −218.1 (1F), −69.7 (3F); <i>m</i>/<i>z</i> (ES+), [M + H]<sup>+</sup> = 491, HRMS (ESI) (MH<sup>+</sup>); calcd, 491.2546; found, 491.2566.</div></div><div id="sec4_1_33" class="NLM_sec NLM_sec_level_3"><div id="ac_i69" class="anchor-spacer"></div><h4 class="article-section__title" id="_i69"> <i>N</i>-(1-(3-Fluoropropyl)azetidin-3-yl)-<i>N</i>-methyl-6-((6<i>S</i>,8<i>R</i>)-8-methyl-7-(2,2,2-trifluoroethyl)-6,7,8,9-tetrahydro-3<i>H</i>-pyrazolo[4,3-<i>f</i>]isoquinolin-6-yl)pyridin-3-amine (<b>37</b>)</h4><div class="NLM_p last">Paraformaldehyde (101 mg, 3.36 mmol) was added to a solution of <i>N</i>-(1-(3-fluoropropyl)azetidin-3-yl)-6-((6<i>S</i>,8<i>R</i>)-8-methyl-7-(2,2,2-trifluoroethyl)-6,7,8,9-tetrahydro-3<i>H</i>-pyrazolo[4,3-<i>f</i>]isoquinolin-6-yl)pyridin-3-amine <b>28</b> (80 mg, 0.17 mmol) in acetic acid (0.84 mL)/iPrOH (0.84 mL), and the reaction was heated to 70 °C for 1 h. NaCNBH<sub>3</sub> (26.4 mg, 0.42 mmol) was added, and the reaction was stirred for a further 1 h. An additional portion of NaCNBH<sub>3</sub> (26.4 mg, 0.42 mmol) was added, and the reaction was stirred at 70 °C for a further 30 min. After cooling, the reaction was diluted with DCM and washed with saturated NaHCO<sub>3</sub> solution. The organic phase was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and evaporated. The crude product was purified by preparative HPLC using decreasingly polar mixtures of water (containing 0.1% NH<sub>3</sub>) and MeCN as eluents. Fractions containing the desired compound were evaporated to dryness to afford the product (66.0 mg, 80%) as a ∼9:1 mixture of diastereoisomers. The mixture was further purified by chiral SFC to afford <i>N</i>-(1-(3-fluoropropyl)azetidin-3-yl)-<i>N</i>-methyl-6-((6<i>S</i>,8<i>R</i>)-8-methyl-7-(2,2,2-trifluoroethyl)-6,7,8,9-tetrahydro-3<i>H</i>-pyrazolo[4,3-<i>f</i>]isoquinolin-6-yl)pyridin-3-amine (36.0 mg, 72%) as a beige solid. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>, 27 °C) 1.09 (d, <i>J</i> = 6.7 Hz, 3H), 1.65 (m, 2H), 2.46 (t, <i>J</i> = 7.0 Hz, 2H), 2.80 (s, 3H), 2.82–2.87 (m, 1H), 2.88 (dd, <i>J</i> = 7.1, 2.6 Hz, 2H), 2.93–3.03 (m, 1H), 3.06 (dd, <i>J</i> = 17.1, 4.5 Hz, 1H), 3.47 (m, 1H), 3.54 (m, 1H), 3.62 (m, 2H), 4.04 (p, <i>J</i> = 6.7 Hz, 1H), 4.46 (dt, <i>J</i> = 47.4, 6.1 Hz, 2H), 4.99 (s, 1H), 6.82 (d, <i>J</i> = 8.6 Hz, 1H), 7.08 (d, <i>J</i> = 1.8 Hz, 2H), 7.15–7.33 (m, 1H), 7.90 (t, <i>J</i> = 1.9 Hz, 1H), 8.05 (d, <i>J</i> = 1.3 Hz, 1H), 12.97 (m, 1H); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>, 27 °C) 16.4, 28.1 (d, <i>J</i> = 19.5 Hz), 30.0, 34.5, 47.2, 48.7 (q, <i>J</i> = 29.7 Hz), 49.5 (2C), 54.6 (d, <i>J</i> = 5.7 Hz), 59.1, 67.2, 82.0 (d, <i>J</i> = 161.3 Hz), 107.6, 121.5, 122.4, 123.4, 126.1, 126.3 (q, <i>J</i> = 278.7 Hz), 126.3, 127.6, 131.8, 134.4, 138.6, 144.2, 151.3; <sup>19</sup>F NMR (376 MHz, DMSO-<i>d</i><sub>6</sub>, 27 °C) −218.1 (1F), −69.7 (3F); <i>m</i>/<i>z</i> (ES+), [M + H]<sup>+</sup> = 491, HRMS (ESI) (MH<sup>+</sup>); calcd, 491.2546; found, 491.2566.</div></div><div id="sec4_1_34" class="NLM_sec NLM_sec_level_3"><div id="ac_i70" class="anchor-spacer"></div><h4 class="article-section__title" id="_i70"> <i>N</i>-((<i>S</i>)-1-(3-Fluoropropyl)pyrrolidin-3-yl)-6-((6<i>S</i>,8<i>R</i>)-8-methyl-7-(2,2,2-trifluoroethyl)-6,7,8,9-tetrahydro-3<i>H</i>-pyrazolo[4,3-<i>f</i>]isoquinolin-6-yl)pyridin-3-amine (<b>38</b>)</h4><div class="NLM_p last">TFA (7.07 mL) was added to a solution of <i>tert</i>-butyl (<i>S</i>)-3-((6-((6<i>S</i>,8<i>R</i>)-8-methyl-7-(2,2,2-trifluoroethyl)-6,7,8,9-tetrahydro-3<i>H</i>-pyrazolo[4,3-<i>f</i>]isoquinolin-6-yl)pyridin-3-yl)amino)pyrrolidine-1-carboxylate <b>75</b> (1.50 g, 2.83 mmol) in DCM (21.2 mL), and the resulting mixture was stirred for 2 h at room temperature. The reaction was diluted with methanol (50 mL) and applied to a prewetted (methanol) SCX-2 cartridge. The cartridge was washed with methanol (100 mL) and eluted with 1.0 M ammonia in methanol (100 mL). The eluent was concentrated <i>in vacuo</i> to give 6-((6<i>S</i>,8<i>R</i>)-8-methyl-7-(2,2,2-trifluoroethyl)-6,7,8,9-tetrahydro-3<i>H</i>-pyrazolo[4,3-<i>f</i>]isoquinolin-6-yl)-<i>N</i>-((<i>S</i>)-pyrrolidin-3-yl)pyridin-3-amine (1.209 g, 99%) as a gum (<i>m</i>/<i>z</i>: ES+ [M + H]<sup>+</sup> 431). 1-Fluoro-3-iodopropane (0.287 mL, 2.81 mmol) was added and <i>N</i>-ethyl-<i>N</i>-isopropylpropan-2-amine (0.587 mL, 3.37 mmol) in DMF (27.2 mL), and the resulting mixture was stirred at room temperature for 72 h. The reaction was partitioned between water (20 mL) and EtOAc (20 mL), and the organic layer was separated and concentrated. Purification of the crude product was achieved by preparative HPLC (Interchim PF-30C18HP-F0220 column) using decreasingly polar mixtures of water (containing 1% NH<sub>3</sub>) and MeCN as eluents. Fractions containing the desired compound were evaporated to dryness. The sample was dissolved in MeOH and separated by SFC using the following chromatographic conditions: Column: Phenomonex Lux C1, 30 × 250 mm, 5 μm, Mobile phase: 30% MeOH + 0.1% NH<sub>3</sub>/70% scCO<sub>2</sub> to afford <i>N</i>-((<i>S</i>)-1-(3-fluoropropyl)pyrrolidin-3-yl)-6-((6<i>S</i>,8<i>R</i>)-8-methyl-7-(2,2,2-trifluoroethyl)-6,7,8,9-tetrahydro-3<i>H</i>-pyrazolo[4,3-<i>f</i>]isoquinolin-6-yl)pyridin-3-amine (0.948 g, 69%) as a yellow solid. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>, 27 °C) 1.09 (d, <i>J</i> = 6.7 Hz, 3H), 1.54 (m, 1H), 1.79 (m, 2H), 2.18 (m, 1H), 2.32 (dd, <i>J</i> = 9.3, 4.6 Hz, 1H), 2.44 (m, 2H), 2.50 (m, 1H), 2.58 (m, 1H), 2.79 (dd, <i>J</i> = 9.3, 6.8 Hz, 1H), 2.84 (dd, <i>J</i> = 17.1, 8.2 Hz, 1H), 2.98 (m, 1H), 3.07 (dd, <i>J</i> = 17.1, 4.6 Hz, 1H), 3.49 (m, 1H), 3.53 (m, 1H), 3.83 (m, 1H), 4.47 (dt, <i>J</i> = 47.5, 6.0 Hz, 2H), 4.93 (s, 1H), 5.91 (d, <i>J</i> = 6.8 Hz, 1H), 6.81 (d, <i>J</i> = 8.6 Hz, 1H), 6.86 (dd, <i>J</i> = 8.6, 2.8 Hz, 1H), 6.96 (d, <i>J</i> = 8.5 Hz, 1H), 7.22 (d, <i>J</i> = 8.6 Hz, 1H), 7.78 (d, <i>J</i> = 2.8 Hz, 1H), 8.05 (s, 1H), 12.96 (m, 1H); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>, 27 °C) 16.2, 29.0 (d, <i>J</i> = 19.3 Hz), 30.2, 31.7, 47.3, 48.7 (q, <i>J</i> = 29.6 Hz), 51.2, 51.3 (d, <i>J</i> = 5.8 Hz), 52.6, 60.2, 67.1, 82.2 (d, <i>J</i> = 161.2 Hz), 107.5, 119.0, 122.4, 123.7, 126.1, 126.3 (q, <i>J</i> = 278.2 Hz), 126.5, 127.5, 131.7, 133.2, 138.5, 143.0, 149.4; <sup>19</sup>F NMR (376 MHz, DMSO-<i>d</i><sub>6</sub>, 27 °C) −218.2 (1F), −69.7 (3F); <i>m</i>/<i>z</i> (ES+), [M + H]<sup>+</sup> = 491, HRMS (ESI) (MH<sup>+</sup>); calcd, 491.2546; found, 491.2566.</div></div><div id="sec4_1_35" class="NLM_sec NLM_sec_level_3"><div id="ac_i71" class="anchor-spacer"></div><h4 class="article-section__title" id="_i71"> <i>N</i>-((<i>S</i>)-1-(3-Fluoropropyl)pyrrolidin-3-yl)-<i>N</i>-methyl-6-((6<i>S</i>,8<i>R</i>)-8-methyl-7-(2,2,2-trifluoroethyl)-6,7,8,9-tetrahydro-3<i>H</i>-pyrazolo[4,3-<i>f</i>]isoquinolin-6-yl)pyridin-3-amine (<b>39</b>)</h4><div class="NLM_p last">NaCNBH<sub>3</sub> (83 mg, 1.33 mmol) was added to a mixture of <i>N</i>-((<i>S</i>)-1-(3-fluoropropyl)pyrrolidin-3-yl)-6-((6<i>S</i>,8<i>R</i>)-8-methyl-7-(2,2,2-trifluoroethyl)-6,7,8,9-tetrahydro-3<i>H</i>-pyrazolo[4,3-<i>f</i>]isoquinolin-6-yl)pyridin-3-amine <b>38</b> (130 mg, 0.27 mmol) and paraformaldehyde (80 mg, 2.65 mmol) in MeOH (2.5 mL) and acetic acid (0.5 mL). The mixture was stirred at 50 °C overnight. Further paraformaldehyde (80 mg, 2.65 mmol) and NaCNBH<sub>3</sub> (83 mg, 1.33 mmol) were added, and the reaction was heated at 50 °C for a further 22 h. The volatiles were evaporated, and the residue was taken up in EtOAc, washed with saturated NaHCO<sub>3</sub> solution, dried over MgSO<sub>4</sub>, filtered, and evaporated. The residue was purified by flash silica chromatography, 0–20% MeOH in DCM to afford a mixture of diasteroisomers. The mixture was further purified by chiral SFC to afford <i>N</i>-((S)-1-(3-fluoropropyl)pyrrolidin-3-yl)-<i>N</i>-methyl-6-((6<i>S</i>,8<i>R</i>)-8-methyl-7-(2,2,2-trifluoroethyl)-6,7,8,9-tetrahydro-3<i>H</i>-pyrazolo[4,3-<i>f</i>]isoquinolin-6-yl)pyridin-3-amine (25.4 mg, 19%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>, 27 °C) 1.09 (d, <i>J</i> = 6.7 Hz, 3H), 1.65 (m, 1H), 1.82 (m, 2H), 2.12 (m, 1H), 2.22 (q, <i>J</i> = 8.2 Hz, 1H), 2.41 (m, 1H), 2.47 (m, 1H), 2.68 (dd, <i>J</i> = 10.0, 3.8 Hz, 1H), 2.79 (dd, <i>J</i> = 8.5, 3.6 Hz, 1H), 2.81 (s, 3H), 2.86 (m, 1H), 2.99 (m, 1H), 3.08 (dd, <i>J</i> = 17.1, 4.6 Hz, 1H), 3.49 (m, 1H), 3.54 (m, 1H), 4.43 (m, 1H), 4.49 (m, 2H), 4.97 (s, 1H), 6.81 (d, <i>J</i> = 8.6 Hz, 1H), 7.03 (d, <i>J</i> = 8.8 Hz, 1H), 7.14 (dd, <i>J</i> = 8.8, 3.1 Hz, 1H), 7.22 (d, <i>J</i> = 8.5 Hz, 1H), 8.00 (d, <i>J</i> = 3.0 Hz, 1H), 8.05 (s, 1H), 12.97 (s, 1H); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>, 27 °C) 16.3, 28.0, 28.9 (d, <i>J</i> = 19.4 Hz), 30.1, 31.8, 47.3, 48.7 (q, <i>J</i> = 30.4 Hz), 51.2 (d, <i>J</i> = 5.7 Hz), 53.4, 56.2, 56.7, 67.0, 82.3 (d, <i>J</i> = 161.4 Hz), 107.5, 120.1, 122.4, 123.4, 126.2, 126.3 (q, <i>J</i> = 278.2 Hz), 126.3, 127.5, 131.7, 133.3, 138.5, 144.5, 149.8; <sup>19</sup>F NMR (376 MHz, DMSO-<i>d</i><sub>6</sub>, 27 °C) −218.3 (1F), −69.7 (3F); <i>m</i>/<i>z</i> (ES+), [M + H]<sup>+</sup> = 505, HRMS (ESI) (MH<sup>+</sup>); calcd, 505.2703; found, 505.2727.</div></div><div id="sec4_1_36" class="NLM_sec NLM_sec_level_3"><div id="ac_i72" class="anchor-spacer"></div><h4 class="article-section__title" id="_i72"> (6<i>S</i>,8<i>R</i>)-6-(5-(((<i>S</i>)-1-(3-Fluoropropyl)pyrrolidin-3-yl)oxy)pyridin-2-yl)-8-methyl-7-(2,2,2-trifluoroethyl)-6,7,8,9-tetrahydro-3<i>H</i>-pyrazolo[4,3-<i>f</i>]isoquinoline (<b>40</b>)</h4><div class="NLM_p last">4 M HCl in dioxane (1.0 mL) was added to a solution of <i>tert</i>-butyl (3<i>S</i>)-3-((6-((6<i>S</i>,8<i>R</i>)-8-methyl-3-(tetrahydro-2<i>H</i>-pyran-2-yl)-7-(2,2,2-trifluoroethyl)-6,7,8,9-tetrahydro-3<i>H</i>-pyrazolo[4,3-<i>f</i>]isoquinolin-6-yl)pyridin-3-yl)oxy)pyrrolidine-1-carboxylate <b>76</b> (0.125 g, 0.20 mmol) in MeOH (1.0 mL), and the reaction was stirred at room temperature for 2 h. The volatiles were evaporated, and then the residue was purified using an SCX-2 cartridge (mobile phase methanol, then 3 N NH<sub>3</sub> in MeOH) to afford (6<i>S</i>,8<i>R</i>)-8-methyl-6-(5-(((<i>S</i>)-pyrrolidin-3-yl)oxy)pyridin-2-yl)-7-(2,2,2-trifluoroethyl)-6,7,8,9-tetrahydro-3<i>H</i>-pyrazolo[4,3-<i>f</i>]isoquinoline (0.072g) as an impure solid (<i>m</i>/<i>z</i>: ES+ [M + H]<sup>+</sup> 432). 1-Fluoro-3-iodopropane (0.030 g, 0.16 mmol) in DMF (0.1 mL) was added to a solution of DIPEA (0.071 mL, 0.41 mmol) and (6<i>S</i>,8<i>R</i>)-8-methyl-6-(5-(((<i>S</i>)-pyrrolidin-3-yl)oxy)pyridin-2-yl)-7-(2,2,2-trifluoroethyl)-6,7,8,9-tetrahydro-3<i>H</i>-pyrazolo[4,3-<i>f</i>]isoquinoline (0.07 g, 0.16 mmol) in DMF (2.0 mL). The reaction was stirred at room temperature for 2 h, and then the reaction was diluted with brine and extracted with EtOAc (3×). The combined organics were washed with water, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and evaporated. The residue was purified by flash silica chromatography, 2–10% (1% NH<sub>4</sub>OH)/MeOH in DCM to afford (6<i>S</i>,8<i>R</i>)-6-(5-(((<i>S</i>)-1-(3-fluoropropyl)pyrrolidin-3-yl)oxy)pyridin-2-yl)-8-methyl-7-(2,2,2-trifluoroethyl)-6,7,8,9-tetrahydro-3<i>H</i>-pyrazolo[4,3-<i>f</i>]isoquinoline (0.012 g, 14%) as a solid. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>, 27 °C) 1.10 (d, <i>J</i> = 6.6 Hz, 3H), 1.79 (m 1H), 1.83 (m, 2H), 2.29 (m, 1H), 2.54 (m, 1H), 2.58 (m, 1H), 2.70 (m, 1H), 2.75 (m, 1H), 2.86 (m, 2H), 3.00 (m, 1H), 3.07 (dd, <i>J</i> = 17.1, 4.6 Hz, 1H), 3.45 (m, 1H), 3.50 (m, 1H), 3.57 (dq, <i>J</i> = 15.5, 9.8 Hz, 1H), 4.47 (dt, <i>J</i> = 47.4, 6.0 Hz, 2H), 4.92 (s, 1H), 5.05 (s, 1H), 6.85 (d, <i>J</i> = 8.6 Hz, 1H), 7.24 (m, 2H), 7.31 (dd, <i>J</i> = 8.7, 2.9 Hz, 1H), 8.06 (s, 1H), 8.09 (d, <i>J</i> = 2.9 Hz, 1H), 12.98 (s, 1H); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>, 27 °C) 16.4, 29.0, 29.8, 31.4, 47.4, 48.7 (q, <i>J</i> = 30.3 Hz), 51.2 (d, <i>J</i> = 5.8 Hz), 52.3, 59.5, 67.1, 76.4, 82.1 (d, <i>J</i> = 161.8 Hz), 107.6, 122.4, 122.7, 124.0, 125.7, 126.2 (q, <i>J</i> = 278.1 Hz), 126.4, 127.6, 131.8, 136.0, 138.6, 152.4, 154.6; <sup>19</sup>F NMR (376 MHz, DMSO-<i>d</i><sub>6</sub>, 27 °C) −218.4 (1F), −69.8 (3F); <i>m</i>/<i>z</i> (ES+), [M + H]<sup>+</sup> = 492, HRMS (ESI) (MH<sup>+</sup>); calcd, 492.2386; found, 492.2369.</div></div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i73" class="anchor-spacer"></div><h3 class="article-section__title" id="_i73"> Biochemical and in Vitro Cell Assays</h3><div class="NLM_p last">Binding, ER agonism, antagonism, downregulation, and cell proliferation assays were carried out as described previously<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> with the exception that MCF-7 (WT) proliferation was measured in the presence of 0.1 nM estradiol. Compounds and fulvestrant obtained from AstraZeneca compound collection were dissolved in DMSO to a concentration of 10 mmol/L and stored under nitrogen. Cell lines were incubated at 37 °C and 5% CO<sub>2</sub> in a humidified atmosphere in RPMI1640 (phenol red-free) supplemented with 5% charcoal-stripped FCS and 2 mmol/L glutamine. MCF-7 cell line authentication date at AstraZeneca cell banking (STR fingerprinting): September 2015.</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i74" class="anchor-spacer"></div><h3 class="article-section__title" id="_i74"> Western Blotting</h3><div class="NLM_p last">Expression levels of protein were assessed using standard Western blotting techniques (NuPAGE Novex 4–12% Bis-Tris gels). Cells were lysed in 25 mmol/L Tris/HCL pH 6.8, 3 mmol/L EDTA, 3 mmol/L EGTA, 50 mmol/L NaF, 2 mmol/L sodium orthovanadate, 270 mmol/L sucrose, 10 mmol/L β-glycerophosphate, 5 mmol/L sodium pyrophosphate, and 0.5% Triton X-100 supplemented with protease inhibitors (Roche) and phosphatase inhibitors (Pierce). Antibodies to ER (SP1, Thermo) or β Actin (4970, CST) were diluted in 5% milk-PBS-0.05% Tween and signal detected using SuperSignal West Dura HRP substrate followed by visualization on a Syngene ChemiGenius Imager.</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i75" class="anchor-spacer"></div><h3 class="article-section__title" id="_i75"> MCF-7 Xenograft Studies</h3><div class="NLM_p last">All animal studies were conducted in accordance with U.K. Home Office legislation, the Animal Scientific Procedures Act 1986, as well as the AstraZeneca Global Bioethics policy, which are consistent with The American Chemical Society Publications rules and ethical guidelines. All experimental work is outlined in project license 40/3483, which has gone through the AstraZeneca Ethical Review Process. Male CB17 SCID mice older than 5–6 weeks and weighing more than 18 g were housed in individually vented caging systems in a 12-h light/12-h dark environment and maintained at uniform temperature and humidity. Mice were anesthetized with isoflurane and surgically implanted with a 0.5 mg/21 day estrogen pellet (Innovative Research, USA) subcutaneously. Twenty-four hours later MCF-7 cells (5 × 10<sup>6</sup>) were implanted subcutaneously in the hind flank. Tumor growth was calculated weekly by bilateral caliper measurement (length × width) and mice randomized into vehicle or treatment groups of nine animals for efficacy studies and five animals for PD studies, with approximate mean start size of 0.2 to 0.4 cm<sup>3</sup> for efficacy studies or 0.5 to 0.8 cm<sup>3</sup> for PD studies. Group size was calculated by a power analysis to enable statistically robust detection of tumor growth inhibition (>9 per group) or pharmacodynamic end point (>5 per group). Compound <b>28</b> was formulated in vehicle (40% PEG 400 (Sigma), 30% of a 20% solution of Captosol (Ligand) and 30% water for injection) at the appropriate concentration to dose at 10 mL/kg. Mice were dosed once daily by oral gavage at the times and doses indicated for the duration of the treatment period. Tumour growth inhibition from start of treatment was assessed by comparison of the mean change in tumor volume for the control and treated groups. Statistical significance was evaluated using a one-tailed Student <i>t</i> test. Tumors were excised at specific time points and fragments snap-frozen in liquid nitrogen and stored at −80 °C.</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i76" class="anchor-spacer"></div><h3 class="article-section__title" id="_i76"> Tumor Protein Analysis</h3><div class="NLM_p last">Tumor fragments were added to cell extraction buffer (Invitrogen: FNN0011) with added Sigma Phosphatase inhibitors (No. 2 (P5726) and 3 (P0044) 1 in 100 dilution) and Roche Complete (11836145001) protease inhibitor, 1 mM DTT and homogenized, sonicated, and centrifuged before protein quantification with Bradford Reagent (Bio-Rad). Equal protein loadings were run on Bis-Tris Criterion gels (4–12% Gels) using standard methods. Detection of PR protein is as described in previous immunoblotting section. Vinculin protein levels were measured as a loading control using V931 Sigma (mouse) and antimouse HRP-linked antibody. An unpaired two-tailed <i>t</i> test was used to examine the statistical differences between the vehicle and treated groups.</div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i77" class="anchor-spacer"></div><h3 class="article-section__title" id="_i77"> NMR Solution Stability</h3><div class="NLM_p last">The hydrolytic stability study in solution was carried out in deuterated pH 4 and 7.4 buffers at 27 °C in the absence of direct light, over a period of 8 days using NMR spectroscopy and LC-MS. Each compound from a 25 mM DMSO-<i>d</i><sub>6</sub> stock was diluted to a final 1 mM concentration in each of the buffers and then transferred to an NMR tube and MS vial. The stability was followed by NMR (500 MHz, water suppression <sup>1</sup>H spectra, 64 scans) and LC-MS at time points 0, 24, 72, and 192 h (8 days). The level of degradation was derived from the ratio of integrals of the parent compound and degradant(s), both in the NMR and LC-MS spectra.</div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i78" class="anchor-spacer"></div><h3 class="article-section__title" id="_i78"> Drug Substance Stability</h3><div class="NLM_p last">Stability samples were prepared as 0.15 mg/mL in 50:50 acetonitrile/water, and assayed using LC-MS. The analysis was carried out on an ACQUITY UPLC System (Waters, Inc., Milford, MA, USA) consisting of a Binary Solvent Manager, Sample Manager, Column Manager, Photodiode Array Detector and Tandem Quadrupole mass detector (TQD). The prepared samples were separated using a 1.7 μm ACQUITY UPLC CSH C18 column with internal dimensions of 2.1 mm × 100 mm (Waters, Inc., Milford, MA, USA). The eluent consisted of a gradient mobile phase run at 0.55 mL/min, with solvent A: 0.1% trifluoroacetic acid in water and solvent B: 0.03% trifluoroacetic acid in acetonitrile. The gradient slope was 5–40% B in 0–8 min, followed by 40–95% B in 8–10 min where the composition was held for 1 min prior to reconditioning for the next injection. Other LC-MS parameters include column temperature of 40 °C and detection by UV absorbance at 263 nm. MS data were obtained in ESI positive mode with the cone voltage at 25 V. Samples were quantified against undegraded compound <b>28</b>, prepared in 50:50 acetonitrile/water.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i79"><a href="/doi/suppl/10.1021/acs.jmedchem.0c01163" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_01221" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_01221" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.0c01163?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01163</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Experimental procedures for the synthesis of intermediates together with biological data and associated errors, NMR conformation, crystallography and molecular formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01163/suppl_file/jm0c01163_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01163/suppl_file/jm0c01163_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01163/suppl_file/jm0c01163_si_001.pdf">jm0c01163_si_001.pdf (2.91 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01163/suppl_file/jm0c01163_si_002.csv">jm0c01163_si_002.csv (3.9 kb)</a></li></ul></div></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">Crystal structures of ER in complex with compound <b>16</b> (6zoq), <b>18</b> (6zos), and <b>28</b> (6zor).</p><div class="testing" data-doi="10.1021/acs.jmedchem.0c01163" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_20523" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_20523" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">James S. Scott</span> - <span class="hlFld-Affiliation affiliation">Oncology
R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-2263-7024" title="Orcid link">http://orcid.org/0000-0002-2263-7024</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#771d161a1e125904141803033716040305160d12191214165914181a"><span class="__cf_email__" data-cfemail="59333834303c772a3a362d2d19382a2d2b38233c373c3a38773a3634">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Thomas A. Moss</span> - <span class="hlFld-Affiliation affiliation">Oncology
R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#73071b1c1e12005d1e1c000033120007011209161d1610125d101c1e"><span class="__cf_email__" data-cfemail="cfbba7a0a2aebce1a2a0bcbc8faebcbbbdaeb5aaa1aaacaee1aca0a2">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Amber Balazs</span> - <span class="hlFld-Affiliation affiliation">Oncology
R&D, AstraZeneca, R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Bernard Barlaam</span> - <span class="hlFld-Affiliation affiliation">Oncology
R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-0904-7556" title="Orcid link">http://orcid.org/0000-0002-0904-7556</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jason Breed</span> - <span class="hlFld-Affiliation affiliation">Discovery
Sciences R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Rodrigo J. Carbajo</span> - <span class="hlFld-Affiliation affiliation">Oncology
R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Elisabetta Chiarparin</span> - <span class="hlFld-Affiliation affiliation">Oncology
R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-2998-1346" title="Orcid link">http://orcid.org/0000-0002-2998-1346</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Paul R. J. Davey</span> - <span class="hlFld-Affiliation affiliation">Oncology
R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Oona Delpuech</span> - <span class="hlFld-Affiliation affiliation">Oncology
R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Stephen Fawell</span> - <span class="hlFld-Affiliation affiliation">Oncology
R&D, AstraZeneca, R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">David I. Fisher</span> - <span class="hlFld-Affiliation affiliation">Discovery
Sciences R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sladjana Gagrica</span> - <span class="hlFld-Affiliation affiliation">Oncology
R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Eric T. Gangl</span> - <span class="hlFld-Affiliation affiliation">Oncology
R&D, AstraZeneca, R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Tyler Grebe</span> - <span class="hlFld-Affiliation affiliation">Oncology
R&D, AstraZeneca, R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ryan D. Greenwood</span> - <span class="hlFld-Affiliation affiliation">Oncology
R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sudhir Hande</span> - <span class="hlFld-Affiliation affiliation">Oncology
R&D, AstraZeneca, R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Holia Hatoum-Mokdad</span> - <span class="hlFld-Affiliation affiliation">Oncology
R&D, AstraZeneca, R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kara Herlihy</span> - <span class="hlFld-Affiliation affiliation">Discovery
Sciences R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Samantha Hughes</span> - <span class="hlFld-Affiliation affiliation">Oncology
R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Thomas A. Hunt</span> - <span class="hlFld-Affiliation affiliation">Oncology
R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hoan Huynh</span> - <span class="hlFld-Affiliation affiliation">Oncology
R&D, AstraZeneca, R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sophie L. M. Janbon</span> - <span class="hlFld-Affiliation affiliation">Early
Chemical Development, Pharmaceutical Sciences,
R&D, Macclesfield, United Kingdom</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-7908-8292" title="Orcid link">http://orcid.org/0000-0001-7908-8292</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Tony Johnson</span> - <span class="hlFld-Affiliation affiliation">Oncology
R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Stefan Kavanagh</span> - <span class="hlFld-Affiliation affiliation">Oncology
Safety, Clinical Pharmacology and Safety
Sciences, R&D, AstraZeneca, Cambridge, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Teresa Klinowska</span> - <span class="hlFld-Affiliation affiliation">Oncology
R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mandy Lawson</span> - <span class="hlFld-Affiliation affiliation">Oncology
R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Andrew S. Lister</span> - <span class="hlFld-Affiliation affiliation">Oncology
R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Stacey Marden</span> - <span class="hlFld-Affiliation affiliation">Advanced
Drug Delivery, Pharmaceutical Sciences,
R&D, Boston, Massachusetts, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Dermot F. McGinnity</span> - <span class="hlFld-Affiliation affiliation">Oncology
R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Christopher J. Morrow</span> - <span class="hlFld-Affiliation affiliation">Oncology
R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">J. Willem M. Nissink</span> - <span class="hlFld-Affiliation affiliation">Oncology
R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-2572-9140" title="Orcid link">http://orcid.org/0000-0003-2572-9140</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Daniel H. O’Donovan</span> - <span class="hlFld-Affiliation affiliation">Oncology
R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-8400-2198" title="Orcid link">http://orcid.org/0000-0002-8400-2198</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Bo Peng</span> - <span class="hlFld-Affiliation affiliation">Oncology
R&D, AstraZeneca, R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Radoslaw Polanski</span> - <span class="hlFld-Affiliation affiliation">Discovery
Sciences R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Darren S. Stead</span> - <span class="hlFld-Affiliation affiliation">Oncology
R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Stephen Stokes</span> - <span class="hlFld-Affiliation affiliation">Oncology
R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kumar Thakur</span> - <span class="hlFld-Affiliation affiliation">Oncology
R&D, AstraZeneca, R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Scott R. Throner</span> - <span class="hlFld-Affiliation affiliation">Oncology
R&D, AstraZeneca, R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michael J. Tucker</span> - <span class="hlFld-Affiliation affiliation">Oncology
R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jeffrey Varnes</span> - <span class="hlFld-Affiliation affiliation">Oncology
R&D, AstraZeneca, R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Haixia Wang</span> - <span class="hlFld-Affiliation affiliation">Oncology
R&D, AstraZeneca, R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">David M. Wilson</span> - <span class="hlFld-Affiliation affiliation">Oncology
R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Dedong Wu</span> - <span class="hlFld-Affiliation affiliation">Advanced
Drug Delivery, Pharmaceutical Sciences,
R&D, Boston, Massachusetts, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ye Wu</span> - <span class="hlFld-Affiliation affiliation">Oncology
R&D, AstraZeneca, R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Bin Yang</span> - <span class="hlFld-Affiliation affiliation">Oncology
R&D, AstraZeneca, R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-1499-5569" title="Orcid link">http://orcid.org/0000-0002-1499-5569</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Wenzhan Yang</span> - <span class="hlFld-Affiliation affiliation">Advanced
Drug Delivery, Pharmaceutical Sciences,
R&D, Boston, Massachusetts, United States</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i81">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_56074" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_56074" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Analytical and Purification teams at AstraZeneca are thanked for their contributions, notably, Emma Gates (HRMS) and Eva Lenz (purity checks). Pete Barton is thanked for help with compilation of the experimental details, Joanna Raubo for the optical rotation data, and Carrie Larner for the secondary pharmacology data. Tom Heightman, Ray Finlay, and Nichola Whalley are thanked for their valuable contributions regarding the manuscript.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">BDE</td><td class="NLM_def"><p class="first last">bond dissociated energy</p></td></tr><tr><td class="NLM_term">Boc</td><td class="NLM_def"><p class="first last"><i>tert</i>-butoxycarbonyl</p></td></tr><tr><td class="NLM_term">CbZ</td><td class="NLM_def"><p class="first last">benzyloxycarbonyl</p></td></tr><tr><td class="NLM_term">Cl</td><td class="NLM_def"><p class="first last">clearance</p></td></tr><tr><td class="NLM_term">CYP</td><td class="NLM_def"><p class="first last">cytochrome P450 enzyme</p></td></tr><tr><td class="NLM_term">DIPEA</td><td class="NLM_def"><p class="first last">di-isopropylethylamine</p></td></tr><tr><td class="NLM_term">ERα</td><td class="NLM_def"><p class="first last">estrogen receptor α</p></td></tr><tr><td class="NLM_term">Fv</td><td class="NLM_def"><p class="first last">fulvestrant</p></td></tr><tr><td class="NLM_term">HATU</td><td class="NLM_def"><p class="first last">hexafluorophosphate azabenzotriazole tetramethyl uranium</p></td></tr><tr><td class="NLM_term">HER2</td><td class="NLM_def"><p class="first last">human epidermal growth factor receptor 2</p></td></tr><tr><td class="NLM_term">hERG</td><td class="NLM_def"><p class="first last">human ether-à-go-go-related gene</p></td></tr><tr><td class="NLM_term">HR</td><td class="NLM_def"><p class="first last">hormone receptors</p></td></tr><tr><td class="NLM_term">LLE</td><td class="NLM_def"><p class="first last">ligand lipophilic efficiency</p></td></tr><tr><td class="NLM_term"><i>P</i><sub>app</sub></td><td class="NLM_def"><p class="first last">apparent permeability</p></td></tr><tr><td class="NLM_term">PMB</td><td class="NLM_def"><p class="first last"><i>p</i>-methoxybenzyl</p></td></tr><tr><td class="NLM_term">PR</td><td class="NLM_def"><p class="first last">progesterone receptor</p></td></tr><tr><td class="NLM_term">RT</td><td class="NLM_def"><p class="first last">room temperature</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structure–activity relationship</p></td></tr><tr><td class="NLM_term">SERD</td><td class="NLM_def"><p class="first last">selective estrogen receptor α degrader</p></td></tr><tr><td class="NLM_term">SGF</td><td class="NLM_def"><p class="first last">simulated gastric fluid</p></td></tr><tr><td class="NLM_term">TBME</td><td class="NLM_def"><p class="first last"><i>tert</i>-butyl methyl ether</p></td></tr><tr><td class="NLM_term">TFA</td><td class="NLM_def"><p class="first last">trifluoroacetic acid</p></td></tr><tr><td class="NLM_term">THIQ</td><td class="NLM_def"><p class="first last">tetrahydroisoquinoline</p></td></tr><tr><td class="NLM_term">THP</td><td class="NLM_def"><p class="first last">tetrahydropyran</p></td></tr><tr><td class="NLM_term">Vd<sub>ss</sub></td><td class="NLM_def"><p class="first last">steady-state volume of distribution</p></td></tr><tr><td class="NLM_term">WT</td><td class="NLM_def"><p class="first last">wild-type</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i83">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_55301" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_55301" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 40 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bray, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferlay, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soerjomataram, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siegel, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torre, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jemal, A.</span></span> <span> </span><span class="NLM_article-title">Global Cancer Statistics 2018: GLOBOCAN Estimates of incidence and mortality worldwide for 36 cancers in 185 countries</span>. <i>Ca-Cancer J. Clin.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>68</i></span>,  <span class="NLM_fpage">394</span>– <span class="NLM_lpage">342</span>, <span class="refDoi"> DOI: 10.3322/caac.21492</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=10.3322%2Fcaac.21492" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=30207593" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=1%3ACAS%3A280%3ADC%252BB3c3otVGlsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2018&pages=394-342&author=F.+Brayauthor=J.+Ferlayauthor=I.+Soerjomataramauthor=R.+L.+Siegelauthor=L.+A.+Torreauthor=A.+Jemal&title=Global+Cancer+Statistics+2018%3A+GLOBOCAN+Estimates+of+incidence+and+mortality+worldwide+for+36+cancers+in+185+countries&doi=10.3322%2Fcaac.21492"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries</span></div><div class="casAuthors">Bray Freddie; Ferlay Jacques; Soerjomataram Isabelle; Siegel Rebecca L; Torre Lindsey A; Jemal Ahmedin</div><div class="citationInfo"><span class="NLM_cas:title">CA: a cancer journal for clinicians</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">394-424</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">This article provides a status report on the global burden of cancer worldwide using the GLOBOCAN 2018 estimates of cancer incidence and mortality produced by the International Agency for Research on Cancer, with a focus on geographic variability across 20 world regions.  There will be an estimated 18.1 million new cancer cases (17.0 million excluding nonmelanoma skin cancer) and 9.6 million cancer deaths (9.5 million excluding nonmelanoma skin cancer) in 2018.  In both sexes combined, lung cancer is the most commonly diagnosed cancer (11.6% of the total cases) and the leading cause of cancer death (18.4% of the total cancer deaths), closely followed by female breast cancer (11.6%), prostate cancer (7.1%), and colorectal cancer (6.1%) for incidence and colorectal cancer (9.2%), stomach cancer (8.2%), and liver cancer (8.2%) for mortality.  Lung cancer is the most frequent cancer and the leading cause of cancer death among males, followed by prostate and colorectal cancer (for incidence) and liver and stomach cancer (for mortality).  Among females, breast cancer is the most commonly diagnosed cancer and the leading cause of cancer death, followed by colorectal and lung cancer (for incidence), and vice versa (for mortality); cervical cancer ranks fourth for both incidence and mortality.  The most frequently diagnosed cancer and the leading cause of cancer death, however, substantially vary across countries and within each country depending on the degree of economic development and associated social and life style factors.  It is noteworthy that high-quality cancer registry data, the basis for planning and implementing evidence-based cancer control programs, are not available in most low- and middle-income countries.  The Global Initiative for Cancer Registry Development is an international partnership that supports better estimation, as well as the collection and use of local data, to prioritize and evaluate national cancer control efforts.  CA: A Cancer Journal for Clinicians 2018;0:1-31. © 2018 American Cancer Society.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQaW5wv8ocuhLxanA7vODO6fW6udTcc2eZLhJeYKBcJDLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3c3otVGlsg%253D%253D&md5=48529f8f794092779d70a27eec5c9017</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.3322%2Fcaac.21492&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3322%252Fcaac.21492%26sid%3Dliteratum%253Aachs%26aulast%3DBray%26aufirst%3DF.%26aulast%3DFerlay%26aufirst%3DJ.%26aulast%3DSoerjomataram%26aufirst%3DI.%26aulast%3DSiegel%26aufirst%3DR.%2BL.%26aulast%3DTorre%26aufirst%3DL.%2BA.%26aulast%3DJemal%26aufirst%3DA.%26atitle%3DGlobal%2520Cancer%2520Statistics%25202018%253A%2520GLOBOCAN%2520Estimates%2520of%2520incidence%2520and%2520mortality%2520worldwide%2520for%252036%2520cancers%2520in%2520185%2520countries%26jtitle%3DCa-Cancer%2520J.%2520Clin.%26date%3D2018%26volume%3D68%26spage%3D394%26epage%3D342%26doi%3D10.3322%2Fcaac.21492" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Howlader, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altekruse, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, V. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarke, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ries, L. A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cronin, K. A.</span></span> <span> </span><span class="NLM_article-title">US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status</span>. <i>JNCI: J. Natl. Cancer Inst.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>106</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">dju055</span>, <span class="refDoi"> DOI: 10.1093/jnci/dju055</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=10.1093%2Fjnci%2Fdju055" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=24777111" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2014&pages=dju055&issue=5&author=N.+Howladerauthor=S.+F.+Altekruseauthor=C.+I.+Liauthor=V.+W.+Chenauthor=C.+A.+Clarkeauthor=L.+A.+G.+Riesauthor=K.+A.+Cronin&title=US+incidence+of+breast+cancer+subtypes+defined+by+joint+hormone+receptor+and+HER2+status&doi=10.1093%2Fjnci%2Fdju055"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1093%2Fjnci%2Fdju055&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjnci%252Fdju055%26sid%3Dliteratum%253Aachs%26aulast%3DHowlader%26aufirst%3DN.%26aulast%3DAltekruse%26aufirst%3DS.%2BF.%26aulast%3DLi%26aufirst%3DC.%2BI.%26aulast%3DChen%26aufirst%3DV.%2BW.%26aulast%3DClarke%26aufirst%3DC.%2BA.%26aulast%3DRies%26aufirst%3DL.%2BA.%2BG.%26aulast%3DCronin%26aufirst%3DK.%2BA.%26atitle%3DUS%2520incidence%2520of%2520breast%2520cancer%2520subtypes%2520defined%2520by%2520joint%2520hormone%2520receptor%2520and%2520HER2%2520status%26jtitle%3DJNCI%253A%2520J.%2520Natl.%2520Cancer%2520Inst.%26date%3D2014%26volume%3D106%26issue%3D5%26spage%3Ddju055%26doi%3D10.1093%2Fjnci%2Fdju055" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jordan, C.</span></span> <span> </span><span class="NLM_article-title">Historical perspective on hormonal therapy of advanced breast cancer</span>. <i>Clin. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">A3</span>– <span class="NLM_lpage">A16</span>, <span class="refDoi"> DOI: 10.1016/S0149-2918(02)85031-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=10.1016%2FS0149-2918%2802%2985031-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=11911507" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=1%3ACAS%3A528%3ADC%252BD38XivV2rsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2002&pages=A3-A16&author=C.+Jordan&title=Historical+perspective+on+hormonal+therapy+of+advanced+breast+cancer&doi=10.1016%2FS0149-2918%2802%2985031-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Historical perspective on hormonal therapy of advanced breast cancer</span></div><div class="casAuthors">Jordan, Craig</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Therapeutics</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">Suppl. A</span>),
    <span class="NLM_cas:pages">A3-A16</span>CODEN:
                <span class="NLM_cas:coden">CLTHDG</span>;
        ISSN:<span class="NLM_cas:issn">0149-2918</span>.
    
            (<span class="NLM_cas:orgname">Excerpta Medica, Inc.</span>)
        </div><div class="casAbstract">A review.  Endocrine therapy is the preferred first-line therapy in patients with nonaggressive, receptor-pos., metastatic breast cancer.  Endocrine therapies in these patients are as effective as chemotherapy in terms of survival and tumor response.  In addn., hormonal therapies produce fewer and less severe adverse effects than does chemotherapy.  Classes of endocrine therapy currently on the market include selective estrogen receptor modulators (SERMs), aromatase inhibitors, and progestins.  For several decades, tamoxifen has been considered the gold std. of therapy.  However, despite its proven efficacy, a high proportion of patients do not respond.  Therefore, a need exists for alternative therapies or for agents to use following tamoxifen failure.  This review article highlights the various endocrine options available for patients with advanced breast cancer and discusses new agents on the horizon.  Although more studies are needed to det. the optimal sequence of hormonal therapy and the ideal agent within each class, the availability of new and multiple options is encouraging for women with advanced breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8mTP9eWmr07Vg90H21EOLACvtfcHk0lj-lI3zOk3o2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XivV2rsbs%253D&md5=67de543952954a1af236113b49111303</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2FS0149-2918%2802%2985031-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0149-2918%252802%252985031-7%26sid%3Dliteratum%253Aachs%26aulast%3DJordan%26aufirst%3DC.%26atitle%3DHistorical%2520perspective%2520on%2520hormonal%2520therapy%2520of%2520advanced%2520breast%2520cancer%26jtitle%3DClin.%2520Ther.%26date%3D2002%26volume%3D24%26spage%3DA3%26epage%3DA16%26doi%3D10.1016%2FS0149-2918%2802%2985031-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braybrooke, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGale, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peto, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pritchard, K. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dowsett, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayes, D. F.</span></span> <span> </span><span class="NLM_article-title">20-Year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>377</i></span> (<span class="NLM_issue">19</span>),  <span class="NLM_fpage">1836</span>– <span class="NLM_lpage">1846</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1701830</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=10.1056%2FNEJMoa1701830" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=29117498" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=1%3ACAS%3A280%3ADC%252BC1M7ptF2lsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=377&publication_year=2017&pages=1836-1846&issue=19&author=H.+Panauthor=R.+Grayauthor=J.+Braybrookeauthor=C.+Daviesauthor=C.+Taylorauthor=P.+McGaleauthor=R.+Petoauthor=K.+I.+Pritchardauthor=J.+Berghauthor=M.+Dowsettauthor=D.+F.+Hayes&title=20-Year+risks+of+breast-cancer+recurrence+after+stopping+endocrine+therapy+at+5+years&doi=10.1056%2FNEJMoa1701830"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years</span></div><div class="casAuthors">Pan Hongchao; Gray Richard; Braybrooke Jeremy; Davies Christina; Taylor Carolyn; McGale Paul; Peto Richard; Pritchard Kathleen I; Bergh Jonas; Dowsett Mitch; Hayes Daniel F</div><div class="citationInfo"><span class="NLM_cas:title">The New England journal of medicine</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">377</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">1836-1846</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  The administration of endocrine therapy for 5 years substantially reduces recurrence rates during and after treatment in women with early-stage, estrogen-receptor (ER)-positive breast cancer.  Extending such therapy beyond 5 years offers further protection but has additional side effects.  Obtaining data on the absolute risk of subsequent distant recurrence if therapy stops at 5 years could help determine whether to extend treatment.  METHODS:  In this meta-analysis of the results of 88 trials involving 62,923 women with ER-positive breast cancer who were disease-free after 5 years of scheduled endocrine therapy, we used Kaplan-Meier and Cox regression analyses, stratified according to trial and treatment, to assess the associations of tumor diameter and nodal status (TN), tumor grade, and other factors with patients' outcomes during the period from 5 to 20 years.  RESULTS:  Breast-cancer recurrences occurred at a steady rate throughout the study period from 5 to 20 years.  The risk of distant recurrence was strongly correlated with the original TN status.  Among the patients with stage T1 disease, the risk of distant recurrence was 13% with no nodal involvement (T1N0), 20% with one to three nodes involved (T1N1-3), and 34% with four to nine nodes involved (T1N4-9); among those with stage T2 disease, the risks were 19% with T2N0, 26% with T2N1-3, and 41% with T2N4-9.  The risk of death from breast cancer was similarly dependent on TN status, but the risk of contralateral breast cancer was not.  Given the TN status, the factors of tumor grade (available in 43,590 patients) and Ki-67 status (available in 7692 patients), which are strongly correlated with each other, were of only moderate independent predictive value for distant recurrence, but the status regarding the progesterone receptor (in 54,115 patients) and human epidermal growth factor receptor type 2 (HER2) (in 15,418 patients in trials with no use of trastuzumab) was not predictive.  During the study period from 5 to 20 years, the absolute risk of distant recurrence among patients with T1N0 breast cancer was 10% for low-grade disease, 13% for moderate-grade disease, and 17% for high-grade disease; the corresponding risks of any recurrence or a contralateral breast cancer were 17%, 22%, and 26%, respectively.  CONCLUSIONS:  After 5 years of adjuvant endocrine therapy, breast-cancer recurrences continued to occur steadily throughout the study period from 5 to 20 years.  The risk of distant recurrence was strongly correlated with the original TN status, with risks ranging from 10 to 41%, depending on TN status and tumor grade. (Funded by Cancer Research UK and others.).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTM3VY-nqM3H5I8NvIb08rbfW6udTcc2ea1etr6qDhLR7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1M7ptF2lsg%253D%253D&md5=3088751774a2cf0a2af929ee7c22c815</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1701830&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1701830%26sid%3Dliteratum%253Aachs%26aulast%3DPan%26aufirst%3DH.%26aulast%3DGray%26aufirst%3DR.%26aulast%3DBraybrooke%26aufirst%3DJ.%26aulast%3DDavies%26aufirst%3DC.%26aulast%3DTaylor%26aufirst%3DC.%26aulast%3DMcGale%26aufirst%3DP.%26aulast%3DPeto%26aufirst%3DR.%26aulast%3DPritchard%26aufirst%3DK.%2BI.%26aulast%3DBergh%26aufirst%3DJ.%26aulast%3DDowsett%26aufirst%3DM.%26aulast%3DHayes%26aufirst%3DD.%2BF.%26atitle%3D20-Year%2520risks%2520of%2520breast-cancer%2520recurrence%2520after%2520stopping%2520endocrine%2520therapy%2520at%25205%2520years%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2017%26volume%3D377%26issue%3D19%26spage%3D1836%26epage%3D1846%26doi%3D10.1056%2FNEJMoa1701830" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cardoso, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Senkus, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papadopoulos, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aapro, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">André, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harbeck, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aguilar
Lopez, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrios, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biganzoli, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boers-Doets, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cardoso, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carey, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortés, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curigliano, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diéras, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El Saghir, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eniu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fallowfield, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Francis, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gelmon, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnston, S. R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaufman, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koppikar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krop, I. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakigudde, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Offersen, B. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohno, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pagani, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paluch-Shimon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Penault-Llorca, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prat, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rugo, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sledge, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spence, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomssen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vorobiof, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norton, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winer, E. P.</span></span> <span> </span><span class="NLM_article-title">4th ESO–ESMO International consensus guidelines for advanced breast cancer (abc 4)</span>. <i>Ann. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>29</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">1634</span>– <span class="NLM_lpage">1657</span>, <span class="refDoi"> DOI: 10.1093/annonc/mdy192</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=10.1093%2Fannonc%2Fmdy192" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=30032243" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=1%3ACAS%3A280%3ADC%252BB3c7gsFyrsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2018&pages=1634-1657&issue=8&author=F.+Cardosoauthor=E.+Senkusauthor=A.+Costaauthor=E.+Papadopoulosauthor=M.+Aaproauthor=F.+Andr%C3%A9author=N.+Harbeckauthor=B.+Aguilar%0ALopezauthor=C.+H.+Barriosauthor=J.+Berghauthor=L.+Biganzoliauthor=C.+B.+Boers-Doetsauthor=M.+J.+Cardosoauthor=L.+A.+Careyauthor=J.+Cort%C3%A9sauthor=G.+Curiglianoauthor=V.+Di%C3%A9rasauthor=N.+S.+El+Saghirauthor=A.+Eniuauthor=L.+Fallowfieldauthor=P.+A.+Francisauthor=K.+Gelmonauthor=S.+R.+D.+Johnstonauthor=B.+Kaufmanauthor=S.+Koppikarauthor=I.+E.+Kropauthor=M.+Mayerauthor=G.+Nakiguddeauthor=B.+V.+Offersenauthor=S.+Ohnoauthor=O.+Paganiauthor=S.+Paluch-Shimonauthor=F.+Penault-Llorcaauthor=A.+Pratauthor=H.+S.+Rugoauthor=G.+W.+Sledgeauthor=D.+Spenceauthor=C.+Thomssenauthor=D.+A.+Vorobiofauthor=B.+Xuauthor=L.+Nortonauthor=E.+P.+Winer&title=4th+ESO%E2%80%93ESMO+International+consensus+guidelines+for+advanced+breast+cancer+%28abc+4%29&doi=10.1093%2Fannonc%2Fmdy192"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)†</span></div><div class="casAuthors">Cardoso F; Senkus E; Costa A; Papadopoulos E; Aapro M; Andre F; Harbeck N; Aguilar Lopez B; Barrios C H; Bergh J; Biganzoli L; Boers-Doets C B; Cardoso M J; Carey L A; Cortes J; Curigliano G; Dieras V; El Saghir N S; Eniu A; Fallowfield L; Francis P A; Gelmon K; Johnston S R D; Kaufman B; Koppikar S; Krop I E; Mayer M; Nakigudde G; Offersen B V; Ohno S; Pagani O; Paluch-Shimon S; Penault-Llorca F; Prat A; Rugo H S; Sledge G W; Spence D; Thomssen C; Vorobiof D A; Xu B; Norton L; Winer E P</div><div class="citationInfo"><span class="NLM_cas:title">Annals of oncology : official journal of the European Society for Medical Oncology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1634-1657</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ4hBRDVFqGsFVwdslNBF-tfW6udTcc2eboxvLd7cCeZbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3c7gsFyrsA%253D%253D&md5=3a51e35d83c428610266f85398c32b55</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdy192&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdy192%26sid%3Dliteratum%253Aachs%26aulast%3DCardoso%26aufirst%3DF.%26aulast%3DSenkus%26aufirst%3DE.%26aulast%3DCosta%26aufirst%3DA.%26aulast%3DPapadopoulos%26aufirst%3DE.%26aulast%3DAapro%26aufirst%3DM.%26aulast%3DAndr%25C3%25A9%26aufirst%3DF.%26aulast%3DHarbeck%26aufirst%3DN.%26aulast%3DAguilar%2BLopez%26aufirst%3DB.%26aulast%3DBarrios%26aufirst%3DC.%2BH.%26aulast%3DBergh%26aufirst%3DJ.%26aulast%3DBiganzoli%26aufirst%3DL.%26aulast%3DBoers-Doets%26aufirst%3DC.%2BB.%26aulast%3DCardoso%26aufirst%3DM.%2BJ.%26aulast%3DCarey%26aufirst%3DL.%2BA.%26aulast%3DCort%25C3%25A9s%26aufirst%3DJ.%26aulast%3DCurigliano%26aufirst%3DG.%26aulast%3DDi%25C3%25A9ras%26aufirst%3DV.%26aulast%3DEl%2BSaghir%26aufirst%3DN.%2BS.%26aulast%3DEniu%26aufirst%3DA.%26aulast%3DFallowfield%26aufirst%3DL.%26aulast%3DFrancis%26aufirst%3DP.%2BA.%26aulast%3DGelmon%26aufirst%3DK.%26aulast%3DJohnston%26aufirst%3DS.%2BR.%2BD.%26aulast%3DKaufman%26aufirst%3DB.%26aulast%3DKoppikar%26aufirst%3DS.%26aulast%3DKrop%26aufirst%3DI.%2BE.%26aulast%3DMayer%26aufirst%3DM.%26aulast%3DNakigudde%26aufirst%3DG.%26aulast%3DOffersen%26aufirst%3DB.%2BV.%26aulast%3DOhno%26aufirst%3DS.%26aulast%3DPagani%26aufirst%3DO.%26aulast%3DPaluch-Shimon%26aufirst%3DS.%26aulast%3DPenault-Llorca%26aufirst%3DF.%26aulast%3DPrat%26aufirst%3DA.%26aulast%3DRugo%26aufirst%3DH.%2BS.%26aulast%3DSledge%26aufirst%3DG.%2BW.%26aulast%3DSpence%26aufirst%3DD.%26aulast%3DThomssen%26aufirst%3DC.%26aulast%3DVorobiof%26aufirst%3DD.%2BA.%26aulast%3DXu%26aufirst%3DB.%26aulast%3DNorton%26aufirst%3DL.%26aulast%3DWiner%26aufirst%3DE.%2BP.%26atitle%3D4th%2520ESO%25E2%2580%2593ESMO%2520International%2520consensus%2520guidelines%2520for%2520advanced%2520breast%2520cancer%2520%2528abc%25204%2529%26jtitle%3DAnn.%2520Oncol.%26date%3D2018%26volume%3D29%26issue%3D8%26spage%3D1634%26epage%3D1657%26doi%3D10.1093%2Fannonc%2Fmdy192" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crowder, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prat, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoog, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffith, O. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fulton, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrison, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mooney, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMichael, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goncalves, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlosberg, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hiken, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saied, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giuntoli, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bumb, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitchens, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phommaly, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kavuri, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McEachern, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pluard, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naughton, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bose, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suresh, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDowell, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michel, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aft, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillanders, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeSchryver, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mills, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez-Angulo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maher, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perou, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mardis, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellis, M. J.</span></span> <span> </span><span class="NLM_article-title">Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts</span>. <i>Cell Rep.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>4</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1116</span>– <span class="NLM_lpage">1130</span>, <span class="refDoi"> DOI: 10.1016/j.celrep.2013.08.022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=10.1016%2Fj.celrep.2013.08.022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=24055055" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVyls7jK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=1116-1130&issue=6&author=S.+Liauthor=D.+Shenauthor=J.+Shaoauthor=R.+Crowderauthor=W.+Liuauthor=A.+Pratauthor=X.+Heauthor=S.+Liuauthor=J.+Hoogauthor=C.+Luauthor=L.+Dingauthor=O.+L.+Griffithauthor=C.+Millerauthor=D.+Larsonauthor=R.+S.+Fultonauthor=M.+Harrisonauthor=T.+Mooneyauthor=J.+F.+McMichaelauthor=J.+Luoauthor=Y.+Taoauthor=R.+Goncalvesauthor=C.+Schlosbergauthor=J.+F.+Hikenauthor=L.+Saiedauthor=C.+Sanchezauthor=T.+Giuntoliauthor=C.+Bumbauthor=C.+Cooperauthor=R.+T.+Kitchensauthor=A.+Linauthor=C.+Phommalyauthor=S.+R.+Daviesauthor=J.+Zhangauthor=M.+S.+Kavuriauthor=D.+McEachernauthor=Y.+Y.+Dongauthor=C.+Maauthor=T.+Pluardauthor=M.+Naughtonauthor=R.+Boseauthor=R.+Sureshauthor=R.+McDowellauthor=L.+Michelauthor=R.+Aftauthor=W.+Gillandersauthor=K.+DeSchryverauthor=R.+K.+Wilsonauthor=S.+Wangauthor=G.+B.+Millsauthor=A.+Gonzalez-Anguloauthor=J.+R.+Edwardsauthor=C.+Maherauthor=C.+M.+Perouauthor=E.+R.+Mardisauthor=M.+J.+Ellis&title=Endocrine-therapy-resistant+ESR1+variants+revealed+by+genomic+characterization+of+breast-cancer-derived+xenografts&doi=10.1016%2Fj.celrep.2013.08.022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Endocrine-Therapy-Resistant ESR1 Variants Revealed by Genomic Characterization of Breast-Cancer-Derived Xenografts</span></div><div class="casAuthors">Li, Shunqiang; Shen, Dong; Shao, Jieya; Crowder, Robert; Liu, Wenbin; Prat, Aleix; He, Xiaping; Liu, Shuying; Hoog, Jeremy; Lu, Charles; Ding, Li; Griffith, Obi L.; Miller, Christopher; Larson, Dave; Fulton, Robert S.; Harrison, Michelle; Mooney, Tom; McMichael, Joshua F.; Luo, Jingqin; Tao, Yu; Goncalves, Rodrigo; Schlosberg, Christopher; Hiken, Jeffrey F.; Saied, Laila; Sanchez, Cesar; Giuntoli, Therese; Bumb, Caroline; Cooper, Crystal; Kitchens, Robert T.; Lin, Austin; Phommaly, Chanpheng; Davies, Sherri R.; Zhang, Jin; Kavuri, Megha Shyam; McEachern, Donna; Dong, Yi Yu; Ma, Cynthia; Pluard, Timothy; Naughton, Michael; Bose, Ron; Suresh, Rama; McDowell, Reida; Michel, Loren; Aft, Rebecca; Gillanders, William; DeSchryver, Katherine; Wilson, Richard K.; Wang, Shaomeng; Mills, Gordon B.; Gonzalez-Angulo, Ana; Edwards, John R.; Maher, Christopher; Perou, Charles M.; Mardis, Elaine R.; Ellis, Matthew J.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Reports</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1116-1130</span>CODEN:
                <span class="NLM_cas:coden">CREED8</span>;
        ISSN:<span class="NLM_cas:issn">2211-1247</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">To characterize patient-derived xenografts (PDXs) for functional studies, we made whole-genome comparisons with originating breast cancers representative of the major intrinsic subtypes.  Structural and copy no. aberrations were found to be retained with high fidelity.  However, at the single-nucleotide level, variable nos. of PDX-specific somatic events were documented, although they were only rarely functionally significant.  Variant allele frequencies were often preserved in the PDXs, demonstrating that clonal representation can be transplantable.  Estrogen-receptor-pos. PDXs were assocd. with ESR1 ligand-binding-domain mutations, gene amplification, or an ESR1/YAP1 translocation.  These events produced different endocrine-therapy-response phenotypes in human, cell line, and PDX endocrine-response studies.  Hence, deeply sequenced PDX models are an important resource for the search for genome-forward treatment options and capture endocrine-drug-resistance etiologies that are not obsd. in std. cell lines.  The originating tumor genome provides a benchmark for assessing genetic drift and clonal representation after transplantation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0Zv5D2HwBxLVg90H21EOLACvtfcHk0lgInakwrwcjVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVyls7jK&md5=9d8c965d5c77060fe177faeb438212eb</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2Fj.celrep.2013.08.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.celrep.2013.08.022%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DS.%26aulast%3DShen%26aufirst%3DD.%26aulast%3DShao%26aufirst%3DJ.%26aulast%3DCrowder%26aufirst%3DR.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DPrat%26aufirst%3DA.%26aulast%3DHe%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DHoog%26aufirst%3DJ.%26aulast%3DLu%26aufirst%3DC.%26aulast%3DDing%26aufirst%3DL.%26aulast%3DGriffith%26aufirst%3DO.%2BL.%26aulast%3DMiller%26aufirst%3DC.%26aulast%3DLarson%26aufirst%3DD.%26aulast%3DFulton%26aufirst%3DR.%2BS.%26aulast%3DHarrison%26aufirst%3DM.%26aulast%3DMooney%26aufirst%3DT.%26aulast%3DMcMichael%26aufirst%3DJ.%2BF.%26aulast%3DLuo%26aufirst%3DJ.%26aulast%3DTao%26aufirst%3DY.%26aulast%3DGoncalves%26aufirst%3DR.%26aulast%3DSchlosberg%26aufirst%3DC.%26aulast%3DHiken%26aufirst%3DJ.%2BF.%26aulast%3DSaied%26aufirst%3DL.%26aulast%3DSanchez%26aufirst%3DC.%26aulast%3DGiuntoli%26aufirst%3DT.%26aulast%3DBumb%26aufirst%3DC.%26aulast%3DCooper%26aufirst%3DC.%26aulast%3DKitchens%26aufirst%3DR.%2BT.%26aulast%3DLin%26aufirst%3DA.%26aulast%3DPhommaly%26aufirst%3DC.%26aulast%3DDavies%26aufirst%3DS.%2BR.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DKavuri%26aufirst%3DM.%2BS.%26aulast%3DMcEachern%26aufirst%3DD.%26aulast%3DDong%26aufirst%3DY.%2BY.%26aulast%3DMa%26aufirst%3DC.%26aulast%3DPluard%26aufirst%3DT.%26aulast%3DNaughton%26aufirst%3DM.%26aulast%3DBose%26aufirst%3DR.%26aulast%3DSuresh%26aufirst%3DR.%26aulast%3DMcDowell%26aufirst%3DR.%26aulast%3DMichel%26aufirst%3DL.%26aulast%3DAft%26aufirst%3DR.%26aulast%3DGillanders%26aufirst%3DW.%26aulast%3DDeSchryver%26aufirst%3DK.%26aulast%3DWilson%26aufirst%3DR.%2BK.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DMills%26aufirst%3DG.%2BB.%26aulast%3DGonzalez-Angulo%26aufirst%3DA.%26aulast%3DEdwards%26aufirst%3DJ.%2BR.%26aulast%3DMaher%26aufirst%3DC.%26aulast%3DPerou%26aufirst%3DC.%2BM.%26aulast%3DMardis%26aufirst%3DE.%2BR.%26aulast%3DEllis%26aufirst%3DM.%2BJ.%26atitle%3DEndocrine-therapy-resistant%2520ESR1%2520variants%2520revealed%2520by%2520genomic%2520characterization%2520of%2520breast-cancer-derived%2520xenografts%26jtitle%3DCell%2520Rep.%26date%3D2013%26volume%3D4%26issue%3D6%26spage%3D1116%26epage%3D1130%26doi%3D10.1016%2Fj.celrep.2013.08.022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jeselsohn, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yelensky, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchwalter, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frampton, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meric-Bernstam, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez-Angulo, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrer-Lozano, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez-Fidalgo, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cristofanilli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gómez, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arteaga, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giltnane, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balko, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cronin, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jarosz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hawryluk, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lipson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otto, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dvir, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soussan-Gutman, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolf, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubinek, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilmore, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schnitt, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Come, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pusztai, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stephens, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, V. A.</span></span> <span> </span><span class="NLM_article-title">Emergence of constitutively active estrogen receptor-α mutations in pretreated advanced estrogen receptor-positive breast cancer</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>20</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">1757</span>– <span class="NLM_lpage">1767</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-13-2332</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=10.1158%2F1078-0432.CCR-13-2332" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=24398047" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=1%3ACAS%3A528%3ADC%252BC2cXls1eiu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2014&pages=1757-1767&issue=7&author=R.+Jeselsohnauthor=R.+Yelenskyauthor=G.+Buchwalterauthor=G.+Framptonauthor=F.+Meric-Bernstamauthor=A.+M.+Gonzalez-Anguloauthor=J.+Ferrer-Lozanoauthor=J.+A.+Perez-Fidalgoauthor=M.+Cristofanilliauthor=H.+G%C3%B3mezauthor=C.+L.+Arteagaauthor=J.+Giltnaneauthor=J.+M.+Balkoauthor=M.+T.+Croninauthor=M.+Jaroszauthor=J.+Sunauthor=M.+Hawrylukauthor=D.+Lipsonauthor=G.+Ottoauthor=J.+S.+Rossauthor=A.+Dvirauthor=L.+Soussan-Gutmanauthor=I.+Wolfauthor=T.+Rubinekauthor=L.+Gilmoreauthor=S.+Schnittauthor=S.+E.+Comeauthor=L.+Pusztaiauthor=P.+Stephensauthor=M.+Brownauthor=V.+A.+Miller&title=Emergence+of+constitutively+active+estrogen+receptor-%CE%B1+mutations+in+pretreated+advanced+estrogen+receptor-positive+breast+cancer&doi=10.1158%2F1078-0432.CCR-13-2332"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Emergence of Constitutively Active Estrogen Receptor-α Mutations in Pretreated Advanced Estrogen Receptor-Positive Breast Cancer</span></div><div class="casAuthors">Jeselsohn, Rinath; Yelensky, Roman; Buchwalter, Gilles; Frampton, Garrett; Meric-Bernstam, Funda; Gonzalez-Angulo, Ana Maria; Ferrer-Lozano, Jaime; Perez-Fidalgo, Jose A.; Cristofanilli, Massimo; Gomez, Henry; Arteaga, Carlos L.; Giltnane, Jennifer; Balko, Justin M.; Cronin, Maureen T.; Jarosz, Mirna; Sun, James; Hawryluk, Matthew; Lipson, Doron; Otto, Geoff; Ross, Jeffrey S.; Dvir, Addie; Soussan-Gutman, Lior; Wolf, Ido; Rubinek, Tamar; Gilmore, Lauren; Schnitt, Stuart; Come, Steven E.; Pusztai, Lajos; Stephens, Philip; Brown, Myles; Miller, Vincent A.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1757-1767</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: We undertook this study to det. the prevalence of estrogen receptor (ER) α (ESR1) mutations throughout the natural history of hormone-dependent breast cancer and to delineate the functional roles of the most commonly detected alterations.  Exptl. Design: We studied a total of 249 tumor specimens from 208 patients.  The specimens include 134 ER-pos. (ER+/HER2-) and, as controls, 115 ER-neg. (ER-) tumors.  The ER+ samples consist of 58 primary breast cancers and 76 metastatic samples.  All tumors were sequenced to high unique coverage using next-generation sequencing targeting the coding sequence of the estrogen receptor and an addnl. 182 cancer-related genes.  Results: Recurring somatic mutations in codons 537 and 538 within the ligand-binding domain of ER were detected in ER+ metastatic disease.  Overall, the frequency of these mutations was 12% [9/76; 95% confidence interval (CI), 6%-21%] in metastatic tumors and in a subgroup of patients who received an av. of 7 lines of treatment the frequency was 20% (5/25; 95% CI, 7%-41%).  These mutations were not detected in primary or treatment-naive ER+ cancer or in any stage of ER- disease.  Functional studies in cell line models demonstrate that these mutations render estrogen receptor constitutive activity and confer partial resistance to currently available endocrine treatments.  Conclusions: In this study, we show evidence for the temporal selection of functional ESR1 mutations as potential drivers of endocrine resistance during the progression of ER+ breast cancer.  Clin Cancer Res; 20(7); 1757-67. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgdteKI6rKn7Vg90H21EOLACvtfcHk0ljFNlmfVXA3MQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXls1eiu74%253D&md5=245ddc458d449b0fd6b1804285fb4ed1</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-13-2332&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-13-2332%26sid%3Dliteratum%253Aachs%26aulast%3DJeselsohn%26aufirst%3DR.%26aulast%3DYelensky%26aufirst%3DR.%26aulast%3DBuchwalter%26aufirst%3DG.%26aulast%3DFrampton%26aufirst%3DG.%26aulast%3DMeric-Bernstam%26aufirst%3DF.%26aulast%3DGonzalez-Angulo%26aufirst%3DA.%2BM.%26aulast%3DFerrer-Lozano%26aufirst%3DJ.%26aulast%3DPerez-Fidalgo%26aufirst%3DJ.%2BA.%26aulast%3DCristofanilli%26aufirst%3DM.%26aulast%3DG%25C3%25B3mez%26aufirst%3DH.%26aulast%3DArteaga%26aufirst%3DC.%2BL.%26aulast%3DGiltnane%26aufirst%3DJ.%26aulast%3DBalko%26aufirst%3DJ.%2BM.%26aulast%3DCronin%26aufirst%3DM.%2BT.%26aulast%3DJarosz%26aufirst%3DM.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DHawryluk%26aufirst%3DM.%26aulast%3DLipson%26aufirst%3DD.%26aulast%3DOtto%26aufirst%3DG.%26aulast%3DRoss%26aufirst%3DJ.%2BS.%26aulast%3DDvir%26aufirst%3DA.%26aulast%3DSoussan-Gutman%26aufirst%3DL.%26aulast%3DWolf%26aufirst%3DI.%26aulast%3DRubinek%26aufirst%3DT.%26aulast%3DGilmore%26aufirst%3DL.%26aulast%3DSchnitt%26aufirst%3DS.%26aulast%3DCome%26aufirst%3DS.%2BE.%26aulast%3DPusztai%26aufirst%3DL.%26aulast%3DStephens%26aufirst%3DP.%26aulast%3DBrown%26aufirst%3DM.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26atitle%3DEmergence%2520of%2520constitutively%2520active%2520estrogen%2520receptor-%25CE%25B1%2520mutations%2520in%2520pretreated%2520advanced%2520estrogen%2520receptor-positive%2520breast%2520cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2014%26volume%3D20%26issue%3D7%26spage%3D1757%26epage%3D1767%26doi%3D10.1158%2F1078-0432.CCR-13-2332" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Razavi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bandlamudi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vasan, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bielski, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donoghue, M. T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jonsson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Penson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pareja, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kundra, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Middha, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zehir, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kandoth, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huberman, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smyth, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jhaveri, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Modi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Traina, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weigelt, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ladanyi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hyman, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schultz, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robson, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hudis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brogi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viale, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norton, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dickler, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berger, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iacobuzio-Donahue, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chandarlapaty, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scaltriti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reis-Filho, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solit, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baselga, J.</span></span> <span> </span><span class="NLM_article-title">The genomic landscape of endocrine-resistant advanced breast cancers</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>34</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">427</span>– <span class="NLM_lpage">438</span>, <span class="refDoi"> DOI: 10.1016/j.ccell.2018.08.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=10.1016%2Fj.ccell.2018.08.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=30205045" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhs12ntLfM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2018&pages=427-438&issue=3&author=P.+Razaviauthor=M.+T.+Changauthor=G.+Xuauthor=C.+Bandlamudiauthor=D.+S.+Rossauthor=N.+Vasanauthor=Y.+Caiauthor=C.+M.+Bielskiauthor=M.+T.+A.+Donoghueauthor=P.+Jonssonauthor=A.+Pensonauthor=R.+Shenauthor=F.+Parejaauthor=R.+Kundraauthor=S.+Middhaauthor=M.+L.+Chengauthor=A.+Zehirauthor=C.+Kandothauthor=R.+Patelauthor=K.+Hubermanauthor=L.+M.+Smythauthor=K.+Jhaveriauthor=S.+Modiauthor=T.+A.+Trainaauthor=C.+Dangauthor=W.+Zhangauthor=B.+Weigeltauthor=B.+T.+Liauthor=M.+Ladanyiauthor=D.+M.+Hymanauthor=N.+Schultzauthor=M.+E.+Robsonauthor=C.+Hudisauthor=E.+Brogiauthor=A.+Vialeauthor=L.+Nortonauthor=M.+N.+Dicklerauthor=M.+F.+Bergerauthor=C.+A.+Iacobuzio-Donahueauthor=S.+Chandarlapatyauthor=M.+Scaltritiauthor=J.+S.+Reis-Filhoauthor=D.+B.+Solitauthor=B.+S.+Taylorauthor=J.+Baselga&title=The+genomic+landscape+of+endocrine-resistant+advanced+breast+cancers&doi=10.1016%2Fj.ccell.2018.08.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers</span></div><div class="casAuthors">Razavi, Pedram; Chang, Matthew T.; Xu, Guotai; Bandlamudi, Chaitanya; Ross, Dara S.; Vasan, Neil; Cai, Yanyan; Bielski, Craig M.; Donoghue, Mark T. A.; Jonsson, Philip; Penson, Alexander; Shen, Ronglai; Pareja, Fresia; Kundra, Ritika; Middha, Sumit; Cheng, Michael L.; Zehir, Ahmet; Kandoth, Cyriac; Patel, Ruchi; Huberman, Kety; Smyth, Lillian M.; Jhaveri, Komal; Modi, Shanu; Traina, Tiffany A.; Dang, Chau; Zhang, Wen; Weigelt, Britta; Li, Bob T.; Ladanyi, Marc; Hyman, David M.; Schultz, Nikolaus; Robson, Mark E.; Hudis, Clifford; Brogi, Edi; Viale, Agnes; Norton, Larry; Dickler, Maura N.; Berger, Michael F.; Iacobuzio-Donahue, Christine A.; Chandarlapaty, Sarat; Scaltriti, Maurizio; Reis-Filho, Jorge S.; Solit, David B.; Taylor, Barry S.; Baselga, Jose</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">427-438.e6</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">We integrated the genomic sequencing of 1,918 breast cancers, including 1,501 hormone receptor-pos. tumors, with detailed clin. information and treatment outcomes.  In 692 tumors previously exposed to hormonal therapy, we identified an increased no. of alterations in genes involved in the mitogen-activated protein kinase (MAPK) pathway and in the estrogen receptor transcriptional machinery.  Activating ERBB2 mutations and NF1 loss-of-function mutations were more than twice as common in endocrine resistant tumors.  Alterations in other MAPK pathway genes (EGFR, KRAS, among others) and estrogen receptor transcriptional regulators (MYC, CTCF, FOXA1, and TBX3) were also enriched.  Altogether, these alterations were present in 22% of tumors, mutually exclusive with ESR1 mutations, and assocd. with a shorter duration of response to subsequent hormonal therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmecqofb9RmrVg90H21EOLACvtfcHk0lh-eFyp2DGKYw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhs12ntLfM&md5=909a0b79bde44a57665f8fbbb63096c6</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2Fj.ccell.2018.08.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccell.2018.08.008%26sid%3Dliteratum%253Aachs%26aulast%3DRazavi%26aufirst%3DP.%26aulast%3DChang%26aufirst%3DM.%2BT.%26aulast%3DXu%26aufirst%3DG.%26aulast%3DBandlamudi%26aufirst%3DC.%26aulast%3DRoss%26aufirst%3DD.%2BS.%26aulast%3DVasan%26aufirst%3DN.%26aulast%3DCai%26aufirst%3DY.%26aulast%3DBielski%26aufirst%3DC.%2BM.%26aulast%3DDonoghue%26aufirst%3DM.%2BT.%2BA.%26aulast%3DJonsson%26aufirst%3DP.%26aulast%3DPenson%26aufirst%3DA.%26aulast%3DShen%26aufirst%3DR.%26aulast%3DPareja%26aufirst%3DF.%26aulast%3DKundra%26aufirst%3DR.%26aulast%3DMiddha%26aufirst%3DS.%26aulast%3DCheng%26aufirst%3DM.%2BL.%26aulast%3DZehir%26aufirst%3DA.%26aulast%3DKandoth%26aufirst%3DC.%26aulast%3DPatel%26aufirst%3DR.%26aulast%3DHuberman%26aufirst%3DK.%26aulast%3DSmyth%26aufirst%3DL.%2BM.%26aulast%3DJhaveri%26aufirst%3DK.%26aulast%3DModi%26aufirst%3DS.%26aulast%3DTraina%26aufirst%3DT.%2BA.%26aulast%3DDang%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DWeigelt%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DB.%2BT.%26aulast%3DLadanyi%26aufirst%3DM.%26aulast%3DHyman%26aufirst%3DD.%2BM.%26aulast%3DSchultz%26aufirst%3DN.%26aulast%3DRobson%26aufirst%3DM.%2BE.%26aulast%3DHudis%26aufirst%3DC.%26aulast%3DBrogi%26aufirst%3DE.%26aulast%3DViale%26aufirst%3DA.%26aulast%3DNorton%26aufirst%3DL.%26aulast%3DDickler%26aufirst%3DM.%2BN.%26aulast%3DBerger%26aufirst%3DM.%2BF.%26aulast%3DIacobuzio-Donahue%26aufirst%3DC.%2BA.%26aulast%3DChandarlapaty%26aufirst%3DS.%26aulast%3DScaltriti%26aufirst%3DM.%26aulast%3DReis-Filho%26aufirst%3DJ.%2BS.%26aulast%3DSolit%26aufirst%3DD.%2BB.%26aulast%3DTaylor%26aufirst%3DB.%2BS.%26aulast%3DBaselga%26aufirst%3DJ.%26atitle%3DThe%2520genomic%2520landscape%2520of%2520endocrine-resistant%2520advanced%2520breast%2520cancers%26jtitle%3DCancer%2520Cell%26date%3D2018%26volume%3D34%26issue%3D3%26spage%3D427%26epage%3D438%26doi%3D10.1016%2Fj.ccell.2018.08.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Osborne, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bardou, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hopp, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chamness, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hilsenbeck, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuqua, S. A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allred, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schiff, R.</span></span> <span> </span><span class="NLM_article-title">Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer</span>. <i>JNCI: J. Nat. Cancer Inst.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>95</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">353</span>– <span class="NLM_lpage">361</span>, <span class="refDoi"> DOI: 10.1093/jnci/95.5.353</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=10.1093%2Fjnci%2F95.5.353" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=12618500" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=1%3ACAS%3A528%3ADC%252BD3sXivVeqsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=2003&pages=353-361&issue=5&author=C.+K.+Osborneauthor=V.+Bardouauthor=T.+A.+Hoppauthor=G.+C.+Chamnessauthor=S.+G.+Hilsenbeckauthor=S.+A.+W.+Fuquaauthor=J.+Wongauthor=D.+C.+Allredauthor=G.+M.+Clarkauthor=R.+Schiff&title=Role+of+the+estrogen+receptor+coactivator+AIB1+%28SRC-3%29+and+HER-2%2Fneu+in+tamoxifen+resistance+in+breast+cancer&doi=10.1093%2Fjnci%2F95.5.353"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer</span></div><div class="casAuthors">Osborne, C. Kent; Bardou, Valerie; Hopp, Torsten A.; Chamness, Gary C.; Hilsenbeck, Susan G.; Fuqua, Suzanne A. W.; Wong, Jiemin; Allred, D. Craig; Clark, Gary M.; Schiff, Rachel</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the National Cancer Institute</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">95</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">353-361</span>CODEN:
                <span class="NLM_cas:coden">JNCIEQ</span>;
        ISSN:<span class="NLM_cas:issn">0027-8874</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">AIB1 (SRC-3) is an estrogen receptor (ER) coactivator that, when overexpressed in cultured cells, can reduce the antagonist activity of tamoxifen-bound ERs.  Signaling through the HER-2 receptor pathway activates AIB1 by phosphorylation.  To det. whether high AIB1 expression alone or together with HER-2 reduces the effectiveness of tamoxifen in breast cancer patients, we quantified expression of AIB1 and HER-2 in tumors from breast cancer patients with long-term clin. follow-up who received either no adjuvant therapy or adjuvant tamoxifen therapy after breast cancer surgery.  AIB1 and HER-2 protein levels in tumors from 316 breast cancer patients were detd. using western blot anal.  Mol. variables (e.g., expression of AIB1, ER, progesterone receptor, p53, Bcl-2), tumor characteristics, and patient outcome were assessed using Spearman rank correlation.  Disease-free survival (DFS) curves were derived from Kaplan-Meier ests., and the curves were compared by log-rank tests.  The effect of AIB1 on DFS adjusted for other prognostic factors was assessed by multivariable anal. using the Cox proportional hazards model.  All statistical tests were two-sided.  High AIB1 expression in patients not receiving adjuvant tamoxifen therapy was assocd. with better prognosis and longer DFS (P = .018, log-rank test).  In contrast, for patients who did receive tamoxifen therapy, high AIB1 expression was assocd. with worse DFS (P = .049, log-rank test), which is indicative of tamoxifen resistance.  The test for interaction between AIB1 expression and tamoxifen therapy was statistically significant (P = .004).  When expression of AIB1 and HER-2 were considered together, patients whose tumors expressed high levels of both AIB1 and HER-2 had worse outcomes with tamoxifen therapy than all other patients combined (P = .002, log-rank test).  The antitumor activity of tamoxifen in patients with breast cancer may be detd., in part, by tumor levels of AIB1 and HER-2.  Thus, AIB1 may be an important diagnostic and therapeutic target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoC6PAwU7VOrrVg90H21EOLACvtfcHk0lh-eFyp2DGKYw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXivVeqsrg%253D&md5=5469b2ee206ada6b884eab780a5884e4</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1093%2Fjnci%2F95.5.353&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjnci%252F95.5.353%26sid%3Dliteratum%253Aachs%26aulast%3DOsborne%26aufirst%3DC.%2BK.%26aulast%3DBardou%26aufirst%3DV.%26aulast%3DHopp%26aufirst%3DT.%2BA.%26aulast%3DChamness%26aufirst%3DG.%2BC.%26aulast%3DHilsenbeck%26aufirst%3DS.%2BG.%26aulast%3DFuqua%26aufirst%3DS.%2BA.%2BW.%26aulast%3DWong%26aufirst%3DJ.%26aulast%3DAllred%26aufirst%3DD.%2BC.%26aulast%3DClark%26aufirst%3DG.%2BM.%26aulast%3DSchiff%26aufirst%3DR.%26atitle%3DRole%2520of%2520the%2520estrogen%2520receptor%2520coactivator%2520AIB1%2520%2528SRC-3%2529%2520and%2520HER-2%252Fneu%2520in%2520tamoxifen%2520resistance%2520in%2520breast%2520cancer%26jtitle%3DJNCI%253A%2520J.%2520Nat.%2520Cancer%2520Inst.%26date%3D2003%26volume%3D95%26issue%3D5%26spage%3D353%26epage%3D361%26doi%3D10.1093%2Fjnci%2F95.5.353" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">McDonnell, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wardell, S. E.</span></span> <span> </span><span class="NLM_article-title">The molecular mechanisms underlying the pharmacological actions of ER modulators: Implications for new drug discovery in breast cancer</span>. <i>Curr. Opin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">620</span>– <span class="NLM_lpage">628</span>, <span class="refDoi"> DOI: 10.1016/j.coph.2010.09.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=10.1016%2Fj.coph.2010.09.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=20926342" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVals73P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2010&pages=620-628&issue=6&author=D.+P.+McDonnellauthor=S.+E.+Wardell&title=The+molecular+mechanisms+underlying+the+pharmacological+actions+of+ER+modulators%3A+Implications+for+new+drug+discovery+in+breast+cancer&doi=10.1016%2Fj.coph.2010.09.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10aR"><div class="casContent"><span class="casTitleNuber">10a</span><div class="casTitle"><span class="NLM_cas:atitle">The molecular mechanisms underlying the pharmacological actions of ER modulators: implications for new drug discovery in breast cancer</span></div><div class="casAuthors">McDonnell, Donald P.; Wardell, Suzanne E.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Pharmacology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">620-628</span>CODEN:
                <span class="NLM_cas:coden">COPUBK</span>;
        ISSN:<span class="NLM_cas:issn">1471-4892</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Our understanding of the mol. mechanisms underlying the pharmacol. actions of estrogen receptor (ER) ligands has evolved considerably in recent years.  Much of this knowledge has come from a detailed dissection of the mechanism(s) of action of the Selective Estrogen Receptor Modulators (SERMs) tamoxifen and raloxifene, so called for their ability to function as ER agonists or antagonists depending on the tissue in which they operate.  These mechanistic insights have had a significant impact on the discovery of second generation SERMs, some of which are in late stage clin. development for the treatment/prevention of breast cancer as well as other estrogenopathies.  In addn. to the SERMs, however, have emerged the Selective Estrogen Degraders (SERDs), which as their name suggests, interact with and facilitate ER turnover in cells.  One drug of this class, fulvestrant, has been approved as a third line treatment for ER-pos. metastatic breast cancer.  Whereas the first generation SERMs/SERDs were discovered in a serendipitous manner, this review will highlight how our understanding of the mol. pharmacol. of ER ligands has been utilized in the development of the next generation of SERMs/SERDs, some of which are likely to have a major impact on the pharmacotherapy of breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8b2l5p-n0bbVg90H21EOLACvtfcHk0li03tEyDGGMaA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVals73P&md5=24d1490ca0b0570c21e9768c9de134d6</span></div><a href="/servlet/linkout?suffix=cit10a&amp;dbid=16384&amp;doi=10.1016%2Fj.coph.2010.09.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.coph.2010.09.007%26sid%3Dliteratum%253Aachs%26aulast%3DMcDonnell%26aufirst%3DD.%2BP.%26aulast%3DWardell%26aufirst%3DS.%2BE.%26atitle%3DThe%2520molecular%2520mechanisms%2520underlying%2520the%2520pharmacological%2520actions%2520of%2520ER%2520modulators%253A%2520Implications%2520for%2520new%2520drug%2520discovery%2520in%2520breast%2520cancer%26jtitle%3DCurr.%2520Opin.%2520Pharmacol.%26date%3D2010%26volume%3D10%26issue%3D6%26spage%3D620%26epage%3D628%26doi%3D10.1016%2Fj.coph.2010.09.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit10b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Shagufta</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmad, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathew, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahman, S.</span></span> <span> </span><span class="NLM_article-title">Recent progress in selective estrogen receptor downregulators (SERDs) for the treatment of breast cancer</span>. <i>RSC Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">438</span>– <span class="NLM_lpage">454</span>, <span class="refDoi"> DOI: 10.1039/C9MD00570F</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=10.1039%2FC9MD00570F" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=1%3ACAS%3A528%3ADC%252BB3cXktl2qsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2020&pages=438-454&issue=4&author=+Shaguftaauthor=I.+Ahmadauthor=S.+Mathewauthor=S.+Rahman&title=Recent+progress+in+selective+estrogen+receptor+downregulators+%28SERDs%29+for+the+treatment+of+breast+cancer&doi=10.1039%2FC9MD00570F"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10bR"><div class="casContent"><span class="casTitleNuber">10b</span><div class="casTitle"><span class="NLM_cas:atitle">Recent progress in selective estrogen receptor downregulators (SERDs) for the treatment of breast cancer</span></div><div class="casAuthors">Shagufta; Ahmad, Irshad; Mathew, Shimy; Rahman, Sofia</div><div class="citationInfo"><span class="NLM_cas:title">RSC Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">438-454</span>CODEN:
                <span class="NLM_cas:coden">RMCSEZ</span>;
        ISSN:<span class="NLM_cas:issn">2632-8682</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Selective estrogen receptor downregulators (SERDs) are a novel class of compds. capable of reducing the ERα protein level and blocking ER activity.  Therefore, SERDs are considered as a significant therapeutic approach to treat ER+ breast cancer in both early stage and more advanced drug-resistant cases.  After the FDA approval of a steroidal drug, fulvestrant, as a SERD for the treatment of breast cancer in patients who have progressed on antihormonal agents, several mols. with diverse chem. structures have been rapidly developed, studied and evaluated for selective estrogen receptor downregulation activity.  Here we compile the promising SERDs reported in recent years and discuss the chem. structure and pharmacol. profile of the most potent compd. of the considered series.  Because of the availability of only a limited no. of effective drugs for the treatment of breast cancer, the quest for a potent SERD with respectable activity and bioavailability is still ongoing.  The goal of this article is to make available to the reader an overview of the current progress in SERDs and provide clues for the future discovery and development of novel pharmacol. potent SERDs for the treatment of breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSZ-tHcNc5-LVg90H21EOLACvtfcHk0li03tEyDGGMaA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXktl2qsrY%253D&md5=73ad3f6be94f660cf47b13146781aa04</span></div><a href="/servlet/linkout?suffix=cit10b&amp;dbid=16384&amp;doi=10.1039%2FC9MD00570F&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC9MD00570F%26sid%3Dliteratum%253Aachs%26aulast%3DShagufta%26aulast%3DAhmad%26aufirst%3DI.%26aulast%3DMathew%26aufirst%3DS.%26aulast%3DRahman%26aufirst%3DS.%26atitle%3DRecent%2520progress%2520in%2520selective%2520estrogen%2520receptor%2520downregulators%2520%2528SERDs%2529%2520for%2520the%2520treatment%2520of%2520breast%2520cancer%26jtitle%3DRSC%2520Med.%2520Chem.%26date%3D2020%26volume%3D11%26issue%3D4%26spage%3D438%26epage%3D454%26doi%3D10.1039%2FC9MD00570F" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wakeling, A. E.</span></span> <span> </span><span class="NLM_article-title">Similarities and distinctions in the mode of action of different classes of antioestrogens</span>. <i>Endocr.-Relat. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">17</span>– <span class="NLM_lpage">28</span>, <span class="refDoi"> DOI: 10.1677/erc.0.0070017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=10.1677%2Ferc.0.0070017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=10808193" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=1%3ACAS%3A528%3ADC%252BD3cXktVyjs7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2000&pages=17-28&issue=1&author=A.+E.+Wakeling&title=Similarities+and+distinctions+in+the+mode+of+action+of+different+classes+of+antioestrogens&doi=10.1677%2Ferc.0.0070017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Similarities and distinctions in the mode of action of different classes of antioestrogens</span></div><div class="casAuthors">Wakeling, A. E.</div><div class="citationInfo"><span class="NLM_cas:title">Endocrine-Related Cancer</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">17-28</span>CODEN:
                <span class="NLM_cas:coden">ERCAE9</span>;
        ISSN:<span class="NLM_cas:issn">1351-0088</span>.
    
            (<span class="NLM_cas:orgname">Society for Endocrinology</span>)
        </div><div class="casAbstract">A review with ∼150 refs. on the title topic with focus on the mechanism of action of the pure antiestrogens, ICI 164384 and ICI 182780, in relation to tamoxifen and the SERMs (selective estrogen receptor modulators).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrME0CIZC-EFLVg90H21EOLACvtfcHk0liHLdGuRfyMhQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXktVyjs7k%253D&md5=13a3e6367adf76dba16465e78bfe6d1b</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1677%2Ferc.0.0070017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1677%252Ferc.0.0070017%26sid%3Dliteratum%253Aachs%26aulast%3DWakeling%26aufirst%3DA.%2BE.%26atitle%3DSimilarities%2520and%2520distinctions%2520in%2520the%2520mode%2520of%2520action%2520of%2520different%2520classes%2520of%2520antioestrogens%26jtitle%3DEndocr.-Relat.%2520Cancer%26date%3D2000%26volume%3D7%26issue%3D1%26spage%3D17%26epage%3D28%26doi%3D10.1677%2Ferc.0.0070017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Robertson, J. F. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bondarenko, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trishkina, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dvorkin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panasci, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manikhas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shparyk, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cardona-Huerta, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheung, K.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Philco-Salas, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruiz-Borrego, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noguchi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowbottom, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stuart, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grinsted, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fazal, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellis, M. J.</span></span> <span> </span><span class="NLM_article-title">Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>388</i></span> (<span class="NLM_issue">10063</span>),  <span class="NLM_fpage">2997</span>– <span class="NLM_lpage">3005</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(16)32389-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=10.1016%2FS0140-6736%2816%2932389-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=27908454" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFKnurnK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=388&publication_year=2016&pages=2997-3005&issue=10063&author=J.+F.+R.+Robertsonauthor=I.+M.+Bondarenkoauthor=E.+Trishkinaauthor=M.+Dvorkinauthor=L.+Panasciauthor=A.+Manikhasauthor=Y.+Shparykauthor=S.+Cardona-Huertaauthor=K.-L.+Cheungauthor=M.+J.+Philco-Salasauthor=M.+Ruiz-Borregoauthor=Z.+Shaoauthor=S.+Noguchiauthor=J.+Rowbottomauthor=M.+Stuartauthor=L.+M.+Grinstedauthor=M.+Fazalauthor=M.+J.+Ellis&title=Fulvestrant+500+mg+versus+anastrozole+1+mg+for+hormone+receptor-positive+advanced+breast+cancer+%28FALCON%29%3A+an+international%2C+randomised%2C+double-blind%2C+phase+3+trial&doi=10.1016%2FS0140-6736%2816%2932389-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial</span></div><div class="casAuthors">Robertson, John F. R.; Bondarenko, Igor M.; Trishkina, Ekaterina; Dvorkin, Mikhail; Panasci, Lawrence; Manikhas, Alexey; Shparyk, Yaroslav; Cardona-Huerta, Servando; Cheung, Kwok-Leung; Philco-Salas, Manuel Jesus; Ruiz-Borrego, Manuel; Shao, Zhimin; Noguchi, Shinzaburo; Rowbottom, Jacqui; Stuart, Mary; Grinsted, Lynda M.; Fazal, Mehdi; Ellis, Matthew J.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">388</span>
        (<span class="NLM_cas:issue">10063</span>),
    <span class="NLM_cas:pages">2997-3005</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Aromatase inhibitors are a std. of care for hormone receptor-pos. locally advanced or metastatic breast cancer.  We investigated whether the selective estrogen receptor degrader fulvestrant could improve progression-free survival compared with anastrozole in postmenopausal patients who had not received previous endocrine therapy.  In this phase 3, randomised, double-blind trial, we recruited eligible patients with histol. confirmed estrogen receptor-pos. or progesterone receptor-pos., or both, locally advanced or metastatic breast cancer from 113 academic hospitals and community centers in 20 countries.  Eligible patients were endocrine therapy-naive, with WHO performance status 0-2, and at least one measurable or non-measurable lesion.  Patients were randomly assigned (1:1) to fulvestrant (500 mg i.m. injection; on days 0, 14, 28, then every 28 days thereafter) or anastrozole (1 mg orally daily) using a computer-generated randomisation scheme.  The primary endpoint was progression-free survival, detd. by Response Evaluation Criteria in Solid Tumors version 1·1, intervention by surgery or radiotherapy because of disease deterioration, or death from any cause, assessed in the intention-to-treat population.  Safety outcomes were assessed in all patients who received at least one dose of randomised treatment (including placebo).  This trial is registered with ClinicalTrials.gov, no. NCT01602380.  Between Oct 17, 2012, and July 11, 2014, 524 patients were enrolled to this study.  Of these, 462 patients were randomised (230 to receive fulvestrant and 232 to receive anastrozole).  Progression-free survival was significantly longer in the fulvestrant group than in the anastrozole group (hazard ratio [HR] 0·797, 95% CI 0·637-0·999, p=0·0486).  Median progression-free survival was 16·6 mo (95% CI 13·83-20·99) in the fulvestrant group vs. 13·8 mo (11·99-16·59) in the anastrozole group.  The most common adverse events were arthralgia (38 [17%] in the fulvestrant group vs 24 [10%] in the anastrozole group) and hot flushes (26 [11%] in the fulvestrant group vs 24 [10%] in the anastrozole group). 16 (7%) of 228 patients in in the fulvestrant group and 11 (5%) of 232 patients in the anastrozole group discontinued because of adverse events.  Fulvestrant has superior efficacy and is a preferred treatment option for patients with hormone receptor-pos. locally advanced or metastatic breast cancer who have not received previous endocrine therapy compared with a third-generation aromatase inhibitor, a std. of care for first-line treatment of these patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGry16EI3NgNOLVg90H21EOLACvtfcHk0liHLdGuRfyMhQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFKnurnK&md5=7d8295fdf38fc5eb5720a7d3cd97d6e9</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2816%2932389-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252816%252932389-3%26sid%3Dliteratum%253Aachs%26aulast%3DRobertson%26aufirst%3DJ.%2BF.%2BR.%26aulast%3DBondarenko%26aufirst%3DI.%2BM.%26aulast%3DTrishkina%26aufirst%3DE.%26aulast%3DDvorkin%26aufirst%3DM.%26aulast%3DPanasci%26aufirst%3DL.%26aulast%3DManikhas%26aufirst%3DA.%26aulast%3DShparyk%26aufirst%3DY.%26aulast%3DCardona-Huerta%26aufirst%3DS.%26aulast%3DCheung%26aufirst%3DK.-L.%26aulast%3DPhilco-Salas%26aufirst%3DM.%2BJ.%26aulast%3DRuiz-Borrego%26aufirst%3DM.%26aulast%3DShao%26aufirst%3DZ.%26aulast%3DNoguchi%26aufirst%3DS.%26aulast%3DRowbottom%26aufirst%3DJ.%26aulast%3DStuart%26aufirst%3DM.%26aulast%3DGrinsted%26aufirst%3DL.%2BM.%26aulast%3DFazal%26aufirst%3DM.%26aulast%3DEllis%26aufirst%3DM.%2BJ.%26atitle%3DFulvestrant%2520500%2520mg%2520versus%2520anastrozole%25201%2520mg%2520for%2520hormone%2520receptor-positive%2520advanced%2520breast%2520cancer%2520%2528FALCON%2529%253A%2520an%2520international%252C%2520randomised%252C%2520double-blind%252C%2520phase%25203%2520trial%26jtitle%3DLancet%26date%3D2016%26volume%3D388%26issue%3D10063%26spage%3D2997%26epage%3D3005%26doi%3D10.1016%2FS0140-6736%2816%2932389-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Robertson, J.</span></span> <span> </span><span class="NLM_article-title">Fulvestrant (Faslodex<sup>®</sup>) – How to make a good drug better</span>. <i>Oncologist</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">774</span>– <span class="NLM_lpage">784</span>, <span class="refDoi"> DOI: 10.1634/theoncologist.12-7-774</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=10.1634%2Ftheoncologist.12-7-774" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=17673609" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=1%3ACAS%3A528%3ADC%252BD2sXpslertbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2007&pages=774-784&issue=7&author=J.+Robertson&title=Fulvestrant+%28Faslodex%C2%AE%29+%E2%80%93+How+to+make+a+good+drug+better&doi=10.1634%2Ftheoncologist.12-7-774"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Fulvestrant (Faslodex)-how to make a good drug better</span></div><div class="casAuthors">Robertson, John F. R.</div><div class="citationInfo"><span class="NLM_cas:title">Oncologist</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">774-784</span>CODEN:
                <span class="NLM_cas:coden">OCOLF6</span>;
        ISSN:<span class="NLM_cas:issn">1083-7159</span>.
    
            (<span class="NLM_cas:orgname">AlphaMed Press</span>)
        </div><div class="casAbstract">A review.  Fulvestrant (Faslodex; AstraZeneca Pharmaceuticals, Wilmington, DE) is an estrogen receptor (ER) antagonist with a novel mode of action; it binds, blocks, and increases degrdn. of ER.  Fulvestrant (at the approved dose [250 mg/mo]) is at least as effective as anastrozole (1 mg/day) in the treatment of postmenopausal women with hormone receptor-pos. advanced breast cancer (HR+ ABC) progressing or recurring on antiestrogen therapy, and is also an active first-line treatment.  Although fulvestrant (250 mg/mo) is clearly effective, it takes 3-6 mo to achieve steady-state plasma levels.  Steady-state concns. are approx. twofold higher than those achieved with a single dose; reaching this earlier, for example, via a loading-dose (LD) regimen (250 mg/mo plus 500 mg on day 0 and 250 mg on day 14 of month 1), may allow responses to be achieved more quickly and limit the possibility of early relapse.  Fulvestrant high-dose (HD) regimens (500 mg/mo) offer the possibility of greater antitumor activity, because (a) ER downregulation is a dose-dependent process (an approx. 70% redn. is obsd. with a single 250 mg dose of fulvestrant) and (b) evidence correlates greater ER downregulation with superior efficacy.  A fulvestrant HD regimen offers the potential of achieving near 100% ER downregulation.  There is also potential to increase fulvestrant-ER binding by reducing plasma estrogen levels, for example, with concomitant aromatase inhibitor treatment.  Several ongoing trials use LD, HD, and combination regimens; results from these studies are awaited with interest.  Meanwhile, fulvestrant (250 mg/mo) remains a valuable addnl. endocrine treatment for postmenopausal women with HR+ ABC recurring or progressing on antiestrogen therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxuzoAnKMBfLVg90H21EOLACvtfcHk0ljeAeuyONlbxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXpslertbg%253D&md5=25f69688f5819c7883f408ad74642058</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1634%2Ftheoncologist.12-7-774&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1634%252Ftheoncologist.12-7-774%26sid%3Dliteratum%253Aachs%26aulast%3DRobertson%26aufirst%3DJ.%26atitle%3DFulvestrant%2520%2528Faslodex%25C2%25AE%2529%2520%25E2%2580%2593%2520How%2520to%2520make%2520a%2520good%2520drug%2520better%26jtitle%3DOncologist%26date%3D2007%26volume%3D12%26issue%3D7%26spage%3D774%26epage%3D784%26doi%3D10.1634%2Ftheoncologist.12-7-774" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kahraman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Govek, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagasawa, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonnefous, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Julien, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Douglas, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sensintaffar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aparicio, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaufman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prudente, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moon, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joseph, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darimont, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brigham, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grillot, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heyman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rix, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hager, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, N. D.</span></span> <span> </span><span class="NLM_article-title">Identification of GDC-0810 (ARN-810), an orally bioavailable selective estrogen receptor degrader (SERD) that demonstrates robust activity in tamoxifen-resistant breast cancer xenografts</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">4888</span>– <span class="NLM_lpage">4904</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00054</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00054" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref14/cit14a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=1%3ACAS%3A528%3ADC%252BC2MXmsFyisb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=4888-4904&issue=12&author=A.+Laiauthor=M.+Kahramanauthor=S.+Govekauthor=J.+Nagasawaauthor=C.+Bonnefousauthor=J.+Julienauthor=K.+Douglasauthor=J.+Sensintaffarauthor=N.+Luauthor=K.-J.+Leeauthor=A.+Aparicioauthor=J.+Kaufmanauthor=J.+Qianauthor=G.+Shaoauthor=R.+Prudenteauthor=M.+J.+Moonauthor=J.+D.+Josephauthor=B.+Darimontauthor=D.+Brighamauthor=K.+Grillotauthor=R.+Heymanauthor=P.+J.+Rixauthor=J.+H.+Hagerauthor=N.+D.+Smith&title=Identification+of+GDC-0810+%28ARN-810%29%2C+an+orally+bioavailable+selective+estrogen+receptor+degrader+%28SERD%29+that+demonstrates+robust+activity+in+tamoxifen-resistant+breast+cancer+xenografts&doi=10.1021%2Facs.jmedchem.5b00054"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14aR"><div class="casContent"><span class="casTitleNuber">14a</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts</span></div><div class="casAuthors">Lai, Andiliy; Kahraman, Mehmet; Govek, Steven; Nagasawa, Johnny; Bonnefous, Celine; Julien, Jackie; Douglas, Karensa; Sensintaffar, John; Lu, Nhin; Lee, Kyoung-jin; Aparicio, Anna; Kaufman, Josh; Qian, Jing; Shao, Gang; Prudente, Rene; Moon, Michael J.; Joseph, James D.; Darimont, Beatrice; Brigham, Daniel; Grillot, Kate; Heyman, Richard; Rix, Peter J.; Hager, Jeffrey H.; Smith, Nicholas D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">4888-4904</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Approx. 80% of breast cancers are estrogen receptor alpha (ER-α) pos., and although women typically initially respond well to antihormonal therapies such as tamoxifen and aromatase inhibitors, resistance often emerges.  Although a variety of resistance mechanism may be at play in this state, there is evidence that in many cases the ER still plays a central role, including mutations in the ER leading to constitutively active receptor.  Fulvestrant is a steroid-based, selective estrogen receptor degrader (SERD) that both antagonizes and degrades ER-α and is active in patients who have progressed on antihormonal agents.  However, fulvestrant suffers from poor pharmaceutical properties and must be administered by i.m. injections that limit the total amt. of drug that can be administered and hence lead to the potential for incomplete receptor blockade.  The authors describe the identification and characterization of a series of small-mol., orally bioavailable SERDs which are potent antagonists and degraders of ER-α and in which the ER-α degrading properties were prospectively optimized.  The lead compd. I (GDC-0810 or ARN-810) demonstrates robust activity in models of tamoxifen-sensitive and tamoxifen-resistant breast cancer, and is currently in clin. trials in women with locally advanced or metastatic estrogen receptor-pos. breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOegJFz-sqwbVg90H21EOLACvtfcHk0ljeAeuyONlbxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXmsFyisb4%253D&md5=e836ec4d593ce6ed2d9622da5cd898e6</span></div><a href="/servlet/linkout?suffix=cit14a&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00054&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00054%26sid%3Dliteratum%253Aachs%26aulast%3DLai%26aufirst%3DA.%26aulast%3DKahraman%26aufirst%3DM.%26aulast%3DGovek%26aufirst%3DS.%26aulast%3DNagasawa%26aufirst%3DJ.%26aulast%3DBonnefous%26aufirst%3DC.%26aulast%3DJulien%26aufirst%3DJ.%26aulast%3DDouglas%26aufirst%3DK.%26aulast%3DSensintaffar%26aufirst%3DJ.%26aulast%3DLu%26aufirst%3DN.%26aulast%3DLee%26aufirst%3DK.-J.%26aulast%3DAparicio%26aufirst%3DA.%26aulast%3DKaufman%26aufirst%3DJ.%26aulast%3DQian%26aufirst%3DJ.%26aulast%3DShao%26aufirst%3DG.%26aulast%3DPrudente%26aufirst%3DR.%26aulast%3DMoon%26aufirst%3DM.%2BJ.%26aulast%3DJoseph%26aufirst%3DJ.%2BD.%26aulast%3DDarimont%26aufirst%3DB.%26aulast%3DBrigham%26aufirst%3DD.%26aulast%3DGrillot%26aufirst%3DK.%26aulast%3DHeyman%26aufirst%3DR.%26aulast%3DRix%26aufirst%3DP.%2BJ.%26aulast%3DHager%26aufirst%3DJ.%2BH.%26aulast%3DSmith%26aufirst%3DN.%2BD.%26atitle%3DIdentification%2520of%2520GDC-0810%2520%2528ARN-810%2529%252C%2520an%2520orally%2520bioavailable%2520selective%2520estrogen%2520receptor%2520degrader%2520%2528SERD%2529%2520that%2520demonstrates%2520robust%2520activity%2520in%2520tamoxifen-resistant%2520breast%2520cancer%2520xenografts%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26issue%3D12%26spage%3D4888%26epage%3D4904%26doi%3D10.1021%2Facs.jmedchem.5b00054" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit14b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Govek, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagasawa, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Douglas, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kahraman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonnefous, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aparicio, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darimont, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grillot, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joseph, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaufman, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moon, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prudente, R. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sensintaffar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rix, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hager, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, N. D.</span></span> <span> </span><span class="NLM_article-title">Optimization of an indazole series of selective estrogen receptor degraders: tumor regression in a tamoxifen-resistant breast cancer xenograft</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>25</i></span> (<span class="NLM_issue">22</span>),  <span class="NLM_fpage">5163</span>– <span class="NLM_lpage">5167</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2015.09.074</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=10.1016%2Fj.bmcl.2015.09.074" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=26463130" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhs1GksbrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=5163-5167&issue=22&author=S.+P.+Govekauthor=J.+Y.+Nagasawaauthor=K.+L.+Douglasauthor=A.+G.+Laiauthor=M.+Kahramanauthor=C.+Bonnefousauthor=A.+M.+Aparicioauthor=B.+D.+Darimontauthor=K.+L.+Grillotauthor=J.+D.+Josephauthor=J.+A.+Kaufmanauthor=K.-J.+Leeauthor=N.+Luauthor=M.+J.+Moonauthor=R.+Y.+Prudenteauthor=J.+Sensintaffarauthor=P.+J.+Rixauthor=J.+H.+Hagerauthor=N.+D.+Smith&title=Optimization+of+an+indazole+series+of+selective+estrogen+receptor+degraders%3A+tumor+regression+in+a+tamoxifen-resistant+breast+cancer+xenograft&doi=10.1016%2Fj.bmcl.2015.09.074"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14bR"><div class="casContent"><span class="casTitleNuber">14b</span><div class="casTitle"><span class="NLM_cas:atitle">Optimization of an indazole series of selective estrogen receptor degraders: Tumor regression in a tamoxifen-resistant breast cancer xenograft</span></div><div class="casAuthors">Govek, Steven P.; Nagasawa, Johnny Y.; Douglas, Karensa L.; Lai, Andiliy G.; Kahraman, Mehmet; Bonnefous, Celine; Aparicio, Anna M.; Darimont, Beatrice D.; Grillot, Katherine L.; Joseph, James D.; Kaufman, Joshua A.; Lee, Kyoung-Jin; Lu, Nhin; Moon, Michael J.; Prudente, Rene Y.; Sensintaffar, John; Rix, Peter J.; Hager, Jeffrey H.; Smith, Nicholas D.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">5163-5167</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Selective estrogen receptor degraders (SERDs) have shown promise for the treatment of ER+ breast cancer.  Disclosed herein is the continued optimization of the authors' indazole series of SERDs.  Exploration of ER degrdn. and antagonism in vitro followed by in vivo antagonism and oral exposure culminated in the discovery of indazoles (I) and (II), which induce tumor regression in a tamoxifen-resistant breast cancer xenograft.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6i7tfU3k5frVg90H21EOLACvtfcHk0ljld5oxd2bwuA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhs1GksbrI&md5=fc890bcabc5f84fce015d50bae14c2b6</span></div><a href="/servlet/linkout?suffix=cit14b&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.09.074&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.09.074%26sid%3Dliteratum%253Aachs%26aulast%3DGovek%26aufirst%3DS.%2BP.%26aulast%3DNagasawa%26aufirst%3DJ.%2BY.%26aulast%3DDouglas%26aufirst%3DK.%2BL.%26aulast%3DLai%26aufirst%3DA.%2BG.%26aulast%3DKahraman%26aufirst%3DM.%26aulast%3DBonnefous%26aufirst%3DC.%26aulast%3DAparicio%26aufirst%3DA.%2BM.%26aulast%3DDarimont%26aufirst%3DB.%2BD.%26aulast%3DGrillot%26aufirst%3DK.%2BL.%26aulast%3DJoseph%26aufirst%3DJ.%2BD.%26aulast%3DKaufman%26aufirst%3DJ.%2BA.%26aulast%3DLee%26aufirst%3DK.-J.%26aulast%3DLu%26aufirst%3DN.%26aulast%3DMoon%26aufirst%3DM.%2BJ.%26aulast%3DPrudente%26aufirst%3DR.%2BY.%26aulast%3DSensintaffar%26aufirst%3DJ.%26aulast%3DRix%26aufirst%3DP.%2BJ.%26aulast%3DHager%26aufirst%3DJ.%2BH.%26aulast%3DSmith%26aufirst%3DN.%2BD.%26atitle%3DOptimization%2520of%2520an%2520indazole%2520series%2520of%2520selective%2520estrogen%2520receptor%2520degraders%253A%2520tumor%2520regression%2520in%2520a%2520tamoxifen-resistant%2520breast%2520cancer%2520xenograft%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D25%26issue%3D22%26spage%3D5163%26epage%3D5167%26doi%3D10.1016%2Fj.bmcl.2015.09.074" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De
Savi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradbury, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabow, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norman, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Almeida, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballard, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buttar, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Callis, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Currie, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curwen, J. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donald, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feron, L. J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gingell, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glossop, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayter, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hussain, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karoutchi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamont, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacFaul, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moss, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pearson, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tonge, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weir, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, Z.</span></span> <span> </span><span class="NLM_article-title">Optimization of a novel binding motif to (<i>E</i>)-3-(3,5-difluoro-4-((1<i>R</i>,3<i>R</i>)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-<i>b</i>]indol-1-yl)phenyl)acrylic acid (AZD9496), a potent and orally bioavailable selective estrogen receptor downregulator and antagonist</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span> (<span class="NLM_issue">20</span>),  <span class="NLM_fpage">8128</span>– <span class="NLM_lpage">8140</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00984</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00984" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsFKiu7fK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=8128-8140&issue=20&author=C.+De%0ASaviauthor=R.+H.+Bradburyauthor=A.+A.+Rabowauthor=R.+A.+Normanauthor=C.+de+Almeidaauthor=D.+M.+Andrewsauthor=P.+Ballardauthor=D.+Buttarauthor=R.+J.+Callisauthor=G.+S.+Currieauthor=J.+O.+Curwenauthor=C.+D.+Daviesauthor=C.+S.+Donaldauthor=L.+J.+L.+Feronauthor=H.+Gingellauthor=S.+C.+Glossopauthor=B.+R.+Hayterauthor=S.+Hussainauthor=G.+Karoutchiauthor=S.+G.+Lamontauthor=P.+MacFaulauthor=T.+A.+Mossauthor=S.+E.+Pearsonauthor=M.+Tongeauthor=G.+E.+Walkerauthor=H.+M.+Weirauthor=Z.+Wilson&title=Optimization+of+a+novel+binding+motif+to+%28E%29-3-%283%2C5-difluoro-4-%28%281R%2C3R%29-2-%282-fluoro-2-methylpropyl%29-3-methyl-2%2C3%2C4%2C9-tetrahydro-1H-pyrido%5B3%2C4-b%5Dindol-1-yl%29phenyl%29acrylic+acid+%28AZD9496%29%2C+a+potent+and+orally+bioavailable+selective+estrogen+receptor+downregulator+and+antagonist&doi=10.1021%2Facs.jmedchem.5b00984"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Optimization of a Novel Binding Motif to (E)-3-(3,5-Difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic Acid (AZD9496), a Potent and Orally Bioavailable Selective Estrogen Receptor Downregulator and Antagonist</span></div><div class="casAuthors">De Savi, Chris; Bradbury, Robert H.; Rabow, Alfred A.; Norman, Richard A.; de Almeida, Camila; Andrews, David M.; Ballard, Peter; Buttar, David; Callis, Rowena J.; Currie, Gordon S.; Curwen, Jon O.; Davies, Chris D.; Donald, Craig S.; Feron, Lyman J. L.; Gingell, Helen; Glossop, Steven C.; Hayter, Barry R.; Hussain, Syeed; Karoutchi, Galith; Lamont, Scott G.; MacFaul, Philip; Moss, Thomas A.; Pearson, Stuart E.; Tonge, Michael; Walker, Graeme E.; Weir, Hazel M.; Wilson, Zena</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">8128-8140</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The discovery of an orally bioavailable selective estrogen receptor downregulator (SERD) with equiv. potency and preclin. pharmacol. to the i.m. SERD fulvestrant is described.  A directed screen identified the 1-aryl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole motif as a novel, druglike ER ligand.  Aided by crystal structures of novel ligands bound to an ER construct, medicinal chem. iterations led to (E)-3-(3,5-difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic acid (30b, AZD9496), a clin. candidate with high oral bioavailability across preclin. species that is currently being evaluated in phase I clin. trials for the treatment of advanced estrogen receptor (ER) pos. breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpP-ZYYxmMtg7Vg90H21EOLACvtfcHk0lhtoLSp5JpRMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsFKiu7fK&md5=df7eee70ca783a2933cd494b53f71488</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00984&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00984%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BSavi%26aufirst%3DC.%26aulast%3DBradbury%26aufirst%3DR.%2BH.%26aulast%3DRabow%26aufirst%3DA.%2BA.%26aulast%3DNorman%26aufirst%3DR.%2BA.%26aulast%3Dde%2BAlmeida%26aufirst%3DC.%26aulast%3DAndrews%26aufirst%3DD.%2BM.%26aulast%3DBallard%26aufirst%3DP.%26aulast%3DButtar%26aufirst%3DD.%26aulast%3DCallis%26aufirst%3DR.%2BJ.%26aulast%3DCurrie%26aufirst%3DG.%2BS.%26aulast%3DCurwen%26aufirst%3DJ.%2BO.%26aulast%3DDavies%26aufirst%3DC.%2BD.%26aulast%3DDonald%26aufirst%3DC.%2BS.%26aulast%3DFeron%26aufirst%3DL.%2BJ.%2BL.%26aulast%3DGingell%26aufirst%3DH.%26aulast%3DGlossop%26aufirst%3DS.%2BC.%26aulast%3DHayter%26aufirst%3DB.%2BR.%26aulast%3DHussain%26aufirst%3DS.%26aulast%3DKaroutchi%26aufirst%3DG.%26aulast%3DLamont%26aufirst%3DS.%2BG.%26aulast%3DMacFaul%26aufirst%3DP.%26aulast%3DMoss%26aufirst%3DT.%2BA.%26aulast%3DPearson%26aufirst%3DS.%2BE.%26aulast%3DTonge%26aufirst%3DM.%26aulast%3DWalker%26aufirst%3DG.%2BE.%26aulast%3DWeir%26aufirst%3DH.%2BM.%26aulast%3DWilson%26aufirst%3DZ.%26atitle%3DOptimization%2520of%2520a%2520novel%2520binding%2520motif%2520to%2520%2528E%2529-3-%25283%252C5-difluoro-4-%2528%25281R%252C3R%2529-2-%25282-fluoro-2-methylpropyl%2529-3-methyl-2%252C3%252C4%252C9-tetrahydro-1H-pyrido%255B3%252C4-b%255Dindol-1-yl%2529phenyl%2529acrylic%2520acid%2520%2528AZD9496%2529%252C%2520a%2520potent%2520and%2520orally%2520bioavailable%2520selective%2520estrogen%2520receptor%2520downregulator%2520and%2520antagonist%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26issue%3D20%26spage%3D8128%26epage%3D8140%26doi%3D10.1021%2Facs.jmedchem.5b00984" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tria, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abrams, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baird, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burks, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Firestone, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaither, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamann, L. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirby, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lombardo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macchi, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonnell, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mishina, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norris, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nunez, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Springer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomsen, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tiong-Yip, C.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peukert, S.</span></span> <span> </span><span class="NLM_article-title">Discovery of LSZ102, a potent, orally bioavailable selective estrogen receptor degrader (SERD) for the treatment of estrogen receptor positive breast cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">2837</span>– <span class="NLM_lpage">2864</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01682</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01682" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=1%3ACAS%3A528%3ADC%252BC1cXltFynurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=2837-2864&issue=7&author=G.+S.+Triaauthor=T.+Abramsauthor=J.+Bairdauthor=H.+E.+Burksauthor=B.+Firestoneauthor=L.+A.+Gaitherauthor=L.+G.+Hamannauthor=G.+Heauthor=C.+A.+Kirbyauthor=S.+Kimauthor=F.+Lombardoauthor=K.+J.+Macchiauthor=D.+P.+McDonnellauthor=Y.+Mishinaauthor=J.+D.+Norrisauthor=J.+Nunezauthor=C.+Springerauthor=Y.+Sunauthor=N.+M.+Thomsenauthor=C.+Wangauthor=J.+Wangauthor=B.+Yuauthor=C.-L.+Tiong-Yipauthor=S.+Peukert&title=Discovery+of+LSZ102%2C+a+potent%2C+orally+bioavailable+selective+estrogen+receptor+degrader+%28SERD%29+for+the+treatment+of+estrogen+receptor+positive+breast+cancer&doi=10.1021%2Facs.jmedchem.7b01682"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of LSZ102, a Potent, Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) for the Treatment of Estrogen Receptor Positive Breast Cancer</span></div><div class="casAuthors">Tria, George S.; Abrams, Tinya; Baird, Jason; Burks, Heather E.; Firestone, Brant; Gaither, L. Alex; Hamann, Lawrence G.; He, Guo; Kirby, Christina A.; Kim, Sunkyu; Lombardo, Franco; Macchi, Kaitlin J.; McDonnell, Donald P.; Mishina, Yuji; Norris, John D.; Nunez, Jill; Springer, Clayton; Sun, Yingchuan; Thomsen, Noel M.; Wang, Chunrong; Wang, Jianling; Yu, Bing; Tiong-Yip, Choi-Lai; Peukert, Stefan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2837-2864</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In breast cancer, estrogen receptor alpha (ERα) pos. cancer accounts for approx. 74% of all diagnoses, and in these settings, it is a primary driver of cell proliferation.  Treatment of ERα pos. breast cancer has long relied on endocrine therapies such as selective estrogen receptor modulators, aromatase inhibitors, and selective estrogen receptor degraders (SERDs).  The steroid-based anti-estrogen fulvestrant, the only approved SERD, is effective in patients who have not previously been treated with endocrine therapy as well as in patients who have progressed after receiving other endocrine therapies.  Its efficacy, however, may be limited due to its poor physicochem. properties.  THe authors describe the design and synthesis of a series of potent benzothiophene-contg. compds. that exhibit oral bioavailability and preclin. activity as SERDs.  This article culminates in the identification of LSZ102 (I), a compd. in clin. development for the treatment of ERα pos. breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcHgOrWwlRvrVg90H21EOLACvtfcHk0lhtoLSp5JpRMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXltFynurc%253D&md5=dba954f9f11121fae1bb50979428a83b</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01682&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01682%26sid%3Dliteratum%253Aachs%26aulast%3DTria%26aufirst%3DG.%2BS.%26aulast%3DAbrams%26aufirst%3DT.%26aulast%3DBaird%26aufirst%3DJ.%26aulast%3DBurks%26aufirst%3DH.%2BE.%26aulast%3DFirestone%26aufirst%3DB.%26aulast%3DGaither%26aufirst%3DL.%2BA.%26aulast%3DHamann%26aufirst%3DL.%2BG.%26aulast%3DHe%26aufirst%3DG.%26aulast%3DKirby%26aufirst%3DC.%2BA.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DLombardo%26aufirst%3DF.%26aulast%3DMacchi%26aufirst%3DK.%2BJ.%26aulast%3DMcDonnell%26aufirst%3DD.%2BP.%26aulast%3DMishina%26aufirst%3DY.%26aulast%3DNorris%26aufirst%3DJ.%2BD.%26aulast%3DNunez%26aufirst%3DJ.%26aulast%3DSpringer%26aufirst%3DC.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DThomsen%26aufirst%3DN.%2BM.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DYu%26aufirst%3DB.%26aulast%3DTiong-Yip%26aufirst%3DC.-L.%26aulast%3DPeukert%26aufirst%3DS.%26atitle%3DDiscovery%2520of%2520LSZ102%252C%2520a%2520potent%252C%2520orally%2520bioavailable%2520selective%2520estrogen%2520receptor%2520degrader%2520%2528SERD%2529%2520for%2520the%2520treatment%2520of%2520estrogen%2520receptor%2520positive%2520breast%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26issue%3D7%26spage%3D2837%26epage%3D2864%26doi%3D10.1021%2Facs.jmedchem.7b01682" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Xiong, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gutgesell, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karumudi, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tonetti, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thatcher, G. R. J.</span></span> <span> </span><span class="NLM_article-title">Novel selective estrogen receptor downregulators (SERDs) developed against treatment-resistant breast cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">1325</span>– <span class="NLM_lpage">1342</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01355</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01355" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref17/cit17a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFWqu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=1325-1342&issue=4&author=R.+Xiongauthor=J.+Zhaoauthor=L.+M.+Gutgesellauthor=Y.+Wangauthor=S.+Leeauthor=B.+Karumudiauthor=H.+Zhaoauthor=Y.+Luauthor=D.+A.+Tonettiauthor=G.+R.+J.+Thatcher&title=Novel+selective+estrogen+receptor+downregulators+%28SERDs%29+developed+against+treatment-resistant+breast+cancer&doi=10.1021%2Facs.jmedchem.6b01355"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17aR"><div class="casContent"><span class="casTitleNuber">17a</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Selective Estrogen Receptor Downregulators (SERDs) Developed against Treatment-Resistant Breast Cancer</span></div><div class="casAuthors">Xiong, Rui; Zhao, Jiong; Gutgesell, Lauren M.; Wang, Yueting; Lee, Sue; Karumudi, Bhargava; Zhao, Huiping; Lu, Yunlong; Tonetti, Debra A.; Thatcher, Gregory R. J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1325-1342</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Resistance to the selective estrogen receptor modulator (SERM) tamoxifen and to aromatase inhibitors that lower circulating estradiol occurs in up to 50% of patients, generally leading to an endocrine-independent ER+ phenotype.  Selective ER downregulators (SERDs) are able to ablate ER and thus theor. to prevent survival of both endocrine-dependent and independent ER+ tumors.  The clin. SERD, fulvestrant, is hampered by i.m. administration and undesirable pharmacokinetics.  Novel SERDs were designed using the 6-OH-benzothiophene (BT) scaffold common to arzoxifene and raloxifene.  Treatment-resistant (TR) ER+ cell lines (MCF-7:5C and MCF-7:TAM1) were used for optimization, followed by validation in the parent endocrine-dependent cell line (MCF-7:WS8), in 2D and 3D cultures, using ERα in-cell westerns, ERE-luciferase, and cell viability assays, with GDC-0810 (ARN-810) used for comparison.  Two BT SERDs with superior in vitro activity to GDC-0810 were studied for bioavailability and shown to cause regression of a TR, endocrine-independent ER+ xenograft superior to GDC-0810.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLqe0A8df78rVg90H21EOLACvtfcHk0ligZx0E-8e5Yg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFWqu70%253D&md5=71dbdfa2152f9e9019e8d138ed41313e</span></div><a href="/servlet/linkout?suffix=cit17a&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01355%26sid%3Dliteratum%253Aachs%26aulast%3DXiong%26aufirst%3DR.%26aulast%3DZhao%26aufirst%3DJ.%26aulast%3DGutgesell%26aufirst%3DL.%2BM.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DLee%26aufirst%3DS.%26aulast%3DKarumudi%26aufirst%3DB.%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DTonetti%26aufirst%3DD.%2BA.%26aulast%3DThatcher%26aufirst%3DG.%2BR.%2BJ.%26atitle%3DNovel%2520selective%2520estrogen%2520receptor%2520downregulators%2520%2528SERDs%2529%2520developed%2520against%2520treatment-resistant%2520breast%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26issue%3D4%26spage%3D1325%26epage%3D1342%26doi%3D10.1021%2Facs.jmedchem.6b01355" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit17b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gutgesell, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiong, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosales, C. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon-Blake, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dye, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubrovyskyii, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lasek, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tonetti, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thatcher, G. R. J.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of basic selective estrogen receptor degraders for endocrine therapy resistant breast cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span> (<span class="NLM_issue">24</span>),  <span class="NLM_fpage">11301</span>– <span class="NLM_lpage">11323</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b01580</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b01580" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref17/cit17b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitF2ntbbE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=11301-11323&issue=24&author=Y.+Luauthor=L.+M.+Gutgesellauthor=R.+Xiongauthor=J.+Zhaoauthor=Y.+Liauthor=C.+I.+Rosalesauthor=M.+Hollasauthor=Z.+Shenauthor=J.+Gordon-Blakeauthor=K.+Dyeauthor=Y.+Wangauthor=S.+Leeauthor=H.+Chenauthor=D.+Heauthor=O.+Dubrovyskyiiauthor=H.+Zhaoauthor=F.+Huangauthor=A.+W.+Lasekauthor=D.+A.+Tonettiauthor=G.+R.+J.+Thatcher&title=Design+and+synthesis+of+basic+selective+estrogen+receptor+degraders+for+endocrine+therapy+resistant+breast+cancer&doi=10.1021%2Facs.jmedchem.9b01580"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17bR"><div class="casContent"><span class="casTitleNuber">17b</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Synthesis of Basic Selective Estrogen Receptor Degraders for Endocrine Therapy Resistant Breast Cancer</span></div><div class="casAuthors">Lu, Yunlong; Gutgesell, Lauren M.; Xiong, Rui; Zhao, Jiong; Li, Yangfeng; Rosales, Carlo I.; Hollas, Michael; Shen, Zhengnan; Gordon-Blake, Jesse; Dye, Katherine; Wang, Yueting; Lee, Sue; Chen, Hu; He, Donghong; Dubrovyskyii, Oleksii; Zhao, Huiping; Huang, Fei; Lasek, Amy W.; Tonetti, Debra A.; Thatcher, Gregory R. J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">11301-11323</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The clin. steroidal selective estrogen receptor (ER) degrader (SERD), fulvestrant, is effective in metastatic breast cancer, but limited by poor pharmacokinetics, prompting the development of orally bioavailable, nonsteroidal SERDs, currently in clin. trials.  These trials address local breast cancer as well as peripheral metastases, but patients with brain metastases are generally excluded because of the lack of blood-brain barrier penetration.  A novel family of benzothiophene SERDs with a basic amino side arm (B-SERDs) was synthesized.  Proteasomal degrdn. of ERα was induced by B-SERDs that achieved the objectives of oral and brain bioavailability, while maintaining high affinity binding to ERα and both potency and efficacy comparable to fulvestrant in cell lines resistant to endocrine therapy or bearing ESR1 mutations.  A novel 3-oxyazetidine side chain was designed, leading to 37d, a B-SERD that caused endocrine-resistant ER+ tumors to regress in a mouse orthotopic xenograft model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBas1lMEet47Vg90H21EOLACvtfcHk0ligZx0E-8e5Yg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitF2ntbbE&md5=59041daf4dfd9beaa5062badebe1e88c</span></div><a href="/servlet/linkout?suffix=cit17b&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b01580%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DY.%26aulast%3DGutgesell%26aufirst%3DL.%2BM.%26aulast%3DXiong%26aufirst%3DR.%26aulast%3DZhao%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DRosales%26aufirst%3DC.%2BI.%26aulast%3DHollas%26aufirst%3DM.%26aulast%3DShen%26aufirst%3DZ.%26aulast%3DGordon-Blake%26aufirst%3DJ.%26aulast%3DDye%26aufirst%3DK.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DLee%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DHe%26aufirst%3DD.%26aulast%3DDubrovyskyii%26aufirst%3DO.%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DHuang%26aufirst%3DF.%26aulast%3DLasek%26aufirst%3DA.%2BW.%26aulast%3DTonetti%26aufirst%3DD.%2BA.%26aulast%3DThatcher%26aufirst%3DG.%2BR.%2BJ.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520basic%2520selective%2520estrogen%2520receptor%2520degraders%2520for%2520endocrine%2520therapy%2520resistant%2520breast%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26issue%3D24%26spage%3D11301%26epage%3D11323%26doi%3D10.1021%2Facs.jmedchem.9b01580" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Garner, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shomali, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paquin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyttle, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hattersley, G.</span></span> <span> </span><span class="NLM_article-title">RAD1901: a novel, orally bioavailable selective estrogen receptor degrader that demonstrates antitumor activity in breast cancer xenograft models</span>. <i>Anti-Cancer Drugs</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>26</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">948</span>– <span class="NLM_lpage">956</span>, <span class="refDoi"> DOI: 10.1097/CAD.0000000000000271</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=10.1097%2FCAD.0000000000000271" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=26164151" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtlGkt7vK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2015&pages=948-956&issue=9&author=F.+Garnerauthor=M.+Shomaliauthor=D.+Paquinauthor=C.+R.+Lyttleauthor=G.+Hattersley&title=RAD1901%3A+a+novel%2C+orally+bioavailable+selective+estrogen+receptor+degrader+that+demonstrates+antitumor+activity+in+breast+cancer+xenograft+models&doi=10.1097%2FCAD.0000000000000271"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">RAD1901: a novel, orally bioavailable selective estrogen receptor degrader that demonstrates antitumor activity in breast cancer xenograft models</span></div><div class="casAuthors">Garner, Fiona; Shomali, Maysoun; Paquin, Dotty; Lyttle, C. Richard; Hattersley, Gary</div><div class="citationInfo"><span class="NLM_cas:title">Anti-Cancer Drugs</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">948-956</span>CODEN:
                <span class="NLM_cas:coden">ANTDEV</span>;
        ISSN:<span class="NLM_cas:issn">0959-4973</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Agents that inhibit estrogen prodn., such as aromatase inhibitors or those that directly block estrogen receptor (ER) activity, such as selective estrogen receptor modulators and selective estrogen receptor degraders, are routinely used in the treatment of ER-pos. breast cancers.  However, although initial treatment with these agents is often successful, many women eventually relapse with drug-resistant breast cancers.  To overcome some of the challenges assocd. with current endocrine therapies and to combat the development of resistance, there is a need for more durable and more effective ER-targeted therapies.  Here we describe and characterize a novel, orally bioavailable small-mol. selective estrogen receptor degrader, RAD1901, and evaluate its therapeutic potential for the treatment of breast cancer.  RAD1901 selectively binds to and degrades the ER and is a potent antagonist of ER-pos. breast cancer cell proliferation.  Importantly, RAD1901 produced a robust and profound inhibition of tumor growth in MCF-7 xenograft models.  In an intracranial MCF-7 model, RAD1901-treated animals survived longer than those treated with either control or fulvestrant, suggesting the potential benefit of RAD1901 in the treatment of ER-pos. breast cancer that has metastasized to the brain.  Finally, RAD1901 preserved ovariectomy-induced bone loss and prevented the uterotropic effects of E2, suggesting that it may act selectively as an agonist in bone but as an antagonist in breast and uterine tissues.  RAD1901 is currently under clin. study in postmenopausal women with ER-pos. advanced breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrA9eopVbfVLbVg90H21EOLACvtfcHk0ligZx0E-8e5Yg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtlGkt7vK&md5=acb860904a82a83b03b97b40420b64e1</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1097%2FCAD.0000000000000271&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FCAD.0000000000000271%26sid%3Dliteratum%253Aachs%26aulast%3DGarner%26aufirst%3DF.%26aulast%3DShomali%26aufirst%3DM.%26aulast%3DPaquin%26aufirst%3DD.%26aulast%3DLyttle%26aufirst%3DC.%2BR.%26aulast%3DHattersley%26aufirst%3DG.%26atitle%3DRAD1901%253A%2520a%2520novel%252C%2520orally%2520bioavailable%2520selective%2520estrogen%2520receptor%2520degrader%2520that%2520demonstrates%2520antitumor%2520activity%2520in%2520breast%2520cancer%2520xenograft%2520models%26jtitle%3DAnti-Cancer%2520Drugs%26date%3D2015%26volume%3D26%26issue%3D9%26spage%3D948%26epage%3D956%26doi%3D10.1097%2FCAD.0000000000000271" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Nagasawa, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Govek, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kahraman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonnefous, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Douglas, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sensintaffar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aparicio, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaufman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prudente, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joseph, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darimont, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brigham, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maheu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heyman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rix, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hager, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, N. D.</span></span> <span> </span><span class="NLM_article-title">Identification of an orally bioavailable chromene-based selective estrogen receptor degrader (SERD) that demonstrates robust activity in a model of tamoxifen-resistant breast cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">7917</span>– <span class="NLM_lpage">7928</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00921</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00921" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVOjsL7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=7917-7928&issue=17&author=J.+Nagasawaauthor=S.+Govekauthor=M.+Kahramanauthor=A.+Laiauthor=C.+Bonnefousauthor=K.+Douglasauthor=J.+Sensintaffarauthor=N.+Luauthor=K.+Leeauthor=A.+Aparicioauthor=J.+Kaufmanauthor=J.+Qianauthor=G.+Shaoauthor=R.+Prudenteauthor=J.+D.+Josephauthor=B.+Darimontauthor=D.+Brighamauthor=K.+Maheuauthor=R.+Heymanauthor=P.+J.+Rixauthor=J.+H.+Hagerauthor=N.+D.+Smith&title=Identification+of+an+orally+bioavailable+chromene-based+selective+estrogen+receptor+degrader+%28SERD%29+that+demonstrates+robust+activity+in+a+model+of+tamoxifen-resistant+breast+cancer&doi=10.1021%2Facs.jmedchem.8b00921"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19aR"><div class="casContent"><span class="casTitleNuber">19a</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of an Orally Bioavailable Chromene-Based Selective Estrogen Receptor Degrader (SERD) That Demonstrates Robust Activity in a Model of Tamoxifen-Resistant Breast Cancer</span></div><div class="casAuthors">Nagasawa, Johnny; Govek, Steven; Kahraman, Mehmet; Lai, Andiliy; Bonnefous, Celine; Douglas, Karensa; Sensintaffar, John; Lu, Nhin; Lee, KyoungJin; Aparicio, Anna; Kaufman, Josh; Qian, Jing; Shao, Gang; Prudente, Rene; Joseph, James D.; Darimont, Beatrice; Brigham, Daniel; Maheu, Kate; Heyman, Richard; Rix, Peter J.; Hager, Jeffrey H.; Smith, Nicholas D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">7917-7928</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Approx. eighty percent of breast cancers are estrogen receptor alpha (ER-α) pos., and although women typically initially respond well to anti-hormonal therapies such as tamoxifen and aromatase inhibitors, resistance often emerges.  Fulvestrant is a steroid-based, selective estrogen receptor degrader (SERD) that both antagonizes and degrades ER-α, and is active in patients who have progressed on anti-hormonal agents.  However fulvestrant suffers from poor pharmaceutical properties and must be administered by intra-muscular injections that limit the total amt. of drug that can be administered, and hence lead to the potential for incomplete receptor blockade.  The authors describe the optimization of ER-α degrdn. efficacy of a chromene series of ER modulators resulting in highly potent and efficacious SERDs such as 14n (3-(3-hydroxyphenyl)-4-methyl-2-(4-((S)-2-((R)-3-methylpyrrolidin-1-yl)propoxy)phenyl)-2H-chromen-6-ol).  The side-chain ring size and stereochem. elements were central in driving degrdn. efficacy, leading to the identification of 14n.  When examd. in a xenograft model of tamoxifen-resistant breast cancer, biphenol chromene 14n (ER-α degrdn. efficacy = 91%) demonstrated robust activity, while despite superior oral exposure, a mono-phenol chromene 15g (3-(4-fluorophenyl)-4-methyl-2-(4-((S)-2-((R)-3-methylpyrrolidin-1-yl)propoxy)phenyl)-2H-chromen-6-ol) (ER-α degrdn. efficacy = 82%) was essentially inactive.  Although not definitively causative, this result suggests that optimizing ER-α degrdn. efficacy leads to compds. with robust effects models of tamoxifen-resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8I60s9csFRrVg90H21EOLACvtfcHk0lh3QP9zWxwcLg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVOjsL7E&md5=9ae708199592455e0a691c7af2e43967</span></div><a href="/servlet/linkout?suffix=cit19a&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00921&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00921%26sid%3Dliteratum%253Aachs%26aulast%3DNagasawa%26aufirst%3DJ.%26aulast%3DGovek%26aufirst%3DS.%26aulast%3DKahraman%26aufirst%3DM.%26aulast%3DLai%26aufirst%3DA.%26aulast%3DBonnefous%26aufirst%3DC.%26aulast%3DDouglas%26aufirst%3DK.%26aulast%3DSensintaffar%26aufirst%3DJ.%26aulast%3DLu%26aufirst%3DN.%26aulast%3DLee%26aufirst%3DK.%26aulast%3DAparicio%26aufirst%3DA.%26aulast%3DKaufman%26aufirst%3DJ.%26aulast%3DQian%26aufirst%3DJ.%26aulast%3DShao%26aufirst%3DG.%26aulast%3DPrudente%26aufirst%3DR.%26aulast%3DJoseph%26aufirst%3DJ.%2BD.%26aulast%3DDarimont%26aufirst%3DB.%26aulast%3DBrigham%26aufirst%3DD.%26aulast%3DMaheu%26aufirst%3DK.%26aulast%3DHeyman%26aufirst%3DR.%26aulast%3DRix%26aufirst%3DP.%2BJ.%26aulast%3DHager%26aufirst%3DJ.%2BH.%26aulast%3DSmith%26aufirst%3DN.%2BD.%26atitle%3DIdentification%2520of%2520an%2520orally%2520bioavailable%2520chromene-based%2520selective%2520estrogen%2520receptor%2520degrader%2520%2528SERD%2529%2520that%2520demonstrates%2520robust%2520activity%2520in%2520a%2520model%2520of%2520tamoxifen-resistant%2520breast%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26issue%3D17%26spage%3D7917%26epage%3D7928%26doi%3D10.1021%2Facs.jmedchem.8b00921" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit19b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Kahraman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Govek, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagasawa, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonnefous, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Douglas, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sensintaffar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aparicio, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaufman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prudente, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joseph, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darimont, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brigham, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heyman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rix, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hager, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, N. D.</span></span> <span> </span><span class="NLM_article-title">Maximizing ER-α degradation maximizes activity in a tamoxifen-resistant breast cancer model: identification of GDC-0927</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">50</span>– <span class="NLM_lpage">55</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.8b00414</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.8b00414" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisVensr3M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=50-55&issue=1&author=M.+Kahramanauthor=S.+P.+Govekauthor=J.+Y.+Nagasawaauthor=A.+Laiauthor=C.+Bonnefousauthor=K.+Douglasauthor=J.+Sensintaffarauthor=N.+Liuauthor=K.+Leeauthor=A.+Aparicioauthor=J.+Kaufmanauthor=J.+Qianauthor=G.+Shaoauthor=R.+Prudenteauthor=J.+D.+Josephauthor=B.+Darimontauthor=D.+Brighamauthor=R.+Heymanauthor=P.+J.+Rixauthor=J.+H.+Hagerauthor=N.+D.+Smith&title=Maximizing+ER-%CE%B1+degradation+maximizes+activity+in+a+tamoxifen-resistant+breast+cancer+model%3A+identification+of+GDC-0927&doi=10.1021%2Facsmedchemlett.8b00414"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19bR"><div class="casContent"><span class="casTitleNuber">19b</span><div class="casTitle"><span class="NLM_cas:atitle">Maximizing ER-α Degradation Maximizes Activity in a Tamoxifen-Resistant Breast Cancer Model: Identification of GDC-0927</span></div><div class="casAuthors">Kahraman, Mehmet; Govek, Steven P.; Nagasawa, Johnny Y.; Lai, Andiliy; Bonnefous, Celine; Douglas, Karensa; Sensintaffar, John; Liu, Nhin; Lee, KyoungJin; Aparicio, Anna; Kaufman, Josh; Qian, Jing; Shao, Gang; Prudente, Rene; Joseph, James D.; Darimont, Beatrice; Brigham, Daniel; Heyman, Richard; Rix, Peter J.; Hager, Jeffrey H.; Smith, Nicholas D.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">50-55</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The further optimization of ER-α degrdn. efficacy of a series of ER modulators by refining side-chain substitution led to efficacious selective estrogen receptor degraders (SERDs).  A fluoromethyl azetidine group was found to be preferred and resulted in the identification of bis-phenol chromene 17ha.  In a tamoxifen-resistant breast cancer xenograft model, 17ha (ER-α degrdn. efficacy = 97%) demonstrated tumor regression, together with robust redn. of intratumoral ER-α levels.  However, despite superior oral exposure, 5a (ER-α degrdn. efficacy = 91%) had inferior activity.  This result suggests that optimizing ER-α degrdn. efficacy leads to compds. with robust effects in a model of tamoxifen-resistant breast cancer.  Compd. 17ha (GDC-0927) was evaluated in clin. trials in women with metastatic estrogen receptor-pos. breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgyUydsTFnYrVg90H21EOLACvtfcHk0lh3QP9zWxwcLg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisVensr3M&md5=324c1697ef350d169a97960de72ee8a9</span></div><a href="/servlet/linkout?suffix=cit19b&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.8b00414&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.8b00414%26sid%3Dliteratum%253Aachs%26aulast%3DKahraman%26aufirst%3DM.%26aulast%3DGovek%26aufirst%3DS.%2BP.%26aulast%3DNagasawa%26aufirst%3DJ.%2BY.%26aulast%3DLai%26aufirst%3DA.%26aulast%3DBonnefous%26aufirst%3DC.%26aulast%3DDouglas%26aufirst%3DK.%26aulast%3DSensintaffar%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DN.%26aulast%3DLee%26aufirst%3DK.%26aulast%3DAparicio%26aufirst%3DA.%26aulast%3DKaufman%26aufirst%3DJ.%26aulast%3DQian%26aufirst%3DJ.%26aulast%3DShao%26aufirst%3DG.%26aulast%3DPrudente%26aufirst%3DR.%26aulast%3DJoseph%26aufirst%3DJ.%2BD.%26aulast%3DDarimont%26aufirst%3DB.%26aulast%3DBrigham%26aufirst%3DD.%26aulast%3DHeyman%26aufirst%3DR.%26aulast%3DRix%26aufirst%3DP.%2BJ.%26aulast%3DHager%26aufirst%3DJ.%2BH.%26aulast%3DSmith%26aufirst%3DN.%2BD.%26atitle%3DMaximizing%2520ER-%25CE%25B1%2520degradation%2520maximizes%2520activity%2520in%2520a%2520tamoxifen-resistant%2520breast%2520cancer%2520model%253A%2520identification%2520of%2520GDC-0927%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D10%26issue%3D1%26spage%3D50%26epage%3D55%26doi%3D10.1021%2Facsmedchemlett.8b00414" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit19c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blake, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedman, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodacre, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ingalla, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiefer, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kleinheinz, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Labadie, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mody, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLean, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metcalfe, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nannini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otwine, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ran, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ray, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roussel, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sambrone, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sampath, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vinogradova, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeap, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zbieg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span> <span> </span><span class="NLM_article-title">Discovery of GNE-149 as a full antagonist and efficient degrader of estrogen receptor alpha for ER+ breast cancer</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">1342</span>– <span class="NLM_lpage">1347</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.0c00224</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.0c00224" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtVSht7vK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2020&pages=1342-1347&author=J.+Liangauthor=R.+Blakeauthor=J.+Changauthor=L.+S.+Friedmanauthor=S.+Goodacreauthor=S.+Hartmanauthor=E.+R.+Ingallaauthor=J.+R.+Kieferauthor=T.+Kleinheinzauthor=S.+Labadieauthor=J.+Liauthor=K.+W.+Laiauthor=J.+Liaoauthor=V.+Modyauthor=N.+McLeanauthor=C.+Metcalfeauthor=M.+Nanniniauthor=D.+Otwineauthor=Y.+Ranauthor=N.+Rayauthor=F.+Rousselauthor=A.+Sambroneauthor=D.+Sampathauthor=M.+Vinogradovaauthor=J.+Waiauthor=T.+Wangauthor=K.+Yeapauthor=A.+Youngauthor=J.+Zbiegauthor=B.+Zhangauthor=X.+Zhengauthor=Y.+Zhongauthor=X.+Wang&title=Discovery+of+GNE-149+as+a+full+antagonist+and+efficient+degrader+of+estrogen+receptor+alpha+for+ER%2B+breast+cancer&doi=10.1021%2Facsmedchemlett.0c00224"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19cR"><div class="casContent"><span class="casTitleNuber">19c</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of GNE-149 as a Full Antagonist and Efficient Degrader of Estrogen Receptor alpha for ER+ Breast Cancer</span></div><div class="casAuthors">Liang, Jun; Blake, Robert; Chang, Jae; Friedman, Lori S.; Goodacre, Simon; Hartman, Steven; Ingalla, Ellen Rei; Kiefer, James R.; Kleinheinz, Tracy; Labadie, Sharada; Li, Jun; Lai, Kwong Wah; Liao, Jiangpeng; Mody, Vidhi; McLean, Neville; Metcalfe, Ciara; Nannini, Michelle; Otwine, Daniel; Ran, Yingqing; Ray, Nick; Roussel, Fabien; Sambrone, Amy; Sampath, Deepak; Vinogradova, Maia; Wai, John; Wang, Tao; Yeap, Kuen; Young, Amy; Zbieg, Jason; Zhang, Birong; Zheng, Xiaoping; Zhong, Yu; Wang, Xiaojing</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1342-1347</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Estrogen receptor alpha (ERα) is a well-validated drug target for ER-pos. (ER+) breast cancer.  Fulvestrant is FDA-approved to treat ER+ breast cancer and works through two mechanisms-as a full antagonist and selective estrogen receptor degrader (SERD)-but lacks oral bioavailability.  Thus, we envisioned a "best-in-class" mol. with the same dual mechanisms as fulvestrant, but with significant oral exposure.  Through lead optimization, we discovered a tool mol. 12 (GNE-149) with improved degrdn. and antiproliferative activity in both MCF7 and T47D cells.  To illustrate the binding mode and key interactions of this scaffold with ERα, we obtained a cocrystal structure of 6 that showed ionic interaction of azetidine with Asp351 residue.  Importantly, 12 showed favorable metabolic stability and good oral exposure. 12 exhibited antagonist effect in the uterus and demonstrated robust dose-dependent efficacy in xenograft models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpb3Gh24AGGw7Vg90H21EOLACvtfcHk0li-u9yvnHNI1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtVSht7vK&md5=9a7c3b93c8974462d8fd848ff0679eca</span></div><a href="/servlet/linkout?suffix=cit19c&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.0c00224&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.0c00224%26sid%3Dliteratum%253Aachs%26aulast%3DLiang%26aufirst%3DJ.%26aulast%3DBlake%26aufirst%3DR.%26aulast%3DChang%26aufirst%3DJ.%26aulast%3DFriedman%26aufirst%3DL.%2BS.%26aulast%3DGoodacre%26aufirst%3DS.%26aulast%3DHartman%26aufirst%3DS.%26aulast%3DIngalla%26aufirst%3DE.%2BR.%26aulast%3DKiefer%26aufirst%3DJ.%2BR.%26aulast%3DKleinheinz%26aufirst%3DT.%26aulast%3DLabadie%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DLai%26aufirst%3DK.%2BW.%26aulast%3DLiao%26aufirst%3DJ.%26aulast%3DMody%26aufirst%3DV.%26aulast%3DMcLean%26aufirst%3DN.%26aulast%3DMetcalfe%26aufirst%3DC.%26aulast%3DNannini%26aufirst%3DM.%26aulast%3DOtwine%26aufirst%3DD.%26aulast%3DRan%26aufirst%3DY.%26aulast%3DRay%26aufirst%3DN.%26aulast%3DRoussel%26aufirst%3DF.%26aulast%3DSambrone%26aufirst%3DA.%26aulast%3DSampath%26aufirst%3DD.%26aulast%3DVinogradova%26aufirst%3DM.%26aulast%3DWai%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DT.%26aulast%3DYeap%26aufirst%3DK.%26aulast%3DYoung%26aufirst%3DA.%26aulast%3DZbieg%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DB.%26aulast%3DZheng%26aufirst%3DX.%26aulast%3DZhong%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DX.%26atitle%3DDiscovery%2520of%2520GNE-149%2520as%2520a%2520full%2520antagonist%2520and%2520efficient%2520degrader%2520of%2520estrogen%2520receptor%2520alpha%2520for%2520ER%252B%2520breast%2520cancer%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2020%26volume%3D11%26spage%3D1342%26epage%3D1347%26doi%3D10.1021%2Facsmedchemlett.0c00224" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">El-Ahmad, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tabart, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halley, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Certal, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Filoche-Rommé, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gruss-Leleu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brollo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fabien, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loyau, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richepin, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pilorge, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desmazeau, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Girardet, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beccari, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Louboutin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lebourg, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le-Roux, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terrier, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vallée, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steier, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathieu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rak, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abecassis, P.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vicat, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benard, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bouaboula, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shomali, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hebert, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levit, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Courjaud, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ginesty, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perrault, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Echeverria, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCort, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schio, L.</span></span> <span> </span><span class="NLM_article-title">Discovery of 6-(2,4-dichlorophenyl)-5-[4-[(3<i>S</i>)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo[7]annulene-2-carboxylic acid (SAR439859), a potent and selective estrogen receptor degrader (SERD) for the treatment of estrogen-receptor-positive breast cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">512</span>– <span class="NLM_lpage">528</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b01293</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b01293" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=1%3ACAS%3A280%3ADC%252BB3Mjos1ejsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=512-528&author=Y.+El-Ahmadauthor=M.+Tabartauthor=F.+Halleyauthor=V.+Certalauthor=F.+Thompsonauthor=B.+Filoche-Romm%C3%A9author=F.+Gruss-Leleuauthor=C.+Mullerauthor=M.+Brolloauthor=L.+Fabienauthor=V.+Loyauauthor=L.+Bertinauthor=P.+Richepinauthor=F.+Pilorgeauthor=P.+Desmazeauauthor=C.+Girardetauthor=S.+Beccariauthor=A.+Louboutinauthor=G.+Lebourgauthor=J.+Le-Rouxauthor=C.+Terrierauthor=F.+Vall%C3%A9eauthor=V.+Steierauthor=M.+Mathieuauthor=A.+Rakauthor=P.-Y.+Abecassisauthor=P.+Vicatauthor=T.+Benardauthor=M.+Bouaboulaauthor=F.+Sunauthor=M.+Shomaliauthor=A.+Hebertauthor=M.+Levitauthor=H.+Chengauthor=A.+Courjaudauthor=C.+Ginestyauthor=C.+Perraultauthor=C.+Garcia-Echeverriaauthor=G.+McCortauthor=L.+Schio&title=Discovery+of+6-%282%2C4-dichlorophenyl%29-5-%5B4-%5B%283S%29-1-%283-fluoropropyl%29pyrrolidin-3-yl%5Doxyphenyl%5D-8%2C9-dihydro-7H-benzo%5B7%5Dannulene-2-carboxylic+acid+%28SAR439859%29%2C+a+potent+and+selective+estrogen+receptor+degrader+%28SERD%29+for+the+treatment+of+estrogen-receptor-positive+breast+cancer&doi=10.1021%2Facs.jmedchem.9b01293"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 6-(2,4-Dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo[7]annulene-2-carboxylic acid (SAR439859), a Potent and Selective Estrogen Receptor Degrader (SERD) for the Treatment of Estrogen-Receptor-Positive Breast Cancer</span></div><div class="casAuthors">El-Ahmad Youssef; Tabart Michel; Halley Frank; Certal Victor; Thompson Fabienne; Filoche-Romme Bruno; Gruss-Leleu Florence; Muller Claire; Brollo Maurice; Fabien Laurence; Loyau Veronique; Bertin Luc; Richepin Patrick; Pilorge Fabienne; Desmazeau Pascal; Girardet Chrystelle; Beccari Sylvie; Louboutin Audrey; Lebourg Gilles; Le-Roux Jacques; Terrier Corinne; Vallee Francois; Steier Valerie; Mathieu Magali; Rak Alexey; Abecassis Pierre-Yves; Vicat Pascale; Benard Tsiala; Courjaud Albane; Ginesty Celine; Perrault Christelle; Garcia-Echeverria Carlos; McCort Gary; Schio Laurent; Bouaboula Monsif; Sun Fangxian; Shomali Maysoun; Hebert Andrew; Levit Mikhail; Cheng Hong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of medicinal chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">512-528</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">More than 75% of breast cancers are estrogen receptor alpha (ERα) positive (ER+), and resistance to current hormone therapies occurs in one-third of ER+ patients.  Tumor resistance is still ERα-dependent, but mutations usually confer constitutive activation to the hormone receptor, rendering ERα modulator drugs such as tamoxifen and aromatase inhibitors ineffective.  Fulvestrant is a potent selective estrogen receptor degrader (SERD), which degrades the ERα receptor in drug-resistant tumors and has been approved for the treatment of hormone-receptor-positive metastatic breast cancer following antiestrogen therapy.  However, fulvestrant shows poor pharmacokinetic properties in human, low solubility, weak permeation, and high metabolism, limiting its administration to inconvenient intramuscular injections.  This Drug Annotation describes the identification and optimization of a new series of potent orally available SERDs, which led to the discovery of 6-(2,4-dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo[7]annulene-2-carboxylic acid (43d), showing promising antitumor activity in breast cancer mice xenograft models and whose properties warranted clinical evaluation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRgG8wK4xhUykloaUqgkFHkfW6udTcc2eYaKS4ZJblwUbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3Mjos1ejsQ%253D%253D&md5=40732bc5b74a05cf8551ad5baea64217</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b01293&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b01293%26sid%3Dliteratum%253Aachs%26aulast%3DEl-Ahmad%26aufirst%3DY.%26aulast%3DTabart%26aufirst%3DM.%26aulast%3DHalley%26aufirst%3DF.%26aulast%3DCertal%26aufirst%3DV.%26aulast%3DThompson%26aufirst%3DF.%26aulast%3DFiloche-Romm%25C3%25A9%26aufirst%3DB.%26aulast%3DGruss-Leleu%26aufirst%3DF.%26aulast%3DMuller%26aufirst%3DC.%26aulast%3DBrollo%26aufirst%3DM.%26aulast%3DFabien%26aufirst%3DL.%26aulast%3DLoyau%26aufirst%3DV.%26aulast%3DBertin%26aufirst%3DL.%26aulast%3DRichepin%26aufirst%3DP.%26aulast%3DPilorge%26aufirst%3DF.%26aulast%3DDesmazeau%26aufirst%3DP.%26aulast%3DGirardet%26aufirst%3DC.%26aulast%3DBeccari%26aufirst%3DS.%26aulast%3DLouboutin%26aufirst%3DA.%26aulast%3DLebourg%26aufirst%3DG.%26aulast%3DLe-Roux%26aufirst%3DJ.%26aulast%3DTerrier%26aufirst%3DC.%26aulast%3DVall%25C3%25A9e%26aufirst%3DF.%26aulast%3DSteier%26aufirst%3DV.%26aulast%3DMathieu%26aufirst%3DM.%26aulast%3DRak%26aufirst%3DA.%26aulast%3DAbecassis%26aufirst%3DP.-Y.%26aulast%3DVicat%26aufirst%3DP.%26aulast%3DBenard%26aufirst%3DT.%26aulast%3DBouaboula%26aufirst%3DM.%26aulast%3DSun%26aufirst%3DF.%26aulast%3DShomali%26aufirst%3DM.%26aulast%3DHebert%26aufirst%3DA.%26aulast%3DLevit%26aufirst%3DM.%26aulast%3DCheng%26aufirst%3DH.%26aulast%3DCourjaud%26aufirst%3DA.%26aulast%3DGinesty%26aufirst%3DC.%26aulast%3DPerrault%26aufirst%3DC.%26aulast%3DGarcia-Echeverria%26aufirst%3DC.%26aulast%3DMcCort%26aufirst%3DG.%26aulast%3DSchio%26aufirst%3DL.%26atitle%3DDiscovery%2520of%25206-%25282%252C4-dichlorophenyl%2529-5-%255B4-%255B%25283S%2529-1-%25283-fluoropropyl%2529pyrrolidin-3-yl%255Doxyphenyl%255D-8%252C9-dihydro-7H-benzo%255B7%255Dannulene-2-carboxylic%2520acid%2520%2528SAR439859%2529%252C%2520a%2520potent%2520and%2520selective%2520estrogen%2520receptor%2520degrader%2520%2528SERD%2529%2520for%2520the%2520treatment%2520of%2520estrogen-receptor-positive%2520breast%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D512%26epage%3D528%26doi%3D10.1021%2Facs.jmedchem.9b01293" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Weir, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradbury, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabow, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buttar, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Callis, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curwen, J. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Almeida, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballard, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hulse, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donald, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feron, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karoutchi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacFaul, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moss, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norman, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pearson, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tonge, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowlinson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powell, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sadler, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richmond, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ladd, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pazolli, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazzola, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Cruz, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Savi, C.</span></span> <span> </span><span class="NLM_article-title">AZD9496: an oral estrogen receptor inhibitor that blocks the growth of ER-positive and ESR1-mutant breast tumors in preclinical models</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>76</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">3307</span>– <span class="NLM_lpage">3318</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-15-2357</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=10.1158%2F0008-5472.CAN-15-2357" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=27020862" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=1%3ACAS%3A528%3ADC%252BC28XovVyktLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2016&pages=3307-3318&issue=11&author=H.+M.+Weirauthor=R.+H.+Bradburyauthor=M.+Lawsonauthor=A.+A.+Rabowauthor=B.+Buttarauthor=R.+J.+Callisauthor=J.+O.+Curwenauthor=C.+de+Almeidaauthor=P.+Ballardauthor=M.+Hulseauthor=C.+S.+Donaldauthor=L.+J.+Feronauthor=G.+Karoutchiauthor=P.+MacFaulauthor=T.+Mossauthor=R.+A.+Normanauthor=S.+E.+Pearsonauthor=M.+Tongeauthor=G.+Daviesauthor=G.+E.+Walkerauthor=Z.+Wilsonauthor=R.+Rowlinsonauthor=S.+Powellauthor=C.+Sadlerauthor=G.+Richmondauthor=B.+Laddauthor=E.+Pazolliauthor=A.+M.+Mazzolaauthor=C.+D%E2%80%99Cruzauthor=C.+De+Savi&title=AZD9496%3A+an+oral+estrogen+receptor+inhibitor+that+blocks+the+growth+of+ER-positive+and+ESR1-mutant+breast+tumors+in+preclinical+models&doi=10.1158%2F0008-5472.CAN-15-2357"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">AZD9496: An Oral Estrogen Receptor Inhibitor That Blocks the Growth of ER-Positive and ESR1-Mutant Breast Tumors in Preclinical Models</span></div><div class="casAuthors">Weir, Hazel M.; Bradbury, Robert H.; Lawson, Mandy; Rabow, Alfred A.; Buttar, David; Callis, Rowena J.; Curwen, Jon O.; de Almeida, Camila; Ballard, Peter; Hulse, Michael; Donald, Craig S.; Feron, Lyman J. L.; Karoutchi, Galith; MacFaul, Philip; Moss, Thomas; Norman, Richard A.; Pearson, Stuart E.; Tonge, Michael; Davies, Gareth; Walker, Graeme E.; Wilson, Zena; Rowlinson, Rachel; Powell, Steve; Sadler, Claire; Richmond, Graham; Ladd, Brendon; Pazolli, Ermira; Mazzola, Anne Marie; D'Cruz, Celina; De Savi, Chris</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3307-3318</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Fulvestrant is an estrogen receptor (ER) antagonist administered to breast cancer patients by monthly i.m. injection.  Given its present limitations of dosing and route of administration, a more flexible orally available compd. has been sought to pursue the potential benefits of this drug in patients with advanced metastatic disease.  Here we report the identification and characterization of AZD9496, a nonsteroidal small-mol. inhibitor of ERα, which is a potent and selective antagonist and downregulator of ERα in vitro and in vivo in ER-pos. models of breast cancer.  Significant tumor growth inhibition was obsd. as low as 0.5 mg/kg dose in the estrogen-dependent MCF-7 xenograft model, where this effect was accompanied by a dose-dependent decrease in PR protein levels, demonstrating potent antagonist activity.  Combining AZD9496 with PI3K pathway and CDK4/6 inhibitors led to further growth-inhibitory effects compared with monotherapy alone.  Tumor regressions were also seen in a long-term estrogen-deprived breast model, where significant downregulation of ERα protein was obsd.  AZD9496 bound and downregulated clin. relevant ESR1 mutants in vitro and inhibited tumor growth in an ESR1-mutant patient-derived xenograft model that included a D538G mutation.  Collectively, the pharmacol. evidence showed that AZD9496 is an oral, nonsteroidal, selective estrogen receptor antagonist and downregulator in ER+ breast cells that could provide meaningful benefit to ER+ breast cancer patients.  AZD9496 is currently being evaluated in a phase I clin. trial.  Cancer Res; 76(11); 3307-18. ©2016 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoP4X3e2iYdcLVg90H21EOLACvtfcHk0lh_g-rBZLnZ_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XovVyktLo%253D&md5=4ff8ab9a9cd379acc031b7c6fd27134c</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-15-2357&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-15-2357%26sid%3Dliteratum%253Aachs%26aulast%3DWeir%26aufirst%3DH.%2BM.%26aulast%3DBradbury%26aufirst%3DR.%2BH.%26aulast%3DLawson%26aufirst%3DM.%26aulast%3DRabow%26aufirst%3DA.%2BA.%26aulast%3DButtar%26aufirst%3DB.%26aulast%3DCallis%26aufirst%3DR.%2BJ.%26aulast%3DCurwen%26aufirst%3DJ.%2BO.%26aulast%3Dde%2BAlmeida%26aufirst%3DC.%26aulast%3DBallard%26aufirst%3DP.%26aulast%3DHulse%26aufirst%3DM.%26aulast%3DDonald%26aufirst%3DC.%2BS.%26aulast%3DFeron%26aufirst%3DL.%2BJ.%26aulast%3DKaroutchi%26aufirst%3DG.%26aulast%3DMacFaul%26aufirst%3DP.%26aulast%3DMoss%26aufirst%3DT.%26aulast%3DNorman%26aufirst%3DR.%2BA.%26aulast%3DPearson%26aufirst%3DS.%2BE.%26aulast%3DTonge%26aufirst%3DM.%26aulast%3DDavies%26aufirst%3DG.%26aulast%3DWalker%26aufirst%3DG.%2BE.%26aulast%3DWilson%26aufirst%3DZ.%26aulast%3DRowlinson%26aufirst%3DR.%26aulast%3DPowell%26aufirst%3DS.%26aulast%3DSadler%26aufirst%3DC.%26aulast%3DRichmond%26aufirst%3DG.%26aulast%3DLadd%26aufirst%3DB.%26aulast%3DPazolli%26aufirst%3DE.%26aulast%3DMazzola%26aufirst%3DA.%2BM.%26aulast%3DD%25E2%2580%2599Cruz%26aufirst%3DC.%26aulast%3DDe%2BSavi%26aufirst%3DC.%26atitle%3DAZD9496%253A%2520an%2520oral%2520estrogen%2520receptor%2520inhibitor%2520that%2520blocks%2520the%2520growth%2520of%2520ER-positive%2520and%2520ESR1-mutant%2520breast%2520tumors%2520in%2520preclinical%2520models%26jtitle%3DCancer%2520Res.%26date%3D2016%26volume%3D76%26issue%3D11%26spage%3D3307%26epage%3D3318%26doi%3D10.1158%2F0008-5472.CAN-15-2357" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hafner, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blake, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chalouni, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, I. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Bruyn, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giltnane, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartman, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heidersbach, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houtman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ingalla, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kategaya, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kleinheinz, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Modrusan, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nannini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oeh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ubhayakar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wertz, I. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sampath, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hager, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedman, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daemen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metcalfe, C.</span></span> <span> </span><span class="NLM_article-title">Therapeutic ligands antagonize estrogen receptor function by impairing its mobility</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>178</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">949</span>– <span class="NLM_lpage">963</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2019.06.026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=10.1016%2Fj.cell.2019.06.026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=31353221" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsVOgsr%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=178&publication_year=2019&pages=949-963&issue=4&author=J.+Guanauthor=W.+Zhouauthor=M.+Hafnerauthor=R.+A.+Blakeauthor=C.+Chalouniauthor=I.+P.+Chenauthor=T.+De+Bruynauthor=J.+M.+Giltnaneauthor=S.+J.+Hartmanauthor=A.+Heidersbachauthor=R.+Houtmanauthor=E.+Ingallaauthor=L.+Kategayaauthor=T.+Kleinheinzauthor=J.+Liauthor=S.+E.+Martinauthor=Z.+Modrusanauthor=M.+Nanniniauthor=J.+Oehauthor=S.+Ubhayakarauthor=X.+Wangauthor=I.+E.+Wertzauthor=A.+Youngauthor=M.+Yuauthor=D.+Sampathauthor=J.+H.+Hagerauthor=L.+S.+Friedmanauthor=A.+Daemenauthor=C.+Metcalfe&title=Therapeutic+ligands+antagonize+estrogen+receptor+function+by+impairing+its+mobility&doi=10.1016%2Fj.cell.2019.06.026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic Ligands Antagonize Estrogen Receptor Function by Impairing Its Mobility</span></div><div class="casAuthors">Guan, Jane; Zhou, Wei; Hafner, Marc; Blake, Robert A.; Chalouni, Cecile; Chen, Irene P.; De Bruyn, Tom; Giltnane, Jennifer M.; Hartman, Steven J.; Heidersbach, Amy; Houtman, Rene; Ingalla, Ellen; Kategaya, Lorn; Kleinheinz, Tracy; Li, Jun; Martin, Scott E.; Modrusan, Zora; Nannini, Michelle; Oeh, Jason; Ubhayakar, Savita; Wang, Xiaojing; Wertz, Ingrid E.; Young, Amy; Yu, Mamie; Sampath, Deepak; Hager, Jeffrey H.; Friedman, Lori S.; Daemen, Anneleen; Metcalfe, Ciara</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">178</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">949-963.e18</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Estrogen receptor-pos. (ER+) breast cancers frequently remain dependent on ER signaling even after acquiring resistance to endocrine agents, prompting the development of optimized ER antagonists.  Fulvestrant is unique among approved ER therapeutics due to its capacity for full ER antagonism, thought to be achieved through ER degrdn.  The clin. potential of fulvestrant is limited by poor physicochem. features, spurring attempts to generate ER degraders with improved drug-like properties.  We show that optimization of ER degrdn. does not guarantee full ER antagonism in breast cancer cells; ER "degraders" exhibit a spectrum of transcriptional activities and anti-proliferative potential.  Mechanistically, we find that fulvestrant-like antagonists suppress ER transcriptional activity not by ER elimination, but by markedly slowing the intra-nuclear mobility of ER.  Increased ER turnover occurs as a consequence of ER immobilization.  These findings provide proof-of-concept that small mol. perturbation of transcription factor mobility may enable therapeutic targeting of this challenging target class.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrX7uBE7ualk7Vg90H21EOLACvtfcHk0lh_g-rBZLnZ_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsVOgsr%252FM&md5=96dddd56a1d3d4244ea38f0e7d17941e</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2019.06.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2019.06.026%26sid%3Dliteratum%253Aachs%26aulast%3DGuan%26aufirst%3DJ.%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DHafner%26aufirst%3DM.%26aulast%3DBlake%26aufirst%3DR.%2BA.%26aulast%3DChalouni%26aufirst%3DC.%26aulast%3DChen%26aufirst%3DI.%2BP.%26aulast%3DDe%2BBruyn%26aufirst%3DT.%26aulast%3DGiltnane%26aufirst%3DJ.%2BM.%26aulast%3DHartman%26aufirst%3DS.%2BJ.%26aulast%3DHeidersbach%26aufirst%3DA.%26aulast%3DHoutman%26aufirst%3DR.%26aulast%3DIngalla%26aufirst%3DE.%26aulast%3DKategaya%26aufirst%3DL.%26aulast%3DKleinheinz%26aufirst%3DT.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DMartin%26aufirst%3DS.%2BE.%26aulast%3DModrusan%26aufirst%3DZ.%26aulast%3DNannini%26aufirst%3DM.%26aulast%3DOeh%26aufirst%3DJ.%26aulast%3DUbhayakar%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DWertz%26aufirst%3DI.%2BE.%26aulast%3DYoung%26aufirst%3DA.%26aulast%3DYu%26aufirst%3DM.%26aulast%3DSampath%26aufirst%3DD.%26aulast%3DHager%26aufirst%3DJ.%2BH.%26aulast%3DFriedman%26aufirst%3DL.%2BS.%26aulast%3DDaemen%26aufirst%3DA.%26aulast%3DMetcalfe%26aufirst%3DC.%26atitle%3DTherapeutic%2520ligands%2520antagonize%2520estrogen%2520receptor%2520function%2520by%2520impairing%2520its%2520mobility%26jtitle%3DCell%26date%3D2019%26volume%3D178%26issue%3D4%26spage%3D949%26epage%3D963%26doi%3D10.1016%2Fj.cell.2019.06.026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scott, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buttar, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carbajo, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curwen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davey, P. R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, R. D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Degorce, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donald, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gangl, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenwood, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groombridge, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamont, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lister, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrow, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moss, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pink, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polanski, R.</span></span> <span> </span><span class="NLM_article-title">Tricyclic Indazoles – A novel class of selective estrogen receptor degrader antagonists</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">1593</span>– <span class="NLM_lpage">1608</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01837</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01837" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2019&pages=1593-1608&issue=3&author=J.+S.+Scottauthor=A.+Baileyauthor=D.+Buttarauthor=R.+J.+Carbajoauthor=J.+Curwenauthor=P.+R.+J.+Daveyauthor=R.+D.+M.+Daviesauthor=S.+L.+Degorceauthor=C.+Donaldauthor=E.+Ganglauthor=R.+Greenwoodauthor=S.+D.+Groombridgeauthor=T.+Johnsonauthor=S.+Lamontauthor=M.+Lawsonauthor=A.+Listerauthor=C.+J.+Morrowauthor=T.+A.+Mossauthor=J.+H.+Pinkauthor=R.+Polanski&title=Tricyclic+Indazoles+%E2%80%93+A+novel+class+of+selective+estrogen+receptor+degrader+antagonists&doi=10.1021%2Facs.jmedchem.8b01837"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01837&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01837%26sid%3Dliteratum%253Aachs%26aulast%3DScott%26aufirst%3DJ.%2BS.%26aulast%3DBailey%26aufirst%3DA.%26aulast%3DButtar%26aufirst%3DD.%26aulast%3DCarbajo%26aufirst%3DR.%2BJ.%26aulast%3DCurwen%26aufirst%3DJ.%26aulast%3DDavey%26aufirst%3DP.%2BR.%2BJ.%26aulast%3DDavies%26aufirst%3DR.%2BD.%2BM.%26aulast%3DDegorce%26aufirst%3DS.%2BL.%26aulast%3DDonald%26aufirst%3DC.%26aulast%3DGangl%26aufirst%3DE.%26aulast%3DGreenwood%26aufirst%3DR.%26aulast%3DGroombridge%26aufirst%3DS.%2BD.%26aulast%3DJohnson%26aufirst%3DT.%26aulast%3DLamont%26aufirst%3DS.%26aulast%3DLawson%26aufirst%3DM.%26aulast%3DLister%26aufirst%3DA.%26aulast%3DMorrow%26aufirst%3DC.%2BJ.%26aulast%3DMoss%26aufirst%3DT.%2BA.%26aulast%3DPink%26aufirst%3DJ.%2BH.%26aulast%3DPolanski%26aufirst%3DR.%26atitle%3DTricyclic%2520Indazoles%2520%25E2%2580%2593%2520A%2520novel%2520class%2520of%2520selective%2520estrogen%2520receptor%2520degrader%2520antagonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D6%26issue%3D3%26spage%3D1593%26epage%3D1608%26doi%3D10.1021%2Facs.jmedchem.8b01837" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scott, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, R. D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Degorce, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacFaul, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gingell, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moss, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norman, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pink, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabow, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, P. D.</span></span> <span> </span><span class="NLM_article-title">Tetrahydroisoquinoline phenols: selective estrogen receptor downregulator antagonists with oral bioavailability in rat</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">94</span>– <span class="NLM_lpage">99</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.5b00413</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.5b00413" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitVGku7bK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=94-99&issue=1&author=J.+S.+Scottauthor=A.+Baileyauthor=R.+D.+M.+Daviesauthor=S.+L.+Degorceauthor=P.+A.+MacFaulauthor=H.+Gingellauthor=T.+Mossauthor=R.+A.+Normanauthor=J.+H.+Pinkauthor=A.+A.+Rabowauthor=B.+Robertsauthor=P.+D.+Smith&title=Tetrahydroisoquinoline+phenols%3A+selective+estrogen+receptor+downregulator+antagonists+with+oral+bioavailability+in+rat&doi=10.1021%2Facsmedchemlett.5b00413"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Tetrahydroisoquinoline Phenols: Selective Estrogen Receptor Downregulator Antagonists with Oral Bioavailability in Rat</span></div><div class="casAuthors">Scott, James S.; Bailey, Andrew; Davies, Robert D. M.; Degorce, Sebastien L.; MacFaul, Philip A.; Gingell, Helen; Moss, Thomas; Norman, Richard A.; Pink, Jennifer H.; Rabow, Alfred A.; Roberts, Bryan; Smith, Peter D.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">94-99</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of tetrahydroisoquinoline phenols was modified to give an estrogen receptor downregulator-antagonist profile.  Optimization around the core, alkyl side chain, and pendant aryl ring resulted in compds. I [R = Ph, PhCH2, i-Bu, etc.] with subnanomolar levels of potency.  The phenol functionality was shown to be required to achieve highly potent compds., but unusually this was compatible with obtaining high oral bioavailabilities in rat.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXOiEPK5ofVLVg90H21EOLACvtfcHk0lh6EczkUgI1hQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitVGku7bK&md5=8c573b4e96e70cf61d40f349a7c19967</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.5b00413&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.5b00413%26sid%3Dliteratum%253Aachs%26aulast%3DScott%26aufirst%3DJ.%2BS.%26aulast%3DBailey%26aufirst%3DA.%26aulast%3DDavies%26aufirst%3DR.%2BD.%2BM.%26aulast%3DDegorce%26aufirst%3DS.%2BL.%26aulast%3DMacFaul%26aufirst%3DP.%2BA.%26aulast%3DGingell%26aufirst%3DH.%26aulast%3DMoss%26aufirst%3DT.%26aulast%3DNorman%26aufirst%3DR.%2BA.%26aulast%3DPink%26aufirst%3DJ.%2BH.%26aulast%3DRabow%26aufirst%3DA.%2BA.%26aulast%3DRoberts%26aufirst%3DB.%26aulast%3DSmith%26aufirst%3DP.%2BD.%26atitle%3DTetrahydroisoquinoline%2520phenols%253A%2520selective%2520estrogen%2520receptor%2520downregulator%2520antagonists%2520with%2520oral%2520bioavailability%2520in%2520rat%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D7%26issue%3D1%26spage%3D94%26epage%3D99%26doi%3D10.1021%2Facsmedchemlett.5b00413" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scott, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breed, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carbajo, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davey, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenwood, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huynh, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klinowska, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrow, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moss, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polanski, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nissink, J. W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varnes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, B.</span></span> <span> </span><span class="NLM_article-title">Building bridges in a series of estrogen receptor degraders: an application of metathesis in medicinal chemistry</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">1492</span>– <span class="NLM_lpage">1497</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.9b00370</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.9b00370" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvVentr3E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=1492-1497&issue=10&author=J.+S.+Scottauthor=J.+Breedauthor=R.+J.+Carbajoauthor=P.+R.+Daveyauthor=R.+Greenwoodauthor=H.+K.+Huynhauthor=T.+Klinowskaauthor=C.+J.+Morrowauthor=T.+A.+Mossauthor=R.+Polanskiauthor=J.+W.+M.+Nissinkauthor=J.+Varnesauthor=B.+Yang&title=Building+bridges+in+a+series+of+estrogen+receptor+degraders%3A+an+application+of+metathesis+in+medicinal+chemistry&doi=10.1021%2Facsmedchemlett.9b00370"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Building Bridges in a Series of Estrogen Receptor Degraders: An Application of Metathesis in Medicinal Chemistry</span></div><div class="casAuthors">Scott, James S.; Breed, Jason; Carbajo, Rodrigo J.; Davey, Paul R.; Greenwood, Ryan; Huynh, Hoan K.; Klinowska, Teresa; Morrow, Christopher J.; Moss, Thomas A.; Polanski, Radoslaw; Nissink, J. Willem M.; Varnes, Jeffrey; Yang, Bin</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1492-1497</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Herein the authors report the use of metathesis to construct a novel tetracyclic core in a series of estrogen receptor degraders.  This improved the chem. stability, as assessed using an NMR-MS based assay, and gave a mol. with excellent physicochem. properties and pharmacokinetics in rat.  X-ray crystallog. established minimal perturbation of the bridged compds. relative to the unbridged analogs in the receptor binding pocket.  Unfortunately, despite retaining excellent binding to ERα, this adversely affected the ability of the compds. to degrade the receptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEcZlsyjk417Vg90H21EOLACvtfcHk0lh6EczkUgI1hQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvVentr3E&md5=76a10d7bedd883966fb7106ccf08a0f0</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.9b00370&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.9b00370%26sid%3Dliteratum%253Aachs%26aulast%3DScott%26aufirst%3DJ.%2BS.%26aulast%3DBreed%26aufirst%3DJ.%26aulast%3DCarbajo%26aufirst%3DR.%2BJ.%26aulast%3DDavey%26aufirst%3DP.%2BR.%26aulast%3DGreenwood%26aufirst%3DR.%26aulast%3DHuynh%26aufirst%3DH.%2BK.%26aulast%3DKlinowska%26aufirst%3DT.%26aulast%3DMorrow%26aufirst%3DC.%2BJ.%26aulast%3DMoss%26aufirst%3DT.%2BA.%26aulast%3DPolanski%26aufirst%3DR.%26aulast%3DNissink%26aufirst%3DJ.%2BW.%2BM.%26aulast%3DVarnes%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DB.%26atitle%3DBuilding%2520bridges%2520in%2520a%2520series%2520of%2520estrogen%2520receptor%2520degraders%253A%2520an%2520application%2520of%2520metathesis%2520in%2520medicinal%2520chemistry%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D10%26issue%3D10%26spage%3D1492%26epage%3D1497%26doi%3D10.1021%2Facsmedchemlett.9b00370" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="note"><p class="first last">This compound was made as part of our internal chemistry program but has since appeared in the literature in other patent applications:</p></div><div class="NLM_citation" id="cit26a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Goodacre, S. C.</span>; <span class="NLM_string-name">Labadie, S.</span>; <span class="NLM_string-name">Liang, J.</span>; <span class="NLM_string-name">Ortwine, D. F.</span>; <span class="NLM_string-name">Ray, N. C.</span>; <span class="NLM_string-name">Wang, X.</span>; <span class="NLM_string-name">Zbieg, J.</span>; <span class="NLM_string-name">Zhang, B.</span></span> <span> </span><span class="NLM_article-title">Tetrahydro-Pyrido[3,4-<i>b</i>]indole Estrogen Receptor Modulators And Uses Thereof</span>. <span class="NLM_patent">WO 2016097072</span>, <span class="NLM_year">2016</span>, Genentech.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=S.+C.+Goodacre&author=S.+Labadie&author=J.+Liang&author=D.+F.+Ortwine&author=N.+C.+Ray&author=X.+Wang&author=J.+Zbieg&author=B.+Zhang&title=Tetrahydro-Pyrido%5B3%2C4-b%5Dindole+Estrogen+Receptor+Modulators+And+Uses+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DGoodacre%26aufirst%3DS.%2BC.%26atitle%3DTetrahydro-Pyrido%255B3%252C4-b%255Dindole%2520Estrogen%2520Receptor%2520Modulators%2520And%2520Uses%2520Thereof%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit26b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Myles, D. C.</span>; <span class="NLM_string-name">Kushner, P. J.</span>; <span class="NLM_string-name">Harmon, C. I.</span></span> <span> </span><span class="NLM_article-title">Tetrahydro-1H-Pyrido[3,4-<i>b</i>]indole Anti-Estrogenic Drugs</span>. <span class="NLM_patent">WO 2017059139</span>, <span class="NLM_year">2017</span>, Olema Pharmaceuticals.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=D.+C.+Myles&author=P.+J.+Kushner&author=C.+I.+Harmon&title=Tetrahydro-1H-Pyrido%5B3%2C4-b%5Dindole+Anti-Estrogenic+Drugs"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMyles%26aufirst%3DD.%2BC.%26atitle%3DTetrahydro-1H-Pyrido%255B3%252C4-b%255Dindole%2520Anti-Estrogenic%2520Drugs%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit26c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Dai, X.</span>; <span class="NLM_string-name">Wang, Y.</span></span> <span> </span><span class="NLM_article-title">Selective Estrogen Receptor Degraders And Uses Thereof</span>. <span class="NLM_patent">WO 2017136688</span>, <span class="NLM_year">2017</span>, InventisBio.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=X.+Dai&author=Y.+Wang&title=Selective+Estrogen+Receptor+Degraders+And+Uses+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DDai%26aufirst%3DX.%26atitle%3DSelective%2520Estrogen%2520Receptor%2520Degraders%2520And%2520Uses%2520Thereof%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span> For a review
of the
Pictet-Spengler reaction and discussion on selectivity, see:<span class="NLM_contrib-group"><span class="NLM_string-name">Cox, E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cook, J. M.</span></span> <span> </span><span class="NLM_article-title">The Pictet-Spengler condensation: a new direction for an old reaction</span>. <i>Chem. Rev.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>95</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1797</span>– <span class="NLM_lpage">1842</span>, <span class="refDoi"> DOI: 10.1021/cr00038a004</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cr00038a004" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=1%3ACAS%3A528%3ADyaK2MXos1Sjtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=1995&pages=1797-1842&issue=6&author=E.+D.+Coxauthor=J.+M.+Cook&title=The+Pictet-Spengler+condensation%3A+a+new+direction+for+an+old+reaction&doi=10.1021%2Fcr00038a004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">The Pictet-Spengler condensation: a new direction for an old reaction</span></div><div class="casAuthors">Cox, Eric D.; Cook, James M.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, D. C.)</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">95</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1797-842</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review with 324 refs. including discussion of condensation in nonacidic aprotic media, modeling the pharmacophore of benzodiazepine receptor sites, enantiospecific total synthesis of indole alkaloids, etc.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZXX6FLFmuQrVg90H21EOLACvtfcHk0ljKQI7gLLOtyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXos1Sjtrc%253D&md5=e8734b59c48cfed82a3b26aa9eeed2e2</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Fcr00038a004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcr00038a004%26sid%3Dliteratum%253Aachs%26aulast%3DCox%26aufirst%3DE.%2BD.%26aulast%3DCook%26aufirst%3DJ.%2BM.%26atitle%3DThe%2520Pictet-Spengler%2520condensation%253A%2520a%2520new%2520direction%2520for%2520an%2520old%2520reaction%26jtitle%3DChem.%2520Rev.%26date%3D1995%26volume%3D95%26issue%3D6%26spage%3D1797%26epage%3D1842%26doi%3D10.1021%2Fcr00038a004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, R. D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pink, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, A.</span></span> <span> </span><span class="NLM_article-title">Synthesis of 8-substituted-6-phenyl-6,7,8,9-tetrahydro-3<i>H</i>-pyrazolo[4,3-<i>f</i>]isoquinolines using Pictet-Spengler and Bischler-Napieralski cyclisation methods</span>. <i>Tetrahedron Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>59</i></span> (<span class="NLM_issue">30</span>),  <span class="NLM_fpage">2917</span>– <span class="NLM_lpage">2920</span>, <span class="refDoi"> DOI: 10.1016/j.tetlet.2018.06.041</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=10.1016%2Fj.tetlet.2018.06.041" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtF2jsrrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2018&pages=2917-2920&issue=30&author=R.+D.+M.+Daviesauthor=J.+H.+Pinkauthor=J.+S.+Scottauthor=A.+Bailey&title=Synthesis+of+8-substituted-6-phenyl-6%2C7%2C8%2C9-tetrahydro-3H-pyrazolo%5B4%2C3-f%5Disoquinolines+using+Pictet-Spengler+and+Bischler-Napieralski+cyclisation+methods&doi=10.1016%2Fj.tetlet.2018.06.041"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28aR"><div class="casContent"><span class="casTitleNuber">28a</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of 8-substituted-6-phenyl-6,7,8,9-tetrahydro-3H-pyrazolo[4,3-f]isoquinolines using Pictet-Spengler and Bischler-Napieralski cyclisation methods</span></div><div class="casAuthors">Davies, Robert D. M.; Pink, Jennifer H.; Scott, James S.; Bailey, Andrew</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron Letters</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">30</span>),
    <span class="NLM_cas:pages">2917-2920</span>CODEN:
                <span class="NLM_cas:coden">TELEAY</span>;
        ISSN:<span class="NLM_cas:issn">0040-4039</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Routes for the synthesis of a set of 8-substituted-6-phenyl-6,7,8,9-tetrahydro-3H-pyrazolo[4,3-f]isoquinolines I [R1 = R2 = H, Me; R1 = H, R2 = Me] are reported.  Pictet-Spengler and Bischler-Napieralski methodologies were employed on the relevant indazole precursors and the merits of the two cyclization reactions for prepg. these structures were assessed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoG9ECcfA1xVbVg90H21EOLACvtfcHk0ljKQI7gLLOtyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtF2jsrrI&md5=ca67573d48141e779f399f8a0a4fe40c</span></div><a href="/servlet/linkout?suffix=cit28a&amp;dbid=16384&amp;doi=10.1016%2Fj.tetlet.2018.06.041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tetlet.2018.06.041%26sid%3Dliteratum%253Aachs%26aulast%3DDavies%26aufirst%3DR.%2BD.%2BM.%26aulast%3DPink%26aufirst%3DJ.%2BH.%26aulast%3DScott%26aufirst%3DJ.%2BS.%26aulast%3DBailey%26aufirst%3DA.%26atitle%3DSynthesis%2520of%25208-substituted-6-phenyl-6%252C7%252C8%252C9-tetrahydro-3H-pyrazolo%255B4%252C3-f%255Disoquinolines%2520using%2520Pictet-Spengler%2520and%2520Bischler-Napieralski%2520cyclisation%2520methods%26jtitle%3DTetrahedron%2520Lett.%26date%3D2018%26volume%3D59%26issue%3D30%26spage%3D2917%26epage%3D2920%26doi%3D10.1016%2Fj.tetlet.2018.06.041" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit28b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lister, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moss, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamont, S. G.</span></span> <span> </span><span class="NLM_article-title">Synthesis of trans 8-substituted-6-phenyl-6,7,8,9-tetrahydro-3<i>H</i>-pyrazolo[4,3-<i>f</i>]isoquinolines using a Pictet-Spengler approach</span>. <i>Tetrahedron Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>59</i></span> (<span class="NLM_issue">51</span>),  <span class="NLM_fpage">4509</span>– <span class="NLM_lpage">4513</span>, <span class="refDoi"> DOI: 10.1016/j.tetlet.2018.11.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=10.1016%2Fj.tetlet.2018.11.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=1%3ACAS%3A528%3ADC%252BC1cXit1Cht7zJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2018&pages=4509-4513&issue=51&author=A.+Baileyauthor=A.+S.+Listerauthor=T.+A.+Mossauthor=J.+S.+Scottauthor=Y.+Wuauthor=S.+G.+Lamont&title=Synthesis+of+trans+8-substituted-6-phenyl-6%2C7%2C8%2C9-tetrahydro-3H-pyrazolo%5B4%2C3-f%5Disoquinolines+using+a+Pictet-Spengler+approach&doi=10.1016%2Fj.tetlet.2018.11.021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28bR"><div class="casContent"><span class="casTitleNuber">28b</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of trans 8-substituted-6-phenyl-6,7,8,9-tetrahydro-3H-pyrazolo[4,3-f]isoquinolines using a Pictet-Spengler approach</span></div><div class="casAuthors">Bailey, Andrew; Lister, Andrew; Moss, Thomas; Scott, James S.; Wu, Ye; Lamont, Scott G.</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron Letters</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">51</span>),
    <span class="NLM_cas:pages">4509-4513</span>CODEN:
                <span class="NLM_cas:coden">TELEAY</span>;
        ISSN:<span class="NLM_cas:issn">0040-4039</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Two complementary approaches for the synthesis of trans 8-substituted-6-phenyl-6,7,8,9-tetrahydro-3H-pyrazolo[4,3-f]isoquinolines I [R = iBu, CH2CHF2, CH2CF3, (1-fluorocyclopropyl)methyl, CH2C(Me)2F; Ar = 4-BrC6H4, 5-Br-2-pyridyl, 4-Br-3-F-C6H3, 4_Br-2,6-di-FC6H2, 4-Br-2-MeOC6H3] was reported.  The first method, directly from α-Me substituted indazole ethanamines, was successful but had limited substrate scope.  The second method utilized a modified Pictet-Spengler cyclization reaction on an aniline substrate followed by late stage construction of the indazole ring and was more versatile in terms of substrate scope.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJuVjpZuGHf7Vg90H21EOLACvtfcHk0lgBuj0ARm3gtQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXit1Cht7zJ&md5=b0f7d200bf1c76f9c1217cb7a58fc7c1</span></div><a href="/servlet/linkout?suffix=cit28b&amp;dbid=16384&amp;doi=10.1016%2Fj.tetlet.2018.11.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tetlet.2018.11.021%26sid%3Dliteratum%253Aachs%26aulast%3DBailey%26aufirst%3DA.%26aulast%3DLister%26aufirst%3DA.%2BS.%26aulast%3DMoss%26aufirst%3DT.%2BA.%26aulast%3DScott%26aufirst%3DJ.%2BS.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DLamont%26aufirst%3DS.%2BG.%26atitle%3DSynthesis%2520of%2520trans%25208-substituted-6-phenyl-6%252C7%252C8%252C9-tetrahydro-3H-pyrazolo%255B4%252C3-f%255Disoquinolines%2520using%2520a%2520Pictet-Spengler%2520approach%26jtitle%3DTetrahedron%2520Lett.%26date%3D2018%26volume%3D59%26issue%3D51%26spage%3D4509%26epage%3D4513%26doi%3D10.1016%2Fj.tetlet.2018.11.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fors, B. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchwald, S. L.</span></span> <span> </span><span class="NLM_article-title">A single phosphine ligand allows palladium-catalyzed intermolecular C−O bond formation with secondary and primary alcohols</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>50</i></span> (<span class="NLM_issue">42</span>),  <span class="NLM_fpage">9943</span>– <span class="NLM_lpage">9947</span>, <span class="refDoi"> DOI: 10.1002/anie.201104361</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=10.1002%2Fanie.201104361" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtFKhs7jE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2011&pages=9943-9947&issue=42&author=X.+Wuauthor=B.+P.+Forsauthor=S.+L.+Buchwald&title=A+single+phosphine+ligand+allows+palladium-catalyzed+intermolecular+C%E2%88%92O+bond+formation+with+secondary+and+primary+alcohols&doi=10.1002%2Fanie.201104361"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">A Single Phosphine Ligand Allows Palladium-Catalyzed Intermolecular C-O Bond Formation with Secondary and Primary Alcohols</span></div><div class="casAuthors">Wu, Xiaoxing; Fors, Brett P.; Buchwald, Stephen L.</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">42</span>),
    <span class="NLM_cas:pages">9943-9947, S9943/1-S9943/134</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">An efficient, general palladium catalyst for C-O bond-forming reactions of secondary and primary alcs. with a range of aryl halides has been developed using RockPhos ligand I.  Heteroaryl halides, and, for the first time, electron-rich aryl halides can be coupled with secondary alcs.  A diverse set of substrate combinations are possible with just a single ligand, thus obviating the need to survey multiple ligands.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1rRsKbYpjabVg90H21EOLACvtfcHk0lgBuj0ARm3gtQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtFKhs7jE&md5=00f2f016dd227483158dacc2e24fb614</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1002%2Fanie.201104361&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201104361%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DX.%26aulast%3DFors%26aufirst%3DB.%2BP.%26aulast%3DBuchwald%26aufirst%3DS.%2BL.%26atitle%3DA%2520single%2520phosphine%2520ligand%2520allows%2520palladium-catalyzed%2520intermolecular%2520C%25E2%2588%2592O%2520bond%2520formation%2520with%2520secondary%2520and%2520primary%2520alcohols%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2011%26volume%3D50%26issue%3D42%26spage%3D9943%26epage%3D9947%26doi%3D10.1002%2Fanie.201104361" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maiti, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fors, B. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henderson, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakamura, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchwald, S. L.</span></span> <span> </span><span class="NLM_article-title">Palladium-catalyzed coupling of functionalized primary and secondary amines with aryl and heteroaryl halides: two ligands suffice in most cases</span>. <i>Chem. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>2</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">57</span>– <span class="NLM_lpage">68</span>, <span class="refDoi"> DOI: 10.1039/C0SC00330A</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=10.1039%2FC0SC00330A" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=22384311" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsFWqsbjF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2011&pages=57-68&issue=1&author=D.+Maitiauthor=B.+P.+Forsauthor=J.+L.+Hendersonauthor=Y.+Nakamuraauthor=S.+L.+Buchwald&title=Palladium-catalyzed+coupling+of+functionalized+primary+and+secondary+amines+with+aryl+and+heteroaryl+halides%3A+two+ligands+suffice+in+most+cases&doi=10.1039%2FC0SC00330A"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Palladium-catalyzed coupling of functionalized primary and secondary amines with aryl and heteroaryl halides: two ligands suffice in most cases</span></div><div class="casAuthors">Maiti, Debabrata; Fors, Brett P.; Henderson, Jaclyn L.; Nakamura, Yoshinori; Buchwald, Stephen L.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Science</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">57-68</span>CODEN:
                <span class="NLM_cas:coden">CSHCCN</span>;
        ISSN:<span class="NLM_cas:issn">2041-6520</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A study on the use of two catalyst systems is reported here.  The ligands used in this study were BrettPhos [i.e., dicyclohexyl[3,6-dimethoxy-2',4',6'-tris(1-methylethyl)[1,1'-biphenyl]-2-yl]phosphine] and RuPhos [i.e., [2',6'-bis(1-methylethoxy)[1,1'-biphenyl]-2-yl]dicyclohexylphosphine].  These ligands provide a wide scope for Pd-catalyzed C-N cross-coupling reactions.  Often low catalyst loadings and short reaction times can be used with functionalized aryl and heteroaryl coupling partners.  The reactions are highly robust and can be set up and performed without the use of a glove box.  These catalysts should find wide application in the synthesis of complex mols. including pharmaceuticals, natural products and functional materials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7MMWmsn65tLVg90H21EOLACvtfcHk0lgBuj0ARm3gtQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsFWqsbjF&md5=217f0d978b9cc44b2b3c468fd291c2b2</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1039%2FC0SC00330A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC0SC00330A%26sid%3Dliteratum%253Aachs%26aulast%3DMaiti%26aufirst%3DD.%26aulast%3DFors%26aufirst%3DB.%2BP.%26aulast%3DHenderson%26aufirst%3DJ.%2BL.%26aulast%3DNakamura%26aufirst%3DY.%26aulast%3DBuchwald%26aufirst%3DS.%2BL.%26atitle%3DPalladium-catalyzed%2520coupling%2520of%2520functionalized%2520primary%2520and%2520secondary%2520amines%2520with%2520aryl%2520and%2520heteroaryl%2520halides%253A%2520two%2520ligands%2520suffice%2520in%2520most%2520cases%26jtitle%3DChem.%2520Sci.%26date%3D2011%26volume%3D2%26issue%3D1%26spage%3D57%26epage%3D68%26doi%3D10.1039%2FC0SC00330A" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vanden
Eynden, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kunchithapatham, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stambuli, J. P.</span></span> <span> </span><span class="NLM_article-title">Calcium-promoted Pictet-Spengler reactions of ketones and aldehydes</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>75</i></span> (<span class="NLM_issue">24</span>),  <span class="NLM_fpage">8542</span>– <span class="NLM_lpage">8549</span>, <span class="refDoi"> DOI: 10.1021/jo1019283</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo1019283" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVGkt7vN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2010&pages=8542-8549&issue=24&author=M.+J.+Vanden%0AEyndenauthor=K.+Kunchithapathamauthor=J.+P.+Stambuli&title=Calcium-promoted+Pictet-Spengler+reactions+of+ketones+and+aldehydes&doi=10.1021%2Fjo1019283"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Calcium-Promoted Pictet-Spengler Reactions of Ketones and Aldehydes</span></div><div class="casAuthors">Vanden Eynden, Matthew J.; Kunchithapatham, Kamala; Stambuli, James P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">8542-8549</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Calcium bis-1,1,1,3,3,3-hexafluoroisopropoxide is an effective catalyst for Pictet-Spengler reactions of 3-hydroxyphenethylamine and 3-hydroxy-4-methoxyphenethylamine with various aldehydes and ketones.  Previous Lewis acid catalyzed Pictet-Spengler reactions of unactivated ketones typically require two sep. reactions (imine formation, cyclization) to obtain the same results.  The reactions described within directly provide 1,1'-disubstituted tetrahydroisoquinolines from the corresponding amine and ketone.  These rare examples of Pictet-Spengler reactions of unactivated ketones demonstrate the unique nature of calcium as a Lewis acid catalyst.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJAHtPvuLZHLVg90H21EOLACvtfcHk0liUc8acRoI8bw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVGkt7vN&md5=ec09721b3ea7da07bdd571c4eb7c4b94</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1021%2Fjo1019283&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo1019283%26sid%3Dliteratum%253Aachs%26aulast%3DVanden%2BEynden%26aufirst%3DM.%2BJ.%26aulast%3DKunchithapatham%26aufirst%3DK.%26aulast%3DStambuli%26aufirst%3DJ.%2BP.%26atitle%3DCalcium-promoted%2520Pictet-Spengler%2520reactions%2520of%2520ketones%2520and%2520aldehydes%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2010%26volume%3D75%26issue%3D24%26spage%3D8542%26epage%3D8549%26doi%3D10.1021%2Fjo1019283" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="note"><p class="first last">In previous work (refs <a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> and <a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a>), we had observed diastereoselective addition into the iminium ion; however, in this case a mixture of epimers of <b>55</b> was obtained. We rationalized this on the basis of the smaller steric bulk of the difluoroethyl group relative to previous alkyl chains we had examined, leading to less facial bias for the addition of the nucleophile. The stereochemistry of <b>31</b> was assigned based on a NOE effect observed between the two methyl groups on the piperidine ring together with the fact that the epimeric isomer of <b>31</b> showed significantly lower activity in both the enzyme (ΔpIC<sub>50</sub> −1.5) and cell (ΔpIC<sub>50</sub> −1.8) assays, consistent with previously established SAR.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fujita, K.-i.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamaguchi, R.</span></span> <span> </span><span class="NLM_article-title">Oxidative cyclization of amino alcohols catalyzed by a Cp*Ir complex. synthesis of indoles, 1,2,3,4-tetrahydroquinolines, and 2,3,4,5-tetrahydro-1-benzazepine</span>. <i>Org. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>4</i></span> (<span class="NLM_issue">16</span>),  <span class="NLM_fpage">2691</span>– <span class="NLM_lpage">2694</span>, <span class="refDoi"> DOI: 10.1021/ol026200s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ol026200s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=1%3ACAS%3A528%3ADC%252BD38Xlt1Cju7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2002&pages=2691-2694&issue=16&author=K.-i.+Fujitaauthor=K.+Yamamotoauthor=R.+Yamaguchi&title=Oxidative+cyclization+of+amino+alcohols+catalyzed+by+a+Cp*Ir+complex.+synthesis+of+indoles%2C+1%2C2%2C3%2C4-tetrahydroquinolines%2C+and+2%2C3%2C4%2C5-tetrahydro-1-benzazepine&doi=10.1021%2Fol026200s"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Oxidative Cyclization of Amino Alcohols Catalyzed by a Cp*Ir Complex. Synthesis of Indoles, 1,2,3,4-Tetrahydroquinolines, and 2,3,4,5-Tetrahydro-1-benzazepine</span></div><div class="casAuthors">Fujita, Kenichi; Yamamoto, Kazunari; Yamaguchi, Ryohei</div><div class="citationInfo"><span class="NLM_cas:title">Organic Letters</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">2691-2694</span>CODEN:
                <span class="NLM_cas:coden">ORLEF7</span>;
        ISSN:<span class="NLM_cas:issn">1523-7060</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A new iridium-catalyzed oxidative cyclization of amino alcs. has been revealed.  Indole derivs. are synthesized in good to excellent yields from 2-aminophenethyl alcs. by means of a [Cp*IrCl2]2/K2CO3 catalytic system.  The present catalytic system is also effective for syntheses of 1,2,3,4-tetrahydroquinolines from 3-(2-aminophenyl)propanols and 2,3,4,5-tetrahydro-1-benzazepine from 4-(2-aminophenyl)butanol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9ywzR01HISLVg90H21EOLACvtfcHk0liUc8acRoI8bw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xlt1Cju7w%253D&md5=48f5b2c85a822a43640a0110aa932c66</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Fol026200s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fol026200s%26sid%3Dliteratum%253Aachs%26aulast%3DFujita%26aufirst%3DK.-i.%26aulast%3DYamamoto%26aufirst%3DK.%26aulast%3DYamaguchi%26aufirst%3DR.%26atitle%3DOxidative%2520cyclization%2520of%2520amino%2520alcohols%2520catalyzed%2520by%2520a%2520Cp%252AIr%2520complex.%2520synthesis%2520of%2520indoles%252C%25201%252C2%252C3%252C4-tetrahydroquinolines%252C%2520and%25202%252C3%252C4%252C5-tetrahydro-1-benzazepine%26jtitle%3DOrg.%2520Lett.%26date%3D2002%26volume%3D4%26issue%3D16%26spage%3D2691%26epage%3D2694%26doi%3D10.1021%2Fol026200s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Degorce, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Callis, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Savi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ducray, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamont, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacFaul, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maudet, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgentin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norman, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peru, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pink, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plé, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, J. S.</span></span> <span> </span><span class="NLM_article-title">Investigation of (<i>E</i>)-3-[4-(2-Oxo-3-aryl-chromen-4-yl)oxyphenyl]acrylic acids as oral selective estrogen receptor down-regulators</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">3522</span>– <span class="NLM_lpage">3533</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00066</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00066" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=1%3ACAS%3A528%3ADC%252BC2MXksl2gsrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=3522-3533&issue=8&author=S.+L.+Degorceauthor=A.+Baileyauthor=R.+Callisauthor=C.+De+Saviauthor=R.+Ducrayauthor=G.+Lamontauthor=P.+MacFaulauthor=M.+Maudetauthor=S.+Martinauthor=R.+Morgentinauthor=R.+A.+Normanauthor=A.+Peruauthor=J.+H.+Pinkauthor=P.+A.+Pl%C3%A9author=B.+Robertsauthor=J.+S.+Scott&title=Investigation+of+%28E%29-3-%5B4-%282-Oxo-3-aryl-chromen-4-yl%29oxyphenyl%5Dacrylic+acids+as+oral+selective+estrogen+receptor+down-regulators&doi=10.1021%2Facs.jmedchem.5b00066"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Investigation of (E)-3-[4-(2-Oxo-3-aryl-chromen-4-yl)oxyphenyl]acrylic Acids as Oral Selective Estrogen Receptor Down-Regulators</span></div><div class="casAuthors">Degorce, Sebastien L.; Bailey, Andrew; Callis, Rowena; De Savi, Chris; Ducray, Richard; Lamont, Gillian; MacFaul, Philip; Maudet, Mickael; Martin, Scott; Morgentin, Remy; Norman, Richard A.; Peru, Aurelien; Pink, Jennifer H.; Ple, Patrick A.; Roberts, Bryan; Scott, James S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3522-3533</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A novel estrogen receptor down-regulator, 7-hydroxycoumarin (5, SS5020), has been reported with antitumor effects against chem. induced mammary tumors.  Here, we report on our own investigation of 7-hydroxycoumarins as potential selective estrogen receptor down-regulators, which led us to the discovery of potent down-regulating antagonists, such as 33.  Subsequent optimization and removal of the 7-hydroxy group led to coumarin 59, which had increased potency and improved rat bioavailability relative to SS5020.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGondIuhUFHcLrVg90H21EOLACvtfcHk0ljG-bwuzxZPbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXksl2gsrc%253D&md5=765350db346581eab5565468f35b55d9</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00066&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00066%26sid%3Dliteratum%253Aachs%26aulast%3DDegorce%26aufirst%3DS.%2BL.%26aulast%3DBailey%26aufirst%3DA.%26aulast%3DCallis%26aufirst%3DR.%26aulast%3DDe%2BSavi%26aufirst%3DC.%26aulast%3DDucray%26aufirst%3DR.%26aulast%3DLamont%26aufirst%3DG.%26aulast%3DMacFaul%26aufirst%3DP.%26aulast%3DMaudet%26aufirst%3DM.%26aulast%3DMartin%26aufirst%3DS.%26aulast%3DMorgentin%26aufirst%3DR.%26aulast%3DNorman%26aufirst%3DR.%2BA.%26aulast%3DPeru%26aufirst%3DA.%26aulast%3DPink%26aufirst%3DJ.%2BH.%26aulast%3DPl%25C3%25A9%26aufirst%3DP.%2BA.%26aulast%3DRoberts%26aufirst%3DB.%26aulast%3DScott%26aufirst%3DJ.%2BS.%26atitle%3DInvestigation%2520of%2520%2528E%2529-3-%255B4-%25282-Oxo-3-aryl-chromen-4-yl%2529oxyphenyl%255Dacrylic%2520acids%2520as%2520oral%2520selective%2520estrogen%2520receptor%2520down-regulators%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26issue%3D8%26spage%3D3522%26epage%3D3533%26doi%3D10.1021%2Facs.jmedchem.5b00066" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="note"><p class="first last">Similar observations have reported by other research groups, for examples see refs <a onclick="showRef(event, 'cit17b'); return false;" href="javascript:void(0);" class="ref cit17b">(17b)</a> and <a onclick="showRef(event, 'cit19c'); return false;" href="javascript:void(0);" class="ref cit19c">(19c)</a>.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="note"><p class="first last">The measured <i>t</i><sub>1/2</sub> of <b>33</b> in pH 10 buffer at 70 °C was 82 h which was extrapolated to an estimated stability <i>t</i><sub>1/2</sub> of 78 days at 25 °C.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Andersson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evertsson, E.</span></span> <span> </span><span class="NLM_article-title">Prediction of drug candidates’ sensitivity toward autoxidation: computational estimation of C-H dissociation energies of carbon-centered radicals</span>. <i>J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>103</i></span>,  <span class="NLM_fpage">1949</span>– <span class="NLM_lpage">1955</span>, <span class="refDoi"> DOI: 10.1002/jps.23986</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=10.1002%2Fjps.23986" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=24823496" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=1%3ACAS%3A528%3ADC%252BC2cXnsl2ksLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2014&pages=1949-1955&author=T.+Anderssonauthor=A.+Brooauthor=E.+Evertsson&title=Prediction+of+drug+candidates%E2%80%99+sensitivity+toward+autoxidation%3A+computational+estimation+of+C-H+dissociation+energies+of+carbon-centered+radicals&doi=10.1002%2Fjps.23986"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Prediction of Drug Candidates Sensitivity Toward Autoxidation: Computational Estimation of C-H Dissociation Energies of Carbon-Centered Radicals</span></div><div class="casAuthors">Andersson, Thomas; Broo, Anders; Evertsson, Emma</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmaceutical Sciences</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1949-1955</span>CODEN:
                <span class="NLM_cas:coden">JPMSAE</span>;
        ISSN:<span class="NLM_cas:issn">0022-3549</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A method to predict a compd.'s sensitivity toward autoxidn. using bond dissocn. energies for hydrogen abstraction is described.  The methodol. is based on quantum mechanics and has been validated with a small mol. test set.  Through this work, it has been obsd. that stabilization of an incipient radical by more than a single functional group is normally required to trigger autoxidn.  The method has also been used to understand salt effects, wherein protonation of a basic amine stabilizes proximal C-H bonds to autoxidn.  It can be used to support understanding of autoxidn. processes and can form a predictive role for propensity to form potentially genotoxic and other degrdn. products.  An automated protocol has been developed that allows the nonspecialist to perform quantum chem. calcns.  The protocol is robust to enable general usage such that drug-like mols. can be handled by the tool and give an answer in hours (up to some days) depending on the size of the mol.  The efficiency of the tool makes it possible to perform risk assessment for autoxidn. of small lists of mols. and could typically be used for short-listed candidates before drug nomination, during drug formulation development, and during due diligence for in-licensing compds. © 2014 Wiley Periodicals, Inc. and the American Pharmacists Assocn. J Pharm Sci.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqeoSZl90Fgv7Vg90H21EOLACvtfcHk0li3NKre7O2dhA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXnsl2ksLs%253D&md5=b97b5da7006ee628987ff3ffa7027cea</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1002%2Fjps.23986&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjps.23986%26sid%3Dliteratum%253Aachs%26aulast%3DAndersson%26aufirst%3DT.%26aulast%3DBroo%26aufirst%3DA.%26aulast%3DEvertsson%26aufirst%3DE.%26atitle%3DPrediction%2520of%2520drug%2520candidates%25E2%2580%2599%2520sensitivity%2520toward%2520autoxidation%253A%2520computational%2520estimation%2520of%2520C-H%2520dissociation%2520energies%2520of%2520carbon-centered%2520radicals%26jtitle%3DJ.%2520Pharm.%2520Sci.%26date%3D2014%26volume%3D103%26spage%3D1949%26epage%3D1955%26doi%3D10.1002%2Fjps.23986" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ghamari, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zarei, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arias-Montano, J.-A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reiner, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dastmalchi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stark, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamzeh-Mivehroud, M.</span></span> <span> </span><span class="NLM_article-title">Histamine H3 receptor antagonists/inverse agonists: Where do they go?</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>200</i></span>,  <span class="NLM_fpage">69</span>– <span class="NLM_lpage">84</span>, <span class="refDoi"> DOI: 10.1016/j.pharmthera.2019.04.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=10.1016%2Fj.pharmthera.2019.04.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=31028835" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=1%3ACAS%3A528%3ADC%252BC1MXovVOmtrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=200&publication_year=2019&pages=69-84&author=N.+Ghamariauthor=O.+Zareiauthor=J.-A.+Arias-Montanoauthor=D.+Reinerauthor=S.+Dastmalchiauthor=H.+Starkauthor=M.+Hamzeh-Mivehroud&title=Histamine+H3+receptor+antagonists%2Finverse+agonists%3A+Where+do+they+go%3F&doi=10.1016%2Fj.pharmthera.2019.04.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Histamine H3 receptor antagonists/inverse agonists: Where do they go?</span></div><div class="casAuthors">Ghamari, Nakisa; Zarei, Omid; Arias-Montano, Jose-Antonio; Reiner, David; Dastmalchi, Siavoush; Stark, Holger; Hamzeh-Mivehroud, Maryam</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">200</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">69-84</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Since the discovery of the histamine H3 receptor in 1983, tremendous advances in the pharmacol. aspects of H3 receptor antagonists/inverse agonists have been accomplished in preclin. studies.  At present, there are several drug candidates that reached clin. trial studies for various indications.  However, entrance of these candidates to the pharmaceutical market is not free from challenges, and a variety of difficulties is engaged with their developmental process.  In this review, the potential role of H3 receptors in the pathophysiol. of various central nervous system, metabolic and allergic diseases is discussed.  Thereafter, the current status for H3 receptor antagonists/inverse agonists in ongoing clin. trial studies is reviewed and obstacles in developing these agents are emphasized.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3IbgM1GUg97Vg90H21EOLACvtfcHk0li3NKre7O2dhA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXovVOmtrs%253D&md5=7129bc498b85275ffa09f839ddeb04a9</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2019.04.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2019.04.007%26sid%3Dliteratum%253Aachs%26aulast%3DGhamari%26aufirst%3DN.%26aulast%3DZarei%26aufirst%3DO.%26aulast%3DArias-Montano%26aufirst%3DJ.-A.%26aulast%3DReiner%26aufirst%3DD.%26aulast%3DDastmalchi%26aufirst%3DS.%26aulast%3DStark%26aufirst%3DH.%26aulast%3DHamzeh-Mivehroud%26aufirst%3DM.%26atitle%3DHistamine%2520H3%2520receptor%2520antagonists%252Finverse%2520agonists%253A%2520Where%2520do%2520they%2520go%253F%26jtitle%3DPharmacol.%2520Ther.%26date%3D2019%26volume%3D200%26spage%3D69%26epage%3D84%26doi%3D10.1016%2Fj.pharmthera.2019.04.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Othman, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haig, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Florian, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Locke, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dutta, S.</span></span> <span> </span><span class="NLM_article-title">Safety, tolerability and pharmacokinetics of the histamine H3 receptor antagonist, ABT-288, in healthy young adults and elderly volunteers</span>. <i>B. J. Clin. Pharm.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>75</i></span>,  <span class="NLM_fpage">1299</span>– <span class="NLM_lpage">1311</span>, <span class="refDoi"> DOI: 10.1111/j.1365-2125.2012.04472.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=10.1111%2Fj.1365-2125.2012.04472.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=23016924" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2013&pages=1299-1311&author=A.+A.+Othmanauthor=G.+Haigauthor=H.+Florianauthor=C.+Lockeauthor=J.+Zhangauthor=S.+Dutta&title=Safety%2C+tolerability+and+pharmacokinetics+of+the+histamine+H3+receptor+antagonist%2C+ABT-288%2C+in+healthy+young+adults+and+elderly+volunteers&doi=10.1111%2Fj.1365-2125.2012.04472.x"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39a&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2125.2012.04472.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2125.2012.04472.x%26sid%3Dliteratum%253Aachs%26aulast%3DOthman%26aufirst%3DA.%2BA.%26aulast%3DHaig%26aufirst%3DG.%26aulast%3DFlorian%26aufirst%3DH.%26aulast%3DLocke%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DDutta%26aufirst%3DS.%26atitle%3DSafety%252C%2520tolerability%2520and%2520pharmacokinetics%2520of%2520the%2520histamine%2520H3%2520receptor%2520antagonist%252C%2520ABT-288%252C%2520in%2520healthy%2520young%2520adults%2520and%2520elderly%2520volunteers%26jtitle%3DB.%2520J.%2520Clin.%2520Pharm.%26date%3D2013%26volume%3D75%26spage%3D1299%26epage%3D1311%26doi%3D10.1111%2Fj.1365-2125.2012.04472.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit39b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Iannone, R.</span>; <span class="NLM_string-name">Renger, J.</span>; <span class="NLM_string-name">Potter, W.</span>; <span class="NLM_string-name">Dijk, D.</span>; <span class="NLM_string-name">Boyle, J.</span>; <span class="NLM_string-name">Palcza, J.</span>; <span class="NLM_string-name">Zhao, B.</span>; <span class="NLM_string-name">Bergman, A.</span>; <span class="NLM_string-name">Van Laere, K.</span>; <span class="NLM_string-name">Bormans, G.</span>; <span class="NLM_string-name">Sanabria, S.</span>; <span class="NLM_string-name">Calder, N.</span>; <span class="NLM_string-name">De Lepeleire, I.</span>; <span class="NLM_string-name">Van Hoydonck, P.</span>; <span class="NLM_string-name">Marsilio, S.</span>; <span class="NLM_string-name">Cerchio, K.</span>; <span class="NLM_string-name">Declercq, R.</span>; <span class="NLM_string-name">Fox-Bosetti, S.</span>; <span class="NLM_string-name">Verma, A.</span>; <span class="NLM_string-name">Van Bortel, L.</span>; <span class="NLM_string-name">Achten, E.</span>; <span class="NLM_string-name">Ma, J.</span>; <span class="NLM_string-name">Hargreaves, R.</span>; <span class="NLM_string-name">Koblan, K.</span>; <span class="NLM_string-name">Chodakewitz, J.</span>; <span class="NLM_string-name">Gottesdiener, K.</span>; <span class="NLM_string-name">Murphy, G.</span></span> <span> </span><span class="NLM_article-title">The Relationship between Brain Receptor Occupancy (RO) and Alerting Effects in Humans Support MK-0249 and MK-3134 as Inverse Agonists at the Histamine Subtype-3 Pre-Synaptic Receptor (H3R)</span>. American College Neuropsychopharmacology 48th Annual Meeting (ACNP), <span class="NLM_publisher-loc">Hollywood, FL</span>, <span class="NLM_year">2009</span>, December 6–10;  <span class="NLM_fpage">198</span> (abstract).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&pages=198&author=R.+Iannone&author=J.+Renger&author=W.+Potter&author=D.+Dijk&author=J.+Boyle&author=J.+Palcza&author=B.+Zhao&author=A.+Bergman&author=K.+Van+Laere&author=G.+Bormans&author=S.+Sanabria&author=N.+Calder&author=I.+De+Lepeleire&author=P.+Van+Hoydonck&author=S.+Marsilio&author=K.+Cerchio&author=R.+Declercq&author=S.+Fox-Bosetti&author=A.+Verma&author=L.+Van+Bortel&author=E.+Achten&author=J.+Ma&author=R.+Hargreaves&author=K.+Koblan&author=J.+Chodakewitz&author=K.+Gottesdiener&author=G.+Murphy&title=The+Relationship+between+Brain+Receptor+Occupancy+%28RO%29+and+Alerting+Effects+in+Humans+Support+MK-0249+and+MK-3134+as+Inverse+Agonists+at+the+Histamine+Subtype-3+Pre-Synaptic+Receptor+%28H3R%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26aulast%3DIannone%26aufirst%3DR.%26atitle%3DThe%2520Relationship%2520between%2520Brain%2520Receptor%2520Occupancy%2520%2528RO%2529%2520and%2520Alerting%2520Effects%2520in%2520Humans%2520Support%2520MK-0249%2520and%2520MK-3134%2520as%2520Inverse%2520Agonists%2520at%2520the%2520Histamine%2520Subtype-3%2520Pre-Synaptic%2520Receptor%2520%2528H3R%2529%26date%3D2009%26spage%3D198" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Callis, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabow, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tonge, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradbury, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Challinor, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, G.</span></span> <span> </span><span class="NLM_article-title">A screening assay cascade to identify and characterize novel selective estrogen receptor downregulators (SERDs)</span>. <i>J. Biomol. Screening</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">748</span>– <span class="NLM_lpage">759</span>, <span class="refDoi"> DOI: 10.1177/1087057115580298</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=10.1177%2F1087057115580298" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=25851036" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsF2nsbzE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2015&pages=748-759&author=R.+Callisauthor=A.+Rabowauthor=M.+Tongeauthor=R.+Bradburyauthor=M.+Challinorauthor=K.+Robertsauthor=K.+Jonesauthor=G.+Walker&title=A+screening+assay+cascade+to+identify+and+characterize+novel+selective+estrogen+receptor+downregulators+%28SERDs%29&doi=10.1177%2F1087057115580298"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">A screening assay cascade to identify and characterize novel selective estrogen receptor downregulators (SERDs)</span></div><div class="casAuthors">Callis, Rowena; Rabow, Alfred; Tonge, Michael; Bradbury, Robert; Challinor, Mairi; Roberts, Karen; Jones, Karen; Walker, Graeme</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biomolecular Screening</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">748-759</span>CODEN:
                <span class="NLM_cas:coden">JBISF3</span>;
        ISSN:<span class="NLM_cas:issn">1087-0571</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">Here, we describe an approach to identify novel selective estrogen receptor downregulator (SERD) compds. with improved properties such as oral bioavailability and the potential of increased efficacy compared to currently marketed drug treatments.  Previously, methodologies such as Western blotting and transient cell reporter assays have been used to identify and characterize SERD compds., but such approaches can be limited due to low throughput and sensitivity, resp.  We have used an endogenous cell-imaging strategy that has both the throughput and sensitivity to support a large-scale hit-to-lead program to identify novel compds.  A screening cascade with a suite of assays has been developed to characterize compds. that modulate estrogen receptor α (ERα)-mediated signaling or downregulate ERα levels in cells.  Initially, from a focused high-throughput screening, novel ERα binders were identified that could be modified chem. into ERα downregulators.  Following this, cellular assays helped det. the mechanism of action of compds. to distinguish between on-target and off-target compds. and differentiate SERDs, selective estrogen receptor modulator (SERM) compds., and agonist ERα ligands.  Data are shown to exemplify the characterization of ERα-mediated signaling inhibitors using a selection of literature compds. and illustrate how this cascade has been used to drive the chem. design of novel SERD compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqNNWMPPJDNrVg90H21EOLACvtfcHk0lhPeVIN1KysfA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsF2nsbzE&md5=13c27dbf08f315d469f81b2bcefb4499</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1177%2F1087057115580298&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1087057115580298%26sid%3Dliteratum%253Aachs%26aulast%3DCallis%26aufirst%3DR.%26aulast%3DRabow%26aufirst%3DA.%26aulast%3DTonge%26aufirst%3DM.%26aulast%3DBradbury%26aufirst%3DR.%26aulast%3DChallinor%26aufirst%3DM.%26aulast%3DRoberts%26aufirst%3DK.%26aulast%3DJones%26aufirst%3DK.%26aulast%3DWalker%26aufirst%3DG.%26atitle%3DA%2520screening%2520assay%2520cascade%2520to%2520identify%2520and%2520characterize%2520novel%2520selective%2520estrogen%2520receptor%2520downregulators%2520%2528SERDs%2529%26jtitle%3DJ.%2520Biomol.%2520Screening%26date%3D2015%26volume%3D20%26spage%3D748%26epage%3D759%26doi%3D10.1177%2F1087057115580298" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10a','cit10b'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14a','cit14b'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17a','cit17b'],'ref18':['cit18'],'ref19':['cit19a','cit19b','cit19c'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26a','cit26b','cit26c'],'ref27':['cit27'],'ref28':['cit28a','cit28b'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':[],'ref33':['cit33'],'ref34':['cit34'],'ref35':[],'ref36':[],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39a','cit39b'],'ref40':['cit40']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 5 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Madhusoodanan Mottamal, Borui Kang, Xianyou Peng, <span class="NLM_string-name hlFld-ContribAuthor">Guangdi Wang</span>. </span><span class="cited-content_cbyCitation_article-title">From Pure Antagonists to Pure Degraders of the Estrogen Receptor: Evolving Strategies for the Same Target. </span><span class="cited-content_cbyCitation_journal-name">ACS Omega</span><span> <strong>2021,</strong> <em>6 </em>
                                    (14)
                                     , 9334-9343. <a href="https://doi.org/10.1021/acsomega.0c06362" title="DOI URL">https://doi.org/10.1021/acsomega.0c06362</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsomega.0c06362&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsomega.0c06362%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Omega%26atitle%3DFrom%252BPure%252BAntagonists%252Bto%252BPure%252BDegraders%252Bof%252Bthe%252BEstrogen%252BReceptor%25253A%252BEvolving%252BStrategies%252Bfor%252Bthe%252BSame%252BTarget%26aulast%3DMottamal%26aufirst%3DMadhusoodanan%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D31122020%26date%3D19032021%26date%3D30032021%26volume%3D6%26issue%3D14%26spage%3D9334%26epage%3D9343" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">James S. Scott, Thomas A. Moss, Bernard Barlaam, Paul R. J. Davey, Gary Fairley, Eric T. Gangl, Ryan D. R. Greenwood, Holia Hatoum-Mokdad, Andrew S. Lister, David Longmire, Radoslaw Polanski, Stephen Stokes, Michael J. Tucker, Jeffrey G. Varnes, <span class="NLM_string-name hlFld-ContribAuthor">Bin Yang</span>. </span><span class="cited-content_cbyCitation_article-title">Addition of Fluorine and a Late-Stage Functionalization (LSF) of the Oral SERD AZD9833. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2020,</strong> <em>11 </em>
                                    (12)
                                     , 2519-2525. <a href="https://doi.org/10.1021/acsmedchemlett.0c00505" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.0c00505</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.0c00505&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.0c00505%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DAddition%252Bof%252BFluorine%252Band%252Ba%252BLate-Stage%252BFunctionalization%252B%252528LSF%252529%252Bof%252Bthe%252BOral%252BSERD%252BAZD9833%26aulast%3DScott%26aufirst%3DJames%2BS.%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D17092020%26date%3D23102020%26date%3D28102020%26volume%3D11%26issue%3D12%26spage%3D2519%26epage%3D2525" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Cristina  Hernando</span>, <span class="hlFld-ContribAuthor ">Belén  Ortega-Morillo</span>, <span class="hlFld-ContribAuthor ">Marta  Tapia</span>, <span class="hlFld-ContribAuthor ">Santiago  Moragón</span>, <span class="hlFld-ContribAuthor ">María Teresa  Martínez</span>, <span class="hlFld-ContribAuthor ">Pilar  Eroles</span>, <span class="hlFld-ContribAuthor ">Iris  Garrido-Cano</span>, <span class="hlFld-ContribAuthor ">Anna  Adam-Artigues</span>, <span class="hlFld-ContribAuthor ">Ana  Lluch</span>, <span class="hlFld-ContribAuthor ">Begoña  Bermejo</span>, <span class="hlFld-ContribAuthor ">Juan Miguel  Cejalvo</span>. </span><span class="cited-content_cbyCitation_article-title">Oral Selective Estrogen Receptor Degraders (SERDs) as a Novel Breast Cancer Therapy: Present and Future from a Clinical Perspective. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Molecular Sciences</span><span> <strong>2021,</strong> <em>22 </em>
                                    (15)
                                     , 7812. <a href="https://doi.org/10.3390/ijms22157812" title="DOI URL">https://doi.org/10.3390/ijms22157812</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ijms22157812&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fijms22157812%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Molecular%2520Sciences%26atitle%3DOral%252BSelective%252BEstrogen%252BReceptor%252BDegraders%252B%252528SERDs%252529%252Bas%252Ba%252BNovel%252BBreast%252BCancer%252BTherapy%25253A%252BPresent%252Band%252BFuture%252Bfrom%252Ba%252BClinical%252BPerspective%26aulast%3DHernando%26aufirst%3DCristina%26date%3D2021%26date%3D2021%26volume%3D22%26issue%3D15%26spage%3D7812" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">. </span><span class="cited-content_cbyCitation_article-title">Synthesis of AZD9833. </span><span class="cited-content_cbyCitation_journal-name">Synfacts</span><span> <strong>2021,</strong>,, 0243. <a href="https://doi.org/10.1055/s-0040-1719368" title="DOI URL">https://doi.org/10.1055/s-0040-1719368</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1055/s-0040-1719368&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1055%2Fs-0040-1719368%26sid%3Dliteratum%253Aachs%26jtitle%3DSynfacts%26atitle%3DSynthesis%252Bof%252BAZD9833%26date%3D2021%26date%3D2021%26volume%3D17%26issue%3D03%26spage%3D0243" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Amber Y. S.  Balazs</span>, <span class="hlFld-ContribAuthor ">Nichola L.  Davies</span>, <span class="hlFld-ContribAuthor ">David  Longmire</span>, <span class="hlFld-ContribAuthor ">Martin J.  Packer</span>, <span class="hlFld-ContribAuthor ">Elisabetta  Chiarparin</span>. </span><span class="cited-content_cbyCitation_article-title">Nuclear magnetic resonance free ligand conformations and atomic resolution dynamics. </span><span class="cited-content_cbyCitation_journal-name">Magnetic Resonance</span><span> <strong>2021,</strong> <em>2 </em>
                                    (1)
                                     , 489-498. <a href="https://doi.org/10.5194/mr-2-489-2021" title="DOI URL">https://doi.org/10.5194/mr-2-489-2021</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.5194/mr-2-489-2021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.5194%2Fmr-2-489-2021%26sid%3Dliteratum%253Aachs%26jtitle%3DMagnetic%2520Resonance%26atitle%3DNuclear%252Bmagnetic%252Bresonance%252Bfree%252Bligand%252Bconformations%252Band%252Batomic%252Bresolution%252Bdynamics%26aulast%3DBalazs%26aufirst%3DAmber%2BY.%2BS.%26date%3D2021%26date%3D2021%26volume%3D2%26issue%3D1%26spage%3D489%26epage%3D498" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01163/20201203/images/medium/jm0c01163_0029.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01163/20201203/images/large/jm0c01163_0029.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01163&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01163/20201203/images/medium/jm0c01163_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01163/20201203/images/large/jm0c01163_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Selected examples of oral SERDs.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01163/20201203/images/large/jm0c01163_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01163&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01163/20201203/images/medium/jm0c01163_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01163/20201203/images/large/jm0c01163_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Medchem strategy for basic series of tricyclic indazole SERDs.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01163/20201203/images/large/jm0c01163_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01163&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01163/20201203/images/medium/jm0c01163_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01163/20201203/images/large/jm0c01163_0013.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Routes to Anilines Bearing a Diversity of <i>N</i>-Alkyl Substituents<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01163/20201203/images/large/jm0c01163_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01163&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) <i>n</i>-BuLi, THF, −78 to 0 °C, 1 h, then 4 N HCl/dioxane, RT, 1 h, 60%; (b) alkyl triflate, DIPEA, 1,4-dioxane, 90 °C, 63–74% or isobutyrylaldehyde, Na(OAc)<sub>3</sub>BH, THF, 0 °C, 56%; (c) benzophenone imine, Pd<sub>2</sub>dba<sub>3</sub>, Rac-BINAP, NaO<sup><i>t</i></sup>Bu, toluene, 90 °C, then 1 N aq. HCl, 71–85%; (d) <i>n</i>-BuLi, THF, −78 to 0 °C, 1 h, then 4 N HCl/dioxane, RT, 4 h; (e) NH<sub>2</sub>OH, NH<sub>2</sub>OH·HCl, EtOH, reflux. 84% over two steps; (f) alkyl triflate, DIPEA, 1,4-dioxane, 90 °C, 44–100% or 1-fluorocyclopropane-1-carboxylic acid, HATU, Et<sub>3</sub>N, DMF, RT, 61%, then BH<sub>3</sub>·THF, THF, 65 °C, 82%.</p></p></figure><figure data-id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01163/20201203/images/medium/jm0c01163_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01163/20201203/images/large/jm0c01163_0014.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Pictet–Spengler Approach to <i>O</i>-Linked Tricyclic Indazoles<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01163/20201203/images/large/jm0c01163_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01163&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) aldehyde, AcOH (1% H<sub>2</sub>O), 90 °C, then aq. HCl or NH<sub>2</sub>OH, 44–100%; (b) NaNO<sub>2</sub>, propionic acid, H<sub>2</sub>O, −20 °C, 17–75%; (c) 3,4-dihydro-2<i>H</i>-pyran, PTSA hydrate, DCM, reflux, 53–99%; (d) 2-[3-(fluoromethyl)azetidin-1-yl]ethanol, RockPhos third generation Pd precatalyst, Cs<sub>2</sub>CO<sub>3</sub>, toluene, 90 °C, 42–78%; (e) 4 N HCl dioxane, RT, 37–78%.</p></p></figure><figure data-id="sch3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01163/20201203/images/medium/jm0c01163_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01163/20201203/images/large/jm0c01163_0015.jpeg" id="rightTab-gr15" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Variation of the <i>O</i>- and <i>N</i>-Linked Basic Substituent<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01163/20201203/images/large/jm0c01163_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01163&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) <i>tert</i>-butyl (3-fluoropropyl)(2-hydroxyethyl)carbamate, RockPhos third generation Pd precatalyst, Cs<sub>2</sub>CO<sub>3</sub>, toluene, 90 °C, 92% (from <b>49g</b>); (b) HCl/dioxane, RT, 29%; (c) <i>N</i><sup>1</sup>-(3-fluoropropyl)ethane-1,2-diamine. 2HCl, BrettPhos third generation Pd precatalyst, NaO<sup>t</sup>Bu, dioxane, 50 °C, 18% (from <b>49h′</b>); (d) (B(Pin))<sub>2</sub>, Pd(dppf)Cl<sub>2</sub>, KOAc, dioxane, 80 °C, 46%; (e) Aq. H<sub>2</sub>O<sub>2</sub>, 1 M NaOH, THF, 5 °C, 63%; (f) <i>tert</i>-butyl 3-hydroxyazetidine-1-carboxylate, DEAD, PPh<sub>3</sub>, toluene, 110 °C, 75% (from <b>51</b>); (g) <i>tert</i>-butyl 3-aminoazetidine-1-carboxylate, BrettPhos third generation Pd precatalyst, Cs<sub>2</sub>CO<sub>3</sub>, dioxane, MW, 100 °C, 91% (from <b>49g</b>); (h) HCl/dioxane, RT, 36–87%; (i) 1-fluoro-3-iodopropane, DIPEA, NMP, RT, 18–39%; (j) 1-(3-fluoropropyl)azetidin-3-amine, BrettPhos third generation Pd precatalyst, NaO<sup>t</sup>Bu, dioxane, 90 °C, then DCM, TFA, RT, 10% (from <b>49h</b>).</p></p></figure><figure data-id="sch4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01163/20201203/images/medium/jm0c01163_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01163/20201203/images/large/jm0c01163_0016.jpeg" id="rightTab-gr16" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Pictet–Spengler Approach to <i>N</i>-Linked Tricyclic Indazoles (Method A)<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01163/20201203/images/large/jm0c01163_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01163&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) aldehyde, AcOH (1% H<sub>2</sub>O), 90 °C, then aq. HCl or NH<sub>2</sub>OH, 16–68%; (b) NaNO<sub>2</sub>, propionic acid, H<sub>2</sub>O, −20 °C, 34–75%; (c) 3,4-dihydro-2<i>H</i>-pyran, PTSA hydrate, DCM; (d) if R<sup>3</sup> = CH<sub>2</sub>OSiPh<sub>2</sub>tBu, 1 M TBAF, THF, RT, 71%; (e) 1-(3-fluoropropyl)azetidin-3-amine or <i>tert</i>-butyl 3-aminoazetidine-1-carboxylate, BrettPhos third generation Pd precatalyst, NaO<sup>t</sup>Bu or Cs<sub>2</sub>CO<sub>3</sub>, dioxane, 27–88%; (f) HCl/dioxane, RT, 40–92%; (f) (when <i>tert</i>-butyl 3-aminoazetidine-1-carboxylate used in step (e)) 1-fluoro-3-iodopropane, DIPEA, NMP, RT, 29–51%.</p></p></figure><figure data-id="sch5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01163/20201203/images/medium/jm0c01163_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01163/20201203/images/large/jm0c01163_0017.jpeg" id="rightTab-gr17" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Pictet–Spengler Approach on Preformed Indazole to Access <b>28</b> (Method B)<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01163/20201203/images/large/jm0c01163_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01163&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) <i>n</i>-BuLi, <i>tert</i>-butyl (<i>R</i>)-4-methyl-1,2,3-oxathiazolidine-3-carboxylate 2,2-dioxide, THF, −78 °C, 57% then HCl/dioxane, DCM, RT, 57%. Isolated as 2HCl salt; (b) 2,2,2-trifluoroethyl trifluoromethanesulfonate, K<sub>2</sub>CO<sub>3</sub>, DCM, reflux, 93%; (c) 5-bromopicolinaldehyde, toluene, TFA, 80 °C, 75%; (d) 1-(3-fluoropropyl)azetidin-3-amine, BrettPhos third generation Pd precatalyst, NaO<sup>t</sup>Bu, dioxane, 55 °C, 74%.</p></p></figure><figure data-id="sch6" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01163/20201203/images/medium/jm0c01163_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01163/20201203/images/large/jm0c01163_0018.jpeg" id="rightTab-gr18" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Oxidation/Grignard Approach to the Quaternary Substituted core <b>31</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01163/20201203/images/large/jm0c01163_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01163&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) cerium(IV) ammonium nitrate, MeCN/H<sub>2</sub>O, RT, then MeMgBr, THF, −78 °C, 14%, 3:2 mixture of diastereoisomers; (b) HCl/dioxane, MeOH, RT, 28%, 3:2 mixture of diastereoisomers; (c) 1-(3-fluoropropyl)azetidin-3-amine, BrettPhos third generation Pd precatalyst, NaO<sup>t</sup>Bu, dioxane, 65 °C, SFC separation, 12%.</p></p></figure><figure data-id="sch7" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01163/20201203/images/medium/jm0c01163_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01163/20201203/images/large/jm0c01163_0019.jpeg" id="rightTab-gr19" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 7. Pictet–Spengler Route to <i>gem</i>-Dimethyl Substituted Tricyclic Indazole <b>32</b> and <b>33</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01163/20201203/images/large/jm0c01163_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01163&amp;id=sch7"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) <i>n</i>-BuLi, 2,2-dimethyloxirane, BF<sub>3</sub>·Et<sub>2</sub>O, THF, −78 °C, 1 h, 62%; (b) 2-chloroacetonitrile, AcOH, H<sub>2</sub>SO<sub>4</sub>, RT, 48 h, 59%; (c) thiourea, EtOH, AcOH, reflux, 16 h, 83%; (d) 5-bromopicolinaldehyde, toluene, TFA, 150 °C, MW, 72%; (e) 3,4-dihydro-2<i>H</i>-pyran, PTSA hydrate, DCM, 50 °C, 95%; (f) 2,2-difluoroethyl trifluoromethanesulfonate (0.4 M in DCM), DIPEA, dioxane, 60 °C, 81%; (g) 1-(3-fluoropropyl)azetidin-3-amine, BrettPhos third generation Pd precatalyst, NaO<sup>t</sup>Bu, dioxane, 60 °C, then DCM, TFA, RT, 68%; (h) SFC chromatography; (i) 2,2,2-trifluoroethyl trifluoromethanesulfonate (0.32 M in chloroform), DIPEA, dioxane, 65 °C, 53%; (j) 5-bromopicolinaldehyde, toluene, TFA, 100 °C, 25%; (k) 1-(3-fluoropropyl)azetidin-3-amine, BrettPhos third generation Pd precatalyst, NaO<sup>t</sup>Bu, dioxane, 80 °C, 30%.</p></p></figure><figure data-id="sch8" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01163/20201203/images/medium/jm0c01163_0020.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01163/20201203/images/large/jm0c01163_0020.jpeg" id="rightTab-gr20" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 8. Pictet–Spengler Route to Tricyclic Indole <b>34</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01163/20201203/images/large/jm0c01163_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01163&amp;id=sch8"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) paraformaldehyde, KOH, DMA, RT, 72%; (b) ammonium formate, Zn, MeOH, RT, 96%; (c) hexane-2,5-dione, PTSA hydrate, toluene, 100 °C, 98%; (d) PMBCl, NaH, NaI, DMF, RT, 80%; (e) <i>n</i>-BuLi, <i>tert</i>-butyl (4<i>R</i>)-4-methyl-1,2-oxathiolane-3-carboxylate 2,2-dioxide, THF, −78 °C, 61%; (f) HCl/dioxane, MeOH, RT, 57%; (g) Aq. NH<sub>2</sub>OH, NH<sub>2</sub>OH.HCl, EtOH, 50 °C, 36%; (h) ethyl 2,2,2-trifluoroacetate, DIPEA, MeOH, RT, quant. (i) BH<sub>3</sub>.THF, THF, 65 °C, 77%; (j) 5-bromopicolinaldehyde, Yb(III)Tf, MeCN/H<sub>2</sub>O, 70 °C, 77%; (k) HCl/dioxane, MeOH, RT, 79%; (l) pentamethylcyclopentadienyl iridium dichloride, K<sub>2</sub>CO<sub>3</sub>, toluene, 100 °C, 80%; (m) 1-(3-fluoropropyl)azetidin-3-amine, BrettPhos third generation Pd precatalyst, NaO<sup>t</sup>Bu, dioxane, 50 °C, 62%.</p></p></figure><figure data-id="sch9" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01163/20201203/images/medium/jm0c01163_0021.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01163/20201203/images/large/jm0c01163_0021.jpeg" id="rightTab-gr21" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 9. Variation of the Azetidine Substituent<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01163/20201203/images/large/jm0c01163_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01163&amp;id=sch9"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) amine, BrettPhos third generation Pd precatalyst, NaO<sup><i>t</i></sup>Bu, dioxane, 57%; (b) TFA, DCM, RT, then 1-fluoro-3-iodopropane, DIPEA, DMF, RT, 75%; (c) paraformaldehyde, NaCNBH<sub>3</sub>, AcOH, <sup><i>i</i></sup>PrOH, 70 °C, 72%.</p></p></figure><figure data-id="sch10" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Scheme 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01163/20201203/images/medium/jm0c01163_0022.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01163/20201203/images/large/jm0c01163_0022.jpeg" id="rightTab-gr22" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 10. Variation of the <i>N</i>-Linked Basic Substituent<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01163/20201203/images/large/jm0c01163_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01163&amp;id=sch10"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) benzyl (2-aminoethyl)(3-fluoropropyl)carbamate, BrettPhos third generation Pd precatalyst, NaO<sup><i>t</i></sup>Bu, dioxane, RT, 58% (from <b>54</b>); (b) Pd/C, H<sub>2</sub>, EtOH, RT, 80%; (c) (X = NH): <i>tert</i>-butyl (<i>S</i>)-3-aminopyrrolidine-1-carboxylate, BrettPhos third generation Pd precatalyst, NaO<sup>t</sup>Bu, dioxane, 80 °C, 81% (from <b>54</b>); (d) (X = O): <i>tert</i>-butyl (<i>S</i>)-3-hydroxypyrrolidine-1-carboxylate, RockPhos third generation Pd precatalyst, Cs<sub>2</sub>CO<sub>3</sub>, toluene, 90 °C, 70% (from <b>49k</b>); (e) DCM, TFA, or HCl/dioxane, MeOH, RT, then 1-fluoro-3-iodopropane, DIPEA, DMF, RT, 14–69%; (f) paraformaldehyde, NaCNBH<sub>3</sub>, AcOH, MeOH, 50 °C, 19%.</p></p></figure><figure data-id="fig3" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01163/20201203/images/medium/jm0c01163_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01163/20201203/images/large/jm0c01163_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. (a) Solution conformation of <b>16</b>. Flexibility is illustrated with thin-wire depictions of the basic group which is capable of adopting different conformations in solution; (b) X-ray crystallography of <b>16</b> (cyan, pdb: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6zoq">6zoq</a>) bound to the ERα ligand binding domain construct with aligned structure of tamoxifen (white, pdb: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5aav">5aav</a>) for reference; (c) aligned protein–ligand crystal structures of <b>16</b> and <b>18</b> (magenta, pdb: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6zos">6zos</a>). The loop connecting helices 11 and 12 is tagged in b and c, as well as key residues.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01163/20201203/images/large/jm0c01163_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01163&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01163/20201203/images/medium/jm0c01163_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01163/20201203/images/large/jm0c01163_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. (a) Molecular conformation of <b>16</b> from single crystal structure; (b) crystal packing of <b>16</b> in the unit cell (the TBME molecules are shown as ball and stick models).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01163/20201203/images/large/jm0c01163_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01163&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01163/20201203/images/medium/jm0c01163_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01163/20201203/images/large/jm0c01163_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Plot of %ER degradation relative to fulvestrant in CAMA-1 and MCF-7 cell lines as measured by Western blot (A = NH/O linkage to indazole scaffold) and trellised by azetidine connectivity.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01163/20201203/images/large/jm0c01163_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01163&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01163/20201203/images/medium/jm0c01163_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01163/20201203/images/large/jm0c01163_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. (a) Conformational analysis by NMR of <b>28</b>. Flexibility is illustrated with thin-wire depictions of the basic group, which is capable of adopting different conformations in solution; (b) X-ray crystallography of <b>28</b> (green, pdb: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6zor">6zor</a>) bound to the ERα ligand binding domain construct; (c) alignment of the binding mode of <b>28</b> with that of <b>1b</b> (yellow, pdb: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5acc">5acc</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01163/20201203/images/large/jm0c01163_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01163&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01163/20201203/images/medium/jm0c01163_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01163/20201203/images/large/jm0c01163_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. (a) Molecular conformation of <b>28</b> from single crystal structure; (b) crystal packing of <b>28</b> in the unit cell.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01163/20201203/images/large/jm0c01163_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01163&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01163/20201203/images/medium/jm0c01163_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01163/20201203/images/large/jm0c01163_0008.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. (a) Treatment of MCF-7 cells with compound <b>28</b> showed a concentration-dependent decrease in ERα expression (black) and no increase in PR expression (blue) consistent with no ERα agonism; (b) ERα protein expression curve (black) and decrease in potency in the presence of 0.25 μM tamoxifen (red) due to competition at the ERα ligand binding site and no effect with cycloheximide (blue); (c) MCF7 cells were treated with DMSO, 1 nM estradiol (E2), or 100 nM 4-OH tamoxifen, fulvestrant, or <b>28</b> for 24 h. Expression of the ERα regulated genes PGR, TFF1, and GREB1 was assessed. Data points represent individual biological repeats, with lines representing mean ± SEM *<i>P</i> < 0.05, **<i>P</i> < 0.01, ***<i>P</i> < 0.001 compared to DMSO control according to a paired student’s <i>t</i> test.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01163/20201203/images/large/jm0c01163_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01163&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01163/20201203/images/medium/jm0c01163_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01163/20201203/images/large/jm0c01163_0009.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Concentration-dependent antagonism of wild-type and Y537S mutant ERα by <b>28</b>. (a) Parental MCF7 cells grown in the presence of 0.1 nM estradiol and (b) MCF7 cells engineered to express a Y537S mutant version of ERα were exposed to <b>28</b> for 24 h. Expression of PR was assessed by immunofluorescence. Data are normalized to DMSO treated cells (0) and 100 nM fulvestrant treated cells (100). Data represent the mean ± SEM from four to five independent experiments.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01163/20201203/images/large/jm0c01163_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01163&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="20" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01163/20201203/images/medium/jm0c01163_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01163/20201203/images/large/jm0c01163_0010.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Concentration-dependent degradation of ERα by fulvestrant and <b>28</b> by Western blot analysis in both MCF-7 (WT) and CAMA-1 cell lines.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01163/20201203/images/large/jm0c01163_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01163&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig11" data-index="21" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01163/20201203/images/medium/jm0c01163_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01163/20201203/images/large/jm0c01163_0011.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Concentration-dependent inhibition of proliferation of wild-type and Y537S mutant ERα by <b>28</b>. (a) Parental MCF7 cells grown in the presence of 0.1 nM estradiol and (b) MCF7 cells engineered to express a Y537S mutant version of ERα were exposed to <b>28</b> for 4 or 6 days, respectively. Total cell number was calculated by using saponin permeabilization and a Sytox green fluorescent end point. Data are expressed as mean % growth ± SEM from at least four independent experiments where zero growth represents the initial seeding density on the day of dosing, and 100% growth represents the vehicle control at the end of incubation.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01163/20201203/images/large/jm0c01163_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01163&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig12" data-index="22" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01163/20201203/images/medium/jm0c01163_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01163/20201203/images/large/jm0c01163_0012.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. <b>28</b> caused antitumor and pharmacodynamic effects on MCF-7 xenografts. MCF-7 cells were injected into male SCID mice supplemented with an estradiol pellet. Once tumors had reached ∼300 mm<sup>3</sup>, they were randomized into groups and treated with vehicle control or doses of <b>28</b>, ranging from 0.5 mg/kg to 50 mg/kg daily, or 5 mg of fulvestrant three times a week for 21 days. (a) Tumor volumes were measured twice a week. Tumor volume is plotted as the geometric mean of the group relative to the day 0 geomean ±95% confidence intervals. To determine statistical significance between groups a one-tailed unpaired <i>t</i> test with Welch’s correction was carried out. **<i>p</i> < 0.01, ***<i>p</i> < 0.001. (b) 24 h after the last dose, tumors were collected, and the level of PR expression in each tumor determined by Western blotting and normalized to expression of vinculin. Data represent individual tumor samples relative to the mean of the vehicle control group. Lines represent the geomean of each group ±95% confidence interval. To determine statistical significance for each group compared to vehicle control a Kruskal–Wallis test followed by Dunn’s posthoc correction was carried out. NS not significant, **<i>p</i> < 0.01, ***<i>p</i> < 0.001.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01163/20201203/images/large/jm0c01163_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01163&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i83">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_04325" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_04325" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 40 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bray, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferlay, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soerjomataram, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siegel, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torre, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jemal, A.</span></span> <span> </span><span class="NLM_article-title">Global Cancer Statistics 2018: GLOBOCAN Estimates of incidence and mortality worldwide for 36 cancers in 185 countries</span>. <i>Ca-Cancer J. Clin.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>68</i></span>,  <span class="NLM_fpage">394</span>– <span class="NLM_lpage">342</span>, <span class="refDoi"> DOI: 10.3322/caac.21492</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=10.3322%2Fcaac.21492" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=30207593" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=1%3ACAS%3A280%3ADC%252BB3c3otVGlsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2018&pages=394-342&author=F.+Brayauthor=J.+Ferlayauthor=I.+Soerjomataramauthor=R.+L.+Siegelauthor=L.+A.+Torreauthor=A.+Jemal&title=Global+Cancer+Statistics+2018%3A+GLOBOCAN+Estimates+of+incidence+and+mortality+worldwide+for+36+cancers+in+185+countries&doi=10.3322%2Fcaac.21492"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries</span></div><div class="casAuthors">Bray Freddie; Ferlay Jacques; Soerjomataram Isabelle; Siegel Rebecca L; Torre Lindsey A; Jemal Ahmedin</div><div class="citationInfo"><span class="NLM_cas:title">CA: a cancer journal for clinicians</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">394-424</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">This article provides a status report on the global burden of cancer worldwide using the GLOBOCAN 2018 estimates of cancer incidence and mortality produced by the International Agency for Research on Cancer, with a focus on geographic variability across 20 world regions.  There will be an estimated 18.1 million new cancer cases (17.0 million excluding nonmelanoma skin cancer) and 9.6 million cancer deaths (9.5 million excluding nonmelanoma skin cancer) in 2018.  In both sexes combined, lung cancer is the most commonly diagnosed cancer (11.6% of the total cases) and the leading cause of cancer death (18.4% of the total cancer deaths), closely followed by female breast cancer (11.6%), prostate cancer (7.1%), and colorectal cancer (6.1%) for incidence and colorectal cancer (9.2%), stomach cancer (8.2%), and liver cancer (8.2%) for mortality.  Lung cancer is the most frequent cancer and the leading cause of cancer death among males, followed by prostate and colorectal cancer (for incidence) and liver and stomach cancer (for mortality).  Among females, breast cancer is the most commonly diagnosed cancer and the leading cause of cancer death, followed by colorectal and lung cancer (for incidence), and vice versa (for mortality); cervical cancer ranks fourth for both incidence and mortality.  The most frequently diagnosed cancer and the leading cause of cancer death, however, substantially vary across countries and within each country depending on the degree of economic development and associated social and life style factors.  It is noteworthy that high-quality cancer registry data, the basis for planning and implementing evidence-based cancer control programs, are not available in most low- and middle-income countries.  The Global Initiative for Cancer Registry Development is an international partnership that supports better estimation, as well as the collection and use of local data, to prioritize and evaluate national cancer control efforts.  CA: A Cancer Journal for Clinicians 2018;0:1-31. © 2018 American Cancer Society.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQaW5wv8ocuhLxanA7vODO6fW6udTcc2ebHAWFc6cajEbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3c3otVGlsg%253D%253D&md5=48529f8f794092779d70a27eec5c9017</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.3322%2Fcaac.21492&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3322%252Fcaac.21492%26sid%3Dliteratum%253Aachs%26aulast%3DBray%26aufirst%3DF.%26aulast%3DFerlay%26aufirst%3DJ.%26aulast%3DSoerjomataram%26aufirst%3DI.%26aulast%3DSiegel%26aufirst%3DR.%2BL.%26aulast%3DTorre%26aufirst%3DL.%2BA.%26aulast%3DJemal%26aufirst%3DA.%26atitle%3DGlobal%2520Cancer%2520Statistics%25202018%253A%2520GLOBOCAN%2520Estimates%2520of%2520incidence%2520and%2520mortality%2520worldwide%2520for%252036%2520cancers%2520in%2520185%2520countries%26jtitle%3DCa-Cancer%2520J.%2520Clin.%26date%3D2018%26volume%3D68%26spage%3D394%26epage%3D342%26doi%3D10.3322%2Fcaac.21492" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Howlader, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altekruse, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, V. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarke, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ries, L. A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cronin, K. A.</span></span> <span> </span><span class="NLM_article-title">US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status</span>. <i>JNCI: J. Natl. Cancer Inst.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>106</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">dju055</span>, <span class="refDoi"> DOI: 10.1093/jnci/dju055</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=10.1093%2Fjnci%2Fdju055" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=24777111" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2014&pages=dju055&issue=5&author=N.+Howladerauthor=S.+F.+Altekruseauthor=C.+I.+Liauthor=V.+W.+Chenauthor=C.+A.+Clarkeauthor=L.+A.+G.+Riesauthor=K.+A.+Cronin&title=US+incidence+of+breast+cancer+subtypes+defined+by+joint+hormone+receptor+and+HER2+status&doi=10.1093%2Fjnci%2Fdju055"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1093%2Fjnci%2Fdju055&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjnci%252Fdju055%26sid%3Dliteratum%253Aachs%26aulast%3DHowlader%26aufirst%3DN.%26aulast%3DAltekruse%26aufirst%3DS.%2BF.%26aulast%3DLi%26aufirst%3DC.%2BI.%26aulast%3DChen%26aufirst%3DV.%2BW.%26aulast%3DClarke%26aufirst%3DC.%2BA.%26aulast%3DRies%26aufirst%3DL.%2BA.%2BG.%26aulast%3DCronin%26aufirst%3DK.%2BA.%26atitle%3DUS%2520incidence%2520of%2520breast%2520cancer%2520subtypes%2520defined%2520by%2520joint%2520hormone%2520receptor%2520and%2520HER2%2520status%26jtitle%3DJNCI%253A%2520J.%2520Natl.%2520Cancer%2520Inst.%26date%3D2014%26volume%3D106%26issue%3D5%26spage%3Ddju055%26doi%3D10.1093%2Fjnci%2Fdju055" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jordan, C.</span></span> <span> </span><span class="NLM_article-title">Historical perspective on hormonal therapy of advanced breast cancer</span>. <i>Clin. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">A3</span>– <span class="NLM_lpage">A16</span>, <span class="refDoi"> DOI: 10.1016/S0149-2918(02)85031-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=10.1016%2FS0149-2918%2802%2985031-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=11911507" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=1%3ACAS%3A528%3ADC%252BD38XivV2rsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2002&pages=A3-A16&author=C.+Jordan&title=Historical+perspective+on+hormonal+therapy+of+advanced+breast+cancer&doi=10.1016%2FS0149-2918%2802%2985031-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Historical perspective on hormonal therapy of advanced breast cancer</span></div><div class="casAuthors">Jordan, Craig</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Therapeutics</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">Suppl. A</span>),
    <span class="NLM_cas:pages">A3-A16</span>CODEN:
                <span class="NLM_cas:coden">CLTHDG</span>;
        ISSN:<span class="NLM_cas:issn">0149-2918</span>.
    
            (<span class="NLM_cas:orgname">Excerpta Medica, Inc.</span>)
        </div><div class="casAbstract">A review.  Endocrine therapy is the preferred first-line therapy in patients with nonaggressive, receptor-pos., metastatic breast cancer.  Endocrine therapies in these patients are as effective as chemotherapy in terms of survival and tumor response.  In addn., hormonal therapies produce fewer and less severe adverse effects than does chemotherapy.  Classes of endocrine therapy currently on the market include selective estrogen receptor modulators (SERMs), aromatase inhibitors, and progestins.  For several decades, tamoxifen has been considered the gold std. of therapy.  However, despite its proven efficacy, a high proportion of patients do not respond.  Therefore, a need exists for alternative therapies or for agents to use following tamoxifen failure.  This review article highlights the various endocrine options available for patients with advanced breast cancer and discusses new agents on the horizon.  Although more studies are needed to det. the optimal sequence of hormonal therapy and the ideal agent within each class, the availability of new and multiple options is encouraging for women with advanced breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8mTP9eWmr07Vg90H21EOLACvtfcHk0lhEOrxtesTgsQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XivV2rsbs%253D&md5=67de543952954a1af236113b49111303</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2FS0149-2918%2802%2985031-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0149-2918%252802%252985031-7%26sid%3Dliteratum%253Aachs%26aulast%3DJordan%26aufirst%3DC.%26atitle%3DHistorical%2520perspective%2520on%2520hormonal%2520therapy%2520of%2520advanced%2520breast%2520cancer%26jtitle%3DClin.%2520Ther.%26date%3D2002%26volume%3D24%26spage%3DA3%26epage%3DA16%26doi%3D10.1016%2FS0149-2918%2802%2985031-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braybrooke, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGale, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peto, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pritchard, K. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dowsett, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayes, D. F.</span></span> <span> </span><span class="NLM_article-title">20-Year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>377</i></span> (<span class="NLM_issue">19</span>),  <span class="NLM_fpage">1836</span>– <span class="NLM_lpage">1846</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1701830</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=10.1056%2FNEJMoa1701830" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=29117498" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=1%3ACAS%3A280%3ADC%252BC1M7ptF2lsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=377&publication_year=2017&pages=1836-1846&issue=19&author=H.+Panauthor=R.+Grayauthor=J.+Braybrookeauthor=C.+Daviesauthor=C.+Taylorauthor=P.+McGaleauthor=R.+Petoauthor=K.+I.+Pritchardauthor=J.+Berghauthor=M.+Dowsettauthor=D.+F.+Hayes&title=20-Year+risks+of+breast-cancer+recurrence+after+stopping+endocrine+therapy+at+5+years&doi=10.1056%2FNEJMoa1701830"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years</span></div><div class="casAuthors">Pan Hongchao; Gray Richard; Braybrooke Jeremy; Davies Christina; Taylor Carolyn; McGale Paul; Peto Richard; Pritchard Kathleen I; Bergh Jonas; Dowsett Mitch; Hayes Daniel F</div><div class="citationInfo"><span class="NLM_cas:title">The New England journal of medicine</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">377</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">1836-1846</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  The administration of endocrine therapy for 5 years substantially reduces recurrence rates during and after treatment in women with early-stage, estrogen-receptor (ER)-positive breast cancer.  Extending such therapy beyond 5 years offers further protection but has additional side effects.  Obtaining data on the absolute risk of subsequent distant recurrence if therapy stops at 5 years could help determine whether to extend treatment.  METHODS:  In this meta-analysis of the results of 88 trials involving 62,923 women with ER-positive breast cancer who were disease-free after 5 years of scheduled endocrine therapy, we used Kaplan-Meier and Cox regression analyses, stratified according to trial and treatment, to assess the associations of tumor diameter and nodal status (TN), tumor grade, and other factors with patients' outcomes during the period from 5 to 20 years.  RESULTS:  Breast-cancer recurrences occurred at a steady rate throughout the study period from 5 to 20 years.  The risk of distant recurrence was strongly correlated with the original TN status.  Among the patients with stage T1 disease, the risk of distant recurrence was 13% with no nodal involvement (T1N0), 20% with one to three nodes involved (T1N1-3), and 34% with four to nine nodes involved (T1N4-9); among those with stage T2 disease, the risks were 19% with T2N0, 26% with T2N1-3, and 41% with T2N4-9.  The risk of death from breast cancer was similarly dependent on TN status, but the risk of contralateral breast cancer was not.  Given the TN status, the factors of tumor grade (available in 43,590 patients) and Ki-67 status (available in 7692 patients), which are strongly correlated with each other, were of only moderate independent predictive value for distant recurrence, but the status regarding the progesterone receptor (in 54,115 patients) and human epidermal growth factor receptor type 2 (HER2) (in 15,418 patients in trials with no use of trastuzumab) was not predictive.  During the study period from 5 to 20 years, the absolute risk of distant recurrence among patients with T1N0 breast cancer was 10% for low-grade disease, 13% for moderate-grade disease, and 17% for high-grade disease; the corresponding risks of any recurrence or a contralateral breast cancer were 17%, 22%, and 26%, respectively.  CONCLUSIONS:  After 5 years of adjuvant endocrine therapy, breast-cancer recurrences continued to occur steadily throughout the study period from 5 to 20 years.  The risk of distant recurrence was strongly correlated with the original TN status, with risks ranging from 10 to 41%, depending on TN status and tumor grade. (Funded by Cancer Research UK and others.).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTM3VY-nqM3H5I8NvIb08rbfW6udTcc2ebU16QPIe-WYLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1M7ptF2lsg%253D%253D&md5=3088751774a2cf0a2af929ee7c22c815</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1701830&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1701830%26sid%3Dliteratum%253Aachs%26aulast%3DPan%26aufirst%3DH.%26aulast%3DGray%26aufirst%3DR.%26aulast%3DBraybrooke%26aufirst%3DJ.%26aulast%3DDavies%26aufirst%3DC.%26aulast%3DTaylor%26aufirst%3DC.%26aulast%3DMcGale%26aufirst%3DP.%26aulast%3DPeto%26aufirst%3DR.%26aulast%3DPritchard%26aufirst%3DK.%2BI.%26aulast%3DBergh%26aufirst%3DJ.%26aulast%3DDowsett%26aufirst%3DM.%26aulast%3DHayes%26aufirst%3DD.%2BF.%26atitle%3D20-Year%2520risks%2520of%2520breast-cancer%2520recurrence%2520after%2520stopping%2520endocrine%2520therapy%2520at%25205%2520years%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2017%26volume%3D377%26issue%3D19%26spage%3D1836%26epage%3D1846%26doi%3D10.1056%2FNEJMoa1701830" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cardoso, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Senkus, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papadopoulos, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aapro, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">André, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harbeck, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aguilar
Lopez, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrios, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biganzoli, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boers-Doets, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cardoso, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carey, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortés, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curigliano, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diéras, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El Saghir, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eniu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fallowfield, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Francis, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gelmon, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnston, S. R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaufman, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koppikar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krop, I. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakigudde, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Offersen, B. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohno, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pagani, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paluch-Shimon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Penault-Llorca, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prat, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rugo, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sledge, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spence, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomssen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vorobiof, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norton, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winer, E. P.</span></span> <span> </span><span class="NLM_article-title">4th ESO–ESMO International consensus guidelines for advanced breast cancer (abc 4)</span>. <i>Ann. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>29</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">1634</span>– <span class="NLM_lpage">1657</span>, <span class="refDoi"> DOI: 10.1093/annonc/mdy192</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=10.1093%2Fannonc%2Fmdy192" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=30032243" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=1%3ACAS%3A280%3ADC%252BB3c7gsFyrsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2018&pages=1634-1657&issue=8&author=F.+Cardosoauthor=E.+Senkusauthor=A.+Costaauthor=E.+Papadopoulosauthor=M.+Aaproauthor=F.+Andr%C3%A9author=N.+Harbeckauthor=B.+Aguilar%0ALopezauthor=C.+H.+Barriosauthor=J.+Berghauthor=L.+Biganzoliauthor=C.+B.+Boers-Doetsauthor=M.+J.+Cardosoauthor=L.+A.+Careyauthor=J.+Cort%C3%A9sauthor=G.+Curiglianoauthor=V.+Di%C3%A9rasauthor=N.+S.+El+Saghirauthor=A.+Eniuauthor=L.+Fallowfieldauthor=P.+A.+Francisauthor=K.+Gelmonauthor=S.+R.+D.+Johnstonauthor=B.+Kaufmanauthor=S.+Koppikarauthor=I.+E.+Kropauthor=M.+Mayerauthor=G.+Nakiguddeauthor=B.+V.+Offersenauthor=S.+Ohnoauthor=O.+Paganiauthor=S.+Paluch-Shimonauthor=F.+Penault-Llorcaauthor=A.+Pratauthor=H.+S.+Rugoauthor=G.+W.+Sledgeauthor=D.+Spenceauthor=C.+Thomssenauthor=D.+A.+Vorobiofauthor=B.+Xuauthor=L.+Nortonauthor=E.+P.+Winer&title=4th+ESO%E2%80%93ESMO+International+consensus+guidelines+for+advanced+breast+cancer+%28abc+4%29&doi=10.1093%2Fannonc%2Fmdy192"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)†</span></div><div class="casAuthors">Cardoso F; Senkus E; Costa A; Papadopoulos E; Aapro M; Andre F; Harbeck N; Aguilar Lopez B; Barrios C H; Bergh J; Biganzoli L; Boers-Doets C B; Cardoso M J; Carey L A; Cortes J; Curigliano G; Dieras V; El Saghir N S; Eniu A; Fallowfield L; Francis P A; Gelmon K; Johnston S R D; Kaufman B; Koppikar S; Krop I E; Mayer M; Nakigudde G; Offersen B V; Ohno S; Pagani O; Paluch-Shimon S; Penault-Llorca F; Prat A; Rugo H S; Sledge G W; Spence D; Thomssen C; Vorobiof D A; Xu B; Norton L; Winer E P</div><div class="citationInfo"><span class="NLM_cas:title">Annals of oncology : official journal of the European Society for Medical Oncology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1634-1657</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ4hBRDVFqGsFVwdslNBF-tfW6udTcc2ebU16QPIe-WYLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3c7gsFyrsA%253D%253D&md5=3a51e35d83c428610266f85398c32b55</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdy192&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdy192%26sid%3Dliteratum%253Aachs%26aulast%3DCardoso%26aufirst%3DF.%26aulast%3DSenkus%26aufirst%3DE.%26aulast%3DCosta%26aufirst%3DA.%26aulast%3DPapadopoulos%26aufirst%3DE.%26aulast%3DAapro%26aufirst%3DM.%26aulast%3DAndr%25C3%25A9%26aufirst%3DF.%26aulast%3DHarbeck%26aufirst%3DN.%26aulast%3DAguilar%2BLopez%26aufirst%3DB.%26aulast%3DBarrios%26aufirst%3DC.%2BH.%26aulast%3DBergh%26aufirst%3DJ.%26aulast%3DBiganzoli%26aufirst%3DL.%26aulast%3DBoers-Doets%26aufirst%3DC.%2BB.%26aulast%3DCardoso%26aufirst%3DM.%2BJ.%26aulast%3DCarey%26aufirst%3DL.%2BA.%26aulast%3DCort%25C3%25A9s%26aufirst%3DJ.%26aulast%3DCurigliano%26aufirst%3DG.%26aulast%3DDi%25C3%25A9ras%26aufirst%3DV.%26aulast%3DEl%2BSaghir%26aufirst%3DN.%2BS.%26aulast%3DEniu%26aufirst%3DA.%26aulast%3DFallowfield%26aufirst%3DL.%26aulast%3DFrancis%26aufirst%3DP.%2BA.%26aulast%3DGelmon%26aufirst%3DK.%26aulast%3DJohnston%26aufirst%3DS.%2BR.%2BD.%26aulast%3DKaufman%26aufirst%3DB.%26aulast%3DKoppikar%26aufirst%3DS.%26aulast%3DKrop%26aufirst%3DI.%2BE.%26aulast%3DMayer%26aufirst%3DM.%26aulast%3DNakigudde%26aufirst%3DG.%26aulast%3DOffersen%26aufirst%3DB.%2BV.%26aulast%3DOhno%26aufirst%3DS.%26aulast%3DPagani%26aufirst%3DO.%26aulast%3DPaluch-Shimon%26aufirst%3DS.%26aulast%3DPenault-Llorca%26aufirst%3DF.%26aulast%3DPrat%26aufirst%3DA.%26aulast%3DRugo%26aufirst%3DH.%2BS.%26aulast%3DSledge%26aufirst%3DG.%2BW.%26aulast%3DSpence%26aufirst%3DD.%26aulast%3DThomssen%26aufirst%3DC.%26aulast%3DVorobiof%26aufirst%3DD.%2BA.%26aulast%3DXu%26aufirst%3DB.%26aulast%3DNorton%26aufirst%3DL.%26aulast%3DWiner%26aufirst%3DE.%2BP.%26atitle%3D4th%2520ESO%25E2%2580%2593ESMO%2520International%2520consensus%2520guidelines%2520for%2520advanced%2520breast%2520cancer%2520%2528abc%25204%2529%26jtitle%3DAnn.%2520Oncol.%26date%3D2018%26volume%3D29%26issue%3D8%26spage%3D1634%26epage%3D1657%26doi%3D10.1093%2Fannonc%2Fmdy192" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crowder, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prat, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoog, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffith, O. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fulton, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrison, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mooney, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMichael, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goncalves, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlosberg, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hiken, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saied, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giuntoli, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bumb, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitchens, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phommaly, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kavuri, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McEachern, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pluard, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naughton, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bose, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suresh, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDowell, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michel, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aft, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillanders, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeSchryver, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mills, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez-Angulo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maher, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perou, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mardis, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellis, M. J.</span></span> <span> </span><span class="NLM_article-title">Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts</span>. <i>Cell Rep.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>4</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1116</span>– <span class="NLM_lpage">1130</span>, <span class="refDoi"> DOI: 10.1016/j.celrep.2013.08.022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=10.1016%2Fj.celrep.2013.08.022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=24055055" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVyls7jK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=1116-1130&issue=6&author=S.+Liauthor=D.+Shenauthor=J.+Shaoauthor=R.+Crowderauthor=W.+Liuauthor=A.+Pratauthor=X.+Heauthor=S.+Liuauthor=J.+Hoogauthor=C.+Luauthor=L.+Dingauthor=O.+L.+Griffithauthor=C.+Millerauthor=D.+Larsonauthor=R.+S.+Fultonauthor=M.+Harrisonauthor=T.+Mooneyauthor=J.+F.+McMichaelauthor=J.+Luoauthor=Y.+Taoauthor=R.+Goncalvesauthor=C.+Schlosbergauthor=J.+F.+Hikenauthor=L.+Saiedauthor=C.+Sanchezauthor=T.+Giuntoliauthor=C.+Bumbauthor=C.+Cooperauthor=R.+T.+Kitchensauthor=A.+Linauthor=C.+Phommalyauthor=S.+R.+Daviesauthor=J.+Zhangauthor=M.+S.+Kavuriauthor=D.+McEachernauthor=Y.+Y.+Dongauthor=C.+Maauthor=T.+Pluardauthor=M.+Naughtonauthor=R.+Boseauthor=R.+Sureshauthor=R.+McDowellauthor=L.+Michelauthor=R.+Aftauthor=W.+Gillandersauthor=K.+DeSchryverauthor=R.+K.+Wilsonauthor=S.+Wangauthor=G.+B.+Millsauthor=A.+Gonzalez-Anguloauthor=J.+R.+Edwardsauthor=C.+Maherauthor=C.+M.+Perouauthor=E.+R.+Mardisauthor=M.+J.+Ellis&title=Endocrine-therapy-resistant+ESR1+variants+revealed+by+genomic+characterization+of+breast-cancer-derived+xenografts&doi=10.1016%2Fj.celrep.2013.08.022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Endocrine-Therapy-Resistant ESR1 Variants Revealed by Genomic Characterization of Breast-Cancer-Derived Xenografts</span></div><div class="casAuthors">Li, Shunqiang; Shen, Dong; Shao, Jieya; Crowder, Robert; Liu, Wenbin; Prat, Aleix; He, Xiaping; Liu, Shuying; Hoog, Jeremy; Lu, Charles; Ding, Li; Griffith, Obi L.; Miller, Christopher; Larson, Dave; Fulton, Robert S.; Harrison, Michelle; Mooney, Tom; McMichael, Joshua F.; Luo, Jingqin; Tao, Yu; Goncalves, Rodrigo; Schlosberg, Christopher; Hiken, Jeffrey F.; Saied, Laila; Sanchez, Cesar; Giuntoli, Therese; Bumb, Caroline; Cooper, Crystal; Kitchens, Robert T.; Lin, Austin; Phommaly, Chanpheng; Davies, Sherri R.; Zhang, Jin; Kavuri, Megha Shyam; McEachern, Donna; Dong, Yi Yu; Ma, Cynthia; Pluard, Timothy; Naughton, Michael; Bose, Ron; Suresh, Rama; McDowell, Reida; Michel, Loren; Aft, Rebecca; Gillanders, William; DeSchryver, Katherine; Wilson, Richard K.; Wang, Shaomeng; Mills, Gordon B.; Gonzalez-Angulo, Ana; Edwards, John R.; Maher, Christopher; Perou, Charles M.; Mardis, Elaine R.; Ellis, Matthew J.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Reports</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1116-1130</span>CODEN:
                <span class="NLM_cas:coden">CREED8</span>;
        ISSN:<span class="NLM_cas:issn">2211-1247</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">To characterize patient-derived xenografts (PDXs) for functional studies, we made whole-genome comparisons with originating breast cancers representative of the major intrinsic subtypes.  Structural and copy no. aberrations were found to be retained with high fidelity.  However, at the single-nucleotide level, variable nos. of PDX-specific somatic events were documented, although they were only rarely functionally significant.  Variant allele frequencies were often preserved in the PDXs, demonstrating that clonal representation can be transplantable.  Estrogen-receptor-pos. PDXs were assocd. with ESR1 ligand-binding-domain mutations, gene amplification, or an ESR1/YAP1 translocation.  These events produced different endocrine-therapy-response phenotypes in human, cell line, and PDX endocrine-response studies.  Hence, deeply sequenced PDX models are an important resource for the search for genome-forward treatment options and capture endocrine-drug-resistance etiologies that are not obsd. in std. cell lines.  The originating tumor genome provides a benchmark for assessing genetic drift and clonal representation after transplantation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0Zv5D2HwBxLVg90H21EOLACvtfcHk0lgP9cubeMibMg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVyls7jK&md5=9d8c965d5c77060fe177faeb438212eb</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2Fj.celrep.2013.08.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.celrep.2013.08.022%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DS.%26aulast%3DShen%26aufirst%3DD.%26aulast%3DShao%26aufirst%3DJ.%26aulast%3DCrowder%26aufirst%3DR.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DPrat%26aufirst%3DA.%26aulast%3DHe%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DHoog%26aufirst%3DJ.%26aulast%3DLu%26aufirst%3DC.%26aulast%3DDing%26aufirst%3DL.%26aulast%3DGriffith%26aufirst%3DO.%2BL.%26aulast%3DMiller%26aufirst%3DC.%26aulast%3DLarson%26aufirst%3DD.%26aulast%3DFulton%26aufirst%3DR.%2BS.%26aulast%3DHarrison%26aufirst%3DM.%26aulast%3DMooney%26aufirst%3DT.%26aulast%3DMcMichael%26aufirst%3DJ.%2BF.%26aulast%3DLuo%26aufirst%3DJ.%26aulast%3DTao%26aufirst%3DY.%26aulast%3DGoncalves%26aufirst%3DR.%26aulast%3DSchlosberg%26aufirst%3DC.%26aulast%3DHiken%26aufirst%3DJ.%2BF.%26aulast%3DSaied%26aufirst%3DL.%26aulast%3DSanchez%26aufirst%3DC.%26aulast%3DGiuntoli%26aufirst%3DT.%26aulast%3DBumb%26aufirst%3DC.%26aulast%3DCooper%26aufirst%3DC.%26aulast%3DKitchens%26aufirst%3DR.%2BT.%26aulast%3DLin%26aufirst%3DA.%26aulast%3DPhommaly%26aufirst%3DC.%26aulast%3DDavies%26aufirst%3DS.%2BR.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DKavuri%26aufirst%3DM.%2BS.%26aulast%3DMcEachern%26aufirst%3DD.%26aulast%3DDong%26aufirst%3DY.%2BY.%26aulast%3DMa%26aufirst%3DC.%26aulast%3DPluard%26aufirst%3DT.%26aulast%3DNaughton%26aufirst%3DM.%26aulast%3DBose%26aufirst%3DR.%26aulast%3DSuresh%26aufirst%3DR.%26aulast%3DMcDowell%26aufirst%3DR.%26aulast%3DMichel%26aufirst%3DL.%26aulast%3DAft%26aufirst%3DR.%26aulast%3DGillanders%26aufirst%3DW.%26aulast%3DDeSchryver%26aufirst%3DK.%26aulast%3DWilson%26aufirst%3DR.%2BK.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DMills%26aufirst%3DG.%2BB.%26aulast%3DGonzalez-Angulo%26aufirst%3DA.%26aulast%3DEdwards%26aufirst%3DJ.%2BR.%26aulast%3DMaher%26aufirst%3DC.%26aulast%3DPerou%26aufirst%3DC.%2BM.%26aulast%3DMardis%26aufirst%3DE.%2BR.%26aulast%3DEllis%26aufirst%3DM.%2BJ.%26atitle%3DEndocrine-therapy-resistant%2520ESR1%2520variants%2520revealed%2520by%2520genomic%2520characterization%2520of%2520breast-cancer-derived%2520xenografts%26jtitle%3DCell%2520Rep.%26date%3D2013%26volume%3D4%26issue%3D6%26spage%3D1116%26epage%3D1130%26doi%3D10.1016%2Fj.celrep.2013.08.022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jeselsohn, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yelensky, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchwalter, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frampton, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meric-Bernstam, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez-Angulo, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrer-Lozano, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez-Fidalgo, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cristofanilli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gómez, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arteaga, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giltnane, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balko, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cronin, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jarosz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hawryluk, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lipson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otto, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dvir, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soussan-Gutman, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolf, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubinek, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilmore, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schnitt, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Come, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pusztai, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stephens, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, V. A.</span></span> <span> </span><span class="NLM_article-title">Emergence of constitutively active estrogen receptor-α mutations in pretreated advanced estrogen receptor-positive breast cancer</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>20</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">1757</span>– <span class="NLM_lpage">1767</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-13-2332</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=10.1158%2F1078-0432.CCR-13-2332" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=24398047" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=1%3ACAS%3A528%3ADC%252BC2cXls1eiu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2014&pages=1757-1767&issue=7&author=R.+Jeselsohnauthor=R.+Yelenskyauthor=G.+Buchwalterauthor=G.+Framptonauthor=F.+Meric-Bernstamauthor=A.+M.+Gonzalez-Anguloauthor=J.+Ferrer-Lozanoauthor=J.+A.+Perez-Fidalgoauthor=M.+Cristofanilliauthor=H.+G%C3%B3mezauthor=C.+L.+Arteagaauthor=J.+Giltnaneauthor=J.+M.+Balkoauthor=M.+T.+Croninauthor=M.+Jaroszauthor=J.+Sunauthor=M.+Hawrylukauthor=D.+Lipsonauthor=G.+Ottoauthor=J.+S.+Rossauthor=A.+Dvirauthor=L.+Soussan-Gutmanauthor=I.+Wolfauthor=T.+Rubinekauthor=L.+Gilmoreauthor=S.+Schnittauthor=S.+E.+Comeauthor=L.+Pusztaiauthor=P.+Stephensauthor=M.+Brownauthor=V.+A.+Miller&title=Emergence+of+constitutively+active+estrogen+receptor-%CE%B1+mutations+in+pretreated+advanced+estrogen+receptor-positive+breast+cancer&doi=10.1158%2F1078-0432.CCR-13-2332"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Emergence of Constitutively Active Estrogen Receptor-α Mutations in Pretreated Advanced Estrogen Receptor-Positive Breast Cancer</span></div><div class="casAuthors">Jeselsohn, Rinath; Yelensky, Roman; Buchwalter, Gilles; Frampton, Garrett; Meric-Bernstam, Funda; Gonzalez-Angulo, Ana Maria; Ferrer-Lozano, Jaime; Perez-Fidalgo, Jose A.; Cristofanilli, Massimo; Gomez, Henry; Arteaga, Carlos L.; Giltnane, Jennifer; Balko, Justin M.; Cronin, Maureen T.; Jarosz, Mirna; Sun, James; Hawryluk, Matthew; Lipson, Doron; Otto, Geoff; Ross, Jeffrey S.; Dvir, Addie; Soussan-Gutman, Lior; Wolf, Ido; Rubinek, Tamar; Gilmore, Lauren; Schnitt, Stuart; Come, Steven E.; Pusztai, Lajos; Stephens, Philip; Brown, Myles; Miller, Vincent A.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1757-1767</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: We undertook this study to det. the prevalence of estrogen receptor (ER) α (ESR1) mutations throughout the natural history of hormone-dependent breast cancer and to delineate the functional roles of the most commonly detected alterations.  Exptl. Design: We studied a total of 249 tumor specimens from 208 patients.  The specimens include 134 ER-pos. (ER+/HER2-) and, as controls, 115 ER-neg. (ER-) tumors.  The ER+ samples consist of 58 primary breast cancers and 76 metastatic samples.  All tumors were sequenced to high unique coverage using next-generation sequencing targeting the coding sequence of the estrogen receptor and an addnl. 182 cancer-related genes.  Results: Recurring somatic mutations in codons 537 and 538 within the ligand-binding domain of ER were detected in ER+ metastatic disease.  Overall, the frequency of these mutations was 12% [9/76; 95% confidence interval (CI), 6%-21%] in metastatic tumors and in a subgroup of patients who received an av. of 7 lines of treatment the frequency was 20% (5/25; 95% CI, 7%-41%).  These mutations were not detected in primary or treatment-naive ER+ cancer or in any stage of ER- disease.  Functional studies in cell line models demonstrate that these mutations render estrogen receptor constitutive activity and confer partial resistance to currently available endocrine treatments.  Conclusions: In this study, we show evidence for the temporal selection of functional ESR1 mutations as potential drivers of endocrine resistance during the progression of ER+ breast cancer.  Clin Cancer Res; 20(7); 1757-67. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgdteKI6rKn7Vg90H21EOLACvtfcHk0lgP9cubeMibMg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXls1eiu74%253D&md5=245ddc458d449b0fd6b1804285fb4ed1</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-13-2332&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-13-2332%26sid%3Dliteratum%253Aachs%26aulast%3DJeselsohn%26aufirst%3DR.%26aulast%3DYelensky%26aufirst%3DR.%26aulast%3DBuchwalter%26aufirst%3DG.%26aulast%3DFrampton%26aufirst%3DG.%26aulast%3DMeric-Bernstam%26aufirst%3DF.%26aulast%3DGonzalez-Angulo%26aufirst%3DA.%2BM.%26aulast%3DFerrer-Lozano%26aufirst%3DJ.%26aulast%3DPerez-Fidalgo%26aufirst%3DJ.%2BA.%26aulast%3DCristofanilli%26aufirst%3DM.%26aulast%3DG%25C3%25B3mez%26aufirst%3DH.%26aulast%3DArteaga%26aufirst%3DC.%2BL.%26aulast%3DGiltnane%26aufirst%3DJ.%26aulast%3DBalko%26aufirst%3DJ.%2BM.%26aulast%3DCronin%26aufirst%3DM.%2BT.%26aulast%3DJarosz%26aufirst%3DM.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DHawryluk%26aufirst%3DM.%26aulast%3DLipson%26aufirst%3DD.%26aulast%3DOtto%26aufirst%3DG.%26aulast%3DRoss%26aufirst%3DJ.%2BS.%26aulast%3DDvir%26aufirst%3DA.%26aulast%3DSoussan-Gutman%26aufirst%3DL.%26aulast%3DWolf%26aufirst%3DI.%26aulast%3DRubinek%26aufirst%3DT.%26aulast%3DGilmore%26aufirst%3DL.%26aulast%3DSchnitt%26aufirst%3DS.%26aulast%3DCome%26aufirst%3DS.%2BE.%26aulast%3DPusztai%26aufirst%3DL.%26aulast%3DStephens%26aufirst%3DP.%26aulast%3DBrown%26aufirst%3DM.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26atitle%3DEmergence%2520of%2520constitutively%2520active%2520estrogen%2520receptor-%25CE%25B1%2520mutations%2520in%2520pretreated%2520advanced%2520estrogen%2520receptor-positive%2520breast%2520cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2014%26volume%3D20%26issue%3D7%26spage%3D1757%26epage%3D1767%26doi%3D10.1158%2F1078-0432.CCR-13-2332" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Razavi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bandlamudi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vasan, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bielski, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donoghue, M. T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jonsson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Penson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pareja, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kundra, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Middha, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zehir, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kandoth, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huberman, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smyth, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jhaveri, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Modi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Traina, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weigelt, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ladanyi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hyman, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schultz, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robson, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hudis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brogi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viale, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norton, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dickler, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berger, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iacobuzio-Donahue, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chandarlapaty, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scaltriti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reis-Filho, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solit, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baselga, J.</span></span> <span> </span><span class="NLM_article-title">The genomic landscape of endocrine-resistant advanced breast cancers</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>34</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">427</span>– <span class="NLM_lpage">438</span>, <span class="refDoi"> DOI: 10.1016/j.ccell.2018.08.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=10.1016%2Fj.ccell.2018.08.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=30205045" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhs12ntLfM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2018&pages=427-438&issue=3&author=P.+Razaviauthor=M.+T.+Changauthor=G.+Xuauthor=C.+Bandlamudiauthor=D.+S.+Rossauthor=N.+Vasanauthor=Y.+Caiauthor=C.+M.+Bielskiauthor=M.+T.+A.+Donoghueauthor=P.+Jonssonauthor=A.+Pensonauthor=R.+Shenauthor=F.+Parejaauthor=R.+Kundraauthor=S.+Middhaauthor=M.+L.+Chengauthor=A.+Zehirauthor=C.+Kandothauthor=R.+Patelauthor=K.+Hubermanauthor=L.+M.+Smythauthor=K.+Jhaveriauthor=S.+Modiauthor=T.+A.+Trainaauthor=C.+Dangauthor=W.+Zhangauthor=B.+Weigeltauthor=B.+T.+Liauthor=M.+Ladanyiauthor=D.+M.+Hymanauthor=N.+Schultzauthor=M.+E.+Robsonauthor=C.+Hudisauthor=E.+Brogiauthor=A.+Vialeauthor=L.+Nortonauthor=M.+N.+Dicklerauthor=M.+F.+Bergerauthor=C.+A.+Iacobuzio-Donahueauthor=S.+Chandarlapatyauthor=M.+Scaltritiauthor=J.+S.+Reis-Filhoauthor=D.+B.+Solitauthor=B.+S.+Taylorauthor=J.+Baselga&title=The+genomic+landscape+of+endocrine-resistant+advanced+breast+cancers&doi=10.1016%2Fj.ccell.2018.08.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers</span></div><div class="casAuthors">Razavi, Pedram; Chang, Matthew T.; Xu, Guotai; Bandlamudi, Chaitanya; Ross, Dara S.; Vasan, Neil; Cai, Yanyan; Bielski, Craig M.; Donoghue, Mark T. A.; Jonsson, Philip; Penson, Alexander; Shen, Ronglai; Pareja, Fresia; Kundra, Ritika; Middha, Sumit; Cheng, Michael L.; Zehir, Ahmet; Kandoth, Cyriac; Patel, Ruchi; Huberman, Kety; Smyth, Lillian M.; Jhaveri, Komal; Modi, Shanu; Traina, Tiffany A.; Dang, Chau; Zhang, Wen; Weigelt, Britta; Li, Bob T.; Ladanyi, Marc; Hyman, David M.; Schultz, Nikolaus; Robson, Mark E.; Hudis, Clifford; Brogi, Edi; Viale, Agnes; Norton, Larry; Dickler, Maura N.; Berger, Michael F.; Iacobuzio-Donahue, Christine A.; Chandarlapaty, Sarat; Scaltriti, Maurizio; Reis-Filho, Jorge S.; Solit, David B.; Taylor, Barry S.; Baselga, Jose</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">427-438.e6</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">We integrated the genomic sequencing of 1,918 breast cancers, including 1,501 hormone receptor-pos. tumors, with detailed clin. information and treatment outcomes.  In 692 tumors previously exposed to hormonal therapy, we identified an increased no. of alterations in genes involved in the mitogen-activated protein kinase (MAPK) pathway and in the estrogen receptor transcriptional machinery.  Activating ERBB2 mutations and NF1 loss-of-function mutations were more than twice as common in endocrine resistant tumors.  Alterations in other MAPK pathway genes (EGFR, KRAS, among others) and estrogen receptor transcriptional regulators (MYC, CTCF, FOXA1, and TBX3) were also enriched.  Altogether, these alterations were present in 22% of tumors, mutually exclusive with ESR1 mutations, and assocd. with a shorter duration of response to subsequent hormonal therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmecqofb9RmrVg90H21EOLACvtfcHk0lhcs-byB9NvAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhs12ntLfM&md5=909a0b79bde44a57665f8fbbb63096c6</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2Fj.ccell.2018.08.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccell.2018.08.008%26sid%3Dliteratum%253Aachs%26aulast%3DRazavi%26aufirst%3DP.%26aulast%3DChang%26aufirst%3DM.%2BT.%26aulast%3DXu%26aufirst%3DG.%26aulast%3DBandlamudi%26aufirst%3DC.%26aulast%3DRoss%26aufirst%3DD.%2BS.%26aulast%3DVasan%26aufirst%3DN.%26aulast%3DCai%26aufirst%3DY.%26aulast%3DBielski%26aufirst%3DC.%2BM.%26aulast%3DDonoghue%26aufirst%3DM.%2BT.%2BA.%26aulast%3DJonsson%26aufirst%3DP.%26aulast%3DPenson%26aufirst%3DA.%26aulast%3DShen%26aufirst%3DR.%26aulast%3DPareja%26aufirst%3DF.%26aulast%3DKundra%26aufirst%3DR.%26aulast%3DMiddha%26aufirst%3DS.%26aulast%3DCheng%26aufirst%3DM.%2BL.%26aulast%3DZehir%26aufirst%3DA.%26aulast%3DKandoth%26aufirst%3DC.%26aulast%3DPatel%26aufirst%3DR.%26aulast%3DHuberman%26aufirst%3DK.%26aulast%3DSmyth%26aufirst%3DL.%2BM.%26aulast%3DJhaveri%26aufirst%3DK.%26aulast%3DModi%26aufirst%3DS.%26aulast%3DTraina%26aufirst%3DT.%2BA.%26aulast%3DDang%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DWeigelt%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DB.%2BT.%26aulast%3DLadanyi%26aufirst%3DM.%26aulast%3DHyman%26aufirst%3DD.%2BM.%26aulast%3DSchultz%26aufirst%3DN.%26aulast%3DRobson%26aufirst%3DM.%2BE.%26aulast%3DHudis%26aufirst%3DC.%26aulast%3DBrogi%26aufirst%3DE.%26aulast%3DViale%26aufirst%3DA.%26aulast%3DNorton%26aufirst%3DL.%26aulast%3DDickler%26aufirst%3DM.%2BN.%26aulast%3DBerger%26aufirst%3DM.%2BF.%26aulast%3DIacobuzio-Donahue%26aufirst%3DC.%2BA.%26aulast%3DChandarlapaty%26aufirst%3DS.%26aulast%3DScaltriti%26aufirst%3DM.%26aulast%3DReis-Filho%26aufirst%3DJ.%2BS.%26aulast%3DSolit%26aufirst%3DD.%2BB.%26aulast%3DTaylor%26aufirst%3DB.%2BS.%26aulast%3DBaselga%26aufirst%3DJ.%26atitle%3DThe%2520genomic%2520landscape%2520of%2520endocrine-resistant%2520advanced%2520breast%2520cancers%26jtitle%3DCancer%2520Cell%26date%3D2018%26volume%3D34%26issue%3D3%26spage%3D427%26epage%3D438%26doi%3D10.1016%2Fj.ccell.2018.08.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Osborne, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bardou, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hopp, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chamness, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hilsenbeck, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuqua, S. A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allred, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schiff, R.</span></span> <span> </span><span class="NLM_article-title">Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer</span>. <i>JNCI: J. Nat. Cancer Inst.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>95</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">353</span>– <span class="NLM_lpage">361</span>, <span class="refDoi"> DOI: 10.1093/jnci/95.5.353</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=10.1093%2Fjnci%2F95.5.353" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=12618500" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=1%3ACAS%3A528%3ADC%252BD3sXivVeqsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=2003&pages=353-361&issue=5&author=C.+K.+Osborneauthor=V.+Bardouauthor=T.+A.+Hoppauthor=G.+C.+Chamnessauthor=S.+G.+Hilsenbeckauthor=S.+A.+W.+Fuquaauthor=J.+Wongauthor=D.+C.+Allredauthor=G.+M.+Clarkauthor=R.+Schiff&title=Role+of+the+estrogen+receptor+coactivator+AIB1+%28SRC-3%29+and+HER-2%2Fneu+in+tamoxifen+resistance+in+breast+cancer&doi=10.1093%2Fjnci%2F95.5.353"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer</span></div><div class="casAuthors">Osborne, C. Kent; Bardou, Valerie; Hopp, Torsten A.; Chamness, Gary C.; Hilsenbeck, Susan G.; Fuqua, Suzanne A. W.; Wong, Jiemin; Allred, D. Craig; Clark, Gary M.; Schiff, Rachel</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the National Cancer Institute</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">95</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">353-361</span>CODEN:
                <span class="NLM_cas:coden">JNCIEQ</span>;
        ISSN:<span class="NLM_cas:issn">0027-8874</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">AIB1 (SRC-3) is an estrogen receptor (ER) coactivator that, when overexpressed in cultured cells, can reduce the antagonist activity of tamoxifen-bound ERs.  Signaling through the HER-2 receptor pathway activates AIB1 by phosphorylation.  To det. whether high AIB1 expression alone or together with HER-2 reduces the effectiveness of tamoxifen in breast cancer patients, we quantified expression of AIB1 and HER-2 in tumors from breast cancer patients with long-term clin. follow-up who received either no adjuvant therapy or adjuvant tamoxifen therapy after breast cancer surgery.  AIB1 and HER-2 protein levels in tumors from 316 breast cancer patients were detd. using western blot anal.  Mol. variables (e.g., expression of AIB1, ER, progesterone receptor, p53, Bcl-2), tumor characteristics, and patient outcome were assessed using Spearman rank correlation.  Disease-free survival (DFS) curves were derived from Kaplan-Meier ests., and the curves were compared by log-rank tests.  The effect of AIB1 on DFS adjusted for other prognostic factors was assessed by multivariable anal. using the Cox proportional hazards model.  All statistical tests were two-sided.  High AIB1 expression in patients not receiving adjuvant tamoxifen therapy was assocd. with better prognosis and longer DFS (P = .018, log-rank test).  In contrast, for patients who did receive tamoxifen therapy, high AIB1 expression was assocd. with worse DFS (P = .049, log-rank test), which is indicative of tamoxifen resistance.  The test for interaction between AIB1 expression and tamoxifen therapy was statistically significant (P = .004).  When expression of AIB1 and HER-2 were considered together, patients whose tumors expressed high levels of both AIB1 and HER-2 had worse outcomes with tamoxifen therapy than all other patients combined (P = .002, log-rank test).  The antitumor activity of tamoxifen in patients with breast cancer may be detd., in part, by tumor levels of AIB1 and HER-2.  Thus, AIB1 may be an important diagnostic and therapeutic target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoC6PAwU7VOrrVg90H21EOLACvtfcHk0lhcs-byB9NvAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXivVeqsrg%253D&md5=5469b2ee206ada6b884eab780a5884e4</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1093%2Fjnci%2F95.5.353&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjnci%252F95.5.353%26sid%3Dliteratum%253Aachs%26aulast%3DOsborne%26aufirst%3DC.%2BK.%26aulast%3DBardou%26aufirst%3DV.%26aulast%3DHopp%26aufirst%3DT.%2BA.%26aulast%3DChamness%26aufirst%3DG.%2BC.%26aulast%3DHilsenbeck%26aufirst%3DS.%2BG.%26aulast%3DFuqua%26aufirst%3DS.%2BA.%2BW.%26aulast%3DWong%26aufirst%3DJ.%26aulast%3DAllred%26aufirst%3DD.%2BC.%26aulast%3DClark%26aufirst%3DG.%2BM.%26aulast%3DSchiff%26aufirst%3DR.%26atitle%3DRole%2520of%2520the%2520estrogen%2520receptor%2520coactivator%2520AIB1%2520%2528SRC-3%2529%2520and%2520HER-2%252Fneu%2520in%2520tamoxifen%2520resistance%2520in%2520breast%2520cancer%26jtitle%3DJNCI%253A%2520J.%2520Nat.%2520Cancer%2520Inst.%26date%3D2003%26volume%3D95%26issue%3D5%26spage%3D353%26epage%3D361%26doi%3D10.1093%2Fjnci%2F95.5.353" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">McDonnell, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wardell, S. E.</span></span> <span> </span><span class="NLM_article-title">The molecular mechanisms underlying the pharmacological actions of ER modulators: Implications for new drug discovery in breast cancer</span>. <i>Curr. Opin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">620</span>– <span class="NLM_lpage">628</span>, <span class="refDoi"> DOI: 10.1016/j.coph.2010.09.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=10.1016%2Fj.coph.2010.09.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=20926342" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVals73P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2010&pages=620-628&issue=6&author=D.+P.+McDonnellauthor=S.+E.+Wardell&title=The+molecular+mechanisms+underlying+the+pharmacological+actions+of+ER+modulators%3A+Implications+for+new+drug+discovery+in+breast+cancer&doi=10.1016%2Fj.coph.2010.09.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10aR"><div class="casContent"><span class="casTitleNuber">10a</span><div class="casTitle"><span class="NLM_cas:atitle">The molecular mechanisms underlying the pharmacological actions of ER modulators: implications for new drug discovery in breast cancer</span></div><div class="casAuthors">McDonnell, Donald P.; Wardell, Suzanne E.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Pharmacology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">620-628</span>CODEN:
                <span class="NLM_cas:coden">COPUBK</span>;
        ISSN:<span class="NLM_cas:issn">1471-4892</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Our understanding of the mol. mechanisms underlying the pharmacol. actions of estrogen receptor (ER) ligands has evolved considerably in recent years.  Much of this knowledge has come from a detailed dissection of the mechanism(s) of action of the Selective Estrogen Receptor Modulators (SERMs) tamoxifen and raloxifene, so called for their ability to function as ER agonists or antagonists depending on the tissue in which they operate.  These mechanistic insights have had a significant impact on the discovery of second generation SERMs, some of which are in late stage clin. development for the treatment/prevention of breast cancer as well as other estrogenopathies.  In addn. to the SERMs, however, have emerged the Selective Estrogen Degraders (SERDs), which as their name suggests, interact with and facilitate ER turnover in cells.  One drug of this class, fulvestrant, has been approved as a third line treatment for ER-pos. metastatic breast cancer.  Whereas the first generation SERMs/SERDs were discovered in a serendipitous manner, this review will highlight how our understanding of the mol. pharmacol. of ER ligands has been utilized in the development of the next generation of SERMs/SERDs, some of which are likely to have a major impact on the pharmacotherapy of breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8b2l5p-n0bbVg90H21EOLACvtfcHk0ljmUteX4OW6IQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVals73P&md5=24d1490ca0b0570c21e9768c9de134d6</span></div><a href="/servlet/linkout?suffix=cit10a&amp;dbid=16384&amp;doi=10.1016%2Fj.coph.2010.09.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.coph.2010.09.007%26sid%3Dliteratum%253Aachs%26aulast%3DMcDonnell%26aufirst%3DD.%2BP.%26aulast%3DWardell%26aufirst%3DS.%2BE.%26atitle%3DThe%2520molecular%2520mechanisms%2520underlying%2520the%2520pharmacological%2520actions%2520of%2520ER%2520modulators%253A%2520Implications%2520for%2520new%2520drug%2520discovery%2520in%2520breast%2520cancer%26jtitle%3DCurr.%2520Opin.%2520Pharmacol.%26date%3D2010%26volume%3D10%26issue%3D6%26spage%3D620%26epage%3D628%26doi%3D10.1016%2Fj.coph.2010.09.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit10b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Shagufta</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmad, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathew, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahman, S.</span></span> <span> </span><span class="NLM_article-title">Recent progress in selective estrogen receptor downregulators (SERDs) for the treatment of breast cancer</span>. <i>RSC Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">438</span>– <span class="NLM_lpage">454</span>, <span class="refDoi"> DOI: 10.1039/C9MD00570F</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=10.1039%2FC9MD00570F" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=1%3ACAS%3A528%3ADC%252BB3cXktl2qsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2020&pages=438-454&issue=4&author=+Shaguftaauthor=I.+Ahmadauthor=S.+Mathewauthor=S.+Rahman&title=Recent+progress+in+selective+estrogen+receptor+downregulators+%28SERDs%29+for+the+treatment+of+breast+cancer&doi=10.1039%2FC9MD00570F"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10bR"><div class="casContent"><span class="casTitleNuber">10b</span><div class="casTitle"><span class="NLM_cas:atitle">Recent progress in selective estrogen receptor downregulators (SERDs) for the treatment of breast cancer</span></div><div class="casAuthors">Shagufta; Ahmad, Irshad; Mathew, Shimy; Rahman, Sofia</div><div class="citationInfo"><span class="NLM_cas:title">RSC Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">438-454</span>CODEN:
                <span class="NLM_cas:coden">RMCSEZ</span>;
        ISSN:<span class="NLM_cas:issn">2632-8682</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Selective estrogen receptor downregulators (SERDs) are a novel class of compds. capable of reducing the ERα protein level and blocking ER activity.  Therefore, SERDs are considered as a significant therapeutic approach to treat ER+ breast cancer in both early stage and more advanced drug-resistant cases.  After the FDA approval of a steroidal drug, fulvestrant, as a SERD for the treatment of breast cancer in patients who have progressed on antihormonal agents, several mols. with diverse chem. structures have been rapidly developed, studied and evaluated for selective estrogen receptor downregulation activity.  Here we compile the promising SERDs reported in recent years and discuss the chem. structure and pharmacol. profile of the most potent compd. of the considered series.  Because of the availability of only a limited no. of effective drugs for the treatment of breast cancer, the quest for a potent SERD with respectable activity and bioavailability is still ongoing.  The goal of this article is to make available to the reader an overview of the current progress in SERDs and provide clues for the future discovery and development of novel pharmacol. potent SERDs for the treatment of breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSZ-tHcNc5-LVg90H21EOLACvtfcHk0ljmUteX4OW6IQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXktl2qsrY%253D&md5=73ad3f6be94f660cf47b13146781aa04</span></div><a href="/servlet/linkout?suffix=cit10b&amp;dbid=16384&amp;doi=10.1039%2FC9MD00570F&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC9MD00570F%26sid%3Dliteratum%253Aachs%26aulast%3DShagufta%26aulast%3DAhmad%26aufirst%3DI.%26aulast%3DMathew%26aufirst%3DS.%26aulast%3DRahman%26aufirst%3DS.%26atitle%3DRecent%2520progress%2520in%2520selective%2520estrogen%2520receptor%2520downregulators%2520%2528SERDs%2529%2520for%2520the%2520treatment%2520of%2520breast%2520cancer%26jtitle%3DRSC%2520Med.%2520Chem.%26date%3D2020%26volume%3D11%26issue%3D4%26spage%3D438%26epage%3D454%26doi%3D10.1039%2FC9MD00570F" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wakeling, A. E.</span></span> <span> </span><span class="NLM_article-title">Similarities and distinctions in the mode of action of different classes of antioestrogens</span>. <i>Endocr.-Relat. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">17</span>– <span class="NLM_lpage">28</span>, <span class="refDoi"> DOI: 10.1677/erc.0.0070017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=10.1677%2Ferc.0.0070017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=10808193" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=1%3ACAS%3A528%3ADC%252BD3cXktVyjs7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2000&pages=17-28&issue=1&author=A.+E.+Wakeling&title=Similarities+and+distinctions+in+the+mode+of+action+of+different+classes+of+antioestrogens&doi=10.1677%2Ferc.0.0070017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Similarities and distinctions in the mode of action of different classes of antioestrogens</span></div><div class="casAuthors">Wakeling, A. E.</div><div class="citationInfo"><span class="NLM_cas:title">Endocrine-Related Cancer</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">17-28</span>CODEN:
                <span class="NLM_cas:coden">ERCAE9</span>;
        ISSN:<span class="NLM_cas:issn">1351-0088</span>.
    
            (<span class="NLM_cas:orgname">Society for Endocrinology</span>)
        </div><div class="casAbstract">A review with ∼150 refs. on the title topic with focus on the mechanism of action of the pure antiestrogens, ICI 164384 and ICI 182780, in relation to tamoxifen and the SERMs (selective estrogen receptor modulators).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrME0CIZC-EFLVg90H21EOLACvtfcHk0ljmUteX4OW6IQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXktVyjs7k%253D&md5=13a3e6367adf76dba16465e78bfe6d1b</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1677%2Ferc.0.0070017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1677%252Ferc.0.0070017%26sid%3Dliteratum%253Aachs%26aulast%3DWakeling%26aufirst%3DA.%2BE.%26atitle%3DSimilarities%2520and%2520distinctions%2520in%2520the%2520mode%2520of%2520action%2520of%2520different%2520classes%2520of%2520antioestrogens%26jtitle%3DEndocr.-Relat.%2520Cancer%26date%3D2000%26volume%3D7%26issue%3D1%26spage%3D17%26epage%3D28%26doi%3D10.1677%2Ferc.0.0070017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Robertson, J. F. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bondarenko, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trishkina, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dvorkin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panasci, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manikhas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shparyk, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cardona-Huerta, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheung, K.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Philco-Salas, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruiz-Borrego, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noguchi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowbottom, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stuart, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grinsted, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fazal, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellis, M. J.</span></span> <span> </span><span class="NLM_article-title">Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>388</i></span> (<span class="NLM_issue">10063</span>),  <span class="NLM_fpage">2997</span>– <span class="NLM_lpage">3005</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(16)32389-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=10.1016%2FS0140-6736%2816%2932389-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=27908454" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFKnurnK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=388&publication_year=2016&pages=2997-3005&issue=10063&author=J.+F.+R.+Robertsonauthor=I.+M.+Bondarenkoauthor=E.+Trishkinaauthor=M.+Dvorkinauthor=L.+Panasciauthor=A.+Manikhasauthor=Y.+Shparykauthor=S.+Cardona-Huertaauthor=K.-L.+Cheungauthor=M.+J.+Philco-Salasauthor=M.+Ruiz-Borregoauthor=Z.+Shaoauthor=S.+Noguchiauthor=J.+Rowbottomauthor=M.+Stuartauthor=L.+M.+Grinstedauthor=M.+Fazalauthor=M.+J.+Ellis&title=Fulvestrant+500+mg+versus+anastrozole+1+mg+for+hormone+receptor-positive+advanced+breast+cancer+%28FALCON%29%3A+an+international%2C+randomised%2C+double-blind%2C+phase+3+trial&doi=10.1016%2FS0140-6736%2816%2932389-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial</span></div><div class="casAuthors">Robertson, John F. R.; Bondarenko, Igor M.; Trishkina, Ekaterina; Dvorkin, Mikhail; Panasci, Lawrence; Manikhas, Alexey; Shparyk, Yaroslav; Cardona-Huerta, Servando; Cheung, Kwok-Leung; Philco-Salas, Manuel Jesus; Ruiz-Borrego, Manuel; Shao, Zhimin; Noguchi, Shinzaburo; Rowbottom, Jacqui; Stuart, Mary; Grinsted, Lynda M.; Fazal, Mehdi; Ellis, Matthew J.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">388</span>
        (<span class="NLM_cas:issue">10063</span>),
    <span class="NLM_cas:pages">2997-3005</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Aromatase inhibitors are a std. of care for hormone receptor-pos. locally advanced or metastatic breast cancer.  We investigated whether the selective estrogen receptor degrader fulvestrant could improve progression-free survival compared with anastrozole in postmenopausal patients who had not received previous endocrine therapy.  In this phase 3, randomised, double-blind trial, we recruited eligible patients with histol. confirmed estrogen receptor-pos. or progesterone receptor-pos., or both, locally advanced or metastatic breast cancer from 113 academic hospitals and community centers in 20 countries.  Eligible patients were endocrine therapy-naive, with WHO performance status 0-2, and at least one measurable or non-measurable lesion.  Patients were randomly assigned (1:1) to fulvestrant (500 mg i.m. injection; on days 0, 14, 28, then every 28 days thereafter) or anastrozole (1 mg orally daily) using a computer-generated randomisation scheme.  The primary endpoint was progression-free survival, detd. by Response Evaluation Criteria in Solid Tumors version 1·1, intervention by surgery or radiotherapy because of disease deterioration, or death from any cause, assessed in the intention-to-treat population.  Safety outcomes were assessed in all patients who received at least one dose of randomised treatment (including placebo).  This trial is registered with ClinicalTrials.gov, no. NCT01602380.  Between Oct 17, 2012, and July 11, 2014, 524 patients were enrolled to this study.  Of these, 462 patients were randomised (230 to receive fulvestrant and 232 to receive anastrozole).  Progression-free survival was significantly longer in the fulvestrant group than in the anastrozole group (hazard ratio [HR] 0·797, 95% CI 0·637-0·999, p=0·0486).  Median progression-free survival was 16·6 mo (95% CI 13·83-20·99) in the fulvestrant group vs. 13·8 mo (11·99-16·59) in the anastrozole group.  The most common adverse events were arthralgia (38 [17%] in the fulvestrant group vs 24 [10%] in the anastrozole group) and hot flushes (26 [11%] in the fulvestrant group vs 24 [10%] in the anastrozole group). 16 (7%) of 228 patients in in the fulvestrant group and 11 (5%) of 232 patients in the anastrozole group discontinued because of adverse events.  Fulvestrant has superior efficacy and is a preferred treatment option for patients with hormone receptor-pos. locally advanced or metastatic breast cancer who have not received previous endocrine therapy compared with a third-generation aromatase inhibitor, a std. of care for first-line treatment of these patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGry16EI3NgNOLVg90H21EOLACvtfcHk0lh3gXprXK9NOQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFKnurnK&md5=7d8295fdf38fc5eb5720a7d3cd97d6e9</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2816%2932389-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252816%252932389-3%26sid%3Dliteratum%253Aachs%26aulast%3DRobertson%26aufirst%3DJ.%2BF.%2BR.%26aulast%3DBondarenko%26aufirst%3DI.%2BM.%26aulast%3DTrishkina%26aufirst%3DE.%26aulast%3DDvorkin%26aufirst%3DM.%26aulast%3DPanasci%26aufirst%3DL.%26aulast%3DManikhas%26aufirst%3DA.%26aulast%3DShparyk%26aufirst%3DY.%26aulast%3DCardona-Huerta%26aufirst%3DS.%26aulast%3DCheung%26aufirst%3DK.-L.%26aulast%3DPhilco-Salas%26aufirst%3DM.%2BJ.%26aulast%3DRuiz-Borrego%26aufirst%3DM.%26aulast%3DShao%26aufirst%3DZ.%26aulast%3DNoguchi%26aufirst%3DS.%26aulast%3DRowbottom%26aufirst%3DJ.%26aulast%3DStuart%26aufirst%3DM.%26aulast%3DGrinsted%26aufirst%3DL.%2BM.%26aulast%3DFazal%26aufirst%3DM.%26aulast%3DEllis%26aufirst%3DM.%2BJ.%26atitle%3DFulvestrant%2520500%2520mg%2520versus%2520anastrozole%25201%2520mg%2520for%2520hormone%2520receptor-positive%2520advanced%2520breast%2520cancer%2520%2528FALCON%2529%253A%2520an%2520international%252C%2520randomised%252C%2520double-blind%252C%2520phase%25203%2520trial%26jtitle%3DLancet%26date%3D2016%26volume%3D388%26issue%3D10063%26spage%3D2997%26epage%3D3005%26doi%3D10.1016%2FS0140-6736%2816%2932389-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Robertson, J.</span></span> <span> </span><span class="NLM_article-title">Fulvestrant (Faslodex<sup>®</sup>) – How to make a good drug better</span>. <i>Oncologist</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">774</span>– <span class="NLM_lpage">784</span>, <span class="refDoi"> DOI: 10.1634/theoncologist.12-7-774</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=10.1634%2Ftheoncologist.12-7-774" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=17673609" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=1%3ACAS%3A528%3ADC%252BD2sXpslertbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2007&pages=774-784&issue=7&author=J.+Robertson&title=Fulvestrant+%28Faslodex%C2%AE%29+%E2%80%93+How+to+make+a+good+drug+better&doi=10.1634%2Ftheoncologist.12-7-774"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Fulvestrant (Faslodex)-how to make a good drug better</span></div><div class="casAuthors">Robertson, John F. R.</div><div class="citationInfo"><span class="NLM_cas:title">Oncologist</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">774-784</span>CODEN:
                <span class="NLM_cas:coden">OCOLF6</span>;
        ISSN:<span class="NLM_cas:issn">1083-7159</span>.
    
            (<span class="NLM_cas:orgname">AlphaMed Press</span>)
        </div><div class="casAbstract">A review.  Fulvestrant (Faslodex; AstraZeneca Pharmaceuticals, Wilmington, DE) is an estrogen receptor (ER) antagonist with a novel mode of action; it binds, blocks, and increases degrdn. of ER.  Fulvestrant (at the approved dose [250 mg/mo]) is at least as effective as anastrozole (1 mg/day) in the treatment of postmenopausal women with hormone receptor-pos. advanced breast cancer (HR+ ABC) progressing or recurring on antiestrogen therapy, and is also an active first-line treatment.  Although fulvestrant (250 mg/mo) is clearly effective, it takes 3-6 mo to achieve steady-state plasma levels.  Steady-state concns. are approx. twofold higher than those achieved with a single dose; reaching this earlier, for example, via a loading-dose (LD) regimen (250 mg/mo plus 500 mg on day 0 and 250 mg on day 14 of month 1), may allow responses to be achieved more quickly and limit the possibility of early relapse.  Fulvestrant high-dose (HD) regimens (500 mg/mo) offer the possibility of greater antitumor activity, because (a) ER downregulation is a dose-dependent process (an approx. 70% redn. is obsd. with a single 250 mg dose of fulvestrant) and (b) evidence correlates greater ER downregulation with superior efficacy.  A fulvestrant HD regimen offers the potential of achieving near 100% ER downregulation.  There is also potential to increase fulvestrant-ER binding by reducing plasma estrogen levels, for example, with concomitant aromatase inhibitor treatment.  Several ongoing trials use LD, HD, and combination regimens; results from these studies are awaited with interest.  Meanwhile, fulvestrant (250 mg/mo) remains a valuable addnl. endocrine treatment for postmenopausal women with HR+ ABC recurring or progressing on antiestrogen therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxuzoAnKMBfLVg90H21EOLACvtfcHk0lh3gXprXK9NOQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXpslertbg%253D&md5=25f69688f5819c7883f408ad74642058</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1634%2Ftheoncologist.12-7-774&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1634%252Ftheoncologist.12-7-774%26sid%3Dliteratum%253Aachs%26aulast%3DRobertson%26aufirst%3DJ.%26atitle%3DFulvestrant%2520%2528Faslodex%25C2%25AE%2529%2520%25E2%2580%2593%2520How%2520to%2520make%2520a%2520good%2520drug%2520better%26jtitle%3DOncologist%26date%3D2007%26volume%3D12%26issue%3D7%26spage%3D774%26epage%3D784%26doi%3D10.1634%2Ftheoncologist.12-7-774" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kahraman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Govek, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagasawa, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonnefous, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Julien, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Douglas, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sensintaffar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aparicio, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaufman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prudente, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moon, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joseph, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darimont, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brigham, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grillot, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heyman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rix, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hager, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, N. D.</span></span> <span> </span><span class="NLM_article-title">Identification of GDC-0810 (ARN-810), an orally bioavailable selective estrogen receptor degrader (SERD) that demonstrates robust activity in tamoxifen-resistant breast cancer xenografts</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">4888</span>– <span class="NLM_lpage">4904</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00054</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00054" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref14/cit14a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=1%3ACAS%3A528%3ADC%252BC2MXmsFyisb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=4888-4904&issue=12&author=A.+Laiauthor=M.+Kahramanauthor=S.+Govekauthor=J.+Nagasawaauthor=C.+Bonnefousauthor=J.+Julienauthor=K.+Douglasauthor=J.+Sensintaffarauthor=N.+Luauthor=K.-J.+Leeauthor=A.+Aparicioauthor=J.+Kaufmanauthor=J.+Qianauthor=G.+Shaoauthor=R.+Prudenteauthor=M.+J.+Moonauthor=J.+D.+Josephauthor=B.+Darimontauthor=D.+Brighamauthor=K.+Grillotauthor=R.+Heymanauthor=P.+J.+Rixauthor=J.+H.+Hagerauthor=N.+D.+Smith&title=Identification+of+GDC-0810+%28ARN-810%29%2C+an+orally+bioavailable+selective+estrogen+receptor+degrader+%28SERD%29+that+demonstrates+robust+activity+in+tamoxifen-resistant+breast+cancer+xenografts&doi=10.1021%2Facs.jmedchem.5b00054"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14aR"><div class="casContent"><span class="casTitleNuber">14a</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts</span></div><div class="casAuthors">Lai, Andiliy; Kahraman, Mehmet; Govek, Steven; Nagasawa, Johnny; Bonnefous, Celine; Julien, Jackie; Douglas, Karensa; Sensintaffar, John; Lu, Nhin; Lee, Kyoung-jin; Aparicio, Anna; Kaufman, Josh; Qian, Jing; Shao, Gang; Prudente, Rene; Moon, Michael J.; Joseph, James D.; Darimont, Beatrice; Brigham, Daniel; Grillot, Kate; Heyman, Richard; Rix, Peter J.; Hager, Jeffrey H.; Smith, Nicholas D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">4888-4904</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Approx. 80% of breast cancers are estrogen receptor alpha (ER-α) pos., and although women typically initially respond well to antihormonal therapies such as tamoxifen and aromatase inhibitors, resistance often emerges.  Although a variety of resistance mechanism may be at play in this state, there is evidence that in many cases the ER still plays a central role, including mutations in the ER leading to constitutively active receptor.  Fulvestrant is a steroid-based, selective estrogen receptor degrader (SERD) that both antagonizes and degrades ER-α and is active in patients who have progressed on antihormonal agents.  However, fulvestrant suffers from poor pharmaceutical properties and must be administered by i.m. injections that limit the total amt. of drug that can be administered and hence lead to the potential for incomplete receptor blockade.  The authors describe the identification and characterization of a series of small-mol., orally bioavailable SERDs which are potent antagonists and degraders of ER-α and in which the ER-α degrading properties were prospectively optimized.  The lead compd. I (GDC-0810 or ARN-810) demonstrates robust activity in models of tamoxifen-sensitive and tamoxifen-resistant breast cancer, and is currently in clin. trials in women with locally advanced or metastatic estrogen receptor-pos. breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOegJFz-sqwbVg90H21EOLACvtfcHk0ljXQrYliLCR9Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXmsFyisb4%253D&md5=e836ec4d593ce6ed2d9622da5cd898e6</span></div><a href="/servlet/linkout?suffix=cit14a&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00054&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00054%26sid%3Dliteratum%253Aachs%26aulast%3DLai%26aufirst%3DA.%26aulast%3DKahraman%26aufirst%3DM.%26aulast%3DGovek%26aufirst%3DS.%26aulast%3DNagasawa%26aufirst%3DJ.%26aulast%3DBonnefous%26aufirst%3DC.%26aulast%3DJulien%26aufirst%3DJ.%26aulast%3DDouglas%26aufirst%3DK.%26aulast%3DSensintaffar%26aufirst%3DJ.%26aulast%3DLu%26aufirst%3DN.%26aulast%3DLee%26aufirst%3DK.-J.%26aulast%3DAparicio%26aufirst%3DA.%26aulast%3DKaufman%26aufirst%3DJ.%26aulast%3DQian%26aufirst%3DJ.%26aulast%3DShao%26aufirst%3DG.%26aulast%3DPrudente%26aufirst%3DR.%26aulast%3DMoon%26aufirst%3DM.%2BJ.%26aulast%3DJoseph%26aufirst%3DJ.%2BD.%26aulast%3DDarimont%26aufirst%3DB.%26aulast%3DBrigham%26aufirst%3DD.%26aulast%3DGrillot%26aufirst%3DK.%26aulast%3DHeyman%26aufirst%3DR.%26aulast%3DRix%26aufirst%3DP.%2BJ.%26aulast%3DHager%26aufirst%3DJ.%2BH.%26aulast%3DSmith%26aufirst%3DN.%2BD.%26atitle%3DIdentification%2520of%2520GDC-0810%2520%2528ARN-810%2529%252C%2520an%2520orally%2520bioavailable%2520selective%2520estrogen%2520receptor%2520degrader%2520%2528SERD%2529%2520that%2520demonstrates%2520robust%2520activity%2520in%2520tamoxifen-resistant%2520breast%2520cancer%2520xenografts%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26issue%3D12%26spage%3D4888%26epage%3D4904%26doi%3D10.1021%2Facs.jmedchem.5b00054" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit14b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Govek, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagasawa, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Douglas, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kahraman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonnefous, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aparicio, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darimont, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grillot, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joseph, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaufman, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moon, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prudente, R. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sensintaffar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rix, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hager, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, N. D.</span></span> <span> </span><span class="NLM_article-title">Optimization of an indazole series of selective estrogen receptor degraders: tumor regression in a tamoxifen-resistant breast cancer xenograft</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>25</i></span> (<span class="NLM_issue">22</span>),  <span class="NLM_fpage">5163</span>– <span class="NLM_lpage">5167</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2015.09.074</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=10.1016%2Fj.bmcl.2015.09.074" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=26463130" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhs1GksbrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=5163-5167&issue=22&author=S.+P.+Govekauthor=J.+Y.+Nagasawaauthor=K.+L.+Douglasauthor=A.+G.+Laiauthor=M.+Kahramanauthor=C.+Bonnefousauthor=A.+M.+Aparicioauthor=B.+D.+Darimontauthor=K.+L.+Grillotauthor=J.+D.+Josephauthor=J.+A.+Kaufmanauthor=K.-J.+Leeauthor=N.+Luauthor=M.+J.+Moonauthor=R.+Y.+Prudenteauthor=J.+Sensintaffarauthor=P.+J.+Rixauthor=J.+H.+Hagerauthor=N.+D.+Smith&title=Optimization+of+an+indazole+series+of+selective+estrogen+receptor+degraders%3A+tumor+regression+in+a+tamoxifen-resistant+breast+cancer+xenograft&doi=10.1016%2Fj.bmcl.2015.09.074"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14bR"><div class="casContent"><span class="casTitleNuber">14b</span><div class="casTitle"><span class="NLM_cas:atitle">Optimization of an indazole series of selective estrogen receptor degraders: Tumor regression in a tamoxifen-resistant breast cancer xenograft</span></div><div class="casAuthors">Govek, Steven P.; Nagasawa, Johnny Y.; Douglas, Karensa L.; Lai, Andiliy G.; Kahraman, Mehmet; Bonnefous, Celine; Aparicio, Anna M.; Darimont, Beatrice D.; Grillot, Katherine L.; Joseph, James D.; Kaufman, Joshua A.; Lee, Kyoung-Jin; Lu, Nhin; Moon, Michael J.; Prudente, Rene Y.; Sensintaffar, John; Rix, Peter J.; Hager, Jeffrey H.; Smith, Nicholas D.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">5163-5167</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Selective estrogen receptor degraders (SERDs) have shown promise for the treatment of ER+ breast cancer.  Disclosed herein is the continued optimization of the authors' indazole series of SERDs.  Exploration of ER degrdn. and antagonism in vitro followed by in vivo antagonism and oral exposure culminated in the discovery of indazoles (I) and (II), which induce tumor regression in a tamoxifen-resistant breast cancer xenograft.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6i7tfU3k5frVg90H21EOLACvtfcHk0ljXQrYliLCR9Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhs1GksbrI&md5=fc890bcabc5f84fce015d50bae14c2b6</span></div><a href="/servlet/linkout?suffix=cit14b&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.09.074&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.09.074%26sid%3Dliteratum%253Aachs%26aulast%3DGovek%26aufirst%3DS.%2BP.%26aulast%3DNagasawa%26aufirst%3DJ.%2BY.%26aulast%3DDouglas%26aufirst%3DK.%2BL.%26aulast%3DLai%26aufirst%3DA.%2BG.%26aulast%3DKahraman%26aufirst%3DM.%26aulast%3DBonnefous%26aufirst%3DC.%26aulast%3DAparicio%26aufirst%3DA.%2BM.%26aulast%3DDarimont%26aufirst%3DB.%2BD.%26aulast%3DGrillot%26aufirst%3DK.%2BL.%26aulast%3DJoseph%26aufirst%3DJ.%2BD.%26aulast%3DKaufman%26aufirst%3DJ.%2BA.%26aulast%3DLee%26aufirst%3DK.-J.%26aulast%3DLu%26aufirst%3DN.%26aulast%3DMoon%26aufirst%3DM.%2BJ.%26aulast%3DPrudente%26aufirst%3DR.%2BY.%26aulast%3DSensintaffar%26aufirst%3DJ.%26aulast%3DRix%26aufirst%3DP.%2BJ.%26aulast%3DHager%26aufirst%3DJ.%2BH.%26aulast%3DSmith%26aufirst%3DN.%2BD.%26atitle%3DOptimization%2520of%2520an%2520indazole%2520series%2520of%2520selective%2520estrogen%2520receptor%2520degraders%253A%2520tumor%2520regression%2520in%2520a%2520tamoxifen-resistant%2520breast%2520cancer%2520xenograft%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D25%26issue%3D22%26spage%3D5163%26epage%3D5167%26doi%3D10.1016%2Fj.bmcl.2015.09.074" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De
Savi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradbury, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabow, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norman, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Almeida, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballard, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buttar, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Callis, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Currie, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curwen, J. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donald, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feron, L. J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gingell, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glossop, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayter, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hussain, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karoutchi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamont, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacFaul, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moss, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pearson, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tonge, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weir, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, Z.</span></span> <span> </span><span class="NLM_article-title">Optimization of a novel binding motif to (<i>E</i>)-3-(3,5-difluoro-4-((1<i>R</i>,3<i>R</i>)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-<i>b</i>]indol-1-yl)phenyl)acrylic acid (AZD9496), a potent and orally bioavailable selective estrogen receptor downregulator and antagonist</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span> (<span class="NLM_issue">20</span>),  <span class="NLM_fpage">8128</span>– <span class="NLM_lpage">8140</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00984</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00984" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsFKiu7fK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=8128-8140&issue=20&author=C.+De%0ASaviauthor=R.+H.+Bradburyauthor=A.+A.+Rabowauthor=R.+A.+Normanauthor=C.+de+Almeidaauthor=D.+M.+Andrewsauthor=P.+Ballardauthor=D.+Buttarauthor=R.+J.+Callisauthor=G.+S.+Currieauthor=J.+O.+Curwenauthor=C.+D.+Daviesauthor=C.+S.+Donaldauthor=L.+J.+L.+Feronauthor=H.+Gingellauthor=S.+C.+Glossopauthor=B.+R.+Hayterauthor=S.+Hussainauthor=G.+Karoutchiauthor=S.+G.+Lamontauthor=P.+MacFaulauthor=T.+A.+Mossauthor=S.+E.+Pearsonauthor=M.+Tongeauthor=G.+E.+Walkerauthor=H.+M.+Weirauthor=Z.+Wilson&title=Optimization+of+a+novel+binding+motif+to+%28E%29-3-%283%2C5-difluoro-4-%28%281R%2C3R%29-2-%282-fluoro-2-methylpropyl%29-3-methyl-2%2C3%2C4%2C9-tetrahydro-1H-pyrido%5B3%2C4-b%5Dindol-1-yl%29phenyl%29acrylic+acid+%28AZD9496%29%2C+a+potent+and+orally+bioavailable+selective+estrogen+receptor+downregulator+and+antagonist&doi=10.1021%2Facs.jmedchem.5b00984"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Optimization of a Novel Binding Motif to (E)-3-(3,5-Difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic Acid (AZD9496), a Potent and Orally Bioavailable Selective Estrogen Receptor Downregulator and Antagonist</span></div><div class="casAuthors">De Savi, Chris; Bradbury, Robert H.; Rabow, Alfred A.; Norman, Richard A.; de Almeida, Camila; Andrews, David M.; Ballard, Peter; Buttar, David; Callis, Rowena J.; Currie, Gordon S.; Curwen, Jon O.; Davies, Chris D.; Donald, Craig S.; Feron, Lyman J. L.; Gingell, Helen; Glossop, Steven C.; Hayter, Barry R.; Hussain, Syeed; Karoutchi, Galith; Lamont, Scott G.; MacFaul, Philip; Moss, Thomas A.; Pearson, Stuart E.; Tonge, Michael; Walker, Graeme E.; Weir, Hazel M.; Wilson, Zena</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">8128-8140</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The discovery of an orally bioavailable selective estrogen receptor downregulator (SERD) with equiv. potency and preclin. pharmacol. to the i.m. SERD fulvestrant is described.  A directed screen identified the 1-aryl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole motif as a novel, druglike ER ligand.  Aided by crystal structures of novel ligands bound to an ER construct, medicinal chem. iterations led to (E)-3-(3,5-difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic acid (30b, AZD9496), a clin. candidate with high oral bioavailability across preclin. species that is currently being evaluated in phase I clin. trials for the treatment of advanced estrogen receptor (ER) pos. breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpP-ZYYxmMtg7Vg90H21EOLACvtfcHk0lj7bNaDoxzBrg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsFKiu7fK&md5=df7eee70ca783a2933cd494b53f71488</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00984&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00984%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BSavi%26aufirst%3DC.%26aulast%3DBradbury%26aufirst%3DR.%2BH.%26aulast%3DRabow%26aufirst%3DA.%2BA.%26aulast%3DNorman%26aufirst%3DR.%2BA.%26aulast%3Dde%2BAlmeida%26aufirst%3DC.%26aulast%3DAndrews%26aufirst%3DD.%2BM.%26aulast%3DBallard%26aufirst%3DP.%26aulast%3DButtar%26aufirst%3DD.%26aulast%3DCallis%26aufirst%3DR.%2BJ.%26aulast%3DCurrie%26aufirst%3DG.%2BS.%26aulast%3DCurwen%26aufirst%3DJ.%2BO.%26aulast%3DDavies%26aufirst%3DC.%2BD.%26aulast%3DDonald%26aufirst%3DC.%2BS.%26aulast%3DFeron%26aufirst%3DL.%2BJ.%2BL.%26aulast%3DGingell%26aufirst%3DH.%26aulast%3DGlossop%26aufirst%3DS.%2BC.%26aulast%3DHayter%26aufirst%3DB.%2BR.%26aulast%3DHussain%26aufirst%3DS.%26aulast%3DKaroutchi%26aufirst%3DG.%26aulast%3DLamont%26aufirst%3DS.%2BG.%26aulast%3DMacFaul%26aufirst%3DP.%26aulast%3DMoss%26aufirst%3DT.%2BA.%26aulast%3DPearson%26aufirst%3DS.%2BE.%26aulast%3DTonge%26aufirst%3DM.%26aulast%3DWalker%26aufirst%3DG.%2BE.%26aulast%3DWeir%26aufirst%3DH.%2BM.%26aulast%3DWilson%26aufirst%3DZ.%26atitle%3DOptimization%2520of%2520a%2520novel%2520binding%2520motif%2520to%2520%2528E%2529-3-%25283%252C5-difluoro-4-%2528%25281R%252C3R%2529-2-%25282-fluoro-2-methylpropyl%2529-3-methyl-2%252C3%252C4%252C9-tetrahydro-1H-pyrido%255B3%252C4-b%255Dindol-1-yl%2529phenyl%2529acrylic%2520acid%2520%2528AZD9496%2529%252C%2520a%2520potent%2520and%2520orally%2520bioavailable%2520selective%2520estrogen%2520receptor%2520downregulator%2520and%2520antagonist%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26issue%3D20%26spage%3D8128%26epage%3D8140%26doi%3D10.1021%2Facs.jmedchem.5b00984" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tria, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abrams, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baird, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burks, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Firestone, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaither, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamann, L. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirby, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lombardo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macchi, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonnell, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mishina, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norris, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nunez, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Springer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomsen, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tiong-Yip, C.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peukert, S.</span></span> <span> </span><span class="NLM_article-title">Discovery of LSZ102, a potent, orally bioavailable selective estrogen receptor degrader (SERD) for the treatment of estrogen receptor positive breast cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">2837</span>– <span class="NLM_lpage">2864</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01682</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01682" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=1%3ACAS%3A528%3ADC%252BC1cXltFynurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=2837-2864&issue=7&author=G.+S.+Triaauthor=T.+Abramsauthor=J.+Bairdauthor=H.+E.+Burksauthor=B.+Firestoneauthor=L.+A.+Gaitherauthor=L.+G.+Hamannauthor=G.+Heauthor=C.+A.+Kirbyauthor=S.+Kimauthor=F.+Lombardoauthor=K.+J.+Macchiauthor=D.+P.+McDonnellauthor=Y.+Mishinaauthor=J.+D.+Norrisauthor=J.+Nunezauthor=C.+Springerauthor=Y.+Sunauthor=N.+M.+Thomsenauthor=C.+Wangauthor=J.+Wangauthor=B.+Yuauthor=C.-L.+Tiong-Yipauthor=S.+Peukert&title=Discovery+of+LSZ102%2C+a+potent%2C+orally+bioavailable+selective+estrogen+receptor+degrader+%28SERD%29+for+the+treatment+of+estrogen+receptor+positive+breast+cancer&doi=10.1021%2Facs.jmedchem.7b01682"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of LSZ102, a Potent, Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) for the Treatment of Estrogen Receptor Positive Breast Cancer</span></div><div class="casAuthors">Tria, George S.; Abrams, Tinya; Baird, Jason; Burks, Heather E.; Firestone, Brant; Gaither, L. Alex; Hamann, Lawrence G.; He, Guo; Kirby, Christina A.; Kim, Sunkyu; Lombardo, Franco; Macchi, Kaitlin J.; McDonnell, Donald P.; Mishina, Yuji; Norris, John D.; Nunez, Jill; Springer, Clayton; Sun, Yingchuan; Thomsen, Noel M.; Wang, Chunrong; Wang, Jianling; Yu, Bing; Tiong-Yip, Choi-Lai; Peukert, Stefan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2837-2864</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In breast cancer, estrogen receptor alpha (ERα) pos. cancer accounts for approx. 74% of all diagnoses, and in these settings, it is a primary driver of cell proliferation.  Treatment of ERα pos. breast cancer has long relied on endocrine therapies such as selective estrogen receptor modulators, aromatase inhibitors, and selective estrogen receptor degraders (SERDs).  The steroid-based anti-estrogen fulvestrant, the only approved SERD, is effective in patients who have not previously been treated with endocrine therapy as well as in patients who have progressed after receiving other endocrine therapies.  Its efficacy, however, may be limited due to its poor physicochem. properties.  THe authors describe the design and synthesis of a series of potent benzothiophene-contg. compds. that exhibit oral bioavailability and preclin. activity as SERDs.  This article culminates in the identification of LSZ102 (I), a compd. in clin. development for the treatment of ERα pos. breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcHgOrWwlRvrVg90H21EOLACvtfcHk0lj7bNaDoxzBrg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXltFynurc%253D&md5=dba954f9f11121fae1bb50979428a83b</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01682&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01682%26sid%3Dliteratum%253Aachs%26aulast%3DTria%26aufirst%3DG.%2BS.%26aulast%3DAbrams%26aufirst%3DT.%26aulast%3DBaird%26aufirst%3DJ.%26aulast%3DBurks%26aufirst%3DH.%2BE.%26aulast%3DFirestone%26aufirst%3DB.%26aulast%3DGaither%26aufirst%3DL.%2BA.%26aulast%3DHamann%26aufirst%3DL.%2BG.%26aulast%3DHe%26aufirst%3DG.%26aulast%3DKirby%26aufirst%3DC.%2BA.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DLombardo%26aufirst%3DF.%26aulast%3DMacchi%26aufirst%3DK.%2BJ.%26aulast%3DMcDonnell%26aufirst%3DD.%2BP.%26aulast%3DMishina%26aufirst%3DY.%26aulast%3DNorris%26aufirst%3DJ.%2BD.%26aulast%3DNunez%26aufirst%3DJ.%26aulast%3DSpringer%26aufirst%3DC.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DThomsen%26aufirst%3DN.%2BM.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DYu%26aufirst%3DB.%26aulast%3DTiong-Yip%26aufirst%3DC.-L.%26aulast%3DPeukert%26aufirst%3DS.%26atitle%3DDiscovery%2520of%2520LSZ102%252C%2520a%2520potent%252C%2520orally%2520bioavailable%2520selective%2520estrogen%2520receptor%2520degrader%2520%2528SERD%2529%2520for%2520the%2520treatment%2520of%2520estrogen%2520receptor%2520positive%2520breast%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26issue%3D7%26spage%3D2837%26epage%3D2864%26doi%3D10.1021%2Facs.jmedchem.7b01682" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Xiong, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gutgesell, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karumudi, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tonetti, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thatcher, G. R. J.</span></span> <span> </span><span class="NLM_article-title">Novel selective estrogen receptor downregulators (SERDs) developed against treatment-resistant breast cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">1325</span>– <span class="NLM_lpage">1342</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01355</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01355" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref17/cit17a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFWqu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=1325-1342&issue=4&author=R.+Xiongauthor=J.+Zhaoauthor=L.+M.+Gutgesellauthor=Y.+Wangauthor=S.+Leeauthor=B.+Karumudiauthor=H.+Zhaoauthor=Y.+Luauthor=D.+A.+Tonettiauthor=G.+R.+J.+Thatcher&title=Novel+selective+estrogen+receptor+downregulators+%28SERDs%29+developed+against+treatment-resistant+breast+cancer&doi=10.1021%2Facs.jmedchem.6b01355"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17aR"><div class="casContent"><span class="casTitleNuber">17a</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Selective Estrogen Receptor Downregulators (SERDs) Developed against Treatment-Resistant Breast Cancer</span></div><div class="casAuthors">Xiong, Rui; Zhao, Jiong; Gutgesell, Lauren M.; Wang, Yueting; Lee, Sue; Karumudi, Bhargava; Zhao, Huiping; Lu, Yunlong; Tonetti, Debra A.; Thatcher, Gregory R. J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1325-1342</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Resistance to the selective estrogen receptor modulator (SERM) tamoxifen and to aromatase inhibitors that lower circulating estradiol occurs in up to 50% of patients, generally leading to an endocrine-independent ER+ phenotype.  Selective ER downregulators (SERDs) are able to ablate ER and thus theor. to prevent survival of both endocrine-dependent and independent ER+ tumors.  The clin. SERD, fulvestrant, is hampered by i.m. administration and undesirable pharmacokinetics.  Novel SERDs were designed using the 6-OH-benzothiophene (BT) scaffold common to arzoxifene and raloxifene.  Treatment-resistant (TR) ER+ cell lines (MCF-7:5C and MCF-7:TAM1) were used for optimization, followed by validation in the parent endocrine-dependent cell line (MCF-7:WS8), in 2D and 3D cultures, using ERα in-cell westerns, ERE-luciferase, and cell viability assays, with GDC-0810 (ARN-810) used for comparison.  Two BT SERDs with superior in vitro activity to GDC-0810 were studied for bioavailability and shown to cause regression of a TR, endocrine-independent ER+ xenograft superior to GDC-0810.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLqe0A8df78rVg90H21EOLACvtfcHk0lj7bNaDoxzBrg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFWqu70%253D&md5=71dbdfa2152f9e9019e8d138ed41313e</span></div><a href="/servlet/linkout?suffix=cit17a&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01355%26sid%3Dliteratum%253Aachs%26aulast%3DXiong%26aufirst%3DR.%26aulast%3DZhao%26aufirst%3DJ.%26aulast%3DGutgesell%26aufirst%3DL.%2BM.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DLee%26aufirst%3DS.%26aulast%3DKarumudi%26aufirst%3DB.%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DTonetti%26aufirst%3DD.%2BA.%26aulast%3DThatcher%26aufirst%3DG.%2BR.%2BJ.%26atitle%3DNovel%2520selective%2520estrogen%2520receptor%2520downregulators%2520%2528SERDs%2529%2520developed%2520against%2520treatment-resistant%2520breast%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26issue%3D4%26spage%3D1325%26epage%3D1342%26doi%3D10.1021%2Facs.jmedchem.6b01355" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit17b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gutgesell, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiong, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosales, C. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon-Blake, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dye, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubrovyskyii, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lasek, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tonetti, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thatcher, G. R. J.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of basic selective estrogen receptor degraders for endocrine therapy resistant breast cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span> (<span class="NLM_issue">24</span>),  <span class="NLM_fpage">11301</span>– <span class="NLM_lpage">11323</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b01580</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b01580" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref17/cit17b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitF2ntbbE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=11301-11323&issue=24&author=Y.+Luauthor=L.+M.+Gutgesellauthor=R.+Xiongauthor=J.+Zhaoauthor=Y.+Liauthor=C.+I.+Rosalesauthor=M.+Hollasauthor=Z.+Shenauthor=J.+Gordon-Blakeauthor=K.+Dyeauthor=Y.+Wangauthor=S.+Leeauthor=H.+Chenauthor=D.+Heauthor=O.+Dubrovyskyiiauthor=H.+Zhaoauthor=F.+Huangauthor=A.+W.+Lasekauthor=D.+A.+Tonettiauthor=G.+R.+J.+Thatcher&title=Design+and+synthesis+of+basic+selective+estrogen+receptor+degraders+for+endocrine+therapy+resistant+breast+cancer&doi=10.1021%2Facs.jmedchem.9b01580"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17bR"><div class="casContent"><span class="casTitleNuber">17b</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Synthesis of Basic Selective Estrogen Receptor Degraders for Endocrine Therapy Resistant Breast Cancer</span></div><div class="casAuthors">Lu, Yunlong; Gutgesell, Lauren M.; Xiong, Rui; Zhao, Jiong; Li, Yangfeng; Rosales, Carlo I.; Hollas, Michael; Shen, Zhengnan; Gordon-Blake, Jesse; Dye, Katherine; Wang, Yueting; Lee, Sue; Chen, Hu; He, Donghong; Dubrovyskyii, Oleksii; Zhao, Huiping; Huang, Fei; Lasek, Amy W.; Tonetti, Debra A.; Thatcher, Gregory R. J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">11301-11323</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The clin. steroidal selective estrogen receptor (ER) degrader (SERD), fulvestrant, is effective in metastatic breast cancer, but limited by poor pharmacokinetics, prompting the development of orally bioavailable, nonsteroidal SERDs, currently in clin. trials.  These trials address local breast cancer as well as peripheral metastases, but patients with brain metastases are generally excluded because of the lack of blood-brain barrier penetration.  A novel family of benzothiophene SERDs with a basic amino side arm (B-SERDs) was synthesized.  Proteasomal degrdn. of ERα was induced by B-SERDs that achieved the objectives of oral and brain bioavailability, while maintaining high affinity binding to ERα and both potency and efficacy comparable to fulvestrant in cell lines resistant to endocrine therapy or bearing ESR1 mutations.  A novel 3-oxyazetidine side chain was designed, leading to 37d, a B-SERD that caused endocrine-resistant ER+ tumors to regress in a mouse orthotopic xenograft model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBas1lMEet47Vg90H21EOLACvtfcHk0lhHt3QT4EIloQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitF2ntbbE&md5=59041daf4dfd9beaa5062badebe1e88c</span></div><a href="/servlet/linkout?suffix=cit17b&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b01580%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DY.%26aulast%3DGutgesell%26aufirst%3DL.%2BM.%26aulast%3DXiong%26aufirst%3DR.%26aulast%3DZhao%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DRosales%26aufirst%3DC.%2BI.%26aulast%3DHollas%26aufirst%3DM.%26aulast%3DShen%26aufirst%3DZ.%26aulast%3DGordon-Blake%26aufirst%3DJ.%26aulast%3DDye%26aufirst%3DK.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DLee%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DHe%26aufirst%3DD.%26aulast%3DDubrovyskyii%26aufirst%3DO.%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DHuang%26aufirst%3DF.%26aulast%3DLasek%26aufirst%3DA.%2BW.%26aulast%3DTonetti%26aufirst%3DD.%2BA.%26aulast%3DThatcher%26aufirst%3DG.%2BR.%2BJ.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520basic%2520selective%2520estrogen%2520receptor%2520degraders%2520for%2520endocrine%2520therapy%2520resistant%2520breast%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26issue%3D24%26spage%3D11301%26epage%3D11323%26doi%3D10.1021%2Facs.jmedchem.9b01580" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Garner, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shomali, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paquin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyttle, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hattersley, G.</span></span> <span> </span><span class="NLM_article-title">RAD1901: a novel, orally bioavailable selective estrogen receptor degrader that demonstrates antitumor activity in breast cancer xenograft models</span>. <i>Anti-Cancer Drugs</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>26</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">948</span>– <span class="NLM_lpage">956</span>, <span class="refDoi"> DOI: 10.1097/CAD.0000000000000271</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=10.1097%2FCAD.0000000000000271" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=26164151" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtlGkt7vK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2015&pages=948-956&issue=9&author=F.+Garnerauthor=M.+Shomaliauthor=D.+Paquinauthor=C.+R.+Lyttleauthor=G.+Hattersley&title=RAD1901%3A+a+novel%2C+orally+bioavailable+selective+estrogen+receptor+degrader+that+demonstrates+antitumor+activity+in+breast+cancer+xenograft+models&doi=10.1097%2FCAD.0000000000000271"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">RAD1901: a novel, orally bioavailable selective estrogen receptor degrader that demonstrates antitumor activity in breast cancer xenograft models</span></div><div class="casAuthors">Garner, Fiona; Shomali, Maysoun; Paquin, Dotty; Lyttle, C. Richard; Hattersley, Gary</div><div class="citationInfo"><span class="NLM_cas:title">Anti-Cancer Drugs</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">948-956</span>CODEN:
                <span class="NLM_cas:coden">ANTDEV</span>;
        ISSN:<span class="NLM_cas:issn">0959-4973</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Agents that inhibit estrogen prodn., such as aromatase inhibitors or those that directly block estrogen receptor (ER) activity, such as selective estrogen receptor modulators and selective estrogen receptor degraders, are routinely used in the treatment of ER-pos. breast cancers.  However, although initial treatment with these agents is often successful, many women eventually relapse with drug-resistant breast cancers.  To overcome some of the challenges assocd. with current endocrine therapies and to combat the development of resistance, there is a need for more durable and more effective ER-targeted therapies.  Here we describe and characterize a novel, orally bioavailable small-mol. selective estrogen receptor degrader, RAD1901, and evaluate its therapeutic potential for the treatment of breast cancer.  RAD1901 selectively binds to and degrades the ER and is a potent antagonist of ER-pos. breast cancer cell proliferation.  Importantly, RAD1901 produced a robust and profound inhibition of tumor growth in MCF-7 xenograft models.  In an intracranial MCF-7 model, RAD1901-treated animals survived longer than those treated with either control or fulvestrant, suggesting the potential benefit of RAD1901 in the treatment of ER-pos. breast cancer that has metastasized to the brain.  Finally, RAD1901 preserved ovariectomy-induced bone loss and prevented the uterotropic effects of E2, suggesting that it may act selectively as an agonist in bone but as an antagonist in breast and uterine tissues.  RAD1901 is currently under clin. study in postmenopausal women with ER-pos. advanced breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrA9eopVbfVLbVg90H21EOLACvtfcHk0lhHt3QT4EIloQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtlGkt7vK&md5=acb860904a82a83b03b97b40420b64e1</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1097%2FCAD.0000000000000271&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FCAD.0000000000000271%26sid%3Dliteratum%253Aachs%26aulast%3DGarner%26aufirst%3DF.%26aulast%3DShomali%26aufirst%3DM.%26aulast%3DPaquin%26aufirst%3DD.%26aulast%3DLyttle%26aufirst%3DC.%2BR.%26aulast%3DHattersley%26aufirst%3DG.%26atitle%3DRAD1901%253A%2520a%2520novel%252C%2520orally%2520bioavailable%2520selective%2520estrogen%2520receptor%2520degrader%2520that%2520demonstrates%2520antitumor%2520activity%2520in%2520breast%2520cancer%2520xenograft%2520models%26jtitle%3DAnti-Cancer%2520Drugs%26date%3D2015%26volume%3D26%26issue%3D9%26spage%3D948%26epage%3D956%26doi%3D10.1097%2FCAD.0000000000000271" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Nagasawa, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Govek, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kahraman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonnefous, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Douglas, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sensintaffar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aparicio, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaufman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prudente, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joseph, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darimont, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brigham, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maheu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heyman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rix, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hager, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, N. D.</span></span> <span> </span><span class="NLM_article-title">Identification of an orally bioavailable chromene-based selective estrogen receptor degrader (SERD) that demonstrates robust activity in a model of tamoxifen-resistant breast cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">7917</span>– <span class="NLM_lpage">7928</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00921</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00921" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVOjsL7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=7917-7928&issue=17&author=J.+Nagasawaauthor=S.+Govekauthor=M.+Kahramanauthor=A.+Laiauthor=C.+Bonnefousauthor=K.+Douglasauthor=J.+Sensintaffarauthor=N.+Luauthor=K.+Leeauthor=A.+Aparicioauthor=J.+Kaufmanauthor=J.+Qianauthor=G.+Shaoauthor=R.+Prudenteauthor=J.+D.+Josephauthor=B.+Darimontauthor=D.+Brighamauthor=K.+Maheuauthor=R.+Heymanauthor=P.+J.+Rixauthor=J.+H.+Hagerauthor=N.+D.+Smith&title=Identification+of+an+orally+bioavailable+chromene-based+selective+estrogen+receptor+degrader+%28SERD%29+that+demonstrates+robust+activity+in+a+model+of+tamoxifen-resistant+breast+cancer&doi=10.1021%2Facs.jmedchem.8b00921"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19aR"><div class="casContent"><span class="casTitleNuber">19a</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of an Orally Bioavailable Chromene-Based Selective Estrogen Receptor Degrader (SERD) That Demonstrates Robust Activity in a Model of Tamoxifen-Resistant Breast Cancer</span></div><div class="casAuthors">Nagasawa, Johnny; Govek, Steven; Kahraman, Mehmet; Lai, Andiliy; Bonnefous, Celine; Douglas, Karensa; Sensintaffar, John; Lu, Nhin; Lee, KyoungJin; Aparicio, Anna; Kaufman, Josh; Qian, Jing; Shao, Gang; Prudente, Rene; Joseph, James D.; Darimont, Beatrice; Brigham, Daniel; Maheu, Kate; Heyman, Richard; Rix, Peter J.; Hager, Jeffrey H.; Smith, Nicholas D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">7917-7928</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Approx. eighty percent of breast cancers are estrogen receptor alpha (ER-α) pos., and although women typically initially respond well to anti-hormonal therapies such as tamoxifen and aromatase inhibitors, resistance often emerges.  Fulvestrant is a steroid-based, selective estrogen receptor degrader (SERD) that both antagonizes and degrades ER-α, and is active in patients who have progressed on anti-hormonal agents.  However fulvestrant suffers from poor pharmaceutical properties and must be administered by intra-muscular injections that limit the total amt. of drug that can be administered, and hence lead to the potential for incomplete receptor blockade.  The authors describe the optimization of ER-α degrdn. efficacy of a chromene series of ER modulators resulting in highly potent and efficacious SERDs such as 14n (3-(3-hydroxyphenyl)-4-methyl-2-(4-((S)-2-((R)-3-methylpyrrolidin-1-yl)propoxy)phenyl)-2H-chromen-6-ol).  The side-chain ring size and stereochem. elements were central in driving degrdn. efficacy, leading to the identification of 14n.  When examd. in a xenograft model of tamoxifen-resistant breast cancer, biphenol chromene 14n (ER-α degrdn. efficacy = 91%) demonstrated robust activity, while despite superior oral exposure, a mono-phenol chromene 15g (3-(4-fluorophenyl)-4-methyl-2-(4-((S)-2-((R)-3-methylpyrrolidin-1-yl)propoxy)phenyl)-2H-chromen-6-ol) (ER-α degrdn. efficacy = 82%) was essentially inactive.  Although not definitively causative, this result suggests that optimizing ER-α degrdn. efficacy leads to compds. with robust effects models of tamoxifen-resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8I60s9csFRrVg90H21EOLACvtfcHk0lgVS1g57f844w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVOjsL7E&md5=9ae708199592455e0a691c7af2e43967</span></div><a href="/servlet/linkout?suffix=cit19a&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00921&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00921%26sid%3Dliteratum%253Aachs%26aulast%3DNagasawa%26aufirst%3DJ.%26aulast%3DGovek%26aufirst%3DS.%26aulast%3DKahraman%26aufirst%3DM.%26aulast%3DLai%26aufirst%3DA.%26aulast%3DBonnefous%26aufirst%3DC.%26aulast%3DDouglas%26aufirst%3DK.%26aulast%3DSensintaffar%26aufirst%3DJ.%26aulast%3DLu%26aufirst%3DN.%26aulast%3DLee%26aufirst%3DK.%26aulast%3DAparicio%26aufirst%3DA.%26aulast%3DKaufman%26aufirst%3DJ.%26aulast%3DQian%26aufirst%3DJ.%26aulast%3DShao%26aufirst%3DG.%26aulast%3DPrudente%26aufirst%3DR.%26aulast%3DJoseph%26aufirst%3DJ.%2BD.%26aulast%3DDarimont%26aufirst%3DB.%26aulast%3DBrigham%26aufirst%3DD.%26aulast%3DMaheu%26aufirst%3DK.%26aulast%3DHeyman%26aufirst%3DR.%26aulast%3DRix%26aufirst%3DP.%2BJ.%26aulast%3DHager%26aufirst%3DJ.%2BH.%26aulast%3DSmith%26aufirst%3DN.%2BD.%26atitle%3DIdentification%2520of%2520an%2520orally%2520bioavailable%2520chromene-based%2520selective%2520estrogen%2520receptor%2520degrader%2520%2528SERD%2529%2520that%2520demonstrates%2520robust%2520activity%2520in%2520a%2520model%2520of%2520tamoxifen-resistant%2520breast%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26issue%3D17%26spage%3D7917%26epage%3D7928%26doi%3D10.1021%2Facs.jmedchem.8b00921" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit19b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Kahraman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Govek, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagasawa, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonnefous, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Douglas, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sensintaffar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aparicio, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaufman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prudente, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joseph, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darimont, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brigham, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heyman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rix, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hager, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, N. D.</span></span> <span> </span><span class="NLM_article-title">Maximizing ER-α degradation maximizes activity in a tamoxifen-resistant breast cancer model: identification of GDC-0927</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">50</span>– <span class="NLM_lpage">55</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.8b00414</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.8b00414" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisVensr3M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=50-55&issue=1&author=M.+Kahramanauthor=S.+P.+Govekauthor=J.+Y.+Nagasawaauthor=A.+Laiauthor=C.+Bonnefousauthor=K.+Douglasauthor=J.+Sensintaffarauthor=N.+Liuauthor=K.+Leeauthor=A.+Aparicioauthor=J.+Kaufmanauthor=J.+Qianauthor=G.+Shaoauthor=R.+Prudenteauthor=J.+D.+Josephauthor=B.+Darimontauthor=D.+Brighamauthor=R.+Heymanauthor=P.+J.+Rixauthor=J.+H.+Hagerauthor=N.+D.+Smith&title=Maximizing+ER-%CE%B1+degradation+maximizes+activity+in+a+tamoxifen-resistant+breast+cancer+model%3A+identification+of+GDC-0927&doi=10.1021%2Facsmedchemlett.8b00414"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19bR"><div class="casContent"><span class="casTitleNuber">19b</span><div class="casTitle"><span class="NLM_cas:atitle">Maximizing ER-α Degradation Maximizes Activity in a Tamoxifen-Resistant Breast Cancer Model: Identification of GDC-0927</span></div><div class="casAuthors">Kahraman, Mehmet; Govek, Steven P.; Nagasawa, Johnny Y.; Lai, Andiliy; Bonnefous, Celine; Douglas, Karensa; Sensintaffar, John; Liu, Nhin; Lee, KyoungJin; Aparicio, Anna; Kaufman, Josh; Qian, Jing; Shao, Gang; Prudente, Rene; Joseph, James D.; Darimont, Beatrice; Brigham, Daniel; Heyman, Richard; Rix, Peter J.; Hager, Jeffrey H.; Smith, Nicholas D.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">50-55</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The further optimization of ER-α degrdn. efficacy of a series of ER modulators by refining side-chain substitution led to efficacious selective estrogen receptor degraders (SERDs).  A fluoromethyl azetidine group was found to be preferred and resulted in the identification of bis-phenol chromene 17ha.  In a tamoxifen-resistant breast cancer xenograft model, 17ha (ER-α degrdn. efficacy = 97%) demonstrated tumor regression, together with robust redn. of intratumoral ER-α levels.  However, despite superior oral exposure, 5a (ER-α degrdn. efficacy = 91%) had inferior activity.  This result suggests that optimizing ER-α degrdn. efficacy leads to compds. with robust effects in a model of tamoxifen-resistant breast cancer.  Compd. 17ha (GDC-0927) was evaluated in clin. trials in women with metastatic estrogen receptor-pos. breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgyUydsTFnYrVg90H21EOLACvtfcHk0lgVS1g57f844w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisVensr3M&md5=324c1697ef350d169a97960de72ee8a9</span></div><a href="/servlet/linkout?suffix=cit19b&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.8b00414&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.8b00414%26sid%3Dliteratum%253Aachs%26aulast%3DKahraman%26aufirst%3DM.%26aulast%3DGovek%26aufirst%3DS.%2BP.%26aulast%3DNagasawa%26aufirst%3DJ.%2BY.%26aulast%3DLai%26aufirst%3DA.%26aulast%3DBonnefous%26aufirst%3DC.%26aulast%3DDouglas%26aufirst%3DK.%26aulast%3DSensintaffar%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DN.%26aulast%3DLee%26aufirst%3DK.%26aulast%3DAparicio%26aufirst%3DA.%26aulast%3DKaufman%26aufirst%3DJ.%26aulast%3DQian%26aufirst%3DJ.%26aulast%3DShao%26aufirst%3DG.%26aulast%3DPrudente%26aufirst%3DR.%26aulast%3DJoseph%26aufirst%3DJ.%2BD.%26aulast%3DDarimont%26aufirst%3DB.%26aulast%3DBrigham%26aufirst%3DD.%26aulast%3DHeyman%26aufirst%3DR.%26aulast%3DRix%26aufirst%3DP.%2BJ.%26aulast%3DHager%26aufirst%3DJ.%2BH.%26aulast%3DSmith%26aufirst%3DN.%2BD.%26atitle%3DMaximizing%2520ER-%25CE%25B1%2520degradation%2520maximizes%2520activity%2520in%2520a%2520tamoxifen-resistant%2520breast%2520cancer%2520model%253A%2520identification%2520of%2520GDC-0927%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D10%26issue%3D1%26spage%3D50%26epage%3D55%26doi%3D10.1021%2Facsmedchemlett.8b00414" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit19c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blake, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedman, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodacre, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ingalla, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiefer, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kleinheinz, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Labadie, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mody, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLean, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metcalfe, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nannini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otwine, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ran, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ray, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roussel, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sambrone, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sampath, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vinogradova, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeap, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zbieg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span> <span> </span><span class="NLM_article-title">Discovery of GNE-149 as a full antagonist and efficient degrader of estrogen receptor alpha for ER+ breast cancer</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">1342</span>– <span class="NLM_lpage">1347</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.0c00224</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.0c00224" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtVSht7vK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2020&pages=1342-1347&author=J.+Liangauthor=R.+Blakeauthor=J.+Changauthor=L.+S.+Friedmanauthor=S.+Goodacreauthor=S.+Hartmanauthor=E.+R.+Ingallaauthor=J.+R.+Kieferauthor=T.+Kleinheinzauthor=S.+Labadieauthor=J.+Liauthor=K.+W.+Laiauthor=J.+Liaoauthor=V.+Modyauthor=N.+McLeanauthor=C.+Metcalfeauthor=M.+Nanniniauthor=D.+Otwineauthor=Y.+Ranauthor=N.+Rayauthor=F.+Rousselauthor=A.+Sambroneauthor=D.+Sampathauthor=M.+Vinogradovaauthor=J.+Waiauthor=T.+Wangauthor=K.+Yeapauthor=A.+Youngauthor=J.+Zbiegauthor=B.+Zhangauthor=X.+Zhengauthor=Y.+Zhongauthor=X.+Wang&title=Discovery+of+GNE-149+as+a+full+antagonist+and+efficient+degrader+of+estrogen+receptor+alpha+for+ER%2B+breast+cancer&doi=10.1021%2Facsmedchemlett.0c00224"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19cR"><div class="casContent"><span class="casTitleNuber">19c</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of GNE-149 as a Full Antagonist and Efficient Degrader of Estrogen Receptor alpha for ER+ Breast Cancer</span></div><div class="casAuthors">Liang, Jun; Blake, Robert; Chang, Jae; Friedman, Lori S.; Goodacre, Simon; Hartman, Steven; Ingalla, Ellen Rei; Kiefer, James R.; Kleinheinz, Tracy; Labadie, Sharada; Li, Jun; Lai, Kwong Wah; Liao, Jiangpeng; Mody, Vidhi; McLean, Neville; Metcalfe, Ciara; Nannini, Michelle; Otwine, Daniel; Ran, Yingqing; Ray, Nick; Roussel, Fabien; Sambrone, Amy; Sampath, Deepak; Vinogradova, Maia; Wai, John; Wang, Tao; Yeap, Kuen; Young, Amy; Zbieg, Jason; Zhang, Birong; Zheng, Xiaoping; Zhong, Yu; Wang, Xiaojing</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1342-1347</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Estrogen receptor alpha (ERα) is a well-validated drug target for ER-pos. (ER+) breast cancer.  Fulvestrant is FDA-approved to treat ER+ breast cancer and works through two mechanisms-as a full antagonist and selective estrogen receptor degrader (SERD)-but lacks oral bioavailability.  Thus, we envisioned a "best-in-class" mol. with the same dual mechanisms as fulvestrant, but with significant oral exposure.  Through lead optimization, we discovered a tool mol. 12 (GNE-149) with improved degrdn. and antiproliferative activity in both MCF7 and T47D cells.  To illustrate the binding mode and key interactions of this scaffold with ERα, we obtained a cocrystal structure of 6 that showed ionic interaction of azetidine with Asp351 residue.  Importantly, 12 showed favorable metabolic stability and good oral exposure. 12 exhibited antagonist effect in the uterus and demonstrated robust dose-dependent efficacy in xenograft models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpb3Gh24AGGw7Vg90H21EOLACvtfcHk0lgVS1g57f844w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtVSht7vK&md5=9a7c3b93c8974462d8fd848ff0679eca</span></div><a href="/servlet/linkout?suffix=cit19c&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.0c00224&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.0c00224%26sid%3Dliteratum%253Aachs%26aulast%3DLiang%26aufirst%3DJ.%26aulast%3DBlake%26aufirst%3DR.%26aulast%3DChang%26aufirst%3DJ.%26aulast%3DFriedman%26aufirst%3DL.%2BS.%26aulast%3DGoodacre%26aufirst%3DS.%26aulast%3DHartman%26aufirst%3DS.%26aulast%3DIngalla%26aufirst%3DE.%2BR.%26aulast%3DKiefer%26aufirst%3DJ.%2BR.%26aulast%3DKleinheinz%26aufirst%3DT.%26aulast%3DLabadie%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DLai%26aufirst%3DK.%2BW.%26aulast%3DLiao%26aufirst%3DJ.%26aulast%3DMody%26aufirst%3DV.%26aulast%3DMcLean%26aufirst%3DN.%26aulast%3DMetcalfe%26aufirst%3DC.%26aulast%3DNannini%26aufirst%3DM.%26aulast%3DOtwine%26aufirst%3DD.%26aulast%3DRan%26aufirst%3DY.%26aulast%3DRay%26aufirst%3DN.%26aulast%3DRoussel%26aufirst%3DF.%26aulast%3DSambrone%26aufirst%3DA.%26aulast%3DSampath%26aufirst%3DD.%26aulast%3DVinogradova%26aufirst%3DM.%26aulast%3DWai%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DT.%26aulast%3DYeap%26aufirst%3DK.%26aulast%3DYoung%26aufirst%3DA.%26aulast%3DZbieg%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DB.%26aulast%3DZheng%26aufirst%3DX.%26aulast%3DZhong%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DX.%26atitle%3DDiscovery%2520of%2520GNE-149%2520as%2520a%2520full%2520antagonist%2520and%2520efficient%2520degrader%2520of%2520estrogen%2520receptor%2520alpha%2520for%2520ER%252B%2520breast%2520cancer%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2020%26volume%3D11%26spage%3D1342%26epage%3D1347%26doi%3D10.1021%2Facsmedchemlett.0c00224" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">El-Ahmad, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tabart, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halley, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Certal, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Filoche-Rommé, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gruss-Leleu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brollo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fabien, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loyau, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richepin, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pilorge, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desmazeau, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Girardet, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beccari, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Louboutin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lebourg, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le-Roux, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terrier, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vallée, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steier, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathieu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rak, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abecassis, P.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vicat, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benard, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bouaboula, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shomali, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hebert, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levit, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Courjaud, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ginesty, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perrault, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Echeverria, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCort, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schio, L.</span></span> <span> </span><span class="NLM_article-title">Discovery of 6-(2,4-dichlorophenyl)-5-[4-[(3<i>S</i>)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo[7]annulene-2-carboxylic acid (SAR439859), a potent and selective estrogen receptor degrader (SERD) for the treatment of estrogen-receptor-positive breast cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">512</span>– <span class="NLM_lpage">528</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b01293</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b01293" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=1%3ACAS%3A280%3ADC%252BB3Mjos1ejsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=512-528&author=Y.+El-Ahmadauthor=M.+Tabartauthor=F.+Halleyauthor=V.+Certalauthor=F.+Thompsonauthor=B.+Filoche-Romm%C3%A9author=F.+Gruss-Leleuauthor=C.+Mullerauthor=M.+Brolloauthor=L.+Fabienauthor=V.+Loyauauthor=L.+Bertinauthor=P.+Richepinauthor=F.+Pilorgeauthor=P.+Desmazeauauthor=C.+Girardetauthor=S.+Beccariauthor=A.+Louboutinauthor=G.+Lebourgauthor=J.+Le-Rouxauthor=C.+Terrierauthor=F.+Vall%C3%A9eauthor=V.+Steierauthor=M.+Mathieuauthor=A.+Rakauthor=P.-Y.+Abecassisauthor=P.+Vicatauthor=T.+Benardauthor=M.+Bouaboulaauthor=F.+Sunauthor=M.+Shomaliauthor=A.+Hebertauthor=M.+Levitauthor=H.+Chengauthor=A.+Courjaudauthor=C.+Ginestyauthor=C.+Perraultauthor=C.+Garcia-Echeverriaauthor=G.+McCortauthor=L.+Schio&title=Discovery+of+6-%282%2C4-dichlorophenyl%29-5-%5B4-%5B%283S%29-1-%283-fluoropropyl%29pyrrolidin-3-yl%5Doxyphenyl%5D-8%2C9-dihydro-7H-benzo%5B7%5Dannulene-2-carboxylic+acid+%28SAR439859%29%2C+a+potent+and+selective+estrogen+receptor+degrader+%28SERD%29+for+the+treatment+of+estrogen-receptor-positive+breast+cancer&doi=10.1021%2Facs.jmedchem.9b01293"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 6-(2,4-Dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo[7]annulene-2-carboxylic acid (SAR439859), a Potent and Selective Estrogen Receptor Degrader (SERD) for the Treatment of Estrogen-Receptor-Positive Breast Cancer</span></div><div class="casAuthors">El-Ahmad Youssef; Tabart Michel; Halley Frank; Certal Victor; Thompson Fabienne; Filoche-Romme Bruno; Gruss-Leleu Florence; Muller Claire; Brollo Maurice; Fabien Laurence; Loyau Veronique; Bertin Luc; Richepin Patrick; Pilorge Fabienne; Desmazeau Pascal; Girardet Chrystelle; Beccari Sylvie; Louboutin Audrey; Lebourg Gilles; Le-Roux Jacques; Terrier Corinne; Vallee Francois; Steier Valerie; Mathieu Magali; Rak Alexey; Abecassis Pierre-Yves; Vicat Pascale; Benard Tsiala; Courjaud Albane; Ginesty Celine; Perrault Christelle; Garcia-Echeverria Carlos; McCort Gary; Schio Laurent; Bouaboula Monsif; Sun Fangxian; Shomali Maysoun; Hebert Andrew; Levit Mikhail; Cheng Hong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of medicinal chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">512-528</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">More than 75% of breast cancers are estrogen receptor alpha (ERα) positive (ER+), and resistance to current hormone therapies occurs in one-third of ER+ patients.  Tumor resistance is still ERα-dependent, but mutations usually confer constitutive activation to the hormone receptor, rendering ERα modulator drugs such as tamoxifen and aromatase inhibitors ineffective.  Fulvestrant is a potent selective estrogen receptor degrader (SERD), which degrades the ERα receptor in drug-resistant tumors and has been approved for the treatment of hormone-receptor-positive metastatic breast cancer following antiestrogen therapy.  However, fulvestrant shows poor pharmacokinetic properties in human, low solubility, weak permeation, and high metabolism, limiting its administration to inconvenient intramuscular injections.  This Drug Annotation describes the identification and optimization of a new series of potent orally available SERDs, which led to the discovery of 6-(2,4-dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo[7]annulene-2-carboxylic acid (43d), showing promising antitumor activity in breast cancer mice xenograft models and whose properties warranted clinical evaluation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRgG8wK4xhUykloaUqgkFHkfW6udTcc2ebR5gMOZZ8cP7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3Mjos1ejsQ%253D%253D&md5=40732bc5b74a05cf8551ad5baea64217</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b01293&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b01293%26sid%3Dliteratum%253Aachs%26aulast%3DEl-Ahmad%26aufirst%3DY.%26aulast%3DTabart%26aufirst%3DM.%26aulast%3DHalley%26aufirst%3DF.%26aulast%3DCertal%26aufirst%3DV.%26aulast%3DThompson%26aufirst%3DF.%26aulast%3DFiloche-Romm%25C3%25A9%26aufirst%3DB.%26aulast%3DGruss-Leleu%26aufirst%3DF.%26aulast%3DMuller%26aufirst%3DC.%26aulast%3DBrollo%26aufirst%3DM.%26aulast%3DFabien%26aufirst%3DL.%26aulast%3DLoyau%26aufirst%3DV.%26aulast%3DBertin%26aufirst%3DL.%26aulast%3DRichepin%26aufirst%3DP.%26aulast%3DPilorge%26aufirst%3DF.%26aulast%3DDesmazeau%26aufirst%3DP.%26aulast%3DGirardet%26aufirst%3DC.%26aulast%3DBeccari%26aufirst%3DS.%26aulast%3DLouboutin%26aufirst%3DA.%26aulast%3DLebourg%26aufirst%3DG.%26aulast%3DLe-Roux%26aufirst%3DJ.%26aulast%3DTerrier%26aufirst%3DC.%26aulast%3DVall%25C3%25A9e%26aufirst%3DF.%26aulast%3DSteier%26aufirst%3DV.%26aulast%3DMathieu%26aufirst%3DM.%26aulast%3DRak%26aufirst%3DA.%26aulast%3DAbecassis%26aufirst%3DP.-Y.%26aulast%3DVicat%26aufirst%3DP.%26aulast%3DBenard%26aufirst%3DT.%26aulast%3DBouaboula%26aufirst%3DM.%26aulast%3DSun%26aufirst%3DF.%26aulast%3DShomali%26aufirst%3DM.%26aulast%3DHebert%26aufirst%3DA.%26aulast%3DLevit%26aufirst%3DM.%26aulast%3DCheng%26aufirst%3DH.%26aulast%3DCourjaud%26aufirst%3DA.%26aulast%3DGinesty%26aufirst%3DC.%26aulast%3DPerrault%26aufirst%3DC.%26aulast%3DGarcia-Echeverria%26aufirst%3DC.%26aulast%3DMcCort%26aufirst%3DG.%26aulast%3DSchio%26aufirst%3DL.%26atitle%3DDiscovery%2520of%25206-%25282%252C4-dichlorophenyl%2529-5-%255B4-%255B%25283S%2529-1-%25283-fluoropropyl%2529pyrrolidin-3-yl%255Doxyphenyl%255D-8%252C9-dihydro-7H-benzo%255B7%255Dannulene-2-carboxylic%2520acid%2520%2528SAR439859%2529%252C%2520a%2520potent%2520and%2520selective%2520estrogen%2520receptor%2520degrader%2520%2528SERD%2529%2520for%2520the%2520treatment%2520of%2520estrogen-receptor-positive%2520breast%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D512%26epage%3D528%26doi%3D10.1021%2Facs.jmedchem.9b01293" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Weir, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradbury, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabow, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buttar, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Callis, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curwen, J. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Almeida, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballard, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hulse, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donald, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feron, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karoutchi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacFaul, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moss, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norman, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pearson, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tonge, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowlinson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powell, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sadler, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richmond, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ladd, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pazolli, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazzola, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Cruz, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Savi, C.</span></span> <span> </span><span class="NLM_article-title">AZD9496: an oral estrogen receptor inhibitor that blocks the growth of ER-positive and ESR1-mutant breast tumors in preclinical models</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>76</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">3307</span>– <span class="NLM_lpage">3318</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-15-2357</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=10.1158%2F0008-5472.CAN-15-2357" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=27020862" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=1%3ACAS%3A528%3ADC%252BC28XovVyktLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2016&pages=3307-3318&issue=11&author=H.+M.+Weirauthor=R.+H.+Bradburyauthor=M.+Lawsonauthor=A.+A.+Rabowauthor=B.+Buttarauthor=R.+J.+Callisauthor=J.+O.+Curwenauthor=C.+de+Almeidaauthor=P.+Ballardauthor=M.+Hulseauthor=C.+S.+Donaldauthor=L.+J.+Feronauthor=G.+Karoutchiauthor=P.+MacFaulauthor=T.+Mossauthor=R.+A.+Normanauthor=S.+E.+Pearsonauthor=M.+Tongeauthor=G.+Daviesauthor=G.+E.+Walkerauthor=Z.+Wilsonauthor=R.+Rowlinsonauthor=S.+Powellauthor=C.+Sadlerauthor=G.+Richmondauthor=B.+Laddauthor=E.+Pazolliauthor=A.+M.+Mazzolaauthor=C.+D%E2%80%99Cruzauthor=C.+De+Savi&title=AZD9496%3A+an+oral+estrogen+receptor+inhibitor+that+blocks+the+growth+of+ER-positive+and+ESR1-mutant+breast+tumors+in+preclinical+models&doi=10.1158%2F0008-5472.CAN-15-2357"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">AZD9496: An Oral Estrogen Receptor Inhibitor That Blocks the Growth of ER-Positive and ESR1-Mutant Breast Tumors in Preclinical Models</span></div><div class="casAuthors">Weir, Hazel M.; Bradbury, Robert H.; Lawson, Mandy; Rabow, Alfred A.; Buttar, David; Callis, Rowena J.; Curwen, Jon O.; de Almeida, Camila; Ballard, Peter; Hulse, Michael; Donald, Craig S.; Feron, Lyman J. L.; Karoutchi, Galith; MacFaul, Philip; Moss, Thomas; Norman, Richard A.; Pearson, Stuart E.; Tonge, Michael; Davies, Gareth; Walker, Graeme E.; Wilson, Zena; Rowlinson, Rachel; Powell, Steve; Sadler, Claire; Richmond, Graham; Ladd, Brendon; Pazolli, Ermira; Mazzola, Anne Marie; D'Cruz, Celina; De Savi, Chris</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3307-3318</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Fulvestrant is an estrogen receptor (ER) antagonist administered to breast cancer patients by monthly i.m. injection.  Given its present limitations of dosing and route of administration, a more flexible orally available compd. has been sought to pursue the potential benefits of this drug in patients with advanced metastatic disease.  Here we report the identification and characterization of AZD9496, a nonsteroidal small-mol. inhibitor of ERα, which is a potent and selective antagonist and downregulator of ERα in vitro and in vivo in ER-pos. models of breast cancer.  Significant tumor growth inhibition was obsd. as low as 0.5 mg/kg dose in the estrogen-dependent MCF-7 xenograft model, where this effect was accompanied by a dose-dependent decrease in PR protein levels, demonstrating potent antagonist activity.  Combining AZD9496 with PI3K pathway and CDK4/6 inhibitors led to further growth-inhibitory effects compared with monotherapy alone.  Tumor regressions were also seen in a long-term estrogen-deprived breast model, where significant downregulation of ERα protein was obsd.  AZD9496 bound and downregulated clin. relevant ESR1 mutants in vitro and inhibited tumor growth in an ESR1-mutant patient-derived xenograft model that included a D538G mutation.  Collectively, the pharmacol. evidence showed that AZD9496 is an oral, nonsteroidal, selective estrogen receptor antagonist and downregulator in ER+ breast cells that could provide meaningful benefit to ER+ breast cancer patients.  AZD9496 is currently being evaluated in a phase I clin. trial.  Cancer Res; 76(11); 3307-18. ©2016 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoP4X3e2iYdcLVg90H21EOLACvtfcHk0lg569-yuBAhyg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XovVyktLo%253D&md5=4ff8ab9a9cd379acc031b7c6fd27134c</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-15-2357&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-15-2357%26sid%3Dliteratum%253Aachs%26aulast%3DWeir%26aufirst%3DH.%2BM.%26aulast%3DBradbury%26aufirst%3DR.%2BH.%26aulast%3DLawson%26aufirst%3DM.%26aulast%3DRabow%26aufirst%3DA.%2BA.%26aulast%3DButtar%26aufirst%3DB.%26aulast%3DCallis%26aufirst%3DR.%2BJ.%26aulast%3DCurwen%26aufirst%3DJ.%2BO.%26aulast%3Dde%2BAlmeida%26aufirst%3DC.%26aulast%3DBallard%26aufirst%3DP.%26aulast%3DHulse%26aufirst%3DM.%26aulast%3DDonald%26aufirst%3DC.%2BS.%26aulast%3DFeron%26aufirst%3DL.%2BJ.%26aulast%3DKaroutchi%26aufirst%3DG.%26aulast%3DMacFaul%26aufirst%3DP.%26aulast%3DMoss%26aufirst%3DT.%26aulast%3DNorman%26aufirst%3DR.%2BA.%26aulast%3DPearson%26aufirst%3DS.%2BE.%26aulast%3DTonge%26aufirst%3DM.%26aulast%3DDavies%26aufirst%3DG.%26aulast%3DWalker%26aufirst%3DG.%2BE.%26aulast%3DWilson%26aufirst%3DZ.%26aulast%3DRowlinson%26aufirst%3DR.%26aulast%3DPowell%26aufirst%3DS.%26aulast%3DSadler%26aufirst%3DC.%26aulast%3DRichmond%26aufirst%3DG.%26aulast%3DLadd%26aufirst%3DB.%26aulast%3DPazolli%26aufirst%3DE.%26aulast%3DMazzola%26aufirst%3DA.%2BM.%26aulast%3DD%25E2%2580%2599Cruz%26aufirst%3DC.%26aulast%3DDe%2BSavi%26aufirst%3DC.%26atitle%3DAZD9496%253A%2520an%2520oral%2520estrogen%2520receptor%2520inhibitor%2520that%2520blocks%2520the%2520growth%2520of%2520ER-positive%2520and%2520ESR1-mutant%2520breast%2520tumors%2520in%2520preclinical%2520models%26jtitle%3DCancer%2520Res.%26date%3D2016%26volume%3D76%26issue%3D11%26spage%3D3307%26epage%3D3318%26doi%3D10.1158%2F0008-5472.CAN-15-2357" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hafner, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blake, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chalouni, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, I. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Bruyn, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giltnane, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartman, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heidersbach, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houtman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ingalla, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kategaya, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kleinheinz, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Modrusan, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nannini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oeh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ubhayakar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wertz, I. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sampath, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hager, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedman, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daemen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metcalfe, C.</span></span> <span> </span><span class="NLM_article-title">Therapeutic ligands antagonize estrogen receptor function by impairing its mobility</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>178</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">949</span>– <span class="NLM_lpage">963</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2019.06.026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=10.1016%2Fj.cell.2019.06.026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=31353221" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsVOgsr%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=178&publication_year=2019&pages=949-963&issue=4&author=J.+Guanauthor=W.+Zhouauthor=M.+Hafnerauthor=R.+A.+Blakeauthor=C.+Chalouniauthor=I.+P.+Chenauthor=T.+De+Bruynauthor=J.+M.+Giltnaneauthor=S.+J.+Hartmanauthor=A.+Heidersbachauthor=R.+Houtmanauthor=E.+Ingallaauthor=L.+Kategayaauthor=T.+Kleinheinzauthor=J.+Liauthor=S.+E.+Martinauthor=Z.+Modrusanauthor=M.+Nanniniauthor=J.+Oehauthor=S.+Ubhayakarauthor=X.+Wangauthor=I.+E.+Wertzauthor=A.+Youngauthor=M.+Yuauthor=D.+Sampathauthor=J.+H.+Hagerauthor=L.+S.+Friedmanauthor=A.+Daemenauthor=C.+Metcalfe&title=Therapeutic+ligands+antagonize+estrogen+receptor+function+by+impairing+its+mobility&doi=10.1016%2Fj.cell.2019.06.026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic Ligands Antagonize Estrogen Receptor Function by Impairing Its Mobility</span></div><div class="casAuthors">Guan, Jane; Zhou, Wei; Hafner, Marc; Blake, Robert A.; Chalouni, Cecile; Chen, Irene P.; De Bruyn, Tom; Giltnane, Jennifer M.; Hartman, Steven J.; Heidersbach, Amy; Houtman, Rene; Ingalla, Ellen; Kategaya, Lorn; Kleinheinz, Tracy; Li, Jun; Martin, Scott E.; Modrusan, Zora; Nannini, Michelle; Oeh, Jason; Ubhayakar, Savita; Wang, Xiaojing; Wertz, Ingrid E.; Young, Amy; Yu, Mamie; Sampath, Deepak; Hager, Jeffrey H.; Friedman, Lori S.; Daemen, Anneleen; Metcalfe, Ciara</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">178</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">949-963.e18</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Estrogen receptor-pos. (ER+) breast cancers frequently remain dependent on ER signaling even after acquiring resistance to endocrine agents, prompting the development of optimized ER antagonists.  Fulvestrant is unique among approved ER therapeutics due to its capacity for full ER antagonism, thought to be achieved through ER degrdn.  The clin. potential of fulvestrant is limited by poor physicochem. features, spurring attempts to generate ER degraders with improved drug-like properties.  We show that optimization of ER degrdn. does not guarantee full ER antagonism in breast cancer cells; ER "degraders" exhibit a spectrum of transcriptional activities and anti-proliferative potential.  Mechanistically, we find that fulvestrant-like antagonists suppress ER transcriptional activity not by ER elimination, but by markedly slowing the intra-nuclear mobility of ER.  Increased ER turnover occurs as a consequence of ER immobilization.  These findings provide proof-of-concept that small mol. perturbation of transcription factor mobility may enable therapeutic targeting of this challenging target class.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrX7uBE7ualk7Vg90H21EOLACvtfcHk0lg569-yuBAhyg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsVOgsr%252FM&md5=96dddd56a1d3d4244ea38f0e7d17941e</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2019.06.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2019.06.026%26sid%3Dliteratum%253Aachs%26aulast%3DGuan%26aufirst%3DJ.%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DHafner%26aufirst%3DM.%26aulast%3DBlake%26aufirst%3DR.%2BA.%26aulast%3DChalouni%26aufirst%3DC.%26aulast%3DChen%26aufirst%3DI.%2BP.%26aulast%3DDe%2BBruyn%26aufirst%3DT.%26aulast%3DGiltnane%26aufirst%3DJ.%2BM.%26aulast%3DHartman%26aufirst%3DS.%2BJ.%26aulast%3DHeidersbach%26aufirst%3DA.%26aulast%3DHoutman%26aufirst%3DR.%26aulast%3DIngalla%26aufirst%3DE.%26aulast%3DKategaya%26aufirst%3DL.%26aulast%3DKleinheinz%26aufirst%3DT.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DMartin%26aufirst%3DS.%2BE.%26aulast%3DModrusan%26aufirst%3DZ.%26aulast%3DNannini%26aufirst%3DM.%26aulast%3DOeh%26aufirst%3DJ.%26aulast%3DUbhayakar%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DWertz%26aufirst%3DI.%2BE.%26aulast%3DYoung%26aufirst%3DA.%26aulast%3DYu%26aufirst%3DM.%26aulast%3DSampath%26aufirst%3DD.%26aulast%3DHager%26aufirst%3DJ.%2BH.%26aulast%3DFriedman%26aufirst%3DL.%2BS.%26aulast%3DDaemen%26aufirst%3DA.%26aulast%3DMetcalfe%26aufirst%3DC.%26atitle%3DTherapeutic%2520ligands%2520antagonize%2520estrogen%2520receptor%2520function%2520by%2520impairing%2520its%2520mobility%26jtitle%3DCell%26date%3D2019%26volume%3D178%26issue%3D4%26spage%3D949%26epage%3D963%26doi%3D10.1016%2Fj.cell.2019.06.026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scott, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buttar, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carbajo, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curwen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davey, P. R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, R. D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Degorce, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donald, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gangl, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenwood, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groombridge, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamont, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lister, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrow, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moss, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pink, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polanski, R.</span></span> <span> </span><span class="NLM_article-title">Tricyclic Indazoles – A novel class of selective estrogen receptor degrader antagonists</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">1593</span>– <span class="NLM_lpage">1608</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01837</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01837" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2019&pages=1593-1608&issue=3&author=J.+S.+Scottauthor=A.+Baileyauthor=D.+Buttarauthor=R.+J.+Carbajoauthor=J.+Curwenauthor=P.+R.+J.+Daveyauthor=R.+D.+M.+Daviesauthor=S.+L.+Degorceauthor=C.+Donaldauthor=E.+Ganglauthor=R.+Greenwoodauthor=S.+D.+Groombridgeauthor=T.+Johnsonauthor=S.+Lamontauthor=M.+Lawsonauthor=A.+Listerauthor=C.+J.+Morrowauthor=T.+A.+Mossauthor=J.+H.+Pinkauthor=R.+Polanski&title=Tricyclic+Indazoles+%E2%80%93+A+novel+class+of+selective+estrogen+receptor+degrader+antagonists&doi=10.1021%2Facs.jmedchem.8b01837"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01837&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01837%26sid%3Dliteratum%253Aachs%26aulast%3DScott%26aufirst%3DJ.%2BS.%26aulast%3DBailey%26aufirst%3DA.%26aulast%3DButtar%26aufirst%3DD.%26aulast%3DCarbajo%26aufirst%3DR.%2BJ.%26aulast%3DCurwen%26aufirst%3DJ.%26aulast%3DDavey%26aufirst%3DP.%2BR.%2BJ.%26aulast%3DDavies%26aufirst%3DR.%2BD.%2BM.%26aulast%3DDegorce%26aufirst%3DS.%2BL.%26aulast%3DDonald%26aufirst%3DC.%26aulast%3DGangl%26aufirst%3DE.%26aulast%3DGreenwood%26aufirst%3DR.%26aulast%3DGroombridge%26aufirst%3DS.%2BD.%26aulast%3DJohnson%26aufirst%3DT.%26aulast%3DLamont%26aufirst%3DS.%26aulast%3DLawson%26aufirst%3DM.%26aulast%3DLister%26aufirst%3DA.%26aulast%3DMorrow%26aufirst%3DC.%2BJ.%26aulast%3DMoss%26aufirst%3DT.%2BA.%26aulast%3DPink%26aufirst%3DJ.%2BH.%26aulast%3DPolanski%26aufirst%3DR.%26atitle%3DTricyclic%2520Indazoles%2520%25E2%2580%2593%2520A%2520novel%2520class%2520of%2520selective%2520estrogen%2520receptor%2520degrader%2520antagonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D6%26issue%3D3%26spage%3D1593%26epage%3D1608%26doi%3D10.1021%2Facs.jmedchem.8b01837" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scott, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, R. D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Degorce, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacFaul, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gingell, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moss, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norman, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pink, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabow, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, P. D.</span></span> <span> </span><span class="NLM_article-title">Tetrahydroisoquinoline phenols: selective estrogen receptor downregulator antagonists with oral bioavailability in rat</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">94</span>– <span class="NLM_lpage">99</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.5b00413</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.5b00413" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitVGku7bK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=94-99&issue=1&author=J.+S.+Scottauthor=A.+Baileyauthor=R.+D.+M.+Daviesauthor=S.+L.+Degorceauthor=P.+A.+MacFaulauthor=H.+Gingellauthor=T.+Mossauthor=R.+A.+Normanauthor=J.+H.+Pinkauthor=A.+A.+Rabowauthor=B.+Robertsauthor=P.+D.+Smith&title=Tetrahydroisoquinoline+phenols%3A+selective+estrogen+receptor+downregulator+antagonists+with+oral+bioavailability+in+rat&doi=10.1021%2Facsmedchemlett.5b00413"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Tetrahydroisoquinoline Phenols: Selective Estrogen Receptor Downregulator Antagonists with Oral Bioavailability in Rat</span></div><div class="casAuthors">Scott, James S.; Bailey, Andrew; Davies, Robert D. M.; Degorce, Sebastien L.; MacFaul, Philip A.; Gingell, Helen; Moss, Thomas; Norman, Richard A.; Pink, Jennifer H.; Rabow, Alfred A.; Roberts, Bryan; Smith, Peter D.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">94-99</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of tetrahydroisoquinoline phenols was modified to give an estrogen receptor downregulator-antagonist profile.  Optimization around the core, alkyl side chain, and pendant aryl ring resulted in compds. I [R = Ph, PhCH2, i-Bu, etc.] with subnanomolar levels of potency.  The phenol functionality was shown to be required to achieve highly potent compds., but unusually this was compatible with obtaining high oral bioavailabilities in rat.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXOiEPK5ofVLVg90H21EOLACvtfcHk0liJGyU97zouYQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitVGku7bK&md5=8c573b4e96e70cf61d40f349a7c19967</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.5b00413&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.5b00413%26sid%3Dliteratum%253Aachs%26aulast%3DScott%26aufirst%3DJ.%2BS.%26aulast%3DBailey%26aufirst%3DA.%26aulast%3DDavies%26aufirst%3DR.%2BD.%2BM.%26aulast%3DDegorce%26aufirst%3DS.%2BL.%26aulast%3DMacFaul%26aufirst%3DP.%2BA.%26aulast%3DGingell%26aufirst%3DH.%26aulast%3DMoss%26aufirst%3DT.%26aulast%3DNorman%26aufirst%3DR.%2BA.%26aulast%3DPink%26aufirst%3DJ.%2BH.%26aulast%3DRabow%26aufirst%3DA.%2BA.%26aulast%3DRoberts%26aufirst%3DB.%26aulast%3DSmith%26aufirst%3DP.%2BD.%26atitle%3DTetrahydroisoquinoline%2520phenols%253A%2520selective%2520estrogen%2520receptor%2520downregulator%2520antagonists%2520with%2520oral%2520bioavailability%2520in%2520rat%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D7%26issue%3D1%26spage%3D94%26epage%3D99%26doi%3D10.1021%2Facsmedchemlett.5b00413" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scott, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breed, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carbajo, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davey, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenwood, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huynh, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klinowska, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrow, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moss, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polanski, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nissink, J. W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varnes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, B.</span></span> <span> </span><span class="NLM_article-title">Building bridges in a series of estrogen receptor degraders: an application of metathesis in medicinal chemistry</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">1492</span>– <span class="NLM_lpage">1497</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.9b00370</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.9b00370" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvVentr3E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=1492-1497&issue=10&author=J.+S.+Scottauthor=J.+Breedauthor=R.+J.+Carbajoauthor=P.+R.+Daveyauthor=R.+Greenwoodauthor=H.+K.+Huynhauthor=T.+Klinowskaauthor=C.+J.+Morrowauthor=T.+A.+Mossauthor=R.+Polanskiauthor=J.+W.+M.+Nissinkauthor=J.+Varnesauthor=B.+Yang&title=Building+bridges+in+a+series+of+estrogen+receptor+degraders%3A+an+application+of+metathesis+in+medicinal+chemistry&doi=10.1021%2Facsmedchemlett.9b00370"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Building Bridges in a Series of Estrogen Receptor Degraders: An Application of Metathesis in Medicinal Chemistry</span></div><div class="casAuthors">Scott, James S.; Breed, Jason; Carbajo, Rodrigo J.; Davey, Paul R.; Greenwood, Ryan; Huynh, Hoan K.; Klinowska, Teresa; Morrow, Christopher J.; Moss, Thomas A.; Polanski, Radoslaw; Nissink, J. Willem M.; Varnes, Jeffrey; Yang, Bin</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1492-1497</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Herein the authors report the use of metathesis to construct a novel tetracyclic core in a series of estrogen receptor degraders.  This improved the chem. stability, as assessed using an NMR-MS based assay, and gave a mol. with excellent physicochem. properties and pharmacokinetics in rat.  X-ray crystallog. established minimal perturbation of the bridged compds. relative to the unbridged analogs in the receptor binding pocket.  Unfortunately, despite retaining excellent binding to ERα, this adversely affected the ability of the compds. to degrade the receptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEcZlsyjk417Vg90H21EOLACvtfcHk0lih2wHcwGlAXA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvVentr3E&md5=76a10d7bedd883966fb7106ccf08a0f0</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.9b00370&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.9b00370%26sid%3Dliteratum%253Aachs%26aulast%3DScott%26aufirst%3DJ.%2BS.%26aulast%3DBreed%26aufirst%3DJ.%26aulast%3DCarbajo%26aufirst%3DR.%2BJ.%26aulast%3DDavey%26aufirst%3DP.%2BR.%26aulast%3DGreenwood%26aufirst%3DR.%26aulast%3DHuynh%26aufirst%3DH.%2BK.%26aulast%3DKlinowska%26aufirst%3DT.%26aulast%3DMorrow%26aufirst%3DC.%2BJ.%26aulast%3DMoss%26aufirst%3DT.%2BA.%26aulast%3DPolanski%26aufirst%3DR.%26aulast%3DNissink%26aufirst%3DJ.%2BW.%2BM.%26aulast%3DVarnes%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DB.%26atitle%3DBuilding%2520bridges%2520in%2520a%2520series%2520of%2520estrogen%2520receptor%2520degraders%253A%2520an%2520application%2520of%2520metathesis%2520in%2520medicinal%2520chemistry%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D10%26issue%3D10%26spage%3D1492%26epage%3D1497%26doi%3D10.1021%2Facsmedchemlett.9b00370" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="note"><p class="first last">This compound was made as part of our internal chemistry program but has since appeared in the literature in other patent applications:</p></div><div class="NLM_citation" id="rightTab-cit26a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Goodacre, S. C.</span>; <span class="NLM_string-name">Labadie, S.</span>; <span class="NLM_string-name">Liang, J.</span>; <span class="NLM_string-name">Ortwine, D. F.</span>; <span class="NLM_string-name">Ray, N. C.</span>; <span class="NLM_string-name">Wang, X.</span>; <span class="NLM_string-name">Zbieg, J.</span>; <span class="NLM_string-name">Zhang, B.</span></span> <span> </span><span class="NLM_article-title">Tetrahydro-Pyrido[3,4-<i>b</i>]indole Estrogen Receptor Modulators And Uses Thereof</span>. <span class="NLM_patent">WO 2016097072</span>, <span class="NLM_year">2016</span>, Genentech.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=S.+C.+Goodacre&author=S.+Labadie&author=J.+Liang&author=D.+F.+Ortwine&author=N.+C.+Ray&author=X.+Wang&author=J.+Zbieg&author=B.+Zhang&title=Tetrahydro-Pyrido%5B3%2C4-b%5Dindole+Estrogen+Receptor+Modulators+And+Uses+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DGoodacre%26aufirst%3DS.%2BC.%26atitle%3DTetrahydro-Pyrido%255B3%252C4-b%255Dindole%2520Estrogen%2520Receptor%2520Modulators%2520And%2520Uses%2520Thereof%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit26b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Myles, D. C.</span>; <span class="NLM_string-name">Kushner, P. J.</span>; <span class="NLM_string-name">Harmon, C. I.</span></span> <span> </span><span class="NLM_article-title">Tetrahydro-1H-Pyrido[3,4-<i>b</i>]indole Anti-Estrogenic Drugs</span>. <span class="NLM_patent">WO 2017059139</span>, <span class="NLM_year">2017</span>, Olema Pharmaceuticals.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=D.+C.+Myles&author=P.+J.+Kushner&author=C.+I.+Harmon&title=Tetrahydro-1H-Pyrido%5B3%2C4-b%5Dindole+Anti-Estrogenic+Drugs"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMyles%26aufirst%3DD.%2BC.%26atitle%3DTetrahydro-1H-Pyrido%255B3%252C4-b%255Dindole%2520Anti-Estrogenic%2520Drugs%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit26c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Dai, X.</span>; <span class="NLM_string-name">Wang, Y.</span></span> <span> </span><span class="NLM_article-title">Selective Estrogen Receptor Degraders And Uses Thereof</span>. <span class="NLM_patent">WO 2017136688</span>, <span class="NLM_year">2017</span>, InventisBio.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=X.+Dai&author=Y.+Wang&title=Selective+Estrogen+Receptor+Degraders+And+Uses+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DDai%26aufirst%3DX.%26atitle%3DSelective%2520Estrogen%2520Receptor%2520Degraders%2520And%2520Uses%2520Thereof%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span> For a review
of the
Pictet-Spengler reaction and discussion on selectivity, see:<span class="NLM_contrib-group"><span class="NLM_string-name">Cox, E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cook, J. M.</span></span> <span> </span><span class="NLM_article-title">The Pictet-Spengler condensation: a new direction for an old reaction</span>. <i>Chem. Rev.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>95</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1797</span>– <span class="NLM_lpage">1842</span>, <span class="refDoi"> DOI: 10.1021/cr00038a004</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cr00038a004" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=1%3ACAS%3A528%3ADyaK2MXos1Sjtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=1995&pages=1797-1842&issue=6&author=E.+D.+Coxauthor=J.+M.+Cook&title=The+Pictet-Spengler+condensation%3A+a+new+direction+for+an+old+reaction&doi=10.1021%2Fcr00038a004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">The Pictet-Spengler condensation: a new direction for an old reaction</span></div><div class="casAuthors">Cox, Eric D.; Cook, James M.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, D. C.)</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">95</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1797-842</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review with 324 refs. including discussion of condensation in nonacidic aprotic media, modeling the pharmacophore of benzodiazepine receptor sites, enantiospecific total synthesis of indole alkaloids, etc.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZXX6FLFmuQrVg90H21EOLACvtfcHk0lih2wHcwGlAXA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXos1Sjtrc%253D&md5=e8734b59c48cfed82a3b26aa9eeed2e2</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Fcr00038a004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcr00038a004%26sid%3Dliteratum%253Aachs%26aulast%3DCox%26aufirst%3DE.%2BD.%26aulast%3DCook%26aufirst%3DJ.%2BM.%26atitle%3DThe%2520Pictet-Spengler%2520condensation%253A%2520a%2520new%2520direction%2520for%2520an%2520old%2520reaction%26jtitle%3DChem.%2520Rev.%26date%3D1995%26volume%3D95%26issue%3D6%26spage%3D1797%26epage%3D1842%26doi%3D10.1021%2Fcr00038a004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, R. D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pink, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, A.</span></span> <span> </span><span class="NLM_article-title">Synthesis of 8-substituted-6-phenyl-6,7,8,9-tetrahydro-3<i>H</i>-pyrazolo[4,3-<i>f</i>]isoquinolines using Pictet-Spengler and Bischler-Napieralski cyclisation methods</span>. <i>Tetrahedron Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>59</i></span> (<span class="NLM_issue">30</span>),  <span class="NLM_fpage">2917</span>– <span class="NLM_lpage">2920</span>, <span class="refDoi"> DOI: 10.1016/j.tetlet.2018.06.041</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=10.1016%2Fj.tetlet.2018.06.041" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtF2jsrrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2018&pages=2917-2920&issue=30&author=R.+D.+M.+Daviesauthor=J.+H.+Pinkauthor=J.+S.+Scottauthor=A.+Bailey&title=Synthesis+of+8-substituted-6-phenyl-6%2C7%2C8%2C9-tetrahydro-3H-pyrazolo%5B4%2C3-f%5Disoquinolines+using+Pictet-Spengler+and+Bischler-Napieralski+cyclisation+methods&doi=10.1016%2Fj.tetlet.2018.06.041"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28aR"><div class="casContent"><span class="casTitleNuber">28a</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of 8-substituted-6-phenyl-6,7,8,9-tetrahydro-3H-pyrazolo[4,3-f]isoquinolines using Pictet-Spengler and Bischler-Napieralski cyclisation methods</span></div><div class="casAuthors">Davies, Robert D. M.; Pink, Jennifer H.; Scott, James S.; Bailey, Andrew</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron Letters</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">30</span>),
    <span class="NLM_cas:pages">2917-2920</span>CODEN:
                <span class="NLM_cas:coden">TELEAY</span>;
        ISSN:<span class="NLM_cas:issn">0040-4039</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Routes for the synthesis of a set of 8-substituted-6-phenyl-6,7,8,9-tetrahydro-3H-pyrazolo[4,3-f]isoquinolines I [R1 = R2 = H, Me; R1 = H, R2 = Me] are reported.  Pictet-Spengler and Bischler-Napieralski methodologies were employed on the relevant indazole precursors and the merits of the two cyclization reactions for prepg. these structures were assessed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoG9ECcfA1xVbVg90H21EOLACvtfcHk0liu6Vymp1wQUw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtF2jsrrI&md5=ca67573d48141e779f399f8a0a4fe40c</span></div><a href="/servlet/linkout?suffix=cit28a&amp;dbid=16384&amp;doi=10.1016%2Fj.tetlet.2018.06.041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tetlet.2018.06.041%26sid%3Dliteratum%253Aachs%26aulast%3DDavies%26aufirst%3DR.%2BD.%2BM.%26aulast%3DPink%26aufirst%3DJ.%2BH.%26aulast%3DScott%26aufirst%3DJ.%2BS.%26aulast%3DBailey%26aufirst%3DA.%26atitle%3DSynthesis%2520of%25208-substituted-6-phenyl-6%252C7%252C8%252C9-tetrahydro-3H-pyrazolo%255B4%252C3-f%255Disoquinolines%2520using%2520Pictet-Spengler%2520and%2520Bischler-Napieralski%2520cyclisation%2520methods%26jtitle%3DTetrahedron%2520Lett.%26date%3D2018%26volume%3D59%26issue%3D30%26spage%3D2917%26epage%3D2920%26doi%3D10.1016%2Fj.tetlet.2018.06.041" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit28b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lister, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moss, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamont, S. G.</span></span> <span> </span><span class="NLM_article-title">Synthesis of trans 8-substituted-6-phenyl-6,7,8,9-tetrahydro-3<i>H</i>-pyrazolo[4,3-<i>f</i>]isoquinolines using a Pictet-Spengler approach</span>. <i>Tetrahedron Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>59</i></span> (<span class="NLM_issue">51</span>),  <span class="NLM_fpage">4509</span>– <span class="NLM_lpage">4513</span>, <span class="refDoi"> DOI: 10.1016/j.tetlet.2018.11.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=10.1016%2Fj.tetlet.2018.11.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=1%3ACAS%3A528%3ADC%252BC1cXit1Cht7zJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2018&pages=4509-4513&issue=51&author=A.+Baileyauthor=A.+S.+Listerauthor=T.+A.+Mossauthor=J.+S.+Scottauthor=Y.+Wuauthor=S.+G.+Lamont&title=Synthesis+of+trans+8-substituted-6-phenyl-6%2C7%2C8%2C9-tetrahydro-3H-pyrazolo%5B4%2C3-f%5Disoquinolines+using+a+Pictet-Spengler+approach&doi=10.1016%2Fj.tetlet.2018.11.021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28bR"><div class="casContent"><span class="casTitleNuber">28b</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of trans 8-substituted-6-phenyl-6,7,8,9-tetrahydro-3H-pyrazolo[4,3-f]isoquinolines using a Pictet-Spengler approach</span></div><div class="casAuthors">Bailey, Andrew; Lister, Andrew; Moss, Thomas; Scott, James S.; Wu, Ye; Lamont, Scott G.</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron Letters</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">51</span>),
    <span class="NLM_cas:pages">4509-4513</span>CODEN:
                <span class="NLM_cas:coden">TELEAY</span>;
        ISSN:<span class="NLM_cas:issn">0040-4039</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Two complementary approaches for the synthesis of trans 8-substituted-6-phenyl-6,7,8,9-tetrahydro-3H-pyrazolo[4,3-f]isoquinolines I [R = iBu, CH2CHF2, CH2CF3, (1-fluorocyclopropyl)methyl, CH2C(Me)2F; Ar = 4-BrC6H4, 5-Br-2-pyridyl, 4-Br-3-F-C6H3, 4_Br-2,6-di-FC6H2, 4-Br-2-MeOC6H3] was reported.  The first method, directly from α-Me substituted indazole ethanamines, was successful but had limited substrate scope.  The second method utilized a modified Pictet-Spengler cyclization reaction on an aniline substrate followed by late stage construction of the indazole ring and was more versatile in terms of substrate scope.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJuVjpZuGHf7Vg90H21EOLACvtfcHk0liu6Vymp1wQUw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXit1Cht7zJ&md5=b0f7d200bf1c76f9c1217cb7a58fc7c1</span></div><a href="/servlet/linkout?suffix=cit28b&amp;dbid=16384&amp;doi=10.1016%2Fj.tetlet.2018.11.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tetlet.2018.11.021%26sid%3Dliteratum%253Aachs%26aulast%3DBailey%26aufirst%3DA.%26aulast%3DLister%26aufirst%3DA.%2BS.%26aulast%3DMoss%26aufirst%3DT.%2BA.%26aulast%3DScott%26aufirst%3DJ.%2BS.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DLamont%26aufirst%3DS.%2BG.%26atitle%3DSynthesis%2520of%2520trans%25208-substituted-6-phenyl-6%252C7%252C8%252C9-tetrahydro-3H-pyrazolo%255B4%252C3-f%255Disoquinolines%2520using%2520a%2520Pictet-Spengler%2520approach%26jtitle%3DTetrahedron%2520Lett.%26date%3D2018%26volume%3D59%26issue%3D51%26spage%3D4509%26epage%3D4513%26doi%3D10.1016%2Fj.tetlet.2018.11.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fors, B. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchwald, S. L.</span></span> <span> </span><span class="NLM_article-title">A single phosphine ligand allows palladium-catalyzed intermolecular C−O bond formation with secondary and primary alcohols</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>50</i></span> (<span class="NLM_issue">42</span>),  <span class="NLM_fpage">9943</span>– <span class="NLM_lpage">9947</span>, <span class="refDoi"> DOI: 10.1002/anie.201104361</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=10.1002%2Fanie.201104361" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtFKhs7jE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2011&pages=9943-9947&issue=42&author=X.+Wuauthor=B.+P.+Forsauthor=S.+L.+Buchwald&title=A+single+phosphine+ligand+allows+palladium-catalyzed+intermolecular+C%E2%88%92O+bond+formation+with+secondary+and+primary+alcohols&doi=10.1002%2Fanie.201104361"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">A Single Phosphine Ligand Allows Palladium-Catalyzed Intermolecular C-O Bond Formation with Secondary and Primary Alcohols</span></div><div class="casAuthors">Wu, Xiaoxing; Fors, Brett P.; Buchwald, Stephen L.</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">42</span>),
    <span class="NLM_cas:pages">9943-9947, S9943/1-S9943/134</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">An efficient, general palladium catalyst for C-O bond-forming reactions of secondary and primary alcs. with a range of aryl halides has been developed using RockPhos ligand I.  Heteroaryl halides, and, for the first time, electron-rich aryl halides can be coupled with secondary alcs.  A diverse set of substrate combinations are possible with just a single ligand, thus obviating the need to survey multiple ligands.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1rRsKbYpjabVg90H21EOLACvtfcHk0lhPgoKBsAQ6xA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtFKhs7jE&md5=00f2f016dd227483158dacc2e24fb614</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1002%2Fanie.201104361&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201104361%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DX.%26aulast%3DFors%26aufirst%3DB.%2BP.%26aulast%3DBuchwald%26aufirst%3DS.%2BL.%26atitle%3DA%2520single%2520phosphine%2520ligand%2520allows%2520palladium-catalyzed%2520intermolecular%2520C%25E2%2588%2592O%2520bond%2520formation%2520with%2520secondary%2520and%2520primary%2520alcohols%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2011%26volume%3D50%26issue%3D42%26spage%3D9943%26epage%3D9947%26doi%3D10.1002%2Fanie.201104361" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maiti, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fors, B. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henderson, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakamura, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchwald, S. L.</span></span> <span> </span><span class="NLM_article-title">Palladium-catalyzed coupling of functionalized primary and secondary amines with aryl and heteroaryl halides: two ligands suffice in most cases</span>. <i>Chem. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>2</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">57</span>– <span class="NLM_lpage">68</span>, <span class="refDoi"> DOI: 10.1039/C0SC00330A</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=10.1039%2FC0SC00330A" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=22384311" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsFWqsbjF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2011&pages=57-68&issue=1&author=D.+Maitiauthor=B.+P.+Forsauthor=J.+L.+Hendersonauthor=Y.+Nakamuraauthor=S.+L.+Buchwald&title=Palladium-catalyzed+coupling+of+functionalized+primary+and+secondary+amines+with+aryl+and+heteroaryl+halides%3A+two+ligands+suffice+in+most+cases&doi=10.1039%2FC0SC00330A"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Palladium-catalyzed coupling of functionalized primary and secondary amines with aryl and heteroaryl halides: two ligands suffice in most cases</span></div><div class="casAuthors">Maiti, Debabrata; Fors, Brett P.; Henderson, Jaclyn L.; Nakamura, Yoshinori; Buchwald, Stephen L.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Science</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">57-68</span>CODEN:
                <span class="NLM_cas:coden">CSHCCN</span>;
        ISSN:<span class="NLM_cas:issn">2041-6520</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A study on the use of two catalyst systems is reported here.  The ligands used in this study were BrettPhos [i.e., dicyclohexyl[3,6-dimethoxy-2',4',6'-tris(1-methylethyl)[1,1'-biphenyl]-2-yl]phosphine] and RuPhos [i.e., [2',6'-bis(1-methylethoxy)[1,1'-biphenyl]-2-yl]dicyclohexylphosphine].  These ligands provide a wide scope for Pd-catalyzed C-N cross-coupling reactions.  Often low catalyst loadings and short reaction times can be used with functionalized aryl and heteroaryl coupling partners.  The reactions are highly robust and can be set up and performed without the use of a glove box.  These catalysts should find wide application in the synthesis of complex mols. including pharmaceuticals, natural products and functional materials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7MMWmsn65tLVg90H21EOLACvtfcHk0lhPgoKBsAQ6xA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsFWqsbjF&md5=217f0d978b9cc44b2b3c468fd291c2b2</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1039%2FC0SC00330A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC0SC00330A%26sid%3Dliteratum%253Aachs%26aulast%3DMaiti%26aufirst%3DD.%26aulast%3DFors%26aufirst%3DB.%2BP.%26aulast%3DHenderson%26aufirst%3DJ.%2BL.%26aulast%3DNakamura%26aufirst%3DY.%26aulast%3DBuchwald%26aufirst%3DS.%2BL.%26atitle%3DPalladium-catalyzed%2520coupling%2520of%2520functionalized%2520primary%2520and%2520secondary%2520amines%2520with%2520aryl%2520and%2520heteroaryl%2520halides%253A%2520two%2520ligands%2520suffice%2520in%2520most%2520cases%26jtitle%3DChem.%2520Sci.%26date%3D2011%26volume%3D2%26issue%3D1%26spage%3D57%26epage%3D68%26doi%3D10.1039%2FC0SC00330A" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vanden
Eynden, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kunchithapatham, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stambuli, J. P.</span></span> <span> </span><span class="NLM_article-title">Calcium-promoted Pictet-Spengler reactions of ketones and aldehydes</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>75</i></span> (<span class="NLM_issue">24</span>),  <span class="NLM_fpage">8542</span>– <span class="NLM_lpage">8549</span>, <span class="refDoi"> DOI: 10.1021/jo1019283</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo1019283" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVGkt7vN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2010&pages=8542-8549&issue=24&author=M.+J.+Vanden%0AEyndenauthor=K.+Kunchithapathamauthor=J.+P.+Stambuli&title=Calcium-promoted+Pictet-Spengler+reactions+of+ketones+and+aldehydes&doi=10.1021%2Fjo1019283"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Calcium-Promoted Pictet-Spengler Reactions of Ketones and Aldehydes</span></div><div class="casAuthors">Vanden Eynden, Matthew J.; Kunchithapatham, Kamala; Stambuli, James P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">8542-8549</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Calcium bis-1,1,1,3,3,3-hexafluoroisopropoxide is an effective catalyst for Pictet-Spengler reactions of 3-hydroxyphenethylamine and 3-hydroxy-4-methoxyphenethylamine with various aldehydes and ketones.  Previous Lewis acid catalyzed Pictet-Spengler reactions of unactivated ketones typically require two sep. reactions (imine formation, cyclization) to obtain the same results.  The reactions described within directly provide 1,1'-disubstituted tetrahydroisoquinolines from the corresponding amine and ketone.  These rare examples of Pictet-Spengler reactions of unactivated ketones demonstrate the unique nature of calcium as a Lewis acid catalyst.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJAHtPvuLZHLVg90H21EOLACvtfcHk0lhPgoKBsAQ6xA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVGkt7vN&md5=ec09721b3ea7da07bdd571c4eb7c4b94</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1021%2Fjo1019283&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo1019283%26sid%3Dliteratum%253Aachs%26aulast%3DVanden%2BEynden%26aufirst%3DM.%2BJ.%26aulast%3DKunchithapatham%26aufirst%3DK.%26aulast%3DStambuli%26aufirst%3DJ.%2BP.%26atitle%3DCalcium-promoted%2520Pictet-Spengler%2520reactions%2520of%2520ketones%2520and%2520aldehydes%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2010%26volume%3D75%26issue%3D24%26spage%3D8542%26epage%3D8549%26doi%3D10.1021%2Fjo1019283" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="note"><p class="first last">In previous work (refs <a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> and <a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a>), we had observed diastereoselective addition into the iminium ion; however, in this case a mixture of epimers of <b>55</b> was obtained. We rationalized this on the basis of the smaller steric bulk of the difluoroethyl group relative to previous alkyl chains we had examined, leading to less facial bias for the addition of the nucleophile. The stereochemistry of <b>31</b> was assigned based on a NOE effect observed between the two methyl groups on the piperidine ring together with the fact that the epimeric isomer of <b>31</b> showed significantly lower activity in both the enzyme (ΔpIC<sub>50</sub> −1.5) and cell (ΔpIC<sub>50</sub> −1.8) assays, consistent with previously established SAR.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fujita, K.-i.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamaguchi, R.</span></span> <span> </span><span class="NLM_article-title">Oxidative cyclization of amino alcohols catalyzed by a Cp*Ir complex. synthesis of indoles, 1,2,3,4-tetrahydroquinolines, and 2,3,4,5-tetrahydro-1-benzazepine</span>. <i>Org. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>4</i></span> (<span class="NLM_issue">16</span>),  <span class="NLM_fpage">2691</span>– <span class="NLM_lpage">2694</span>, <span class="refDoi"> DOI: 10.1021/ol026200s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ol026200s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=1%3ACAS%3A528%3ADC%252BD38Xlt1Cju7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2002&pages=2691-2694&issue=16&author=K.-i.+Fujitaauthor=K.+Yamamotoauthor=R.+Yamaguchi&title=Oxidative+cyclization+of+amino+alcohols+catalyzed+by+a+Cp*Ir+complex.+synthesis+of+indoles%2C+1%2C2%2C3%2C4-tetrahydroquinolines%2C+and+2%2C3%2C4%2C5-tetrahydro-1-benzazepine&doi=10.1021%2Fol026200s"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Oxidative Cyclization of Amino Alcohols Catalyzed by a Cp*Ir Complex. Synthesis of Indoles, 1,2,3,4-Tetrahydroquinolines, and 2,3,4,5-Tetrahydro-1-benzazepine</span></div><div class="casAuthors">Fujita, Kenichi; Yamamoto, Kazunari; Yamaguchi, Ryohei</div><div class="citationInfo"><span class="NLM_cas:title">Organic Letters</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">2691-2694</span>CODEN:
                <span class="NLM_cas:coden">ORLEF7</span>;
        ISSN:<span class="NLM_cas:issn">1523-7060</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A new iridium-catalyzed oxidative cyclization of amino alcs. has been revealed.  Indole derivs. are synthesized in good to excellent yields from 2-aminophenethyl alcs. by means of a [Cp*IrCl2]2/K2CO3 catalytic system.  The present catalytic system is also effective for syntheses of 1,2,3,4-tetrahydroquinolines from 3-(2-aminophenyl)propanols and 2,3,4,5-tetrahydro-1-benzazepine from 4-(2-aminophenyl)butanol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9ywzR01HISLVg90H21EOLACvtfcHk0ljzUXSSMohxlQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xlt1Cju7w%253D&md5=48f5b2c85a822a43640a0110aa932c66</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Fol026200s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fol026200s%26sid%3Dliteratum%253Aachs%26aulast%3DFujita%26aufirst%3DK.-i.%26aulast%3DYamamoto%26aufirst%3DK.%26aulast%3DYamaguchi%26aufirst%3DR.%26atitle%3DOxidative%2520cyclization%2520of%2520amino%2520alcohols%2520catalyzed%2520by%2520a%2520Cp%252AIr%2520complex.%2520synthesis%2520of%2520indoles%252C%25201%252C2%252C3%252C4-tetrahydroquinolines%252C%2520and%25202%252C3%252C4%252C5-tetrahydro-1-benzazepine%26jtitle%3DOrg.%2520Lett.%26date%3D2002%26volume%3D4%26issue%3D16%26spage%3D2691%26epage%3D2694%26doi%3D10.1021%2Fol026200s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Degorce, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Callis, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Savi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ducray, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamont, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacFaul, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maudet, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgentin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norman, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peru, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pink, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plé, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, J. S.</span></span> <span> </span><span class="NLM_article-title">Investigation of (<i>E</i>)-3-[4-(2-Oxo-3-aryl-chromen-4-yl)oxyphenyl]acrylic acids as oral selective estrogen receptor down-regulators</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">3522</span>– <span class="NLM_lpage">3533</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00066</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00066" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=1%3ACAS%3A528%3ADC%252BC2MXksl2gsrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=3522-3533&issue=8&author=S.+L.+Degorceauthor=A.+Baileyauthor=R.+Callisauthor=C.+De+Saviauthor=R.+Ducrayauthor=G.+Lamontauthor=P.+MacFaulauthor=M.+Maudetauthor=S.+Martinauthor=R.+Morgentinauthor=R.+A.+Normanauthor=A.+Peruauthor=J.+H.+Pinkauthor=P.+A.+Pl%C3%A9author=B.+Robertsauthor=J.+S.+Scott&title=Investigation+of+%28E%29-3-%5B4-%282-Oxo-3-aryl-chromen-4-yl%29oxyphenyl%5Dacrylic+acids+as+oral+selective+estrogen+receptor+down-regulators&doi=10.1021%2Facs.jmedchem.5b00066"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Investigation of (E)-3-[4-(2-Oxo-3-aryl-chromen-4-yl)oxyphenyl]acrylic Acids as Oral Selective Estrogen Receptor Down-Regulators</span></div><div class="casAuthors">Degorce, Sebastien L.; Bailey, Andrew; Callis, Rowena; De Savi, Chris; Ducray, Richard; Lamont, Gillian; MacFaul, Philip; Maudet, Mickael; Martin, Scott; Morgentin, Remy; Norman, Richard A.; Peru, Aurelien; Pink, Jennifer H.; Ple, Patrick A.; Roberts, Bryan; Scott, James S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3522-3533</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A novel estrogen receptor down-regulator, 7-hydroxycoumarin (5, SS5020), has been reported with antitumor effects against chem. induced mammary tumors.  Here, we report on our own investigation of 7-hydroxycoumarins as potential selective estrogen receptor down-regulators, which led us to the discovery of potent down-regulating antagonists, such as 33.  Subsequent optimization and removal of the 7-hydroxy group led to coumarin 59, which had increased potency and improved rat bioavailability relative to SS5020.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGondIuhUFHcLrVg90H21EOLACvtfcHk0ljzUXSSMohxlQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXksl2gsrc%253D&md5=765350db346581eab5565468f35b55d9</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00066&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00066%26sid%3Dliteratum%253Aachs%26aulast%3DDegorce%26aufirst%3DS.%2BL.%26aulast%3DBailey%26aufirst%3DA.%26aulast%3DCallis%26aufirst%3DR.%26aulast%3DDe%2BSavi%26aufirst%3DC.%26aulast%3DDucray%26aufirst%3DR.%26aulast%3DLamont%26aufirst%3DG.%26aulast%3DMacFaul%26aufirst%3DP.%26aulast%3DMaudet%26aufirst%3DM.%26aulast%3DMartin%26aufirst%3DS.%26aulast%3DMorgentin%26aufirst%3DR.%26aulast%3DNorman%26aufirst%3DR.%2BA.%26aulast%3DPeru%26aufirst%3DA.%26aulast%3DPink%26aufirst%3DJ.%2BH.%26aulast%3DPl%25C3%25A9%26aufirst%3DP.%2BA.%26aulast%3DRoberts%26aufirst%3DB.%26aulast%3DScott%26aufirst%3DJ.%2BS.%26atitle%3DInvestigation%2520of%2520%2528E%2529-3-%255B4-%25282-Oxo-3-aryl-chromen-4-yl%2529oxyphenyl%255Dacrylic%2520acids%2520as%2520oral%2520selective%2520estrogen%2520receptor%2520down-regulators%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26issue%3D8%26spage%3D3522%26epage%3D3533%26doi%3D10.1021%2Facs.jmedchem.5b00066" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="note"><p class="first last">Similar observations have reported by other research groups, for examples see refs <a onclick="showRef(event, 'cit17b'); return false;" href="javascript:void(0);" class="ref cit17b">(17b)</a> and <a onclick="showRef(event, 'cit19c'); return false;" href="javascript:void(0);" class="ref cit19c">(19c)</a>.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="note"><p class="first last">The measured <i>t</i><sub>1/2</sub> of <b>33</b> in pH 10 buffer at 70 °C was 82 h which was extrapolated to an estimated stability <i>t</i><sub>1/2</sub> of 78 days at 25 °C.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Andersson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evertsson, E.</span></span> <span> </span><span class="NLM_article-title">Prediction of drug candidates’ sensitivity toward autoxidation: computational estimation of C-H dissociation energies of carbon-centered radicals</span>. <i>J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>103</i></span>,  <span class="NLM_fpage">1949</span>– <span class="NLM_lpage">1955</span>, <span class="refDoi"> DOI: 10.1002/jps.23986</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=10.1002%2Fjps.23986" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=24823496" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=1%3ACAS%3A528%3ADC%252BC2cXnsl2ksLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2014&pages=1949-1955&author=T.+Anderssonauthor=A.+Brooauthor=E.+Evertsson&title=Prediction+of+drug+candidates%E2%80%99+sensitivity+toward+autoxidation%3A+computational+estimation+of+C-H+dissociation+energies+of+carbon-centered+radicals&doi=10.1002%2Fjps.23986"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Prediction of Drug Candidates Sensitivity Toward Autoxidation: Computational Estimation of C-H Dissociation Energies of Carbon-Centered Radicals</span></div><div class="casAuthors">Andersson, Thomas; Broo, Anders; Evertsson, Emma</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmaceutical Sciences</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1949-1955</span>CODEN:
                <span class="NLM_cas:coden">JPMSAE</span>;
        ISSN:<span class="NLM_cas:issn">0022-3549</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A method to predict a compd.'s sensitivity toward autoxidn. using bond dissocn. energies for hydrogen abstraction is described.  The methodol. is based on quantum mechanics and has been validated with a small mol. test set.  Through this work, it has been obsd. that stabilization of an incipient radical by more than a single functional group is normally required to trigger autoxidn.  The method has also been used to understand salt effects, wherein protonation of a basic amine stabilizes proximal C-H bonds to autoxidn.  It can be used to support understanding of autoxidn. processes and can form a predictive role for propensity to form potentially genotoxic and other degrdn. products.  An automated protocol has been developed that allows the nonspecialist to perform quantum chem. calcns.  The protocol is robust to enable general usage such that drug-like mols. can be handled by the tool and give an answer in hours (up to some days) depending on the size of the mol.  The efficiency of the tool makes it possible to perform risk assessment for autoxidn. of small lists of mols. and could typically be used for short-listed candidates before drug nomination, during drug formulation development, and during due diligence for in-licensing compds. © 2014 Wiley Periodicals, Inc. and the American Pharmacists Assocn. J Pharm Sci.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqeoSZl90Fgv7Vg90H21EOLACvtfcHk0lgjd9s3pIdoag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXnsl2ksLs%253D&md5=b97b5da7006ee628987ff3ffa7027cea</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1002%2Fjps.23986&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjps.23986%26sid%3Dliteratum%253Aachs%26aulast%3DAndersson%26aufirst%3DT.%26aulast%3DBroo%26aufirst%3DA.%26aulast%3DEvertsson%26aufirst%3DE.%26atitle%3DPrediction%2520of%2520drug%2520candidates%25E2%2580%2599%2520sensitivity%2520toward%2520autoxidation%253A%2520computational%2520estimation%2520of%2520C-H%2520dissociation%2520energies%2520of%2520carbon-centered%2520radicals%26jtitle%3DJ.%2520Pharm.%2520Sci.%26date%3D2014%26volume%3D103%26spage%3D1949%26epage%3D1955%26doi%3D10.1002%2Fjps.23986" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ghamari, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zarei, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arias-Montano, J.-A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reiner, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dastmalchi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stark, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamzeh-Mivehroud, M.</span></span> <span> </span><span class="NLM_article-title">Histamine H3 receptor antagonists/inverse agonists: Where do they go?</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>200</i></span>,  <span class="NLM_fpage">69</span>– <span class="NLM_lpage">84</span>, <span class="refDoi"> DOI: 10.1016/j.pharmthera.2019.04.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=10.1016%2Fj.pharmthera.2019.04.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=31028835" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=1%3ACAS%3A528%3ADC%252BC1MXovVOmtrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=200&publication_year=2019&pages=69-84&author=N.+Ghamariauthor=O.+Zareiauthor=J.-A.+Arias-Montanoauthor=D.+Reinerauthor=S.+Dastmalchiauthor=H.+Starkauthor=M.+Hamzeh-Mivehroud&title=Histamine+H3+receptor+antagonists%2Finverse+agonists%3A+Where+do+they+go%3F&doi=10.1016%2Fj.pharmthera.2019.04.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Histamine H3 receptor antagonists/inverse agonists: Where do they go?</span></div><div class="casAuthors">Ghamari, Nakisa; Zarei, Omid; Arias-Montano, Jose-Antonio; Reiner, David; Dastmalchi, Siavoush; Stark, Holger; Hamzeh-Mivehroud, Maryam</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">200</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">69-84</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Since the discovery of the histamine H3 receptor in 1983, tremendous advances in the pharmacol. aspects of H3 receptor antagonists/inverse agonists have been accomplished in preclin. studies.  At present, there are several drug candidates that reached clin. trial studies for various indications.  However, entrance of these candidates to the pharmaceutical market is not free from challenges, and a variety of difficulties is engaged with their developmental process.  In this review, the potential role of H3 receptors in the pathophysiol. of various central nervous system, metabolic and allergic diseases is discussed.  Thereafter, the current status for H3 receptor antagonists/inverse agonists in ongoing clin. trial studies is reviewed and obstacles in developing these agents are emphasized.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3IbgM1GUg97Vg90H21EOLACvtfcHk0lgjd9s3pIdoag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXovVOmtrs%253D&md5=7129bc498b85275ffa09f839ddeb04a9</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2019.04.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2019.04.007%26sid%3Dliteratum%253Aachs%26aulast%3DGhamari%26aufirst%3DN.%26aulast%3DZarei%26aufirst%3DO.%26aulast%3DArias-Montano%26aufirst%3DJ.-A.%26aulast%3DReiner%26aufirst%3DD.%26aulast%3DDastmalchi%26aufirst%3DS.%26aulast%3DStark%26aufirst%3DH.%26aulast%3DHamzeh-Mivehroud%26aufirst%3DM.%26atitle%3DHistamine%2520H3%2520receptor%2520antagonists%252Finverse%2520agonists%253A%2520Where%2520do%2520they%2520go%253F%26jtitle%3DPharmacol.%2520Ther.%26date%3D2019%26volume%3D200%26spage%3D69%26epage%3D84%26doi%3D10.1016%2Fj.pharmthera.2019.04.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Othman, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haig, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Florian, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Locke, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dutta, S.</span></span> <span> </span><span class="NLM_article-title">Safety, tolerability and pharmacokinetics of the histamine H3 receptor antagonist, ABT-288, in healthy young adults and elderly volunteers</span>. <i>B. J. Clin. Pharm.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>75</i></span>,  <span class="NLM_fpage">1299</span>– <span class="NLM_lpage">1311</span>, <span class="refDoi"> DOI: 10.1111/j.1365-2125.2012.04472.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=10.1111%2Fj.1365-2125.2012.04472.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=23016924" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2013&pages=1299-1311&author=A.+A.+Othmanauthor=G.+Haigauthor=H.+Florianauthor=C.+Lockeauthor=J.+Zhangauthor=S.+Dutta&title=Safety%2C+tolerability+and+pharmacokinetics+of+the+histamine+H3+receptor+antagonist%2C+ABT-288%2C+in+healthy+young+adults+and+elderly+volunteers&doi=10.1111%2Fj.1365-2125.2012.04472.x"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39a&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2125.2012.04472.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2125.2012.04472.x%26sid%3Dliteratum%253Aachs%26aulast%3DOthman%26aufirst%3DA.%2BA.%26aulast%3DHaig%26aufirst%3DG.%26aulast%3DFlorian%26aufirst%3DH.%26aulast%3DLocke%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DDutta%26aufirst%3DS.%26atitle%3DSafety%252C%2520tolerability%2520and%2520pharmacokinetics%2520of%2520the%2520histamine%2520H3%2520receptor%2520antagonist%252C%2520ABT-288%252C%2520in%2520healthy%2520young%2520adults%2520and%2520elderly%2520volunteers%26jtitle%3DB.%2520J.%2520Clin.%2520Pharm.%26date%3D2013%26volume%3D75%26spage%3D1299%26epage%3D1311%26doi%3D10.1111%2Fj.1365-2125.2012.04472.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit39b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Iannone, R.</span>; <span class="NLM_string-name">Renger, J.</span>; <span class="NLM_string-name">Potter, W.</span>; <span class="NLM_string-name">Dijk, D.</span>; <span class="NLM_string-name">Boyle, J.</span>; <span class="NLM_string-name">Palcza, J.</span>; <span class="NLM_string-name">Zhao, B.</span>; <span class="NLM_string-name">Bergman, A.</span>; <span class="NLM_string-name">Van Laere, K.</span>; <span class="NLM_string-name">Bormans, G.</span>; <span class="NLM_string-name">Sanabria, S.</span>; <span class="NLM_string-name">Calder, N.</span>; <span class="NLM_string-name">De Lepeleire, I.</span>; <span class="NLM_string-name">Van Hoydonck, P.</span>; <span class="NLM_string-name">Marsilio, S.</span>; <span class="NLM_string-name">Cerchio, K.</span>; <span class="NLM_string-name">Declercq, R.</span>; <span class="NLM_string-name">Fox-Bosetti, S.</span>; <span class="NLM_string-name">Verma, A.</span>; <span class="NLM_string-name">Van Bortel, L.</span>; <span class="NLM_string-name">Achten, E.</span>; <span class="NLM_string-name">Ma, J.</span>; <span class="NLM_string-name">Hargreaves, R.</span>; <span class="NLM_string-name">Koblan, K.</span>; <span class="NLM_string-name">Chodakewitz, J.</span>; <span class="NLM_string-name">Gottesdiener, K.</span>; <span class="NLM_string-name">Murphy, G.</span></span> <span> </span><span class="NLM_article-title">The Relationship between Brain Receptor Occupancy (RO) and Alerting Effects in Humans Support MK-0249 and MK-3134 as Inverse Agonists at the Histamine Subtype-3 Pre-Synaptic Receptor (H3R)</span>. American College Neuropsychopharmacology 48th Annual Meeting (ACNP), <span class="NLM_publisher-loc">Hollywood, FL</span>, <span class="NLM_year">2009</span>, December 6–10;  <span class="NLM_fpage">198</span> (abstract).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&pages=198&author=R.+Iannone&author=J.+Renger&author=W.+Potter&author=D.+Dijk&author=J.+Boyle&author=J.+Palcza&author=B.+Zhao&author=A.+Bergman&author=K.+Van+Laere&author=G.+Bormans&author=S.+Sanabria&author=N.+Calder&author=I.+De+Lepeleire&author=P.+Van+Hoydonck&author=S.+Marsilio&author=K.+Cerchio&author=R.+Declercq&author=S.+Fox-Bosetti&author=A.+Verma&author=L.+Van+Bortel&author=E.+Achten&author=J.+Ma&author=R.+Hargreaves&author=K.+Koblan&author=J.+Chodakewitz&author=K.+Gottesdiener&author=G.+Murphy&title=The+Relationship+between+Brain+Receptor+Occupancy+%28RO%29+and+Alerting+Effects+in+Humans+Support+MK-0249+and+MK-3134+as+Inverse+Agonists+at+the+Histamine+Subtype-3+Pre-Synaptic+Receptor+%28H3R%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26aulast%3DIannone%26aufirst%3DR.%26atitle%3DThe%2520Relationship%2520between%2520Brain%2520Receptor%2520Occupancy%2520%2528RO%2529%2520and%2520Alerting%2520Effects%2520in%2520Humans%2520Support%2520MK-0249%2520and%2520MK-3134%2520as%2520Inverse%2520Agonists%2520at%2520the%2520Histamine%2520Subtype-3%2520Pre-Synaptic%2520Receptor%2520%2528H3R%2529%26date%3D2009%26spage%3D198" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Callis, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabow, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tonge, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradbury, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Challinor, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, G.</span></span> <span> </span><span class="NLM_article-title">A screening assay cascade to identify and characterize novel selective estrogen receptor downregulators (SERDs)</span>. <i>J. Biomol. Screening</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">748</span>– <span class="NLM_lpage">759</span>, <span class="refDoi"> DOI: 10.1177/1087057115580298</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=10.1177%2F1087057115580298" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=25851036" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsF2nsbzE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2015&pages=748-759&author=R.+Callisauthor=A.+Rabowauthor=M.+Tongeauthor=R.+Bradburyauthor=M.+Challinorauthor=K.+Robertsauthor=K.+Jonesauthor=G.+Walker&title=A+screening+assay+cascade+to+identify+and+characterize+novel+selective+estrogen+receptor+downregulators+%28SERDs%29&doi=10.1177%2F1087057115580298"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">A screening assay cascade to identify and characterize novel selective estrogen receptor downregulators (SERDs)</span></div><div class="casAuthors">Callis, Rowena; Rabow, Alfred; Tonge, Michael; Bradbury, Robert; Challinor, Mairi; Roberts, Karen; Jones, Karen; Walker, Graeme</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biomolecular Screening</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">748-759</span>CODEN:
                <span class="NLM_cas:coden">JBISF3</span>;
        ISSN:<span class="NLM_cas:issn">1087-0571</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">Here, we describe an approach to identify novel selective estrogen receptor downregulator (SERD) compds. with improved properties such as oral bioavailability and the potential of increased efficacy compared to currently marketed drug treatments.  Previously, methodologies such as Western blotting and transient cell reporter assays have been used to identify and characterize SERD compds., but such approaches can be limited due to low throughput and sensitivity, resp.  We have used an endogenous cell-imaging strategy that has both the throughput and sensitivity to support a large-scale hit-to-lead program to identify novel compds.  A screening cascade with a suite of assays has been developed to characterize compds. that modulate estrogen receptor α (ERα)-mediated signaling or downregulate ERα levels in cells.  Initially, from a focused high-throughput screening, novel ERα binders were identified that could be modified chem. into ERα downregulators.  Following this, cellular assays helped det. the mechanism of action of compds. to distinguish between on-target and off-target compds. and differentiate SERDs, selective estrogen receptor modulator (SERM) compds., and agonist ERα ligands.  Data are shown to exemplify the characterization of ERα-mediated signaling inhibitors using a selection of literature compds. and illustrate how this cascade has been used to drive the chem. design of novel SERD compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqNNWMPPJDNrVg90H21EOLACvtfcHk0lgPC2XkdBg_qQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsF2nsbzE&md5=13c27dbf08f315d469f81b2bcefb4499</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1177%2F1087057115580298&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1087057115580298%26sid%3Dliteratum%253Aachs%26aulast%3DCallis%26aufirst%3DR.%26aulast%3DRabow%26aufirst%3DA.%26aulast%3DTonge%26aufirst%3DM.%26aulast%3DBradbury%26aufirst%3DR.%26aulast%3DChallinor%26aufirst%3DM.%26aulast%3DRoberts%26aufirst%3DK.%26aulast%3DJones%26aufirst%3DK.%26aulast%3DWalker%26aufirst%3DG.%26atitle%3DA%2520screening%2520assay%2520cascade%2520to%2520identify%2520and%2520characterize%2520novel%2520selective%2520estrogen%2520receptor%2520downregulators%2520%2528SERDs%2529%26jtitle%3DJ.%2520Biomol.%2520Screening%26date%3D2015%26volume%3D20%26spage%3D748%26epage%3D759%26doi%3D10.1177%2F1087057115580298" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6zoq" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6zoq','PDB','6zoq'); return false;">PDB: 6zoq</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5aav" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5aav','PDB','5aav'); return false;">PDB: 5aav</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6zos" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6zos','PDB','6zos'); return false;">PDB: 6zos</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6zor" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6zor','PDB','6zor'); return false;">PDB: 6zor</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5acc" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5acc','PDB','5acc'); return false;">PDB: 5acc</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i79"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01163">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_18023"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c01163?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01163</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Experimental procedures for the synthesis of intermediates together with biological data and associated errors, NMR conformation, crystallography and molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01163/suppl_file/jm0c01163_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01163/suppl_file/jm0c01163_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01163/suppl_file/jm0c01163_si_001.pdf">jm0c01163_si_001.pdf (2.91 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01163/suppl_file/jm0c01163_si_002.csv">jm0c01163_si_002.csv (3.9 kb)</a></li></ul></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">Crystal structures of ER in complex with compound <b>16</b> (6zoq), <b>18</b> (6zos), and <b>28</b> (6zor).</p><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.0c01163&amp;pbContext=%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2020.63.issue-23%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.0c01163%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.0c01163" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                7MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"6799ce92cd1b3db2","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
